{"eb78c049ddae3d4769515ac771c1285446939f89": [["IntroductionMiddle East Respiratory Syndrome (MERS-CoV) was first isolated in September 2012 from a patient in Saudi Arabia who presented two months earlier with severe acute respiratory infection and acute renal failure [1] .", [["respiratory", "ANATOMY", 175, 186], ["renal", "ANATOMY", 207, 212], ["IntroductionMiddle East Respiratory Syndrome", "DISEASE", 0, 44], ["acute respiratory infection", "DISEASE", 169, 196], ["acute renal failure", "DISEASE", 201, 220], ["patient", "ORGANISM", 100, 107], ["renal", "ORGAN", 207, 212], ["patient", "SPECIES", 100, 107], ["IntroductionMiddle East Respiratory Syndrome (MERS-CoV", "SPECIES", 0, 54], ["IntroductionMiddle East Respiratory Syndrome", "PROBLEM", 0, 44], ["severe acute respiratory infection", "PROBLEM", 162, 196], ["acute renal failure", "PROBLEM", 201, 220], ["Respiratory Syndrome", "OBSERVATION", 24, 44], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["respiratory", "ANATOMY", 175, 186], ["infection", "OBSERVATION", 187, 196], ["acute", "OBSERVATION_MODIFIER", 201, 206], ["renal", "ANATOMY", 207, 212], ["failure", "OBSERVATION", 213, 220]]], ["Retrospective testing of samples in Jordan identified earlier cases from a nosocomial outbreak in April 2012 [2] .", [["samples", "ANATOMY", 25, 32], ["Retrospective testing", "TEST", 0, 21]]], ["Although the majority of MERS-CoV cases (\u223c75%) have occurred in Saudi Arabia, 25 other countries have confirmed imported or autochthonously transmitted cases ( Fig. 1) [3, 4] .", [["MERS-CoV", "ORGANISM", 25, 33], ["MERS-CoV", "SPECIES", 25, 33], ["CoV cases", "TEST", 30, 39]]], ["The most recent and largest outbreak outside of Saudi Arabia occurred in South Korea in May 2015 [5] , raising concern for an eruption of regional outbreaks or accelerated global spread, similar to the phylogenetically related severe acute respiratory syndrome coronavirus (SARS-CoV) that killed nearly a thousand people a decade earlier [6] .", [["acute respiratory syndrome coronavirus", "DISEASE", 234, 272], ["SARS-CoV)", "DISEASE", 274, 283], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 227, 272], ["SARS-CoV", "ORGANISM", 274, 282], ["people", "SPECIES", 314, 320], ["severe acute respiratory syndrome coronavirus", "SPECIES", 227, 272], ["SARS-CoV", "SPECIES", 274, 282], ["an eruption of regional outbreaks", "PROBLEM", 123, 156], ["accelerated global spread", "PROBLEM", 160, 185], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 227, 272], ["largest", "OBSERVATION_MODIFIER", 20, 27], ["outbreak", "OBSERVATION_MODIFIER", 28, 36], ["regional", "OBSERVATION_MODIFIER", 138, 146], ["outbreaks", "OBSERVATION", 147, 156], ["accelerated", "OBSERVATION_MODIFIER", 160, 171], ["global spread", "OBSERVATION", 172, 185], ["severe", "OBSERVATION_MODIFIER", 227, 233], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["respiratory syndrome coronavirus", "OBSERVATION", 240, 272]]], ["Although the definitive host for MERS-CoV has not yet been established, closely related coronaviruses have been isolated from bats across wide geographic areas [7] [8] [9] .", [["MERS-CoV", "ORGANISM", 33, 41], ["coronaviruses", "ORGANISM", 88, 101], ["MERS-CoV", "SPECIES", 33, 41], ["coronaviruses", "PROBLEM", 88, 101], ["coronaviruses", "OBSERVATION", 88, 101]]], ["Mounting evidence has strongly implicated dromedary camels as the intermediate animal reservoir, as serological surveys throughout the Middle East and North Africa have demonstrated them to have a high prevalence of MERS-CoV binding or neutralizing Abs [10] [11] [12] [13] .", [["dromedary camels", "ORGANISM", 42, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 216, 224], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 253, 272], ["MERS-CoV", "SPECIES", 216, 224], ["the intermediate animal reservoir", "TREATMENT", 62, 95], ["CoV binding", "PROBLEM", 221, 232], ["neutralizing Abs", "TEST", 236, 252]]], ["Additionally, outbreak investigations have suggested epidemiologic linkage between farm camels and human cases [14] .IntroductionMERS-CoV is a spherical, enveloped, single-stranded, positive sense RNA beta-coronavirus [1, 15] .", [["human", "ORGANISM", 99, 104], ["IntroductionMERS-CoV", "GENE_OR_GENE_PRODUCT", 117, 137], ["CoV", "DNA", 134, 137], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["outbreak investigations", "TEST", 14, 37], ["spherical", "OBSERVATION_MODIFIER", 143, 152], ["enveloped", "OBSERVATION_MODIFIER", 154, 163]]], ["Its genome contains a replicase * Tel.: +13015003600. locus at the 5 end and codes for structural proteins toward the 3 end.", [["locus", "CELLULAR_COMPONENT", 54, 59], ["5 end", "DNA", 67, 72], ["structural proteins", "PROTEIN", 87, 106], ["replicase", "OBSERVATION_MODIFIER", 22, 31]]], ["The most immunogenic of the viral proteins is Spike (S), a trimeric, envelope-anchored, type I fusion glycoprotein that interfaces with its human host cognate receptor, dipeptidyl peptidase 4 (DPP4), to mediate viral entry [16, 17] .", [["Spike (S)", "GENE_OR_GENE_PRODUCT", 46, 55], ["human", "ORGANISM", 140, 145], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 169, 191], ["DPP4", "GENE_OR_GENE_PRODUCT", 193, 197], ["viral proteins", "PROTEIN", 28, 42], ["Spike (S)", "PROTEIN", 46, 55], ["trimeric, envelope-anchored, type I fusion glycoprotein", "PROTEIN", 59, 114], ["human host cognate receptor", "PROTEIN", 140, 167], ["dipeptidyl peptidase 4", "PROTEIN", 169, 191], ["DPP4", "PROTEIN", 193, 197], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["the viral proteins", "PROBLEM", 24, 42], ["a trimeric, envelope-anchored, type I fusion glycoprotein", "TREATMENT", 57, 114], ["its human host cognate receptor", "TREATMENT", 136, 167], ["dipeptidyl peptidase", "TREATMENT", 169, 189], ["DPP4", "TEST", 193, 197], ["most immunogenic", "OBSERVATION_MODIFIER", 4, 20], ["viral proteins", "OBSERVATION", 28, 42]]], ["S comprises two subunits: S1, which contains the receptor-binding domain and determines cell tropism; and S2, the location of the cell fusion machinery.", [["cell", "ANATOMY", 88, 92], ["cell", "ANATOMY", 130, 134], ["S1", "GENE_OR_GENE_PRODUCT", 26, 28], ["cell", "CELL", 88, 92], ["S2", "GENE_OR_GENE_PRODUCT", 106, 108], ["cell", "CELL", 130, 134], ["S1", "PROTEIN", 26, 28], ["receptor-binding domain", "PROTEIN", 49, 72], ["S2", "PROTEIN", 106, 108], ["the cell fusion machinery", "TREATMENT", 126, 151], ["S1", "ANATOMY", 26, 28], ["binding domain", "OBSERVATION", 58, 72], ["cell tropism", "OBSERVATION", 88, 100], ["cell fusion", "OBSERVATION", 130, 141]]], ["Although DPP4 has a broad tissue distribution, most of the clinical manifestations of MERS-CoV can be attributed to its localization to the lower respiratory tract [18, 19] .", [["tissue", "ANATOMY", 26, 32], ["lower respiratory tract", "ANATOMY", 140, 163], ["DPP4", "GENE_OR_GENE_PRODUCT", 9, 13], ["tissue", "TISSUE", 26, 32], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["lower", "ORGANISM_SUBDIVISION", 140, 145], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["DPP4", "PROTEIN", 9, 13], ["MERS-CoV", "SPECIES", 86, 94], ["DPP4", "TREATMENT", 9, 13], ["a broad tissue distribution", "PROBLEM", 18, 45], ["CoV", "PROBLEM", 91, 94], ["broad tissue", "OBSERVATION_MODIFIER", 20, 32], ["distribution", "OBSERVATION_MODIFIER", 33, 45], ["lower", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163]]], ["Much like other coronaviruses, MERS-CoV can also cause significant dysfunction of the gastrointestinal, cardiovascular, renal, and neurologic systems.", [["gastrointestinal", "ANATOMY", 86, 102], ["cardiovascular", "ANATOMY", 104, 118], ["renal", "ANATOMY", 120, 125], ["neurologic", "ANATOMY", 131, 141], ["dysfunction of the gastrointestinal, cardiovascular, renal, and neurologic systems", "DISEASE", 67, 149], ["coronaviruses", "ORGANISM", 16, 29], ["MERS-CoV", "ORGANISM", 31, 39], ["gastrointestinal", "ORGAN", 86, 102], ["cardiovascular", "ANATOMICAL_SYSTEM", 104, 118], ["renal", "ORGAN", 120, 125], ["MERS-CoV", "SPECIES", 31, 39], ["other coronaviruses", "PROBLEM", 10, 29], ["significant dysfunction of the gastrointestinal, cardiovascular, renal, and neurologic systems", "PROBLEM", 55, 149], ["coronaviruses", "OBSERVATION", 16, 29], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["dysfunction", "OBSERVATION", 67, 78], ["gastrointestinal", "ANATOMY", 86, 102], ["renal", "ANATOMY", 120, 125]]], ["MERS-CoV is distinct, though, in its tendency to cause greatest harm to older individuals with concurrent comorbidities of one or more of these organ-systems [20, 21] .IntroductionDespite past efforts to develop coronavirus countermeasures in response to the SARS-CoV pandemic, there are currently no prophylactic or therapeutic interventions of proven efficacy for MERS-CoV or any other coronavirus infection.", [["organ", "ANATOMY", 144, 149], ["coronavirus", "DISEASE", 212, 223], ["SARS-CoV pandemic", "DISEASE", 259, 276], ["coronavirus infection", "DISEASE", 388, 409], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["organ", "ORGAN", 144, 149], ["coronavirus", "ORGANISM", 212, 223], ["SARS-CoV", "ORGANISM", 259, 267], ["MERS-CoV", "ORGANISM", 366, 374], ["coronavirus", "ORGANISM", 388, 399], ["coronavirus", "SPECIES", 388, 399], ["MERS-CoV", "SPECIES", 0, 8], ["coronavirus", "SPECIES", 212, 223], ["SARS-CoV", "SPECIES", 259, 267], ["MERS-CoV", "SPECIES", 366, 374], ["concurrent comorbidities", "PROBLEM", 95, 119], ["coronavirus countermeasures", "TREATMENT", 212, 239], ["the SARS-CoV pandemic", "PROBLEM", 255, 276], ["therapeutic interventions", "TREATMENT", 317, 342], ["MERS", "PROBLEM", 366, 370], ["CoV", "PROBLEM", 371, 374], ["any other coronavirus infection", "PROBLEM", 378, 409], ["CoV", "OBSERVATION", 5, 8], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["coronavirus", "OBSERVATION_MODIFIER", 388, 399], ["infection", "OBSERVATION", 400, 409]]], ["Although combination treatment with ribavirin and interferons were shown to improve clinical outcomes in MERS-CoV-infected non-human primates (NHPs), treatment was initiated very soon after viral challenge (\u223c8 h) and results have not been replicated in humans [22] .", [["ribavirin", "CHEMICAL", 36, 45], ["MERS-CoV-infected", "DISEASE", 105, 122], ["ribavirin", "CHEMICAL", 36, 45], ["ribavirin", "SIMPLE_CHEMICAL", 36, 45], ["MERS-CoV", "ORGANISM", 105, 113], ["non-human primates", "ORGANISM", 123, 141], ["NHPs", "ORGANISM", 143, 147], ["humans", "ORGANISM", 253, 259], ["interferons", "PROTEIN", 50, 61], ["humans", "SPECIES", 253, 259], ["MERS-CoV", "SPECIES", 105, 113], ["NHPs", "SPECIES", 143, 147], ["humans", "SPECIES", 253, 259], ["ribavirin", "TREATMENT", 36, 45], ["interferons", "TREATMENT", 50, 61], ["treatment", "TREATMENT", 150, 159], ["viral challenge", "TEST", 190, 205]]], ["In fact, no experimental interventions have demonstrated appreciable benefit in acutely ill patients in a consistent or controlled manner.", [["acutely ill", "DISEASE", 80, 91], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["experimental interventions", "TREATMENT", 12, 38], ["no", "UNCERTAINTY", 9, 11]]], ["Rapidly scaled treatments based on naturally occurring neutralizing antibodies such as convalescent plasma or hyperimmune globulin, on the other hand, have demonstrated mortality reductions for other respiratory infections and may hold promise for MERS-CoV as well [23] .", [["plasma", "ANATOMY", 100, 106], ["respiratory", "ANATOMY", 200, 211], ["respiratory infections", "DISEASE", 200, 222], ["convalescent", "ORGANISM", 87, 99], ["plasma", "ORGANISM_SUBSTANCE", 100, 106], ["hyperimmune", "ORGANISM", 110, 121], ["globulin", "GENE_OR_GENE_PRODUCT", 122, 130], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 248, 256], ["neutralizing antibodies", "PROTEIN", 55, 78], ["hyperimmune globulin", "PROTEIN", 110, 130], ["hyperimmune", "SPECIES", 110, 121], ["MERS-CoV", "SPECIES", 248, 256], ["Rapidly scaled treatments", "TREATMENT", 0, 25], ["neutralizing antibodies", "TREATMENT", 55, 78], ["convalescent plasma", "TEST", 87, 106], ["hyperimmune globulin", "TREATMENT", 110, 130], ["mortality reductions", "TREATMENT", 169, 189], ["other respiratory infections", "PROBLEM", 194, 222], ["hyperimmune globulin", "OBSERVATION", 110, 130], ["respiratory", "ANATOMY", 200, 211], ["infections", "OBSERVATION", 212, 222]]], ["Supportive management, adapted from guidelines developed for SARS-CoV, has thus far been the mainstay of MERS-CoV treatment.Prospective for an effective human vaccineThe global will to develop a coronavirus vaccine faded in the aftermath of SARS-CoV pandemic but has since gained renewed momentum in the face of the current MERS-CoV outbreak.", [["SARS-CoV", "DISEASE", 61, 69], ["coronavirus", "DISEASE", 195, 206], ["SARS-CoV pandemic", "DISEASE", 241, 258], ["SARS-CoV", "ORGANISM", 61, 69], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["human", "ORGANISM", 153, 158], ["coronavirus", "ORGANISM", 195, 206], ["SARS-CoV", "ORGANISM", 241, 249], ["MERS-CoV", "ORGANISM", 324, 332], ["human", "SPECIES", 153, 158], ["SARS-CoV", "SPECIES", 61, 69], ["human", "SPECIES", 153, 158], ["SARS-CoV", "SPECIES", 241, 249], ["Supportive management", "TREATMENT", 0, 21], ["SARS", "PROBLEM", 61, 65], ["CoV treatment", "TREATMENT", 110, 123], ["an effective human vaccine", "TREATMENT", 140, 166], ["a coronavirus vaccine", "TREATMENT", 193, 214], ["SARS", "PROBLEM", 241, 245], ["CoV pandemic", "PROBLEM", 246, 258], ["CoV outbreak", "PROBLEM", 329, 341], ["coronavirus", "OBSERVATION", 195, 206]]], ["Previous approaches to coronavirus vaccine development were broad and included whole-inactivated and live-attenuated viruses, recombinant vectors and protein subunits, as well as DNA and RNA based platforms [6] .", [["coronavirus", "DISEASE", 23, 34], ["coronavirus", "ORGANISM", 23, 34], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["recombinant vectors", "DNA", 126, 145], ["protein subunits", "PROTEIN", 150, 166], ["coronavirus", "SPECIES", 23, 34], ["coronavirus vaccine", "TREATMENT", 23, 42], ["attenuated viruses", "PROBLEM", 106, 124], ["recombinant vectors", "TREATMENT", 126, 145], ["protein subunits", "TREATMENT", 150, 166]]], ["Most developers based their immunogen designs on the S surface glycoprotein, the primary target for neutralizing antibodies during any natural coronavirus infection.", [["coronavirus infection", "DISEASE", 143, 164], ["natural coronavirus", "ORGANISM", 135, 154], ["S surface glycoprotein", "PROTEIN", 53, 75], ["neutralizing antibodies", "PROTEIN", 100, 123], ["the S surface glycoprotein", "TREATMENT", 49, 75], ["neutralizing antibodies", "PROBLEM", 100, 123], ["any natural coronavirus infection", "PROBLEM", 131, 164], ["coronavirus", "OBSERVATION_MODIFIER", 143, 154], ["infection", "OBSERVATION", 155, 164]]], ["A number of preclinical and clinical studies showed that the SARS-CoV S1 protein subunit, and specifically the RBD at its core, could serve as a dominant target for neutralizing antibodies in mice, non-human primates, and humans [24] .", [["SARS-CoV S1", "GENE_OR_GENE_PRODUCT", 61, 72], ["RBD", "GENE_OR_GENE_PRODUCT", 111, 114], ["mice", "ORGANISM", 192, 196], ["non-human primates", "ORGANISM", 198, 216], ["humans", "ORGANISM", 222, 228], ["SARS-CoV S1 protein subunit", "PROTEIN", 61, 88], ["RBD", "PROTEIN", 111, 114], ["neutralizing antibodies", "PROTEIN", 165, 188], ["mice", "SPECIES", 192, 196], ["humans", "SPECIES", 222, 228], ["SARS-CoV", "SPECIES", 61, 69], ["mice", "SPECIES", 192, 196], ["humans", "SPECIES", 222, 228], ["clinical studies", "TEST", 28, 44], ["the SARS", "TEST", 57, 65], ["the RBD", "PROBLEM", 107, 114], ["neutralizing antibodies", "TEST", 165, 188]]], ["S1, therefore, became the basis for a number of promising SARS-CoV vaccine candidates.Prospective for an effective human vaccineThe S1 protein subunit and RBD have also been the basis for several MERS-CoV vaccine candidates (Fig. 2 ) [25] [26] [27] [28] [29] .", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["SARS-CoV", "ORGANISM", 58, 66], ["human", "ORGANISM", 115, 120], ["S1", "GENE_OR_GENE_PRODUCT", 132, 134], ["RBD", "GENE_OR_GENE_PRODUCT", 155, 158], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 196, 204], ["Fig. 2 ) [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 225, 258], ["S1 protein subunit", "PROTEIN", 132, 150], ["RBD", "PROTEIN", 155, 158], ["human", "SPECIES", 115, 120], ["SARS-CoV", "SPECIES", 58, 66], ["human", "SPECIES", 115, 120], ["promising SARS", "PROBLEM", 48, 62], ["CoV vaccine candidates", "TREATMENT", 63, 85], ["an effective human vaccine", "TREATMENT", 102, 128], ["The S1 protein subunit", "TREATMENT", 128, 150], ["RBD", "PROBLEM", 155, 158], ["several MERS-CoV vaccine candidates", "TREATMENT", 188, 223]]], ["Resolution of RBD crystal structures alone or in complex with the DPP4 receptor [25, 30, 31] have informed the design of immunogens that have been expressed either as recombinant protein fragments or conjugates to the fragment crystallizable (Fc) region of human antibodies.", [["DPP4", "GENE_OR_GENE_PRODUCT", 66, 70], ["human", "ORGANISM", 257, 262], ["RBD", "PROTEIN", 14, 17], ["DPP4 receptor", "PROTEIN", 66, 79], ["recombinant protein fragments", "PROTEIN", 167, 196], ["fragment crystallizable (Fc) region", "PROTEIN", 218, 253], ["human antibodies", "PROTEIN", 257, 273], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 257, 262], ["RBD crystal structures", "PROBLEM", 14, 36], ["immunogens", "TREATMENT", 121, 131], ["recombinant protein fragments", "PROBLEM", 167, 196], ["human antibodies", "PROBLEM", 257, 273], ["RBD", "OBSERVATION", 14, 17], ["human antibodies", "OBSERVATION", 257, 273]]], ["Both types of constructs, in formulation with aluminum salt or oil-in-water adjuvants, have elicited neutralizing antibodies of high potency across multiple viral strains.", [["aluminum salt", "CHEMICAL", 46, 59], ["aluminum salt", "CHEMICAL", 46, 59], ["aluminum salt", "SIMPLE_CHEMICAL", 46, 59], ["oil", "SIMPLE_CHEMICAL", 63, 66], ["neutralizing antibodies", "PROTEIN", 101, 124], ["aluminum salt", "TREATMENT", 46, 59], ["oil-in-water adjuvants", "TREATMENT", 63, 85], ["neutralizing antibodies", "PROBLEM", 101, 124], ["high potency across multiple viral strains", "PROBLEM", 128, 170], ["constructs", "OBSERVATION", 14, 24], ["high potency", "OBSERVATION_MODIFIER", 128, 140], ["viral strains", "OBSERVATION", 157, 170]]], ["Despite their demonstrated immunogenicity in animal models and anticipated safety in humans, RBD or S1-subunit based vaccine candidates are limited in their epitope breadth.", [["humans", "ORGANISM", 85, 91], ["RBD", "GENE_OR_GENE_PRODUCT", 93, 96], ["S1", "GENE_OR_GENE_PRODUCT", 100, 102], ["RBD", "PROTEIN", 93, 96], ["S1", "PROTEIN", 100, 102], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["RBD", "PROBLEM", 93, 96], ["S1-subunit based vaccine", "TREATMENT", 100, 124]]], ["Although the coronavirus genomes are not as variable as other RNA viruses, the RBD is the most mutable region, containing mutation sites that define antibody escape variants [25, 32] .", [["coronavirus", "ORGANISM", 13, 24], ["RBD", "GENE_OR_GENE_PRODUCT", 79, 82], ["coronavirus genomes", "DNA", 13, 32], ["RBD", "PROTEIN", 79, 82], ["mutation sites", "DNA", 122, 136], ["coronavirus", "SPECIES", 13, 24], ["the coronavirus genomes", "PROBLEM", 9, 32], ["other RNA viruses", "PROBLEM", 56, 73], ["mutation sites", "PROBLEM", 122, 136], ["antibody escape variants", "PROBLEM", 149, 173], ["coronavirus genomes", "OBSERVATION", 13, 32], ["viruses", "OBSERVATION", 66, 73], ["RBD", "OBSERVATION", 79, 82], ["most mutable", "OBSERVATION_MODIFIER", 90, 102], ["antibody escape", "OBSERVATION", 149, 164]]], ["Thus, vaccine candidates that elicit a more diverse antibody repertoire as well as a robust cellular immune response may offer the advantage of broader and more durable protection.Prospective for an effective human vaccineFull-length S used as an immunogen could at least increase the breadth of the antibody response; however, it has been difficult to express, and may require additional work to produce a stable soluble trimer of the S ectodomain.", [["cellular", "ANATOMY", 92, 100], ["cellular", "CELL", 92, 100], ["human", "ORGANISM", 209, 214], ["antibody repertoire", "PROTEIN", 52, 71], ["human vaccineFull-length S", "DNA", 209, 235], ["S ectodomain", "PROTEIN", 436, 448], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 209, 214], ["vaccine", "TREATMENT", 6, 13], ["a more diverse antibody repertoire", "PROBLEM", 37, 71], ["an effective human vaccineFull-length S", "TREATMENT", 196, 235], ["an immunogen", "TREATMENT", 244, 256], ["stable", "OBSERVATION_MODIFIER", 407, 413]]], ["Investigators at the University of Maryland, in collaboration with Novavax, Inc., have overcome this problem through the development of S rosettes that are stable and immunogenic in murine models [33] .", [["S rosettes", "CELL", 136, 146], ["murine", "ORGANISM", 182, 188], ["S rosettes", "CELL_LINE", 136, 146], ["murine", "SPECIES", 182, 188], ["Novavax", "TREATMENT", 67, 74], ["this problem", "PROBLEM", 96, 108], ["S rosettes", "PROBLEM", 136, 146], ["stable", "OBSERVATION_MODIFIER", 156, 162]]], ["Vaccines that mimic natural infection, such as live-attenuated viruses or recombinant viral vectors, may elicit even more robust immunity.", [["infection", "DISEASE", 28, 37], ["Vaccines", "TREATMENT", 0, 8], ["natural infection", "PROBLEM", 20, 37], ["attenuated viruses", "PROBLEM", 52, 70], ["recombinant viral vectors", "TREATMENT", 74, 99], ["natural", "OBSERVATION_MODIFIER", 20, 27], ["infection", "OBSERVATION", 28, 37]]], ["Live attenuated viruses have historically been among the most immunogenic platforms available, as they have the capacity to present multiple antigens across the viral life cycle in their native conformations.", [["Live attenuated viruses", "PROBLEM", 0, 23], ["the capacity", "PROBLEM", 108, 120], ["viruses", "OBSERVATION", 16, 23]]], ["Although a live-attenuated MERS-CoV has yet to be tested, one has been constructed and has the potential to be protective [34] .", [["MERS-CoV", "ORGANISM", 27, 35], ["MERS-CoV", "SPECIES", 27, 35]]], ["However, manufacturing live-attenuated viruses requires containment in a biosafety level 3 or 4 facility.", [["attenuated", "OBSERVATION_MODIFIER", 28, 38], ["viruses", "OBSERVATION", 39, 46]]], ["Additionally, live-attenuated viruses carry the hazards of inadequate attenuation or reversion to wild type form and causing disseminated disease, particularly in immunocompromised hosts.", [["disseminated disease", "DISEASE", 125, 145], ["inadequate attenuation", "PROBLEM", 59, 81], ["disseminated disease", "PROBLEM", 125, 145], ["immunocompromised hosts", "PROBLEM", 163, 186], ["viruses", "OBSERVATION", 30, 37], ["inadequate attenuation", "OBSERVATION_MODIFIER", 59, 81], ["disseminated", "OBSERVATION_MODIFIER", 125, 137], ["disease", "OBSERVATION", 138, 145], ["immunocompromised hosts", "OBSERVATION", 163, 186]]], ["Given that moderately immunocompromised adults with co-morbidities such as diabetes mellitus and chronic kidney disease have suffered the most severe MERS-CoV disease, these individuals may comprise a target population for immunization, thus making a live-attenuated virus vaccine a less viable option.", [["kidney", "ANATOMY", 105, 111], ["diabetes mellitus", "DISEASE", 75, 92], ["chronic kidney disease", "DISEASE", 97, 119], ["MERS-CoV disease", "DISEASE", 150, 166], ["kidney", "ORGAN", 105, 111], ["individuals", "ORGANISM", 174, 185], ["MERS-CoV", "SPECIES", 150, 158], ["moderately immunocompromised adults", "PROBLEM", 11, 46], ["co-morbidities", "PROBLEM", 52, 66], ["diabetes mellitus", "PROBLEM", 75, 92], ["chronic kidney disease", "PROBLEM", 97, 119], ["CoV disease", "PROBLEM", 155, 166], ["immunization", "TREATMENT", 223, 235], ["a live-attenuated virus vaccine", "TREATMENT", 249, 280], ["moderately", "OBSERVATION_MODIFIER", 11, 21], ["immunocompromised", "OBSERVATION", 22, 39], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["kidney", "ANATOMY", 105, 111], ["disease", "OBSERVATION", 112, 119], ["most severe", "OBSERVATION_MODIFIER", 138, 149], ["CoV disease", "OBSERVATION", 155, 166]]], ["Replication competent viral vectors could pose a similar threat for disseminated disease in the immunosuppressed.", [["Replication competent viral vectors", "TREATMENT", 0, 35], ["disseminated disease in the immunosuppressed", "PROBLEM", 68, 112], ["viral vectors", "OBSERVATION", 22, 35], ["immunosuppressed", "OBSERVATION", 96, 112]]], ["Replication deficient vectors, however, avoid that risk while maintaining the advantages of native antigen presentation, elicitation of T cell immunity and the ability to express multiple antigens.", [["T cell", "ANATOMY", 136, 142], ["antigen", "GENE_OR_GENE_PRODUCT", 99, 106], ["T cell", "CELL", 136, 142], ["antigens", "PROTEIN", 188, 196], ["Replication deficient vectors", "TREATMENT", 0, 29], ["T cell immunity", "TREATMENT", 136, 151]]], ["To date, two recombinant vector platforms-modified Although replication deficient vectors are relatively safe and immunogenic, their ability to deliver genetic material for expression could be impeded by pre-existing or developing immunity to the vector itself.", [["two recombinant vector platforms", "TREATMENT", 9, 41], ["replication deficient vectors", "TREATMENT", 60, 89]]], ["One way to overcome this limitation is by administering different vectors in a so-called prime-boost immunization regimen.", [["different vectors", "TREATMENT", 56, 73], ["boost immunization regimen", "TREATMENT", 95, 121]]], ["As this strategy has been effective for other pathogens, it is likely that the same success could be recapitulated for MERS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 119, 127], ["MERS-CoV", "SPECIES", 119, 127], ["other pathogens", "PROBLEM", 40, 55]]], ["The use of more than one type of platform or antigen in a single vaccine also increases the likelihood of inducing a broad repertoire of antibodies with diverse mechanisms of viral neutralization.", [["antibodies", "PROTEIN", 137, 147], ["antigen", "TREATMENT", 45, 52], ["a single vaccine", "TREATMENT", 56, 72], ["a broad repertoire of antibodies", "PROBLEM", 115, 147], ["viral neutralization", "PROBLEM", 175, 195], ["viral neutralization", "OBSERVATION", 175, 195]]], ["One vaccine regimen developed at the US National Institutes of Health is based on full-length S DNA and a truncated S1 subunit glycoprotein and has elicited neutralizing antibodies in mice directed at both the S1-within and outside the RBD-and S2 subunits.", [["DNA", "CELLULAR_COMPONENT", 96, 99], ["mice", "ORGANISM", 184, 188], ["S1", "GENE_OR_GENE_PRODUCT", 210, 212], ["RBD", "GENE_OR_GENE_PRODUCT", 236, 239], ["S2", "GENE_OR_GENE_PRODUCT", 244, 246], ["full-length S DNA", "DNA", 82, 99], ["truncated S1 subunit glycoprotein", "PROTEIN", 106, 139], ["neutralizing antibodies", "PROTEIN", 157, 180], ["S1", "PROTEIN", 210, 212], ["RBD", "PROTEIN", 236, 239], ["S2 subunits", "PROTEIN", 244, 255], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 184, 188], ["One vaccine regimen", "TREATMENT", 0, 19], ["a truncated S1 subunit glycoprotein", "PROBLEM", 104, 139], ["neutralizing antibodies", "PROBLEM", 157, 180], ["neutralizing antibodies", "OBSERVATION", 157, 180], ["S1", "ANATOMY", 210, 212], ["RBD", "ANATOMY", 236, 239], ["S2", "ANATOMY", 244, 246]]], ["Immunization with these constructs also protected NHPs from severe lung disease after intra-tracheal challenge with MERS-CoV [25] .", [["lung", "ANATOMY", 67, 71], ["intra-tracheal", "ANATOMY", 86, 100], ["lung disease", "DISEASE", 67, 79], ["NHPs", "ORGANISM", 50, 54], ["lung", "ORGAN", 67, 71], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 116, 124], ["NHPs", "SPECIES", 50, 54], ["MERS-CoV", "SPECIES", 116, 124], ["Immunization", "TREATMENT", 0, 12], ["severe lung disease", "PROBLEM", 60, 79], ["intra-tracheal challenge", "TREATMENT", 86, 110], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["lung", "ANATOMY", 67, 71], ["disease", "OBSERVATION", 72, 79]]], ["A DNAonly vaccine, expressing multiple antigens, has also been developed by Inovio Pharmaceuticals and GeneOne Life Science Inc. and has been advanced to a Phase I first-in-human trial.Monoclonal antibodies (mAbs) in developmentEach of the vaccine candidates that have been mentioned is being developed for prophylactic use.", [["human", "ORGANISM", 173, 178], ["Monoclonal antibodies", "PROTEIN", 185, 206], ["mAbs", "PROTEIN", 208, 212], ["human", "SPECIES", 173, 178], ["A DNAonly vaccine", "TREATMENT", 0, 17], ["Inovio Pharmaceuticals", "TREATMENT", 76, 98], ["Monoclonal antibodies (mAbs", "TREATMENT", 185, 212], ["the vaccine candidates", "TREATMENT", 236, 258]]], ["However, as the total number of cases (>1600) [3, 4] and reproductive rate (\u223c0.7) of MERS-CoV are both relatively low [39] , it will be difficult to define the target populations for vaccination that would support the investment in manufacturing and advanced product development.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 85, 93], ["MERS-CoV", "SPECIES", 85, 93], ["reproductive rate", "TEST", 57, 74], ["MERS-CoV", "TEST", 85, 93], ["vaccination", "TREATMENT", 183, 194]]], ["Also, with such low incidence and lack of robust animal models, it would be difficult to achieve a vaccine efficacy result that would be sufficient to support licensure.", [["such low incidence", "PROBLEM", 11, 29], ["a vaccine efficacy", "TREATMENT", 97, 115]]], ["Human mAbs, on the other hand, could be used without as much discrimination in an outbreak setting for post-exposure prophylaxis and early treatment.", [["Human", "ORGANISM", 0, 5], ["mAbs", "GENE_OR_GENE_PRODUCT", 6, 10], ["Human mAbs", "PROTEIN", 0, 10], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human mAbs", "TREATMENT", 0, 10], ["post-exposure prophylaxis", "TREATMENT", 103, 128], ["early treatment", "TREATMENT", 133, 148]]], ["The advantages of mAbs over polyclonal antibodies (administered through convalescent plasma or hyperimmune globulin) are their higher potency, greater specificity, more extensive pre-licensing evaluation and consequently improved safety profile.", [["plasma", "ANATOMY", 85, 91], ["mAbs", "GENE_OR_GENE_PRODUCT", 18, 22], ["convalescent", "ORGANISM", 72, 84], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["hyperimmune", "ORGANISM", 95, 106], ["globulin", "GENE_OR_GENE_PRODUCT", 107, 115], ["mAbs", "PROTEIN", 18, 22], ["polyclonal antibodies", "PROTEIN", 28, 49], ["hyperimmune globulin", "PROTEIN", 95, 115], ["mAbs over polyclonal antibodies", "TREATMENT", 18, 49], ["convalescent plasma or hyperimmune globulin", "TREATMENT", 72, 115], ["extensive pre-licensing evaluation", "TEST", 169, 203], ["higher potency", "OBSERVATION_MODIFIER", 127, 141]]], ["Additionally, mAbs can help define immunogenic epitopes through crystallographic analysis, thereby providing atomic level detail for the design of better immunogens.", [["mAbs", "PROTEIN", 14, 18], ["mAbs", "TREATMENT", 14, 18], ["crystallographic analysis", "TEST", 64, 89]]], ["However, the timeline for mAb development may be longer and potentially cost more than some vaccines.Monoclonal antibodies (mAbs) in developmentDespite requirements for greater upfront investment, several groups have developed highly potent mAbs that are currently being advanced through pre-clinical stages of testing (Fig. 3) .", [["mAb", "GENE_OR_GENE_PRODUCT", 26, 29], ["mAb", "PROTEIN", 26, 29], ["Monoclonal antibodies", "PROTEIN", 101, 122], ["mAbs", "PROTEIN", 124, 128], ["mAbs", "PROTEIN", 241, 245], ["some vaccines", "TREATMENT", 87, 100], ["Monoclonal antibodies (mAbs", "TREATMENT", 101, 128], ["greater upfront investment", "TREATMENT", 169, 195], ["testing", "TEST", 311, 318]]], ["Some have been isolated from immunized animals (mice/humanized mice/NHPs) [25, 40] , while others have been identified from either an antibody human phage library [41] [42] [43] [44] or memory B cells of infected and recovered human survivors [45] .", [["memory B cells", "ANATOMY", 186, 200], ["animals", "ORGANISM", 39, 46], ["mice", "ORGANISM", 48, 52], ["humanized mice/NHPs", "ORGANISM", 53, 72], ["human", "ORGANISM", 143, 148], ["memory B cells", "CELL", 186, 200], ["human", "ORGANISM", 227, 232], ["memory B cells", "CELL_TYPE", 186, 200], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 63, 67], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 227, 232], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 63, 67], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 227, 232], ["immunized animals (mice/humanized mice/NHPs", "TREATMENT", 29, 72], ["memory B cells", "TEST", 186, 200]]], ["Almost all of the mAbs that have been reported target the Spike RBD.", [["RBD", "DISEASE", 64, 67], ["mAbs", "GENE_OR_GENE_PRODUCT", 18, 22], ["mAbs", "PROTEIN", 18, 22], ["Spike RBD", "PROTEIN", 58, 67], ["the Spike RBD", "PROBLEM", 54, 67]]], ["It is likely that mAbs directed at other sites on the Spike glycoprotein have been recovered but are not as potent neutralizers.", [["mAbs", "GENE_OR_GENE_PRODUCT", 18, 22], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 54, 72], ["mAbs", "PROTEIN", 18, 22], ["Spike glycoprotein", "PROTEIN", 54, 72], ["mAbs", "PROBLEM", 18, 22], ["the Spike glycoprotein", "TREATMENT", 50, 72], ["is likely", "UNCERTAINTY", 3, 12], ["mAbs", "OBSERVATION", 18, 22]]], ["Most of those that have been published bind to recombinant Spike with picomolar affinity and neutralize MERS-CoV pseudovirus at a half maximal inhibitory concentration (IC 50 ) of 0.1 mcg/l or less.", [["Spike", "GENE_OR_GENE_PRODUCT", 59, 64], ["MERS-CoV pseudovirus", "ORGANISM", 104, 124], ["Spike", "PROTEIN", 59, 64], ["MERS-CoV pseudovirus", "SPECIES", 104, 124], ["picomolar affinity", "TREATMENT", 70, 88], ["neutralize MERS", "TREATMENT", 93, 108], ["CoV pseudovirus", "TREATMENT", 109, 124], ["a half maximal inhibitory concentration (IC", "TREATMENT", 128, 171]]], ["Additionally, some have demonstrated protective efficacy in pre-and post-exposure prophylaxis animal models [44, 45] .", [["protective", "OBSERVATION_MODIFIER", 37, 47], ["efficacy", "OBSERVATION_MODIFIER", 48, 56]]], ["The successes thus far in isolating potent and protective mAbs may prove useful for therapeutic development where the target population is well defined.", [["mAbs", "PROTEIN", 58, 62], ["protective mAbs", "TREATMENT", 47, 62]]], ["It may prove more challenging to advancing these products to licensure and fullscale production at affordable costs for the purpose of prophylaxis in as of yet undefined populations.Target populations for vaccinationThe vaguely defined epidemiology of MERS-CoV has complicated the design and implementation of appropriate public health countermeasures.", [["MERS-CoV", "ORGANISM", 252, 260], ["MERS-CoV", "SPECIES", 252, 260], ["advancing these products", "TREATMENT", 33, 57], ["prophylaxis", "TREATMENT", 135, 146], ["vaccination", "TREATMENT", 205, 216]]], ["Most transmission events have occurred either in the setting of household clusters or nosocomial outbreaks [46] [47] [48] [49] [50] [51] .", [["Most transmission events", "PROBLEM", 0, 24], ["nosocomial outbreaks", "PROBLEM", 86, 106]]], ["It is also likely that the virus has been introduced multiple times into human populations from a large zoonotic reservoir, i.e. dromedary camels.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["the virus", "PROBLEM", 23, 32], ["a large zoonotic reservoir", "TREATMENT", 96, 122], ["also likely", "UNCERTAINTY", 6, 17], ["virus", "OBSERVATION", 27, 32], ["large", "OBSERVATION_MODIFIER", 98, 103], ["zoonotic reservoir", "OBSERVATION", 104, 122]]], ["Given the broad distribution and ownership of camels in the Arabian Peninsula where most cases have occurred, a targeted vaccine campaign may prove difficult.", [["a targeted vaccine campaign", "TREATMENT", 110, 137], ["broad", "OBSERVATION_MODIFIER", 10, 15], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["Arabian Peninsula", "ANATOMY", 60, 77]]], ["As the outbreak in the Republic of Korea revealed, patients and workers in the same healthcare facility as an infected patient are at high risk for secondary acquisition.", [["patients", "ORGANISM", 51, 59], ["patient", "ORGANISM", 119, 126], ["patients", "SPECIES", 51, 59], ["patient", "SPECIES", 119, 126], ["secondary acquisition", "TEST", 148, 169], ["infected", "OBSERVATION", 110, 118]]], ["An optimal strategy may be to use vaccines in conjunction with stringent infection control practices in hospitals where MERS-CoV cases are being treated.Target populations for vaccinationThe epidemiologic link of MERS-CoV between bats, camels, and humans presents an opportunity for a veterinary vaccine to interrupt the transmission cycle.", [["infection", "DISEASE", 73, 82], ["MERS-CoV", "ORGANISM", 120, 128], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 213, 221], ["bats", "ORGANISM", 230, 234], ["humans", "ORGANISM", 248, 254], ["humans", "SPECIES", 248, 254], ["MERS-CoV", "SPECIES", 120, 128], ["MERS-CoV", "SPECIES", 213, 221], ["humans", "SPECIES", 248, 254], ["vaccines", "TREATMENT", 34, 42], ["stringent infection control practices", "TREATMENT", 63, 100], ["CoV cases", "PROBLEM", 125, 134], ["vaccination", "TREATMENT", 176, 187], ["a veterinary vaccine", "TREATMENT", 283, 303], ["infection", "OBSERVATION", 73, 82]]], ["A successful precedent for this so-called \"OneHealth\" approach toward mitigating human disease with a veterinary vaccine exists in the example of Equivac \u00ae , a Hendra virus vaccine developed solely for horses [52] .", [["human disease", "DISEASE", 81, 94], ["Equivac \u00ae", "CHEMICAL", 146, 155], ["Hendra virus", "DISEASE", 160, 172], ["human", "ORGANISM", 81, 86], ["Equivac \u00ae", "SIMPLE_CHEMICAL", 146, 155], ["Hendra virus", "ORGANISM", 160, 172], ["human", "SPECIES", 81, 86], ["Hendra virus vaccine", "SPECIES", 160, 180], ["human", "SPECIES", 81, 86], ["Hendra virus", "SPECIES", 160, 172], ["mitigating human disease", "PROBLEM", 70, 94], ["a veterinary vaccine", "TREATMENT", 100, 120], ["a Hendra virus vaccine", "TREATMENT", 158, 180]]], ["Although Hendra virus is even more rare than MERS-CoV, it is highly fatal with no treatment other than intensive supportive management.", [["Hendra virus", "DISEASE", 9, 21], ["Hendra virus", "ORGANISM", 9, 21], ["MERS-CoV", "ORGANISM", 45, 53], ["Hendra virus", "SPECIES", 9, 21], ["MERS-CoV", "SPECIES", 45, 53], ["Hendra virus", "PROBLEM", 9, 21], ["treatment", "TREATMENT", 82, 91], ["intensive supportive management", "TREATMENT", 103, 134], ["virus", "OBSERVATION", 16, 21]]], ["In 2012, a protein subunit vaccine was licensed and rolled-out in Australia, where all outbreaks of the virus occurred.", [["a protein subunit vaccine", "TREATMENT", 9, 34], ["the virus", "PROBLEM", 100, 109], ["virus", "OBSERVATION", 104, 109]]], ["Since that time, the incidence in horses has fallen precipitously and no human cases have been detected [53] .", [["horses", "ORGANISM", 34, 40], ["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["horses", "SPECIES", 34, 40], ["human", "SPECIES", 73, 78]]], ["A similar strategy may be applicable to MERS-CoV; however, a veterinary vaccination in this context would be deployed solely for the sake of protecting humans, as the virus causes only mild upper respiratory illness in camels.", [["upper respiratory illness", "DISEASE", 190, 215], ["MERS-CoV", "ORGANISM", 40, 48], ["humans", "ORGANISM", 152, 158], ["humans", "SPECIES", 152, 158], ["MERS-CoV", "SPECIES", 40, 48], ["humans", "SPECIES", 152, 158], ["a veterinary vaccination", "TREATMENT", 59, 83], ["the virus", "PROBLEM", 163, 172], ["mild upper respiratory illness in camels", "PROBLEM", 185, 225], ["mild", "OBSERVATION_MODIFIER", 185, 189], ["upper", "ANATOMY_MODIFIER", 190, 195], ["respiratory", "ANATOMY", 196, 207], ["illness", "OBSERVATION", 208, 215]]], ["Safety and reduction in viral shedding would have to be demonstrated in immunization, challenge and transmission studies of camel or camelid populations, one of which has shown efficacy [54] .Knowledge gaps and ways forwardOne of the primary challenges to developing countermeasures to MERS-CoV is the lack of an appropriate animal model that recapitulates the natural history of human disease.", [["camel", "ORGANISM", 124, 129], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 286, 294], ["human", "ORGANISM", 380, 385], ["human", "SPECIES", 380, 385], ["camel", "SPECIES", 124, 129], ["MERS-CoV", "SPECIES", 286, 294], ["human", "SPECIES", 380, 385], ["reduction", "TREATMENT", 11, 20], ["viral shedding", "PROBLEM", 24, 38], ["immunization", "TREATMENT", 72, 84], ["transmission studies", "TEST", 100, 120], ["human disease", "PROBLEM", 380, 393], ["human disease", "OBSERVATION", 380, 393]]], ["Much of the difficulty originates from the absence of the virus's cognate DPP4 receptor.", [["DPP4 receptor", "GENE_OR_GENE_PRODUCT", 74, 87], ["DPP4 receptor", "PROTEIN", 74, 87]]], ["One group approached this problem by successfully transducing mice with an adenoviral vector expressing human DPP4 [55] .", [["mice", "ORGANISM", 62, 66], ["adenoviral", "ORGANISM", 75, 85], ["human", "ORGANISM", 104, 109], ["DPP4", "GENE_OR_GENE_PRODUCT", 110, 114], ["human DPP4", "PROTEIN", 104, 114], ["mice", "SPECIES", 62, 66], ["human", "SPECIES", 104, 109], ["mice", "SPECIES", 62, 66], ["adenoviral", "SPECIES", 75, 85], ["human", "SPECIES", 104, 109], ["an adenoviral vector", "TREATMENT", 72, 92]]], ["Although more relevant than a standard murine model, transient transduction of the desired protein may result in inconsistent tissue expression of adenovirus antigens.", [["tissue", "ANATOMY", 126, 132], ["murine", "ORGANISM", 39, 45], ["tissue", "TISSUE", 126, 132], ["adenovirus", "ORGANISM", 147, 157], ["adenovirus antigens", "PROTEIN", 147, 166], ["murine", "SPECIES", 39, 45], ["the desired protein", "PROBLEM", 79, 98], ["inconsistent tissue expression of adenovirus antigens", "PROBLEM", 113, 166], ["inconsistent tissue", "OBSERVATION_MODIFIER", 113, 132], ["adenovirus", "OBSERVATION", 147, 157]]], ["Agrawal et al. made an important advance with the development of a transgenic mouse model that demonstrated productive, disseminated MERS-CoV infection [56] .", [["MERS-CoV infection", "DISEASE", 133, 151], ["mouse", "ORGANISM", 78, 83], ["MERS-CoV", "ORGANISM", 133, 141], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 78, 83], ["MERS-CoV", "SPECIES", 133, 141], ["a transgenic mouse model", "TREATMENT", 65, 89], ["productive, disseminated MERS", "PROBLEM", 108, 137], ["CoV infection", "PROBLEM", 138, 151], ["productive", "OBSERVATION_MODIFIER", 108, 118], ["disseminated", "OBSERVATION_MODIFIER", 120, 132]]], ["Although rhesus macaques do not manifest full clinical disease, they develop a transient lower respiratory infection that can be quantified and evaluated by computed tomography.", [["respiratory", "ANATOMY", 95, 106], ["respiratory infection", "DISEASE", 95, 116], ["rhesus", "ORGANISM", 9, 15], ["macaques", "ORGANISM", 16, 24], ["rhesus macaques", "SPECIES", 9, 24], ["rhesus macaques", "SPECIES", 9, 24], ["full clinical disease", "PROBLEM", 41, 62], ["a transient lower respiratory infection", "PROBLEM", 77, 116], ["computed tomography", "TEST", 157, 176], ["transient", "OBSERVATION_MODIFIER", 79, 88], ["lower", "ANATOMY_MODIFIER", 89, 94], ["respiratory", "ANATOMY", 95, 106], ["infection", "OBSERVATION", 107, 116]]], ["Investigators at the NIH Rocky Mountain Laboratories (RML) and Integrated Research Facility (IRF) have also independently been developing potentially lethal marmoset models that could be used for the evaluation of vaccines, mAbs and therapeutics [57] .Knowledge gaps and ways forwardAs MERS-CoV vaccines-both active and passive-are developed and tested, not only will more relevant animal models be required, but there will also be a need for a more detailed understanding of the epidemiology, immunology, and pathogenesis of the virus.", [["marmoset", "ORGANISM", 157, 165], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 286, 294], ["mAbs", "PROTEIN", 224, 228], ["marmoset", "SPECIES", 157, 165], ["lethal marmoset models", "TREATMENT", 150, 172], ["the evaluation", "TEST", 196, 210], ["vaccines", "TREATMENT", 214, 222], ["CoV vaccines", "TREATMENT", 291, 303], ["the virus", "PROBLEM", 526, 535]]], ["In the aftermath of the West African Ebola virus epidemic and in the face of the current Zika virus outbreak, the global health community has coalesced around the realization that a multi-faceted plan is required to quickly and efficiently respond to global public health emergencies.", [["Ebola virus", "DISEASE", 37, 48], ["Zika virus", "DISEASE", 89, 99], ["Ebola virus", "ORGANISM", 37, 48], ["Zika virus", "ORGANISM", 89, 99], ["Ebola virus", "SPECIES", 37, 48], ["African Ebola virus", "SPECIES", 29, 48], ["Zika virus", "SPECIES", 89, 99], ["Zika virus", "OBSERVATION", 89, 99]]], ["The World Health Organization is currently developing a blueprint by which that preparation and response can follow, with MERS-CoV highlighted as a case study.", [["MERS-CoV", "SPECIES", 122, 130], ["a case study", "TEST", 146, 158]]], ["Although MERS-CoV still causes relatively few cases in a limited geographic distribution, its high case fatality and sudden outbreak in in Korea have proven it to be a pathogen of public health concern.", [["MERS-CoV", "ORGANISM", 9, 17], ["MERS-CoV", "SPECIES", 9, 17], ["sudden outbreak", "PROBLEM", 117, 132]]], ["The concentration of the epidemic to Saudi Arabia also raises the specter of international spread every year during Hajj, one of the largest mass gathering events in the world.", [["concentration", "OBSERVATION_MODIFIER", 4, 17], ["largest", "OBSERVATION_MODIFIER", 133, 140], ["mass", "OBSERVATION", 141, 145]]], ["Ultimately, the development of a safe and effective vaccine for MERS-CoV may not yield its greatest benefit for the current epidemic but for the knowledge gained in creating a platform for combating coronaviruses as a whole.Conflict of interestThe opinions expressed herein are those of the authors and should not be construed as official or representing the views of the US Department of Defense or the Department of the Army.", [["coronaviruses", "DISEASE", 199, 212], ["MERS-CoV", "ORGANISM", 64, 72], ["coronaviruses", "ORGANISM", 199, 212], ["MERS-CoV", "SPECIES", 64, 72], ["a safe and effective vaccine", "TREATMENT", 31, 59], ["coronaviruses", "PROBLEM", 199, 212]]]], "PMC7261809": [["General Concept ::: IntroductionIt has been shown that different pro-inflammatory cytokines such as interleukin\ufeff-1\u03b2 (IL-1\u03b2), IL-6, and tumor necrosis factor\ufeff-\u03b1 (TNF-\u03b1) are involved in both term and preterm labor.", [["necrosis", "DISEASE", 141, 149], ["preterm labor", "DISEASE", 198, 211], ["interleukin\ufeff-1\u03b2", "GENE_OR_GENE_PRODUCT", 100, 115], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["tumor necrosis factor\ufeff-\u03b1", "GENE_OR_GENE_PRODUCT", 135, 159], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 161, 166], ["pro-inflammatory cytokines", "PROTEIN", 65, 91], ["interleukin\ufeff-1\u03b2 (IL-1\u03b2", "PROTEIN", 100, 122], ["IL-6", "PROTEIN", 125, 129], ["tumor necrosis factor\ufeff-\u03b1", "PROTEIN", 135, 159], ["TNF-\u03b1", "PROTEIN", 161, 166], ["different pro-inflammatory cytokines", "PROBLEM", 55, 91], ["interleukin\ufeff", "TEST", 100, 112], ["IL", "TEST", 117, 119], ["IL", "TEST", 125, 127], ["tumor necrosis factor\ufeff", "PROBLEM", 135, 157], ["preterm labor", "PROBLEM", 198, 211], ["tumor necrosis", "OBSERVATION", 135, 149], ["preterm labor", "OBSERVATION", 198, 211]]], ["The mentioned cytokines trigger the production of uterine activation proteins and chemokines, and therefore cause preterm parturition.24,25 As would be discussed, using some antibiotics in the absence of bacterial infection increases release of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-\u03b1, all being capable of inducing preterm parturition through different pathways.", [["uterine", "ANATOMY", 50, 57], ["preterm parturition", "DISEASE", 114, 133], ["infection", "DISEASE", 214, 223], ["uterine activation proteins", "GENE_OR_GENE_PRODUCT", 50, 77], ["IL-1", "GENE_OR_GENE_PRODUCT", 280, 284], ["IL-6", "GENE_OR_GENE_PRODUCT", 286, 290], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 296, 301], ["cytokines", "PROTEIN", 14, 23], ["uterine activation proteins", "PROTEIN", 50, 77], ["chemokines", "PROTEIN", 82, 92], ["pro-inflammatory cytokines", "PROTEIN", 245, 271], ["IL-1, IL-6", "PROTEIN", 280, 290], ["TNF", "PROTEIN", 296, 299], ["The mentioned cytokines", "TREATMENT", 0, 23], ["uterine activation proteins", "TREATMENT", 50, 77], ["chemokines", "TREATMENT", 82, 92], ["preterm parturition", "PROBLEM", 114, 133], ["some antibiotics", "TREATMENT", 169, 185], ["bacterial infection", "PROBLEM", 204, 223], ["pro-inflammatory cytokines", "TREATMENT", 245, 271], ["IL", "TEST", 280, 282], ["preterm parturition", "PROBLEM", 333, 352], ["uterine", "ANATOMY", 50, 57], ["bacterial", "OBSERVATION_MODIFIER", 204, 213], ["infection", "OBSERVATION", 214, 223], ["pro-inflammatory cytokines", "OBSERVATION", 245, 271]]], ["Moreover, the cytokine release could be amplified by antibiotic-induced endotoxemia through activation of Toll-like receptors (TLRs).", [["endotoxemia", "DISEASE", 72, 83], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 106, 125], ["TLRs", "GENE_OR_GENE_PRODUCT", 127, 131], ["cytokine", "PROTEIN", 14, 22], ["Toll-like receptors", "PROTEIN", 106, 125], ["TLRs", "PROTEIN", 127, 131], ["the cytokine release", "TREATMENT", 10, 30], ["antibiotic", "TREATMENT", 53, 63]]], ["Thus, consumption of non-indicated antibiotics for non-infected pregnant women, especially those more prone to preterm parturition, may increase the risk of preterm parturition.Interleukin-1 ::: Pro-Inflammatory Cytokines and Preterm Labor ::: IntroductionIL-1\u03b2 is one of the most important members of the IL-1 family26 with affinity to its receptors; IL-1R1 and IL-1R2.26,27 As a major mediator of inflammation, IL-1\u03b2 is involved in different disorders such as infections, autoimmune, and degenerative diseases which affect a wide variety of organs and cells.", [["organs", "ANATOMY", 543, 549], ["cells", "ANATOMY", 554, 559], ["preterm parturition", "DISEASE", 111, 130], ["preterm parturition", "DISEASE", 157, 176], ["inflammation", "DISEASE", 399, 411], ["infections", "DISEASE", 462, 472], ["degenerative diseases", "DISEASE", 490, 511], ["women", "ORGANISM", 73, 78], ["Interleukin-1", "GENE_OR_GENE_PRODUCT", 177, 190], ["IntroductionIL-1\u03b2", "GENE_OR_GENE_PRODUCT", 244, 261], ["IL-1 family26", "GENE_OR_GENE_PRODUCT", 306, 319], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 352, 358], ["IL-1R2.26,27", "GENE_OR_GENE_PRODUCT", 363, 375], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 413, 418], ["organs", "ORGAN", 543, 549], ["cells", "CELL", 554, 559], ["Interleukin-1", "PROTEIN", 177, 190], ["Pro-Inflammatory Cytokines", "PROTEIN", 195, 221], ["IntroductionIL-1\u03b2", "PROTEIN", 244, 261], ["IL-1 family26", "PROTEIN", 306, 319], ["IL", "PROTEIN", 352, 354], ["1R1", "PROTEIN", 355, 358], ["IL", "PROTEIN", 363, 365], ["IL-1\u03b2", "PROTEIN", 413, 418], ["women", "SPECIES", 73, 78], ["non-indicated antibiotics", "TREATMENT", 21, 46], ["preterm parturition", "PROBLEM", 157, 176], ["Pro-Inflammatory Cytokines", "PROBLEM", 195, 221], ["Preterm Labor", "PROBLEM", 226, 239], ["IntroductionIL", "TREATMENT", 244, 258], ["IL", "TEST", 352, 354], ["inflammation", "PROBLEM", 399, 411], ["different disorders", "PROBLEM", 434, 453], ["infections", "PROBLEM", 462, 472], ["autoimmune", "PROBLEM", 474, 484], ["degenerative diseases", "PROBLEM", 490, 511], ["preterm parturition", "OBSERVATION", 157, 176], ["Pro-Inflammatory Cytokines", "OBSERVATION", 195, 221], ["inflammation", "OBSERVATION", 399, 411], ["infections", "OBSERVATION", 462, 472], ["degenerative", "OBSERVATION_MODIFIER", 490, 502], ["diseases", "OBSERVATION", 503, 511]]], ["IL-1\u03b2 expresses from hematopoietic cells such as macrophages, monocytes, microglia, and dendritic cells.", [["hematopoietic cells", "ANATOMY", 21, 40], ["macrophages", "ANATOMY", 49, 60], ["monocytes", "ANATOMY", 62, 71], ["microglia", "ANATOMY", 73, 82], ["dendritic cells", "ANATOMY", 88, 103], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["hematopoietic cells", "CELL", 21, 40], ["macrophages", "CELL", 49, 60], ["monocytes", "CELL", 62, 71], ["microglia", "CELL", 73, 82], ["dendritic cells", "CELL", 88, 103], ["IL-1\u03b2", "PROTEIN", 0, 5], ["hematopoietic cells", "CELL_TYPE", 21, 40], ["macrophages", "CELL_TYPE", 49, 60], ["monocytes", "CELL_TYPE", 62, 71], ["microglia", "CELL_TYPE", 73, 82], ["dendritic cells", "CELL_TYPE", 88, 103], ["IL", "TREATMENT", 0, 2], ["hematopoietic cells", "PROBLEM", 21, 40], ["macrophages", "PROBLEM", 49, 60], ["monocytes", "TEST", 62, 71], ["microglia", "PROBLEM", 73, 82], ["dendritic cells", "PROBLEM", 88, 103], ["hematopoietic cells", "OBSERVATION", 21, 40], ["macrophages", "ANATOMY", 49, 60], ["monocytes", "ANATOMY", 62, 71], ["microglia", "ANATOMY", 73, 82], ["dendritic cells", "OBSERVATION", 88, 103]]], ["This pro-inflammatory cytokine produces from the mentioned resources through different pathways such as TLR activation and pro-inflammatory cytokine activities (such as TNF-\u03b1 and even IL-1\u03b2 itself).27 IL-1\u03b2 is the first known pro-inflammatory cytokine involved in preterm parturition produced following the release of different other cytokines including TNF-\u03b1, IL-1\u03b1, and IL-1\u03b2 itself.25 The role of IL-1\u03b2 during parturition has been proved by being detected in the myometrium, cervix, and fetal membranes,28 especially in non-infective preterm parturition.29 In an invivo study in mice, it was shown that IL-1\u03b2 administration induces premature contractility of the myometrium.30 Moreover, in-vivo studies have determined that the administration of IL-1\u03b2 could induce preterm labor which, by the way, could be prevented using the antagonist of IL-1 receptor.31,32 Beside term parturition, studies have evaluated the role of IL-1\u03b2 in preterm labor.", [["myometrium", "ANATOMY", 466, 476], ["cervix", "ANATOMY", 478, 484], ["fetal membranes", "ANATOMY", 490, 505], ["myometrium", "ANATOMY", 666, 676], ["preterm parturition", "DISEASE", 537, 556], ["preterm labor", "DISEASE", 768, 781], ["preterm labor", "DISEASE", 933, 946], ["TLR", "GENE_OR_GENE_PRODUCT", 104, 107], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 169, 174], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 184, 189], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 201, 206], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 354, 359], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 361, 366], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 372, 377], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 400, 405], ["myometrium", "MULTI-TISSUE_STRUCTURE", 466, 476], ["cervix", "MULTI-TISSUE_STRUCTURE", 478, 484], ["fetal membranes", "MULTI-TISSUE_STRUCTURE", 490, 505], ["mice", "ORGANISM", 582, 586], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 606, 611], ["myometrium", "MULTI-TISSUE_STRUCTURE", 666, 676], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 749, 754], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 844, 857], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 924, 929], ["pro-inflammatory cytokine", "PROTEIN", 5, 30], ["TLR", "PROTEIN", 104, 107], ["pro-inflammatory cytokine", "PROTEIN", 123, 148], ["TNF", "PROTEIN", 169, 172], ["\u03b1", "PROTEIN", 173, 174], ["IL", "PROTEIN", 184, 186], ["\u03b2", "PROTEIN", 188, 189], ["IL-1\u03b2", "PROTEIN", 201, 206], ["pro-inflammatory cytokine", "PROTEIN", 226, 251], ["cytokines", "PROTEIN", 334, 343], ["TNF", "PROTEIN", 354, 357], ["IL-1\u03b1", "PROTEIN", 361, 366], ["IL-1\u03b2", "PROTEIN", 372, 377], ["IL-1\u03b2", "PROTEIN", 400, 405], ["IL-1\u03b2", "PROTEIN", 606, 611], ["IL-1\u03b2", "PROTEIN", 749, 754], ["IL-1 receptor", "PROTEIN", 844, 857], ["IL-1\u03b2", "PROTEIN", 924, 929], ["mice", "SPECIES", 582, 586], ["mice", "SPECIES", 582, 586], ["TLR activation", "TREATMENT", 104, 118], ["pro-inflammatory cytokine activities", "PROBLEM", 123, 159], ["TNF", "TEST", 169, 172], ["even IL", "TREATMENT", 179, 186], ["preterm parturition", "PROBLEM", 264, 283], ["different other cytokines", "TREATMENT", 318, 343], ["TNF", "TREATMENT", 354, 357], ["IL", "TREATMENT", 361, 363], ["non-infective preterm parturition", "PROBLEM", 523, 556], ["an invivo study", "TEST", 563, 578], ["IL-1\u03b2 administration", "TREATMENT", 606, 626], ["premature contractility of the myometrium", "PROBLEM", 635, 676], ["the administration of IL", "TREATMENT", 727, 751], ["preterm labor", "PROBLEM", 768, 781], ["the antagonist of IL", "TREATMENT", 826, 846], ["Beside term parturition", "PROBLEM", 864, 887], ["preterm labor", "PROBLEM", 933, 946], ["pro-inflammatory cytokine", "OBSERVATION", 123, 148], ["pro-inflammatory cytokine", "OBSERVATION", 226, 251], ["myometrium", "ANATOMY", 466, 476], ["cervix", "ANATOMY", 478, 484], ["fetal membranes", "ANATOMY", 490, 505], ["myometrium", "ANATOMY", 666, 676], ["preterm labor", "OBSERVATION", 933, 946]]], ["According to the data, the IL-1\u03b2 concentration was increased in amniotic fluid (AF)33,34 and plasma35 of women with preterm labor.", [["amniotic fluid", "ANATOMY", 64, 78], ["preterm labor", "DISEASE", 116, 129], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 27, 32], ["amniotic fluid", "ORGANISM_SUBSTANCE", 64, 78], ["women", "ORGANISM", 105, 110], ["IL-1\u03b2", "PROTEIN", 27, 32], ["women", "SPECIES", 105, 110], ["the IL-1\u03b2 concentration", "TREATMENT", 23, 46], ["amniotic fluid", "TEST", 64, 78], ["preterm labor", "PROBLEM", 116, 129], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["amniotic fluid", "OBSERVATION", 64, 78]]], ["Also, systemic administration of IL-1\u03b2 in pregnant rhesus monkeys was also proven to stimulate the uterine contractility as well as significantly increase the production of other pro-inflammatory cytokines such as IL-6 and TNF-\u03b1 along with different prostaglandins (PGs) including PGF2\u03b1 and PGE2.36 PGF2\u03b1, on the other hand, has been introduced as the most potent contractile prostanoid in parturition which acts through its receptor, PGF receptor (PTGFR).37 Furthermore, IL-1\u03b2 is able to activate prostaglandin H synthase 2 (PGHS-2; also known as cyclooxygenase-2 or COX-2) which is responsible for the synthesis of prostaglandins.38\u201340 As it has been shown, IL-1\u03b2 (targeting amnion epithelial cells) is able to increase matrix metalloproteinase\ufeff-9 (MMP-9) expression which leads to degradation of the amniochorionic membrane as well as cervical ripening.41Tumor Necrosis Factor-\u03b1 ::: Pro-Inflammatory Cytokines and Preterm Labor ::: IntroductionTNF-\u03b1 is a pro-inflammatory cytokine belonging to the TNF superfamily which couples to its specific receptors: TNF receptor-1 (TNFR1 or p55) and TNFR2 (p75).", [["uterine", "ANATOMY", 99, 106], ["amnion epithelial cells", "ANATOMY", 677, 700], ["amniochorionic membrane", "ANATOMY", 803, 826], ["cervical", "ANATOMY", 838, 846], ["prostaglandins", "CHEMICAL", 250, 264], ["PGs", "CHEMICAL", 266, 269], ["PGF2", "CHEMICAL", 281, 285], ["PGE2", "CHEMICAL", 291, 295], ["PGF2\u03b1", "CHEMICAL", 299, 304], ["prostaglandin H", "CHEMICAL", 498, 513], ["prostaglandins", "CHEMICAL", 617, 631], ["prostaglandins", "CHEMICAL", 250, 264], ["PGF2\u03b1", "CHEMICAL", 281, 286], ["PGE2", "CHEMICAL", 291, 295], ["PGF2\u03b1", "CHEMICAL", 299, 304], ["prostaglandin H", "CHEMICAL", 498, 513], ["prostaglandins", "CHEMICAL", 617, 631], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 33, 38], ["rhesus", "ORGANISM", 51, 57], ["monkeys", "ORGANISM", 58, 65], ["uterine", "ORGAN", 99, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 214, 218], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 223, 228], ["prostaglandins", "SIMPLE_CHEMICAL", 250, 264], ["PGs", "SIMPLE_CHEMICAL", 266, 269], ["PGF2\u03b1", "SIMPLE_CHEMICAL", 281, 286], ["PGE2.36 PGF2\u03b1", "SIMPLE_CHEMICAL", 291, 304], ["PGF receptor", "GENE_OR_GENE_PRODUCT", 435, 447], ["PTGFR", "GENE_OR_GENE_PRODUCT", 449, 454], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 472, 477], ["prostaglandin H synthase 2", "GENE_OR_GENE_PRODUCT", 498, 524], ["PGHS-2", "GENE_OR_GENE_PRODUCT", 526, 532], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 548, 564], ["COX-2", "GENE_OR_GENE_PRODUCT", 568, 573], ["prostaglandins", "SIMPLE_CHEMICAL", 617, 631], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 660, 665], ["amnion epithelial cells", "CELL", 677, 700], ["matrix metalloproteinase\ufeff-9", "GENE_OR_GENE_PRODUCT", 722, 749], ["MMP-9", "GENE_OR_GENE_PRODUCT", 751, 756], ["amniochorionic membrane", "CELLULAR_COMPONENT", 803, 826], ["cervical", "ORGAN", 838, 846], ["IntroductionTNF-\u03b1", "GENE_OR_GENE_PRODUCT", 935, 952], ["TNF", "GENE_OR_GENE_PRODUCT", 1001, 1004], ["TNF receptor-1", "GENE_OR_GENE_PRODUCT", 1058, 1072], ["TNFR1", "GENE_OR_GENE_PRODUCT", 1074, 1079], ["p55", "GENE_OR_GENE_PRODUCT", 1083, 1086], ["TNFR2", "GENE_OR_GENE_PRODUCT", 1092, 1097], ["p75", "GENE_OR_GENE_PRODUCT", 1099, 1102], ["IL-1\u03b2", "PROTEIN", 33, 38], ["pro-inflammatory cytokines", "PROTEIN", 179, 205], ["IL-6", "PROTEIN", 214, 218], ["TNF", "PROTEIN", 223, 226], ["PGF receptor", "PROTEIN", 435, 447], ["PTGFR", "PROTEIN", 449, 454], ["IL-1\u03b2", "PROTEIN", 472, 477], ["prostaglandin H synthase 2", "PROTEIN", 498, 524], ["PGHS-2", "PROTEIN", 526, 532], ["cyclooxygenase", "PROTEIN", 548, 562], ["COX", "PROTEIN", 568, 571], ["IL-1\u03b2", "PROTEIN", 660, 665], ["amnion epithelial cells", "CELL_TYPE", 677, 700], ["matrix metalloproteinase\ufeff-9 (MMP-9", "PROTEIN", 722, 756], ["Pro-Inflammatory Cytokines", "PROTEIN", 886, 912], ["IntroductionTNF-\u03b1", "PROTEIN", 935, 952], ["pro-inflammatory cytokine", "PROTEIN", 958, 983], ["TNF superfamily", "PROTEIN", 1001, 1016], ["TNF receptor-1", "PROTEIN", 1058, 1072], ["TNFR1", "PROTEIN", 1074, 1079], ["p55", "PROTEIN", 1083, 1086], ["TNFR2", "PROTEIN", 1092, 1097], ["p75", "PROTEIN", 1099, 1102], ["rhesus monkeys", "SPECIES", 51, 65], ["rhesus monkeys", "SPECIES", 51, 65], ["systemic administration of IL", "TREATMENT", 6, 35], ["other pro-inflammatory cytokines", "PROBLEM", 173, 205], ["IL", "TEST", 214, 216], ["TNF", "TEST", 223, 226], ["different prostaglandins (PGs", "TREATMENT", 240, 269], ["PGF2", "TREATMENT", 281, 285], ["PGE2", "TREATMENT", 291, 295], ["prostaglandin H synthase", "TEST", 498, 522], ["PGHS", "TEST", 526, 530], ["cyclooxygenase", "TEST", 548, 562], ["COX", "TEST", 568, 571], ["the synthesis of prostaglandins", "TREATMENT", 600, 631], ["IL", "TEST", 660, 662], ["targeting amnion epithelial cells", "TREATMENT", 667, 700], ["matrix metalloproteinase\ufeff", "TEST", 722, 747], ["MMP", "TEST", 751, 754], ["degradation of the amniochorionic membrane", "PROBLEM", 784, 826], ["cervical ripening", "TREATMENT", 838, 855], ["Pro-Inflammatory Cytokines", "PROBLEM", 886, 912], ["Preterm Labor", "PROBLEM", 917, 930], ["a pro-inflammatory cytokine", "TREATMENT", 956, 983], ["the TNF superfamily", "TREATMENT", 997, 1016], ["TNF receptor", "TEST", 1058, 1070], ["TNFR2", "TEST", 1092, 1097], ["uterine", "ANATOMY", 99, 106], ["amnion epithelial", "ANATOMY", 677, 694], ["amniochorionic membrane", "ANATOMY", 803, 826], ["cervical", "ANATOMY", 838, 846], ["Necrosis", "OBSERVATION", 864, 872]]], ["This cytokine has a wide range of activity in different inflammatory and non-inflammatory situations such as cachexia, septic shock, inflammatory disorders, and autoimmune diseases. \ufeffThe same as IL-1\u03b2, TNF-\u03b1 is expressed by different cells such as macrophages, monocytes, dendritic cells, B and T cells, and activated natural killer cells.42,43 Similar to IL-1\u03b2, TNF-\u03b1 is another pro-inflammatory cytokine elevated in AF of women with preterm parturition.33 This cytokine is also involved in the regulation and stimulation of PG synthesis during preterm parturition, such as COX-2.", [["cachexia", "ANATOMY", 109, 117], ["cells", "ANATOMY", 234, 239], ["macrophages", "ANATOMY", 248, 259], ["monocytes", "ANATOMY", 261, 270], ["dendritic cells", "ANATOMY", 272, 287], ["B", "ANATOMY", 289, 290], ["T cells", "ANATOMY", 295, 302], ["natural killer cells", "ANATOMY", 318, 338], ["cachexia", "DISEASE", 109, 117], ["septic shock", "DISEASE", 119, 131], ["inflammatory disorders", "DISEASE", 133, 155], ["autoimmune diseases", "DISEASE", 161, 180], ["AF", "DISEASE", 418, 420], ["preterm parturition", "DISEASE", 435, 454], ["PG", "CHEMICAL", 526, 528], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 195, 200], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 202, 207], ["cells", "CELL", 234, 239], ["macrophages", "CELL", 248, 259], ["monocytes", "CELL", 261, 270], ["dendritic cells", "CELL", 272, 287], ["B", "CELL", 289, 290], ["T cells", "CELL", 295, 302], ["natural killer cells", "CELL", 318, 338], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 356, 361], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 363, 368], ["women", "ORGANISM", 424, 429], ["PG", "SIMPLE_CHEMICAL", 526, 528], ["COX-2", "GENE_OR_GENE_PRODUCT", 575, 580], ["cytokine", "PROTEIN", 5, 13], ["IL-1\u03b2", "PROTEIN", 195, 200], ["TNF-\u03b1", "PROTEIN", 202, 207], ["macrophages", "CELL_TYPE", 248, 259], ["monocytes", "CELL_TYPE", 261, 270], ["dendritic cells", "CELL_TYPE", 272, 287], ["B and T cells", "CELL_TYPE", 289, 302], ["activated natural killer cells", "CELL_TYPE", 308, 338], ["IL", "PROTEIN", 356, 358], ["TNF-\u03b1", "PROTEIN", 363, 368], ["pro-inflammatory cytokine", "PROTEIN", 380, 405], ["cytokine", "PROTEIN", 463, 471], ["COX", "PROTEIN", 575, 578], ["women", "SPECIES", 424, 429], ["different inflammatory and non-inflammatory situations", "PROBLEM", 46, 100], ["cachexia", "PROBLEM", 109, 117], ["septic shock", "PROBLEM", 119, 131], ["inflammatory disorders", "PROBLEM", 133, 155], ["autoimmune diseases", "PROBLEM", 161, 180], ["IL", "TEST", 195, 197], ["TNF", "TEST", 202, 205], ["macrophages", "TEST", 248, 259], ["monocytes", "TEST", 261, 270], ["dendritic cells", "PROBLEM", 272, 287], ["B and T cells", "PROBLEM", 289, 302], ["activated natural killer cells", "PROBLEM", 308, 338], ["IL", "TEST", 356, 358], ["TNF", "TEST", 363, 366], ["another pro-inflammatory cytokine elevated", "PROBLEM", 372, 414], ["preterm parturition", "PROBLEM", 435, 454], ["PG synthesis", "TREATMENT", 526, 538], ["preterm parturition", "PROBLEM", 546, 565], ["wide range", "OBSERVATION_MODIFIER", 20, 30], ["activity", "OBSERVATION_MODIFIER", 34, 42], ["different", "OBSERVATION_MODIFIER", 46, 55], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68], ["non-inflammatory", "OBSERVATION_MODIFIER", 73, 89], ["cachexia", "OBSERVATION", 109, 117], ["septic shock", "OBSERVATION", 119, 131], ["inflammatory", "OBSERVATION_MODIFIER", 133, 145], ["autoimmune diseases", "OBSERVATION", 161, 180], ["macrophages", "ANATOMY", 248, 259], ["dendritic cells", "OBSERVATION", 272, 287], ["natural killer cells", "OBSERVATION", 318, 338], ["preterm parturition", "OBSERVATION", 435, 454]]], ["Also, TNF-\u03b1 and IL-1\u03b2 could decrease levels of chorionic prostaglandin 15-hydroxy dehydrogenase (PGDH) in cultured chorion and placental trophoblast cells.", [["chorion", "ANATOMY", 115, 122], ["placental trophoblast cells", "ANATOMY", 127, 154], ["prostaglandin 15-hydroxy", "CHEMICAL", 57, 81], ["prostaglandin 15-hydroxy", "CHEMICAL", 57, 81], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 6, 11], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 16, 21], ["chorionic prostaglandin 15-hydroxy dehydrogenase", "GENE_OR_GENE_PRODUCT", 47, 95], ["PGDH", "GENE_OR_GENE_PRODUCT", 97, 101], ["chorion", "CELL", 115, 122], ["placental trophoblast cells", "CELL", 127, 154], ["TNF", "PROTEIN", 6, 9], ["IL-1\u03b2", "PROTEIN", 16, 21], ["chorionic prostaglandin 15-hydroxy dehydrogenase", "PROTEIN", 47, 95], ["PGDH", "PROTEIN", 97, 101], ["placental trophoblast cells", "CELL_TYPE", 127, 154], ["TNF", "TEST", 6, 9], ["IL", "TEST", 16, 18], ["chorionic prostaglandin", "PROBLEM", 47, 70], ["hydroxy dehydrogenase (PGDH)", "PROBLEM", 74, 102], ["cultured chorion and placental trophoblast cells", "PROBLEM", 106, 154], ["placental trophoblast cells", "OBSERVATION", 127, 154]]], ["PGDH could inactivate the PGs through catalyzing them to natural substances.24 Moreover, it has been shown that topical administration of TNF-\u03b1 could stimulate cervical ripening.25 According to the data, knockout mice lacking receptors for both IL-1\u03b2 and TNF-\u03b1 had a significantly lower rate of preterm labor following intrauterine inoculation of killed Escherichia coli (E.\ufeffcoli) in comparison to the wild types.", [["cervical", "ANATOMY", 160, 168], ["intrauterine", "ANATOMY", 319, 331], ["PGDH", "CHEMICAL", 0, 4], ["TNF-\u03b1", "CHEMICAL", 138, 143], ["preterm labor", "DISEASE", 295, 308], ["PGDH", "CHEMICAL", 0, 4], ["PGDH", "SIMPLE_CHEMICAL", 0, 4], ["PGs", "SIMPLE_CHEMICAL", 26, 29], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 138, 143], ["cervical", "ORGAN", 160, 168], ["mice", "ORGANISM", 213, 217], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 245, 250], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 255, 260], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 319, 331], ["Escherichia coli", "ORGANISM", 354, 370], ["E.\ufeffcoli", "ORGANISM", 372, 379], ["TNF", "PROTEIN", 138, 141], ["IL-1\u03b2", "PROTEIN", 245, 250], ["TNF", "PROTEIN", 255, 258], ["mice", "SPECIES", 213, 217], ["Escherichia coli", "SPECIES", 354, 370], ["mice", "SPECIES", 213, 217], ["Escherichia coli", "SPECIES", 354, 370], ["PGDH", "PROBLEM", 0, 4], ["topical administration of TNF", "TREATMENT", 112, 141], ["cervical ripening", "PROBLEM", 160, 177], ["TNF", "PROBLEM", 255, 258], ["preterm labor", "PROBLEM", 295, 308], ["intrauterine inoculation", "PROBLEM", 319, 343], ["killed Escherichia coli (E.\ufeffcoli", "PROBLEM", 347, 379], ["cervical", "ANATOMY", 160, 168], ["Escherichia coli", "OBSERVATION", 354, 370]]], ["This result was accompanied by lower levels of COX-2 in the myometrial tissue in the knockout group in comparison to the controls.44 As it has been studied, inhibiting COX-2 in mice is associated with the prevention of inflammation-induced preterm parturition.45 Furthermore, in a study on rhesus monkeys, the release of bacterial-induced TNF-\u03b1 and IL-1\u03b2 led to more uterine contractility.46 Like IL-1\u03b2, TNF-\u03b1 could increase MMP-9 activity, expression, and activity and secretion in trophoblast, chorion cells, and amnion cells, respectively.41 Moreover, it has been shown that TNF-\u03b1 could induce mRNA expression of MMP-1, MMP-3, and MMP-9 in cervical smooth muscle cells after 24\u201348 h of administration.", [["myometrial tissue", "ANATOMY", 60, 77], ["uterine", "ANATOMY", 367, 374], ["trophoblast", "ANATOMY", 483, 494], ["chorion cells", "ANATOMY", 496, 509], ["amnion cells", "ANATOMY", 515, 527], ["cervical smooth muscle cells", "ANATOMY", 643, 671], ["inflammation", "DISEASE", 219, 231], ["preterm parturition", "DISEASE", 240, 259], ["COX-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["myometrial tissue", "TISSUE", 60, 77], ["COX-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["mice", "ORGANISM", 177, 181], ["rhesus", "ORGANISM", 290, 296], ["monkeys", "ORGANISM", 297, 304], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 339, 344], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 349, 354], ["uterine", "ORGAN", 367, 374], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 397, 402], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 404, 409], ["MMP-9", "GENE_OR_GENE_PRODUCT", 425, 430], ["trophoblast", "CELL", 483, 494], ["chorion cells", "CELL", 496, 509], ["amnion cells", "CELL", 515, 527], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 578, 583], ["MMP-1", "GENE_OR_GENE_PRODUCT", 616, 621], ["MMP-3", "GENE_OR_GENE_PRODUCT", 623, 628], ["MMP-9", "GENE_OR_GENE_PRODUCT", 634, 639], ["cervical smooth muscle cells", "CELL", 643, 671], ["COX-2", "PROTEIN", 47, 52], ["COX-2", "PROTEIN", 168, 173], ["TNF", "PROTEIN", 339, 342], ["IL-1\u03b2", "PROTEIN", 349, 354], ["IL", "PROTEIN", 397, 399], ["TNF", "PROTEIN", 404, 407], ["MMP", "PROTEIN", 425, 428], ["trophoblast, chorion cells", "CELL_TYPE", 483, 509], ["amnion cells", "CELL_TYPE", 515, 527], ["TNF", "PROTEIN", 578, 581], ["MMP-1", "PROTEIN", 616, 621], ["MMP-3", "PROTEIN", 623, 628], ["MMP-9", "PROTEIN", 634, 639], ["cervical smooth muscle cells", "CELL_TYPE", 643, 671], ["mice", "SPECIES", 177, 181], ["rhesus monkeys", "SPECIES", 290, 304], ["mice", "SPECIES", 177, 181], ["rhesus monkeys", "SPECIES", 290, 304], ["lower levels of COX", "PROBLEM", 31, 50], ["inflammation", "PROBLEM", 219, 231], ["preterm parturition", "PROBLEM", 240, 259], ["a study", "TEST", 279, 286], ["bacterial-induced TNF", "TREATMENT", 321, 342], ["IL", "TREATMENT", 349, 351], ["TNF", "TEST", 404, 407], ["MMP", "TEST", 425, 428], ["secretion in trophoblast, chorion cells", "TEST", 470, 509], ["TNF", "TEST", 578, 581], ["MMP", "TEST", 616, 619], ["MMP", "TEST", 623, 626], ["MMP", "TEST", 634, 637], ["COX", "OBSERVATION", 47, 50], ["myometrial tissue", "ANATOMY", 60, 77], ["inflammation", "OBSERVATION", 219, 231], ["preterm parturition", "OBSERVATION", 240, 259], ["uterine contractility", "ANATOMY", 367, 388], ["trophoblast", "ANATOMY", 483, 494], ["chorion cells", "ANATOMY", 496, 509], ["amnion cells", "ANATOMY", 515, 527], ["cervical", "ANATOMY", 643, 651], ["smooth muscle", "ANATOMY", 652, 665]]], ["This pattern is also seen in treatment with IL-1\u03b2.47Interleukin-6 ::: Pro-Inflammatory Cytokines and Preterm Labor ::: IntroductionThe IL-6 cytokine family consists of different cytokines such as IL-6, IL-11, IL-27, and leukemia inhibitory factor.48 IL-6, which is the most important pro-inflammatory cytokine in this family, plays a critical role in the inflammation cascade.", [["inflammation", "DISEASE", 355, 367], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 52, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 135, 139], ["IL-6", "GENE_OR_GENE_PRODUCT", 196, 200], ["IL-11", "GENE_OR_GENE_PRODUCT", 202, 207], ["IL-27", "GENE_OR_GENE_PRODUCT", 209, 214], ["leukemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 220, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 250, 254], ["IL-1\u03b2", "PROTEIN", 44, 49], ["Interleukin-6", "PROTEIN", 52, 65], ["Pro-Inflammatory Cytokines", "PROTEIN", 70, 96], ["IL-6 cytokine family", "PROTEIN", 135, 155], ["cytokines", "PROTEIN", 178, 187], ["IL-27", "PROTEIN", 209, 214], ["leukemia inhibitory factor", "PROTEIN", 220, 246], ["IL-6", "PROTEIN", 250, 254], ["pro-inflammatory cytokine", "PROTEIN", 284, 309], ["treatment with IL", "TREATMENT", 29, 46], ["Pro-Inflammatory Cytokines", "PROBLEM", 70, 96], ["Preterm Labor", "PROBLEM", 101, 114], ["The IL", "TREATMENT", 131, 137], ["different cytokines", "TREATMENT", 168, 187], ["IL", "TEST", 196, 198], ["IL", "TEST", 202, 204], ["IL", "TEST", 209, 211], ["leukemia inhibitory factor", "PROBLEM", 220, 246], ["the inflammation cascade", "TREATMENT", 351, 375], ["Pro-Inflammatory Cytokines", "OBSERVATION", 70, 96], ["leukemia inhibitory", "OBSERVATION", 220, 239], ["most important", "OBSERVATION_MODIFIER", 269, 283], ["pro-inflammatory cytokine", "OBSERVATION", 284, 309], ["inflammation", "OBSERVATION", 355, 367]]], ["This pro-inflammatory cytokine is involved in the pathogenesis of different autoimmune and inflammation\ufeff-dependent diseases and mostly acts through binding to its receptor, IL-6R.49 This pro-inflammatory cytokine has shown to be increased in preterm parturition even in asymptomatic women.50,51 Pregnant IL-6 knocked\ufeff-out mice have been demonstrated to have a delay in delivery compared to the wild types.", [["preterm parturition", "DISEASE", 242, 261], ["IL-6R.49", "GENE_OR_GENE_PRODUCT", 173, 181], ["women", "ORGANISM", 283, 288], ["IL-6", "GENE_OR_GENE_PRODUCT", 304, 308], ["mice", "ORGANISM", 322, 326], ["pro-inflammatory cytokine", "PROTEIN", 5, 30], ["IL", "PROTEIN", 173, 175], ["pro-inflammatory cytokine", "PROTEIN", 187, 212], ["women", "SPECIES", 283, 288], ["mice", "SPECIES", 322, 326], ["mice", "SPECIES", 322, 326], ["different autoimmune and inflammation\ufeff", "PROBLEM", 66, 104], ["dependent diseases", "PROBLEM", 105, 123], ["preterm parturition", "PROBLEM", 242, 261], ["Pregnant IL", "TEST", 295, 306], ["a delay in delivery", "PROBLEM", 358, 377], ["different", "OBSERVATION_MODIFIER", 66, 75], ["autoimmune", "OBSERVATION", 76, 86], ["dependent", "OBSERVATION_MODIFIER", 105, 114], ["diseases", "OBSERVATION", 115, 123], ["shown to be", "UNCERTAINTY", 217, 228], ["increased", "OBSERVATION_MODIFIER", 229, 238], ["preterm parturition", "OBSERVATION", 242, 261]]], ["This delay is proved to be accelerated through the administration of exogenous IL-6.", [["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["exogenous IL-6", "PROTEIN", 69, 83], ["exogenous IL", "TREATMENT", 69, 81]]], ["Moreover, after lipopolysaccharide (LPS) treatment, the IL-6 knocked\ufeff-out mice group showed lower prevalence of preterm parturition in comparison to the wild types.", [["lipopolysaccharide", "CHEMICAL", 16, 34], ["LPS", "CHEMICAL", 36, 39], ["preterm parturition", "DISEASE", 112, 131], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 16, 34], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["mice", "ORGANISM", 74, 78], ["IL-6", "PROTEIN", 56, 60], ["mice", "SPECIES", 74, 78], ["lipopolysaccharide (LPS) treatment", "TREATMENT", 16, 50], ["the IL", "TREATMENT", 52, 58], ["preterm parturition", "PROBLEM", 112, 131], ["lower prevalence", "OBSERVATION_MODIFIER", 92, 108], ["preterm parturition", "OBSERVATION", 112, 131]]], ["In the IL-6 knocked\ufeff-out mice, oxytocin receptor(Oxtr) mRNA expression was 73% lower than the wild type \ufeffon day 19.5 post coitus, which reached acomparable level with wild type with a 1-day delay.", [["oxytocin", "CHEMICAL", 31, 39], ["oxytocin", "CHEMICAL", 31, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 7, 11], ["mice", "ORGANISM", 25, 29], ["oxytocin receptor", "GENE_OR_GENE_PRODUCT", 31, 48], ["Oxtr", "GENE_OR_GENE_PRODUCT", 49, 53], ["oxytocin receptor(Oxtr) mRNA", "RNA", 31, 59], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["oxytocin receptor", "TREATMENT", 31, 48], ["mRNA expression", "TEST", 55, 70]]], ["Also, in the wild type group during day 19.5 post coitum to the labor time, PTGFR and prostaglandin-endoperoxide synthase 2(PTGS2) showed a 3.9 and 2.6 (respectively) fold increase.", [["prostaglandin-endoperoxide", "CHEMICAL", 86, 112], ["prostaglandin-endoperoxide", "CHEMICAL", 86, 112], ["PTGFR", "GENE_OR_GENE_PRODUCT", 76, 81], ["prostaglandin-endoperoxide synthase 2", "GENE_OR_GENE_PRODUCT", 86, 123], ["PTGS2", "GENE_OR_GENE_PRODUCT", 124, 129], ["PTGFR", "PROTEIN", 76, 81], ["prostaglandin-endoperoxide synthase 2", "PROTEIN", 86, 123], ["PTGS2", "PROTEIN", 124, 129], ["PTGFR and prostaglandin-endoperoxide synthase", "TEST", 76, 121], ["PTGS2", "TEST", 124, 129]]], ["On the other hand, the knocked\ufeff-out mice showed a similar increase in the expression of PTGFR and PTGS2 from day 20.5 post coitum.52 More interestingly, the amount of PTGFR, as the receptor of most important uterine contractile prostanoid (PGF-2\u03b1), was shown to increase in both term and preterm parturition.24 Also, it has been demonstrated that IL-6 is able to induce PGE2 production in amnion and decidual cells.53 According to the data, IL-6 is also responsible for an increase in MMP-9 and MMP-2 activity through targeting trophoblasts.41 Furthermore, data have cleared that IL-1\u03b2 and IL-6 are able to induce oxytocin secretion in human uterine smooth muscle cells.54 Considering the affirmed role of oxytocin and PGs in term and preterm parturition, it seems that they could be involved in the possible hypothesized molecular pathways caused by IL-6 and IL-1\u03b2 in preterm parturition.55 Furthermore, IL-1\u03b2 seems to be capable of increasing PGE2 production from human amnion cells.56 Some of the most important roles of pro-inflammatory cytokines in term/preterm labor have been provided in Table 1.", [["uterine", "ANATOMY", 208, 215], ["amnion", "ANATOMY", 389, 395], ["decidual cells", "ANATOMY", 400, 414], ["trophoblasts", "ANATOMY", 528, 540], ["uterine smooth muscle cells", "ANATOMY", 642, 669], ["amnion cells", "ANATOMY", 972, 984], ["PGE2", "CHEMICAL", 370, 374], ["oxytocin", "CHEMICAL", 614, 622], ["oxytocin", "CHEMICAL", 706, 714], ["preterm parturition", "DISEASE", 869, 888], ["PGE2", "CHEMICAL", 945, 949], ["preterm labor", "DISEASE", 1059, 1072], ["PGE2", "CHEMICAL", 370, 374], ["oxytocin", "CHEMICAL", 614, 622], ["oxytocin", "CHEMICAL", 706, 714], ["PGE2", "CHEMICAL", 945, 949], ["mice", "ORGANISM", 36, 40], ["PTGFR", "GENE_OR_GENE_PRODUCT", 88, 93], ["PTGS2", "GENE_OR_GENE_PRODUCT", 98, 103], ["PTGFR", "GENE_OR_GENE_PRODUCT", 167, 172], ["uterine contractile prostanoid", "GENE_OR_GENE_PRODUCT", 208, 238], ["PGF-2\u03b1", "GENE_OR_GENE_PRODUCT", 240, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 347, 351], ["PGE2", "SIMPLE_CHEMICAL", 370, 374], ["amnion", "CELL", 389, 395], ["decidual cells", "CELL", 400, 414], ["IL-6", "GENE_OR_GENE_PRODUCT", 441, 445], ["MMP-9", "GENE_OR_GENE_PRODUCT", 485, 490], ["MMP-2", "GENE_OR_GENE_PRODUCT", 495, 500], ["trophoblasts", "CELL", 528, 540], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 580, 585], ["IL-6", "GENE_OR_GENE_PRODUCT", 590, 594], ["oxytocin", "SIMPLE_CHEMICAL", 614, 622], ["human", "ORGANISM", 636, 641], ["uterine smooth muscle cells", "CELL", 642, 669], ["oxytocin", "SIMPLE_CHEMICAL", 706, 714], ["PGs", "SIMPLE_CHEMICAL", 719, 722], ["IL-6", "GENE_OR_GENE_PRODUCT", 851, 855], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 860, 865], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 905, 910], ["PGE2", "SIMPLE_CHEMICAL", 945, 949], ["human", "ORGANISM", 966, 971], ["amnion cells", "CELL", 972, 984], ["PTGFR", "PROTEIN", 88, 93], ["PTGS2", "PROTEIN", 98, 103], ["PTGFR", "PROTEIN", 167, 172], ["uterine contractile prostanoid (PGF-2\u03b1", "PROTEIN", 208, 246], ["IL-6", "PROTEIN", 347, 351], ["PGE2", "PROTEIN", 370, 374], ["amnion and decidual cells", "CELL_TYPE", 389, 414], ["IL-6", "PROTEIN", 441, 445], ["MMP", "PROTEIN", 485, 488], ["MMP", "PROTEIN", 495, 498], ["trophoblasts", "CELL_TYPE", 528, 540], ["IL-1\u03b2", "PROTEIN", 580, 585], ["IL-6", "PROTEIN", 590, 594], ["human uterine smooth muscle cells", "CELL_TYPE", 636, 669], ["IL-6", "PROTEIN", 851, 855], ["IL-1\u03b2", "PROTEIN", 860, 865], ["IL-1\u03b2", "PROTEIN", 905, 910], ["PGE2", "PROTEIN", 945, 949], ["human amnion cells", "CELL_TYPE", 966, 984], ["pro-inflammatory cytokines", "PROTEIN", 1024, 1050], ["mice", "SPECIES", 36, 40], ["human", "SPECIES", 636, 641], ["human", "SPECIES", 966, 971], ["mice", "SPECIES", 36, 40], ["human", "SPECIES", 636, 641], ["human", "SPECIES", 966, 971], ["PTGFR and PTGS2", "PROBLEM", 88, 103], ["PTGFR", "TREATMENT", 167, 172], ["preterm parturition", "PROBLEM", 288, 307], ["PGE2 production in amnion and decidual cells", "PROBLEM", 370, 414], ["MMP", "TEST", 485, 488], ["MMP", "TEST", 495, 498], ["IL", "TEST", 580, 582], ["oxytocin secretion in human uterine smooth muscle cells", "PROBLEM", 614, 669], ["oxytocin and PGs", "TREATMENT", 706, 722], ["preterm parturition", "PROBLEM", 869, 888], ["increasing PGE2 production", "PROBLEM", 934, 960], ["human amnion cells", "TREATMENT", 966, 984], ["pro-inflammatory cytokines", "TREATMENT", 1024, 1050], ["preterm labor", "PROBLEM", 1059, 1072], ["similar", "OBSERVATION_MODIFIER", 50, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["amount", "OBSERVATION_MODIFIER", 157, 163], ["contractile prostanoid", "OBSERVATION", 216, 238], ["increase", "OBSERVATION_MODIFIER", 262, 270], ["both term", "OBSERVATION_MODIFIER", 274, 283], ["preterm parturition", "OBSERVATION", 288, 307], ["amnion", "ANATOMY", 389, 395], ["decidual cells", "OBSERVATION", 400, 414], ["increase", "OBSERVATION_MODIFIER", 473, 481], ["human uterine", "ANATOMY", 636, 649], ["smooth muscle cells", "OBSERVATION", 650, 669], ["preterm parturition", "OBSERVATION", 869, 888], ["increasing", "OBSERVATION_MODIFIER", 934, 944], ["PGE2", "OBSERVATION", 945, 949], ["human amnion cells", "OBSERVATION", 966, 984], ["pro-inflammatory cytokines", "OBSERVATION", 1024, 1050]]]], "3c4f6a15937affaf17af8ba34d069cc71968db53": [["IntroductionCurrently, most of the human beings in the world suffer from different kinds of diseases caused by DNA and RNA viruses.", [["human", "ORGANISM", 35, 40], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["diseases", "PROBLEM", 92, 100], ["DNA and RNA viruses", "PROBLEM", 111, 130], ["diseases", "OBSERVATION", 92, 100], ["RNA viruses", "OBSERVATION", 119, 130]]], ["These diseases are mostly diagnosed but difficult to cure.", [["These diseases", "PROBLEM", 0, 14], ["diseases", "OBSERVATION", 6, 14]]], ["Vaccination is a reliable tool to fight viral diseases, but it is only available against few viruses.", [["viral diseases", "DISEASE", 40, 54], ["Vaccination", "TREATMENT", 0, 11], ["fight viral diseases", "PROBLEM", 34, 54]]], ["The difficulties associated with national or worldwide vaccination programs make antiviral chemotherapy an even more practical approach in the fight against epidemic viral infections.", [["viral infections", "DISEASE", 166, 182], ["worldwide vaccination programs", "TREATMENT", 45, 75], ["antiviral chemotherapy", "TREATMENT", 81, 103], ["epidemic viral infections", "PROBLEM", 157, 182]]], ["Nucleoside analogs are synthetic compounds that are structurally similar to natural nucleosides and can serve as building blocks of DNA and RNA.", [["Nucleoside", "CHEMICAL", 0, 10], ["Nucleoside", "CHEMICAL", 0, 10], ["nucleosides", "CHEMICAL", 84, 95], ["Nucleoside analogs", "SIMPLE_CHEMICAL", 0, 18], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["RNA", "RNA", 140, 143], ["Nucleoside analogs", "TREATMENT", 0, 18], ["synthetic compounds", "PROBLEM", 23, 42], ["natural nucleosides", "TREATMENT", 76, 95], ["DNA and RNA", "PROBLEM", 132, 143]]], ["They can act as competitive inhibitors of viral and cellular DNA and RNA polymerases or alternatively can be incorporated into growing DNA and RNA strands causing chain termination [1] .Introductiona-Aminophosphonates are defined as structural analogs of natural amino acids.", [["cellular", "ANATOMY", 52, 60], ["Introductiona-Aminophosphonates", "CHEMICAL", 186, 217], ["amino acids", "CHEMICAL", 263, 274], ["Introductiona-Aminophosphonates", "CHEMICAL", 186, 217], ["amino acids", "CHEMICAL", 263, 274], ["cellular DNA", "CELLULAR_COMPONENT", 52, 64], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["Introductiona-Aminophosphonates", "SIMPLE_CHEMICAL", 186, 217], ["natural", "SIMPLE_CHEMICAL", 255, 262], ["amino acids", "AMINO_ACID", 263, 274], ["viral and cellular DNA and RNA polymerases", "RNA", 42, 84], ["RNA strands", "RNA", 143, 154], ["competitive inhibitors", "TREATMENT", 16, 38], ["viral and cellular DNA and RNA polymerases", "PROBLEM", 42, 84], ["Introductiona", "TREATMENT", 186, 199], ["Aminophosphonates", "TREATMENT", 200, 217], ["natural amino acids", "TREATMENT", 255, 274]]], ["Some of the aminophosphonates were described as anticancer agents [2] , enzyme inhibitors [3] , peptide mimetics [4] , antibiotics and pharmacological agents [5] .", [["anticancer", "ANATOMY", 48, 58], ["aminophosphonates", "CHEMICAL", 12, 29], ["aminophosphonates", "CHEMICAL", 12, 29], ["aminophosphonates", "SIMPLE_CHEMICAL", 12, 29], ["anticancer agents [2] , enzyme inhibitors [3] , peptide mimetics [4]", "SIMPLE_CHEMICAL", 48, 116], ["the aminophosphonates", "TREATMENT", 8, 29], ["anticancer agents", "TREATMENT", 48, 65], ["enzyme inhibitors", "TREATMENT", 72, 89], ["peptide mimetics", "TREATMENT", 96, 112], ["antibiotics", "TREATMENT", 119, 130], ["pharmacological agents", "TREATMENT", 135, 157]]], ["E-mail: joachim.engels@chemie.uni-frankfurt.de Fax: \u00fe49 69 79829148 been reported to be interesting carriers for the transport of hydrophilic molecules across bilayer lipid membranes [6] .", [["bilayer lipid membranes", "ANATOMY", 159, 182], ["\u00fe49 69 79829148", "CHEMICAL", 52, 67], ["hydrophilic molecules", "PROTEIN", 130, 151], ["the transport of hydrophilic molecules across bilayer lipid membranes", "TREATMENT", 113, 182]]], ["The a-aminophosphonate derivatives are often synthesized via the Kabachnik-Fields reaction by coupling of a carbonyl compound, an amine, and a hydroxyphosphoryl compound using various catalysts [7] [8] [9] .Introduction1,2,3-Triazoles were prepared by Huisgen in the 1960s [10] using the 1,3-dipolar cycloaddition reaction with acetylenes.", [["a-aminophosphonate", "CHEMICAL", 4, 22], ["amine", "CHEMICAL", 130, 135], ["hydroxyphosphoryl", "CHEMICAL", 143, 160], ["2,3-Triazoles", "CHEMICAL", 221, 234], ["Huisgen", "CHEMICAL", 252, 259], ["acetylenes", "CHEMICAL", 328, 338], ["a-aminophosphonate", "CHEMICAL", 4, 22], ["carbonyl", "CHEMICAL", 108, 116], ["amine", "CHEMICAL", 130, 135], ["hydroxyphosphoryl", "CHEMICAL", 143, 160], ["2,3-Triazoles", "CHEMICAL", 221, 234], ["Huisgen", "CHEMICAL", 252, 259], ["acetylenes", "CHEMICAL", 328, 338], ["a-aminophosphonate derivatives", "SIMPLE_CHEMICAL", 4, 34], ["carbonyl compound", "SIMPLE_CHEMICAL", 108, 125], ["amine", "SIMPLE_CHEMICAL", 130, 135], ["hydroxyphosphoryl compound", "SIMPLE_CHEMICAL", 143, 169], ["[7] [8] [9]", "SIMPLE_CHEMICAL", 194, 205], ["2,3-Triazoles", "SIMPLE_CHEMICAL", 221, 234], ["Huisgen", "SIMPLE_CHEMICAL", 252, 259], ["1,3-dipolar cycloaddition", "SIMPLE_CHEMICAL", 288, 313], ["acetylenes", "SIMPLE_CHEMICAL", 328, 338], ["The a-aminophosphonate derivatives", "TREATMENT", 0, 34], ["a carbonyl compound", "TREATMENT", 106, 125], ["an amine", "TREATMENT", 127, 135], ["a hydroxyphosphoryl compound using various catalysts", "TREATMENT", 141, 193], ["Triazoles", "TREATMENT", 225, 234], ["the 1,3-dipolar cycloaddition reaction", "TREATMENT", 284, 322], ["acetylenes", "TREATMENT", 328, 338]]], ["After approximately four decades, this reaction has acquired considerable attention owing to the introduction of copper(I) as catalyst by Medal and then by Sharpless [11] [12] [13] .", [["copper", "CHEMICAL", 113, 119], ["copper(I)", "CHEMICAL", 113, 122], ["copper(I)", "SIMPLE_CHEMICAL", 113, 122], ["Medal", "SIMPLE_CHEMICAL", 138, 143], ["Sharpless [11] [12] [13]", "SIMPLE_CHEMICAL", 156, 180], ["this reaction", "PROBLEM", 34, 47]]], ["The copper-catalyzed cycloaddition of azides and alkynes (CuAAC) also known as \"click chemistry\" offers a simple access to the 1,4-isomer in very short reaction times.IntroductionFurther, nucleosides containing 1,2,3-triazole ring have been of special interest in drug development research.", [["azides and alkynes", "CHEMICAL", 38, 56], ["CuAAC", "CHEMICAL", 58, 63], ["1,4-isomer", "CHEMICAL", 127, 137], ["nucleosides", "CHEMICAL", 188, 199], ["1,2,3-triazole", "CHEMICAL", 211, 225], ["azides", "CHEMICAL", 38, 44], ["alkynes", "CHEMICAL", 49, 56], ["CuAAC", "CHEMICAL", 58, 63], ["nucleosides", "CHEMICAL", 188, 199], ["1,2,3-triazole", "CHEMICAL", 211, 225], ["azides", "SIMPLE_CHEMICAL", 38, 44], ["alkynes", "SIMPLE_CHEMICAL", 49, 56], ["CuAAC", "SIMPLE_CHEMICAL", 58, 63], ["1,4-isomer", "SIMPLE_CHEMICAL", 127, 137], ["nucleosides", "SIMPLE_CHEMICAL", 188, 199], ["1,2,3-triazole ring", "SIMPLE_CHEMICAL", 211, 230], ["The copper-catalyzed cycloaddition of azides", "TREATMENT", 0, 44], ["alkynes (CuAAC", "TREATMENT", 49, 63], ["nucleosides", "TREATMENT", 188, 199], ["triazole ring", "TREATMENT", 217, 230]]], ["Some synthetic triazoles have displayed interesting biological activities and several analogs have been tested against hepatitis C and HIV-1 viruses [14] [15] [16] [17] [18] .", [["triazoles", "CHEMICAL", 15, 24], ["hepatitis C", "DISEASE", 119, 130], ["triazoles", "CHEMICAL", 15, 24], ["triazoles", "SIMPLE_CHEMICAL", 15, 24], ["hepatitis C", "ORGANISM", 119, 130], ["HIV-1", "ORGANISM", 135, 140], ["viruses", "ORGANISM", 141, 148], ["[14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 149, 173], ["HIV-1", "SPECIES", 135, 140], ["HIV-1", "SPECIES", 135, 140], ["Some synthetic triazoles", "TREATMENT", 0, 24], ["interesting biological activities", "PROBLEM", 40, 73], ["several analogs", "TREATMENT", 78, 93], ["hepatitis C", "PROBLEM", 119, 130], ["HIV", "TEST", 135, 138]]], ["Moreover, nucleoside and acyclonucleoside analogs containing 1,2,3-triazole and phosphonate structures have been described as potent antiviral agents [19] [20] [21] .IntroductionHerein, we describe the synthesis of novel hybrid molecules containing triazolyl-nucleoside linked to a-aminophosphonates by a phenyl ring.", [["nucleoside", "CHEMICAL", 10, 20], ["acyclonucleoside", "CHEMICAL", 25, 41], ["1,2,3-triazole", "CHEMICAL", 61, 75], ["phosphonate", "CHEMICAL", 80, 91], ["triazolyl-nucleoside", "CHEMICAL", 249, 269], ["a-aminophosphonates", "CHEMICAL", 280, 299], ["phenyl", "CHEMICAL", 305, 311], ["nucleoside", "CHEMICAL", 10, 20], ["acyclonucleoside", "CHEMICAL", 25, 41], ["1,2,3-triazole", "CHEMICAL", 61, 75], ["phosphonate", "CHEMICAL", 80, 91], ["triazolyl-nucleoside", "CHEMICAL", 249, 269], ["a-aminophosphonates", "CHEMICAL", 280, 299], ["phenyl", "CHEMICAL", 305, 311], ["nucleoside", "SIMPLE_CHEMICAL", 10, 20], ["acyclonucleoside analogs", "SIMPLE_CHEMICAL", 25, 49], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 61, 75], ["phosphonate structures", "SIMPLE_CHEMICAL", 80, 102], ["[19] [20] [21]", "SIMPLE_CHEMICAL", 150, 164], ["triazolyl-nucleoside", "SIMPLE_CHEMICAL", 249, 269], ["a-aminophosphonates", "SIMPLE_CHEMICAL", 280, 299], ["phenyl ring", "SIMPLE_CHEMICAL", 305, 316], ["nucleoside and acyclonucleoside analogs", "TREATMENT", 10, 49], ["triazole and phosphonate structures", "TREATMENT", 67, 102], ["potent antiviral agents", "TREATMENT", 126, 149], ["novel hybrid molecules", "TREATMENT", 215, 237], ["triazolyl", "TREATMENT", 249, 258], ["nucleoside", "TREATMENT", 259, 269], ["a-aminophosphonates", "TREATMENT", 280, 299], ["a phenyl ring", "TREATMENT", 303, 316]]], ["The choice of these structures is based on the combination of both pharmacophore parts, the phenyl-triazolyl-riboside and the a-aminophosphonates, which are known to have significant pharmacological properties.", [["phenyl-triazolyl-riboside", "CHEMICAL", 92, 117], ["a-aminophosphonates", "CHEMICAL", 126, 145], ["phenyl-triazolyl-riboside", "CHEMICAL", 92, 117], ["a-aminophosphonates", "CHEMICAL", 126, 145], ["phenyl-triazolyl-riboside", "SIMPLE_CHEMICAL", 92, 117], ["a-aminophosphonates", "SIMPLE_CHEMICAL", 126, 145], ["the phenyl-triazolyl", "TREATMENT", 88, 108], ["riboside", "TREATMENT", 109, 117], ["the a-aminophosphonates", "TREATMENT", 122, 145]]], ["Our synthesis strategy is based on the use of two reactions: Kabachnick-Fields reaction and 1,3-dipolar cycloaddition.", [["Kabachnick", "CHEMICAL", 61, 71], ["1,3-dipolar", "CHEMICAL", 92, 103], ["Kabachnick", "SIMPLE_CHEMICAL", 61, 71], ["1,3-dipolar cycloaddition", "SIMPLE_CHEMICAL", 92, 117], ["Our synthesis strategy", "TREATMENT", 0, 22], ["Kabachnick-Fields reaction", "TREATMENT", 61, 87], ["dipolar cycloaddition", "TREATMENT", 96, 117]]], ["The compounds obtained were tested against selected DNA and RNA viruses.Results and discussion ChemistryThe synthesis of the desired compounds (4a-j and 5a-j) is depicted in Scheme 1.", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["selected DNA and RNA viruses", "PROBLEM", 43, 71], ["RNA viruses", "OBSERVATION", 60, 71]]], ["Initially, the a-aminophosphonate compounds were prepared in good yields via the Kabachnik-Fields reaction.", [["a-aminophosphonate", "CHEMICAL", 15, 33], ["a-aminophosphonate", "CHEMICAL", 15, 33], ["a-aminophosphonate compounds", "SIMPLE_CHEMICAL", 15, 43], ["the a-aminophosphonate compounds", "TREATMENT", 11, 43]]], ["The 4-[(trimethylsilyl)ethynyl]benzaldehyde 1 was reacted with diethylphosphite and corresponding amine in acetonitrile using molecular iodine as catalyst [22] [23] [24] .", [["4-[(trimethylsilyl)ethynyl]benzaldehyde", "CHEMICAL", 4, 43], ["diethylphosphite", "CHEMICAL", 63, 79], ["amine", "CHEMICAL", 98, 103], ["acetonitrile", "CHEMICAL", 107, 119], ["iodine", "CHEMICAL", 136, 142], ["4-[(trimethylsilyl)ethynyl]benzaldehyde", "CHEMICAL", 4, 43], ["diethylphosphite", "CHEMICAL", 63, 79], ["amine", "CHEMICAL", 98, 103], ["acetonitrile", "CHEMICAL", 107, 119], ["iodine", "CHEMICAL", 136, 142], ["4-[(trimethylsilyl)ethynyl]benzaldehyde 1", "SIMPLE_CHEMICAL", 4, 45], ["diethylphosphite", "SIMPLE_CHEMICAL", 63, 79], ["amine", "SIMPLE_CHEMICAL", 98, 103], ["acetonitrile", "SIMPLE_CHEMICAL", 107, 119], ["iodine", "SIMPLE_CHEMICAL", 136, 142], ["[22] [23] [24]", "SIMPLE_CHEMICAL", 155, 169], ["The 4-[(trimethylsilyl)ethynyl]benzaldehyde", "TREATMENT", 0, 43], ["diethylphosphite", "TREATMENT", 63, 79], ["molecular iodine as catalyst", "TREATMENT", 126, 154]]], ["The latter is low-priced, readily available, non-metallic, and nontoxic.", [["low", "OBSERVATION_MODIFIER", 14, 17], ["nontoxic", "OBSERVATION_MODIFIER", 63, 71]]], ["The next step is deprotection of the trimethylsilyl group.", [["trimethylsilyl", "CHEMICAL", 37, 51], ["trimethylsilyl", "CHEMICAL", 37, 51], ["trimethylsilyl", "SIMPLE_CHEMICAL", 37, 51], ["deprotection of the trimethylsilyl group", "TREATMENT", 17, 57]]], ["For this purpose, tetrabutylammonium fluoride (TBAF) in tetrahydrofurane (THF) was used to give the terminal alkyne [25] .", [["tetrabutylammonium fluoride", "CHEMICAL", 18, 45], ["TBAF", "CHEMICAL", 47, 51], ["tetrahydrofurane", "CHEMICAL", 56, 72], ["THF", "CHEMICAL", 74, 77], ["tetrabutylammonium fluoride", "CHEMICAL", 18, 45], ["TBAF", "CHEMICAL", 47, 51], ["tetrahydrofurane", "CHEMICAL", 56, 72], ["THF", "CHEMICAL", 74, 77], ["alkyne", "CHEMICAL", 109, 115], ["tetrabutylammonium fluoride", "SIMPLE_CHEMICAL", 18, 45], ["TBAF", "SIMPLE_CHEMICAL", 47, 51], ["tetrahydrofurane", "SIMPLE_CHEMICAL", 56, 72], ["THF", "SIMPLE_CHEMICAL", 74, 77], ["tetrabutylammonium fluoride (TBAF) in tetrahydrofurane (THF)", "TREATMENT", 18, 78], ["the terminal alkyne", "TREATMENT", 96, 115]]], ["The structures of 2e, 2f, 3d, and 3g were confirmed by X-ray diffraction (Fig. 1 ).", [["3g", "SIMPLE_CHEMICAL", 34, 36], ["X-ray diffraction", "TEST", 55, 72], ["structures", "ANATOMY_MODIFIER", 4, 14]]], ["According to the crystal data, the structures are similar for these compounds.", [["the crystal data", "TEST", 13, 29]]], ["The P-C bond has a staggered conformation, with the two six-membered groups with respect to the P --O double bond.", [["P-C", "CHEMICAL", 4, 7], ["P", "CHEMICAL", 96, 97], ["O", "CHEMICAL", 100, 101]]], ["The two benzene rings are almost perpendicular in all four compounds.", [["benzene", "CHEMICAL", 8, 15], ["benzene", "CHEMICAL", 8, 15], ["benzene rings", "SIMPLE_CHEMICAL", 8, 21], ["The two benzene rings", "TREATMENT", 0, 21], ["two", "OBSERVATION_MODIFIER", 4, 7], ["benzene rings", "OBSERVATION", 8, 21], ["almost", "OBSERVATION_MODIFIER", 26, 32], ["perpendicular", "OBSERVATION_MODIFIER", 33, 46], ["all", "OBSERVATION_MODIFIER", 50, 53], ["four compounds", "OBSERVATION_MODIFIER", 54, 68]]], ["In each crystal structure (2e, 3d, and 3g), the molecules are arranged as centrosymmetric or pseudocentrosymmetric dimers related by two N-H\u00c1 \u00c1 \u00c1O --P hydrogen bonds.", [["N-H\u00c1", "CHEMICAL", 137, 141], ["N-H\u00c1", "CHEMICAL", 137, 141], ["\u00c1O", "CHEMICAL", 144, 146], ["P", "CHEMICAL", 149, 150], ["hydrogen", "CHEMICAL", 151, 159], ["N-H\u00c1 \u00c1 \u00c1O --P hydrogen bonds", "SIMPLE_CHEMICAL", 137, 165], ["3d", "TEST", 31, 33], ["centrosymmetric or pseudocentrosymmetric dimers", "PROBLEM", 74, 121], ["crystal structure", "OBSERVATION", 8, 25], ["hydrogen bonds", "OBSERVATION", 151, 165]]], ["On the other hand, in the crystal structure of 2f, the hydrogen bond N-H\u00c1 \u00c1 \u00c1O --P is not found, and the molecules are arranged as centrosymmetric dimers linked by C methyl -H\u00c1 \u00c1 \u00c1O --P hydrogen bonds [26] .Results and discussion ChemistryNext, the 1,2,3-triazolyl-nucleosides were prepared using the 1,3-dipolar cycloaddition reaction.", [["N-H\u00c1", "CHEMICAL", 69, 73], ["C methyl -H\u00c1", "CHEMICAL", 164, 176], ["1,2,3-triazolyl-nucleosides", "CHEMICAL", 249, 276], ["hydrogen", "CHEMICAL", 55, 63], ["N-H\u00c1 \u00c1 \u00c1O --P", "CHEMICAL", 69, 82], ["C methyl -H\u00c1", "CHEMICAL", 164, 176], ["\u00c1O", "CHEMICAL", 179, 181], ["P", "CHEMICAL", 184, 185], ["hydrogen", "CHEMICAL", 186, 194], ["1,2,3-triazolyl-nucleosides", "CHEMICAL", 249, 276], ["hydrogen bond N-H\u00c1", "SIMPLE_CHEMICAL", 55, 73], ["C methyl -H\u00c1 \u00c1 \u00c1O --P hydrogen bonds [26]", "SIMPLE_CHEMICAL", 164, 205], ["1,2,3-triazolyl-nucleosides", "SIMPLE_CHEMICAL", 249, 276], ["1,3-dipolar", "SIMPLE_CHEMICAL", 301, 312], ["P", "PROTEIN", 81, 82], ["centrosymmetric dimers", "PROTEIN", 131, 153], ["the hydrogen bond N", "TEST", 51, 70], ["C methyl", "TEST", 164, 172], ["ChemistryNext", "TEST", 230, 243], ["triazolyl-nucleosides", "TREATMENT", 255, 276], ["the 1,3-dipolar cycloaddition reaction", "TREATMENT", 297, 335]]], ["For this, the terminal alkynes 3a-j and b-azido-ribose [27] were coupled using the Cu alkyne-azide cycloaddition in basic medium (triethylamine) and the reaction was carried out under microwave irradiation [28] .", [["alkynes 3a-j and b-azido-ribose", "CHEMICAL", 23, 54], ["Cu alkyne-azide", "CHEMICAL", 83, 98], ["triethylamine", "CHEMICAL", 130, 143], ["alkynes", "CHEMICAL", 23, 30], ["b-azido-ribose", "CHEMICAL", 40, 54], ["Cu alkyne-azide", "CHEMICAL", 83, 98], ["triethylamine", "CHEMICAL", 130, 143], ["3a-j", "SIMPLE_CHEMICAL", 31, 35], ["b-azido-ribose [27]", "SIMPLE_CHEMICAL", 40, 59], ["Cu alkyne-azide", "SIMPLE_CHEMICAL", 83, 98], ["triethylamine", "SIMPLE_CHEMICAL", 130, 143], ["the terminal alkynes 3a", "TREATMENT", 10, 33], ["b-azido-ribose", "TREATMENT", 40, 54], ["the Cu alkyne-azide cycloaddition", "TREATMENT", 79, 112], ["basic medium (triethylamine", "TREATMENT", 116, 143], ["the reaction", "PROBLEM", 149, 161], ["microwave irradiation", "TREATMENT", 184, 205]]], ["Microwave heating has been shown to increase reaction yields and to speed up reaction time [29] , b-azido-ribose is slightly unstable under micro-wave conditions and was used in excess.", [["b-azido-ribose", "CHEMICAL", 98, 112], ["b-azido-ribose", "CHEMICAL", 98, 112], ["b-azido-ribose", "SIMPLE_CHEMICAL", 98, 112], ["Microwave heating", "TREATMENT", 0, 17], ["increase reaction", "PROBLEM", 36, 53], ["slightly unstable", "PROBLEM", 116, 133]]], ["The configuration at the anomeric carbon C1 0 is retained as it is present in the b-azido-ribose.", [["b-azido-ribose", "CHEMICAL", 82, 96], ["carbon C1 0", "CHEMICAL", 34, 45], ["b-azido", "CHEMICAL", 82, 89], ["ribose", "CHEMICAL", 90, 96], ["b-azido-ribose", "SIMPLE_CHEMICAL", 82, 96], ["anomeric", "ANATOMY_MODIFIER", 25, 33], ["carbon C1", "OBSERVATION", 34, 43], ["ribose", "ANATOMY_MODIFIER", 90, 96]]], ["The hydroxyl functions were protected by benzoyl groups prior to the CuAAC reaction in order to increase the solubility of the compounds.", [["hydroxyl", "CHEMICAL", 4, 12], ["benzoyl", "CHEMICAL", 41, 48], ["CuAAC", "CHEMICAL", 69, 74], ["hydroxyl", "CHEMICAL", 4, 12], ["benzoyl", "CHEMICAL", 41, 48], ["CuAAC", "CHEMICAL", 69, 74], ["hydroxyl", "SIMPLE_CHEMICAL", 4, 12], ["benzoyl", "SIMPLE_CHEMICAL", 41, 48], ["CuAAC", "SIMPLE_CHEMICAL", 69, 74], ["The hydroxyl functions", "TEST", 0, 22], ["benzoyl groups", "TREATMENT", 41, 55], ["the CuAAC reaction", "TREATMENT", 65, 83], ["hydroxyl functions", "OBSERVATION", 4, 22]]], ["The structures of all compounds were confirmed on the basis of 1 H, 13 C NMR spectra as well as by high-resolution mass spectrometry.", [["H", "CHEMICAL", 65, 66], ["C", "CHEMICAL", 71, 72], ["C NMR spectra", "TEST", 71, 84], ["high-resolution mass spectrometry", "PROBLEM", 99, 132], ["all", "OBSERVATION_MODIFIER", 18, 21], ["compounds", "OBSERVATION", 22, 31], ["mass spectrometry", "OBSERVATION", 115, 132]]], ["In the 1 H NMR spectra of the intermediates, the triazole proton appears as a singlet in the aromatic region while the anomeric proton appears as a multiplet around 6 ppm.Results and discussion ChemistryThe last step involves the removal of the benzoyl protecting groups from O2 0 , O3 0 , and O5 0 positions of D-ribose 4a-j using sodium methoxide (NaOMe) in methanol [30] to afford the desired 1,2,3-triazole nucleosides 5a-j (Table 1 ).Biological testingThe antiviral activities of the synthesized compounds (4a-j, 5a-j) were tested against different viruses: HIV-1 and HIV-2 in MT4 cell cultures; herpes simplex virus-1 (HSV-1) (Kos strain), herpes simplex virus-2 (HSV-2) (G strain), HSV-1 thymidine kinase deficient, acyclovir-resistant (TK \u00c0 Kos, ACV r ), vaccinia virus, vesicular stomatitis virus (VSV), adenovirus-2, varicella- a) All products were characterized by 1 H NMR, 13 C NMR, and mass spectrometry. b) Yields of isolated products for the CuAAC reaction. c) Yields of isolated products for the protection reaction.Biological testinginfluenza A H1N1 subtype, influenza A H3N2 subtype, and influenza B virus in MDCK (Madin-Darby canine kidney) cells.Biological testingThe following reference compounds were included: tenofovir (PMPA), AMD3100, ganciclovir, cidofovir, acyclovir, brivudin, the lectins Hippeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA), dextran sulfate (molecular weight 10000, DS-10000), ribavirin, oseltamivir carboxylate, amantadine and rimantadine, zalcitabine and alovudine.Biological testingThe antiviral activity was expressed as the EC 50 : the compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%.", [["MT4 cell cultures", "ANATOMY", 582, 599], ["MDCK", "ANATOMY", 1127, 1131], ["kidney) cells", "ANATOMY", 1152, 1165], ["EC", "ANATOMY", 1593, 1595], ["plaque", "ANATOMY", 1688, 1694], ["triazole", "CHEMICAL", 49, 57], ["benzoyl", "CHEMICAL", 245, 252], ["O2", "CHEMICAL", 276, 278], ["O3", "CHEMICAL", 283, 285], ["O5", "CHEMICAL", 294, 296], ["D-ribose", "CHEMICAL", 312, 320], ["sodium methoxide", "CHEMICAL", 332, 348], ["NaOMe", "CHEMICAL", 350, 355], ["1,2,3-triazole", "CHEMICAL", 396, 410], ["4a-j, 5a-j", "CHEMICAL", 512, 522], ["herpes simplex", "DISEASE", 601, 615], ["herpes simplex", "DISEASE", 646, 660], ["thymidine", "CHEMICAL", 695, 704], ["acyclovir", "CHEMICAL", 723, 732], ["ACV", "CHEMICAL", 754, 757], ["vaccinia virus", "DISEASE", 763, 777], ["vesicular stomatitis", "DISEASE", 779, 799], ["CuAAC", "CHEMICAL", 957, 962], ["influenza A H3N2 subtype", "DISEASE", 1076, 1100], ["influenza B", "DISEASE", 1106, 1117], ["tenofovir", "CHEMICAL", 1233, 1242], ["PMPA", "CHEMICAL", 1244, 1248], ["AMD3100", "CHEMICAL", 1251, 1258], ["ganciclovir", "CHEMICAL", 1260, 1271], ["cidofovir", "CHEMICAL", 1273, 1282], ["acyclovir", "CHEMICAL", 1284, 1293], ["brivudin", "CHEMICAL", 1295, 1303], ["dextran sulfate", "CHEMICAL", 1389, 1404], ["DS-10000", "CHEMICAL", 1430, 1438], ["ribavirin", "CHEMICAL", 1441, 1450], ["oseltamivir carboxylate", "CHEMICAL", 1452, 1475], ["amantadine", "CHEMICAL", 1477, 1487], ["rimantadine", "CHEMICAL", 1492, 1503], ["zalcitabine", "CHEMICAL", 1505, 1516], ["alovudine", "CHEMICAL", 1521, 1530], ["cytopathogenicity", "DISEASE", 1661, 1678], ["plaque", "DISEASE", 1688, 1694], ["H", "CHEMICAL", 9, 10], ["triazole", "CHEMICAL", 49, 57], ["benzoyl", "CHEMICAL", 245, 252], ["O2", "CHEMICAL", 276, 278], ["O3 0", "CHEMICAL", 283, 287], ["O5", "CHEMICAL", 294, 296], ["D-ribose", "CHEMICAL", 312, 320], ["sodium methoxide", "CHEMICAL", 332, 348], ["NaOMe", "CHEMICAL", 350, 355], ["methanol", "CHEMICAL", 360, 368], ["1,2,3-triazole nucleosides", "CHEMICAL", 396, 422], ["thymidine", "CHEMICAL", 695, 704], ["acyclovir", "CHEMICAL", 723, 732], ["1 H", "CHEMICAL", 876, 879], ["C", "CHEMICAL", 888, 889], ["tenofovir", "CHEMICAL", 1233, 1242], ["PMPA", "CHEMICAL", 1244, 1248], ["AMD3100", "CHEMICAL", 1251, 1258], ["ganciclovir", "CHEMICAL", 1260, 1271], ["cidofovir", "CHEMICAL", 1273, 1282], ["acyclovir", "CHEMICAL", 1284, 1293], ["brivudin", "CHEMICAL", 1295, 1303], ["ribavirin", "CHEMICAL", 1441, 1450], ["oseltamivir carboxylate", "CHEMICAL", 1452, 1475], ["amantadine", "CHEMICAL", 1477, 1487], ["rimantadine", "CHEMICAL", 1492, 1503], ["zalcitabine", "CHEMICAL", 1505, 1516], ["alovudine", "CHEMICAL", 1521, 1530], ["triazole", "SIMPLE_CHEMICAL", 49, 57], ["benzoyl", "SIMPLE_CHEMICAL", 245, 252], ["O2 0", "SIMPLE_CHEMICAL", 276, 280], ["O3 0", "SIMPLE_CHEMICAL", 283, 287], ["O5 0 positions", "SIMPLE_CHEMICAL", 294, 308], ["D-ribose 4a-j", "SIMPLE_CHEMICAL", 312, 325], ["sodium methoxide", "SIMPLE_CHEMICAL", 332, 348], ["NaOMe", "SIMPLE_CHEMICAL", 350, 355], ["methanol [30]", "SIMPLE_CHEMICAL", 360, 373], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 396, 410], ["4a-j, 5a-j", "SIMPLE_CHEMICAL", 512, 522], ["HIV-1", "ORGANISM", 563, 568], ["HIV-2", "ORGANISM", 573, 578], ["MT4 cell cultures;", "ORGANISM", 582, 600], ["herpes simplex virus-1", "ORGANISM", 601, 623], ["HSV-1", "ORGANISM", 625, 630], ["Kos strain", "ORGANISM", 633, 643], ["herpes simplex virus-2", "ORGANISM", 646, 668], ["HSV-2) (G strain", "ORGANISM", 670, 686], ["HSV-1", "ORGANISM", 689, 694], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 695, 711], ["acyclovir", "SIMPLE_CHEMICAL", 723, 732], ["TK \u00c0 Kos", "ORGANISM", 744, 752], ["ACV r )", "ORGANISM", 754, 761], ["vaccinia virus", "ORGANISM", 763, 777], ["vesicular stomatitis virus", "ORGANISM", 779, 805], ["VSV", "ORGANISM", 807, 810], ["adenovirus-2", "ORGANISM", 813, 825], ["CuAAC", "SIMPLE_CHEMICAL", 957, 962], ["testinginfluenza A H1N1", "ORGANISM", 1043, 1066], ["influenza A H3N2", "ORGANISM", 1076, 1092], ["influenza B virus", "ORGANISM", 1106, 1123], ["MDCK", "CELL", 1127, 1131], ["Madin-Darby canine kidney) cells", "CELL", 1133, 1165], ["tenofovir", "SIMPLE_CHEMICAL", 1233, 1242], ["PMPA", "SIMPLE_CHEMICAL", 1244, 1248], ["AMD3100", "SIMPLE_CHEMICAL", 1251, 1258], ["ganciclovir", "SIMPLE_CHEMICAL", 1260, 1271], ["cidofovir", "SIMPLE_CHEMICAL", 1273, 1282], ["acyclovir", "SIMPLE_CHEMICAL", 1284, 1293], ["brivudin", "SIMPLE_CHEMICAL", 1295, 1303], ["Hippeastrum hybrid agglutinin", "ORGANISM", 1317, 1346], ["HHA", "SIMPLE_CHEMICAL", 1348, 1351], ["Urtica dioica", "ORGANISM", 1357, 1370], ["agglutinin", "SIMPLE_CHEMICAL", 1371, 1381], ["UDA", "SIMPLE_CHEMICAL", 1383, 1386], ["dextran sulfate", "SIMPLE_CHEMICAL", 1389, 1404], ["DS-10000", "SIMPLE_CHEMICAL", 1430, 1438], ["ribavirin", "SIMPLE_CHEMICAL", 1441, 1450], ["oseltamivir carboxylate", "SIMPLE_CHEMICAL", 1452, 1475], ["amantadine", "SIMPLE_CHEMICAL", 1477, 1487], ["rimantadine", "SIMPLE_CHEMICAL", 1492, 1503], ["zalcitabine", "SIMPLE_CHEMICAL", 1505, 1516], ["alovudine", "SIMPLE_CHEMICAL", 1521, 1530], ["EC", "CELL", 1593, 1595], ["viral plaque", "PATHOLOGICAL_FORMATION", 1682, 1694], ["MT4 cell cultures", "CELL_LINE", 582, 599], ["MDCK (Madin-Darby canine kidney) cells", "CELL_LINE", 1127, 1165], ["HIV-1", "SPECIES", 563, 568], ["HIV-2", "SPECIES", 573, 578], ["herpes simplex virus-1", "SPECIES", 601, 623], ["HSV-1", "SPECIES", 625, 630], ["herpes simplex virus-2", "SPECIES", 646, 668], ["HSV-2", "SPECIES", 670, 675], ["HSV-1", "SPECIES", 689, 694], ["vaccinia virus", "SPECIES", 763, 777], ["vesicular stomatitis virus", "SPECIES", 779, 805], ["VSV", "SPECIES", 807, 810], ["influenza A H3N2", "SPECIES", 1076, 1092], ["influenza B virus", "SPECIES", 1106, 1123], ["Urtica dioica", "SPECIES", 1357, 1370], ["HIV-1", "SPECIES", 563, 568], ["HIV-2", "SPECIES", 573, 578], ["herpes simplex virus-1", "SPECIES", 601, 623], ["HSV-1", "SPECIES", 625, 630], ["herpes simplex virus-2 (HSV-2)", "SPECIES", 646, 676], ["HSV-1", "SPECIES", 689, 694], ["vaccinia virus", "SPECIES", 763, 777], ["stomatitis virus", "SPECIES", 789, 805], ["VSV", "SPECIES", 807, 810], ["influenza B virus", "SPECIES", 1106, 1123], ["canine", "SPECIES", 1145, 1151], ["Urtica dioica", "SPECIES", 1357, 1370], ["the triazole proton", "TREATMENT", 45, 64], ["a singlet in the aromatic region", "TREATMENT", 76, 108], ["the anomeric proton", "TREATMENT", 115, 134], ["the removal", "TREATMENT", 226, 237], ["the benzoyl protecting groups", "TREATMENT", 241, 270], ["O2", "TREATMENT", 276, 278], ["D-ribose 4a", "TREATMENT", 312, 323], ["sodium methoxide (NaOMe) in methanol", "TREATMENT", 332, 368], ["triazole nucleosides", "TREATMENT", 402, 422], ["Biological testing", "TEST", 439, 457], ["the synthesized compounds", "TEST", 485, 510], ["different viruses", "PROBLEM", 544, 561], ["HIV", "TEST", 563, 566], ["HIV", "TEST", 573, 576], ["MT4 cell cultures", "TEST", 582, 599], ["herpes simplex virus", "TEST", 601, 621], ["HSV", "TEST", 625, 628], ["Kos strain", "TEST", 633, 643], ["herpes simplex virus", "TEST", 646, 666], ["HSV", "TEST", 670, 673], ["G strain", "TEST", 678, 686], ["HSV", "TEST", 689, 692], ["thymidine kinase deficient", "TEST", 695, 721], ["acyclovir", "TEST", 723, 732], ["resistant (TK \u00c0 Kos", "PROBLEM", 733, 752], ["ACV", "TEST", 754, 757], ["vaccinia virus", "PROBLEM", 763, 777], ["vesicular stomatitis virus (VSV)", "PROBLEM", 779, 811], ["adenovirus", "PROBLEM", 813, 823], ["varicella", "PROBLEM", 827, 836], ["H NMR", "TEST", 878, 883], ["C NMR", "TEST", 888, 893], ["mass spectrometry", "PROBLEM", 899, 916], ["isolated products", "TREATMENT", 931, 948], ["the CuAAC reaction", "PROBLEM", 953, 971], ["isolated products", "TREATMENT", 986, 1003], ["the protection reaction", "PROBLEM", 1008, 1031], ["Biological testinginfluenza A H1N1 subtype", "PROBLEM", 1032, 1074], ["influenza", "PROBLEM", 1076, 1085], ["A H3N2 subtype", "PROBLEM", 1086, 1100], ["influenza B virus", "PROBLEM", 1106, 1123], ["MDCK", "TEST", 1127, 1131], ["Madin-Darby canine kidney) cells", "TREATMENT", 1133, 1165], ["Biological testing", "TEST", 1166, 1184], ["tenofovir (PMPA)", "TREATMENT", 1233, 1249], ["AMD3100", "TREATMENT", 1251, 1258], ["ganciclovir", "TREATMENT", 1260, 1271], ["cidofovir", "TREATMENT", 1273, 1282], ["acyclovir", "TREATMENT", 1284, 1293], ["brivudin", "TREATMENT", 1295, 1303], ["the lectins Hippeastrum hybrid agglutinin (HHA)", "TREATMENT", 1305, 1352], ["Urtica dioica agglutinin (UDA)", "TREATMENT", 1357, 1387], ["dextran sulfate (molecular weight", "TREATMENT", 1389, 1422], ["DS", "TEST", 1430, 1432], ["ribavirin", "TREATMENT", 1441, 1450], ["oseltamivir carboxylate", "TREATMENT", 1452, 1475], ["amantadine", "TREATMENT", 1477, 1487], ["rimantadine", "TREATMENT", 1492, 1503], ["zalcitabine", "TREATMENT", 1505, 1516], ["alovudine", "TREATMENT", 1521, 1530], ["Biological testing", "TEST", 1531, 1549], ["the compound concentration", "PROBLEM", 1601, 1627], ["virus", "PROBLEM", 1647, 1652], ["induced cytopathogenicity", "PROBLEM", 1653, 1678], ["viral plaque formation", "PROBLEM", 1682, 1704], ["aromatic", "ANATOMY_MODIFIER", 93, 101], ["anomeric proton", "OBSERVATION", 119, 134], ["antiviral activities", "OBSERVATION", 461, 481], ["vesicular stomatitis", "ANATOMY", 779, 799], ["mass spectrometry", "OBSERVATION", 899, 916], ["isolated products", "OBSERVATION", 931, 948], ["CuAAC reaction", "OBSERVATION", 957, 971], ["kidney", "ANATOMY", 1152, 1158], ["antiviral activity", "OBSERVATION", 1553, 1571], ["viral plaque", "OBSERVATION", 1682, 1694]]], ["The cytotoxicity of the tested compounds toward the uninfected host cells was defined as the minimum cytotoxic concentration (MCC) that causes a microscopically detectable alteration of normal cell morphology.", [["cells", "ANATOMY", 68, 73], ["cell", "ANATOMY", 193, 197], ["host cells", "CELL", 63, 73], ["cell", "CELL", 193, 197], ["uninfected host cells", "CELL_TYPE", 52, 73], ["the minimum cytotoxic concentration", "TEST", 89, 124], ["a microscopically detectable alteration of normal cell morphology", "PROBLEM", 143, 208], ["uninfected", "OBSERVATION_MODIFIER", 52, 62], ["host cells", "OBSERVATION", 63, 73], ["microscopically", "OBSERVATION_MODIFIER", 145, 160], ["detectable", "OBSERVATION_MODIFIER", 161, 171], ["alteration", "OBSERVATION_MODIFIER", 172, 182], ["normal cell morphology", "OBSERVATION", 186, 208]]], ["The 50% cytotoxic concentration (CC 50 ), causing a 50% decrease in cell viability was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay system.", [["cell", "ANATOMY", 68, 72], ["CC", "CHEMICAL", 33, 35], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 119, 207], ["MTS", "CHEMICAL", 209, 212], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 119, 207], ["MTS", "CHEMICAL", 209, 212], ["cell", "CELL", 68, 72], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "SIMPLE_CHEMICAL", 119, 207], ["MTS", "SIMPLE_CHEMICAL", 209, 212], ["The 50% cytotoxic concentration (CC", "TREATMENT", 0, 35], ["a 50% decrease in cell viability", "PROBLEM", 50, 82], ["a colorimetric", "TREATMENT", 104, 118], ["dimethylthiazol", "TREATMENT", 126, 141], ["carboxymethoxyphenyl)", "TREATMENT", 153, 174], ["tetrazolium (MTS)", "TREATMENT", 196, 213], ["cell viability", "OBSERVATION", 68, 82]]], ["The tested compounds (4a-j, 5a-j) displayed no antiviral activity against the different viruses tested except for compounds 4b and 4c that showed a slight inhibition of respiratory syncytial virus replication ( Table 2 ) and compounds 5c, 5f, and 5g that displayed weak activity against both TK \u00fe and TK \u00c0 VZV strains (see Supporting Information).", [["4a-j, 5a-j", "CHEMICAL", 22, 32], ["respiratory syncytial virus replication", "DISEASE", 169, 208], ["compounds 5c, 5f, and 5g", "CHEMICAL", 225, 249], ["4a-j, 5a-j", "SIMPLE_CHEMICAL", 22, 32], ["respiratory syncytial virus", "ORGANISM", 169, 196], ["5g", "SIMPLE_CHEMICAL", 247, 249], ["VZV", "ORGANISM", 306, 309], ["respiratory syncytial virus", "SPECIES", 169, 196], ["TK \u00c0 VZV", "SPECIES", 301, 309], ["The tested compounds", "TEST", 0, 20], ["antiviral activity", "PROBLEM", 47, 65], ["the different viruses", "PROBLEM", 74, 95], ["compounds 4b", "TEST", 114, 126], ["respiratory syncytial virus replication", "TREATMENT", 169, 208], ["weak activity", "PROBLEM", 265, 278], ["VZV strains", "PROBLEM", 306, 317], ["no", "UNCERTAINTY", 44, 46], ["antiviral activity", "OBSERVATION", 47, 65], ["viruses", "OBSERVATION", 88, 95], ["slight", "OBSERVATION_MODIFIER", 148, 154], ["inhibition", "OBSERVATION_MODIFIER", 155, 165], ["respiratory syncytial virus", "OBSERVATION", 169, 196]]], ["Although compound 4h had some activity against Coxsackie virus B4 in Vero cell cultures, no activity was seen in HeLa cells (Tables 2 and 3 ).ConclusionA series of novel 1,2,3-triazolyl ribosides linked to a-aminophosphonates (4a-j, 5a-j) were successfully prepared in high yield via the Kabachnik-Fields reaction and a Cu(I)-catalyzed alkyne-azide cycloaddition under microwave irradiation.", [["Vero cell cultures", "ANATOMY", 69, 87], ["HeLa cells", "ANATOMY", 113, 123], ["1,2,3-triazolyl ribosides", "CHEMICAL", 170, 195], ["a-aminophosphonates", "CHEMICAL", 206, 225], ["4a-j, 5a-j", "CHEMICAL", 227, 237], ["Kabachnik", "CHEMICAL", 288, 297], ["Cu", "CHEMICAL", 320, 322], ["alkyne-azide", "CHEMICAL", 336, 348], ["1,2,3-triazolyl ribosides", "CHEMICAL", 170, 195], ["a-aminophosphonates", "CHEMICAL", 206, 225], ["Cu(I)", "CHEMICAL", 320, 325], ["alkyne-azide", "CHEMICAL", 336, 348], ["Coxsackie virus B4", "ORGANISM", 47, 65], ["Vero cell cultures", "CELL", 69, 87], ["HeLa cells", "CELL", 113, 123], ["1,2,3-triazolyl ribosides", "SIMPLE_CHEMICAL", 170, 195], ["a-aminophosphonates", "SIMPLE_CHEMICAL", 206, 225], ["4a-j, 5a-j)", "SIMPLE_CHEMICAL", 227, 238], ["Cu(I)", "SIMPLE_CHEMICAL", 320, 325], ["alkyne-azide", "SIMPLE_CHEMICAL", 336, 348], ["Vero cell cultures", "CELL_LINE", 69, 87], ["HeLa cells", "CELL_LINE", 113, 123], ["Coxsackie virus", "SPECIES", 47, 62], ["Coxsackie virus", "SPECIES", 47, 62], ["Coxsackie virus B4", "PROBLEM", 47, 65], ["Vero cell cultures", "TEST", 69, 87], ["HeLa cells", "TEST", 113, 123], ["ConclusionA series", "TEST", 142, 160], ["novel", "TEST", 164, 169], ["triazolyl ribosides", "TREATMENT", 176, 195], ["a-aminophosphonates", "TEST", 206, 225], ["a Cu(I)-catalyzed alkyne-azide cycloaddition", "TREATMENT", 318, 362], ["microwave irradiation", "TREATMENT", 369, 390], ["Vero cell", "OBSERVATION_MODIFIER", 69, 78], ["no", "UNCERTAINTY", 89, 91], ["activity", "OBSERVATION_MODIFIER", 92, 100]]], ["The synthesized compounds were evaluated against a broad range of DNA and RNA viruses, some of them showing modest activity against respiratory syncytial virus (compounds 4b and 4c) and varicella-zoster virus (compounds 5c, 5f, and 5g).GeneralReactions were carried out in a microwave oven model AVM510/WP/WH.", [["respiratory syncytial virus", "DISEASE", 132, 159], ["varicella-zoster", "DISEASE", 186, 202], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["respiratory syncytial virus", "ORGANISM", 132, 159], ["varicella-zoster virus", "ORGANISM", 186, 208], ["respiratory syncytial virus", "SPECIES", 132, 159], ["varicella-zoster virus", "SPECIES", 186, 208], ["respiratory syncytial virus", "SPECIES", 132, 159], ["varicella-zoster virus", "SPECIES", 186, 208], ["a broad range of DNA", "PROBLEM", 49, 69], ["RNA viruses", "PROBLEM", 74, 85], ["respiratory syncytial virus", "PROBLEM", 132, 159], ["varicella-zoster virus", "PROBLEM", 186, 208], ["RNA viruses", "OBSERVATION", 74, 85], ["syncytial virus", "OBSERVATION", 144, 159], ["varicella", "ANATOMY", 186, 195], ["zoster virus", "OBSERVATION", 196, 208]]], ["Reactions were monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254 (Merck, Darmstadt, Germany); UV light was used for visualization of the spots.", [["silica", "CHEMICAL", 73, 79], ["thin layer chromatography", "TEST", 28, 53], ["precoated silica gel", "TREATMENT", 63, 83], ["UV light", "TREATMENT", 121, 129], ["the spots", "PROBLEM", 160, 169], ["spots", "OBSERVATION", 164, 169]]], ["All products were purified by column chromatography on silica gel (100-200 mesh; Merck).", [["silica gel", "CHEMICAL", 55, 65], ["silica gel", "CHEMICAL", 55, 65], ["silica", "SIMPLE_CHEMICAL", 55, 61], ["All products", "TREATMENT", 0, 12], ["silica gel", "TREATMENT", 55, 65]]], ["1 C NMR spectra were recorded on a Bruker 300 and 75 MHz spectrometer, respectively, SiMe 4 was used as internal standard.", [["SiMe 4", "CHEMICAL", 85, 91], ["C", "CHEMICAL", 2, 3], ["NMR spectra", "TEST", 4, 15]]], ["Chemical shifts are given in ppm and coupling constants (J) in MHz and multiplicity is reported as s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet).", [["d (doublet), t (triplet)", "TREATMENT", 112, 136]]], ["Mass spectra were produced by ESI/MS and MALDI-TOF-MS.H NMR andGeneral procedure for the synthesis of diethyl [(4-(2-(trimethylsilyl)ethynyl)phenyl)(aryl or alkylamino)methyl]phosphonates 2a-jH NMR andThe compounds 2a-j were synthesized by reaction of commercial (Sigma-Aldrich) 4-[(trimethylsilyl)ethynyl]benzaldehyde 1 (1 mmol), diethylphosphite (1.2 equiv.), and corresponding amine (1.2 equiv.) in acetonitrile (3 mL) using molecular iodine (0.2 equiv.) as catalyst at room temperature, the reaction mixture was stirred at room temperature for 1 h.", [["diethyl [(4-(2-(trimethylsilyl)ethynyl)phenyl)(aryl or alkylamino)methyl]phosphonates 2a-jH", "CHEMICAL", 102, 193], ["4-[(trimethylsilyl)ethynyl]benzaldehyde", "CHEMICAL", 279, 318], ["diethylphosphite", "CHEMICAL", 331, 347], ["amine", "CHEMICAL", 380, 385], ["acetonitrile", "CHEMICAL", 402, 414], ["iodine", "CHEMICAL", 438, 444], ["diethyl [(4-(2-(trimethylsilyl)ethynyl)phenyl)(aryl or alkylamino)methyl]phosphonates", "CHEMICAL", 102, 187], ["jH", "CHEMICAL", 191, 193], ["4-[(trimethylsilyl)ethynyl]benzaldehyde", "CHEMICAL", 279, 318], ["diethylphosphite", "CHEMICAL", 331, 347], ["amine", "CHEMICAL", 380, 385], ["acetonitrile", "CHEMICAL", 402, 414], ["iodine", "CHEMICAL", 438, 444], ["diethyl [(4-(2-(trimethylsilyl)ethynyl)phenyl)(aryl or alkylamino)methyl]phosphonates 2a-jH", "SIMPLE_CHEMICAL", 102, 193], ["2a-j", "SIMPLE_CHEMICAL", 215, 219], ["Sigma-Aldrich) 4-[(trimethylsilyl)ethynyl]benzaldehyde 1 (1 mmol)", "SIMPLE_CHEMICAL", 264, 329], ["diethylphosphite", "SIMPLE_CHEMICAL", 331, 347], ["amine", "SIMPLE_CHEMICAL", 380, 385], ["acetonitrile", "SIMPLE_CHEMICAL", 402, 414], ["iodine", "SIMPLE_CHEMICAL", 438, 444], ["Mass spectra", "PROBLEM", 0, 12], ["ESI", "TEST", 30, 33], ["MS", "TEST", 34, 36], ["MALDI", "TEST", 41, 46], ["TOF", "TEST", 47, 50], ["General procedure", "TREATMENT", 63, 80], ["the synthesis of diethyl [(4-(2-(trimethylsilyl)ethynyl)phenyl)(aryl or alkylamino)methyl]phosphonates", "TREATMENT", 85, 187], ["jH NMR", "TEST", 191, 197], ["The compounds", "TREATMENT", 201, 214], ["commercial (Sigma-Aldrich)", "TREATMENT", 252, 278], ["[(trimethylsilyl)ethynyl]benzaldehyde", "TREATMENT", 281, 318], ["diethylphosphite", "TREATMENT", 331, 347], ["acetonitrile", "TREATMENT", 402, 414], ["molecular iodine", "TREATMENT", 428, 444]]], ["Then, the solvent was removed under reduced pressure.", [["the solvent", "TREATMENT", 6, 17], ["reduced", "OBSERVATION_MODIFIER", 36, 43], ["pressure", "OBSERVATION_MODIFIER", 44, 52]]], ["The resulting residue was purified by column chromatography using ethyl acetate/hexane as eluent.", [["ethyl acetate/hexane", "CHEMICAL", 66, 86], ["ethyl acetate", "CHEMICAL", 66, 79], ["hexane", "CHEMICAL", 80, 86], ["ethyl acetate", "SIMPLE_CHEMICAL", 66, 79], ["hexane", "SIMPLE_CHEMICAL", 80, 86], ["The resulting residue", "PROBLEM", 0, 21], ["ethyl acetate/hexane", "TREATMENT", 66, 86]]], ["13 General procedure for the synthesis of diethyl [(4-(2,3,5tri-O-benzoyl-b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)(aryl or alkylamino)(phenyl)methyl]phosphonates 4a-jH NMR andThe trimethylsilyl ethynyl phenyl a-aminophosphonates 2 (0.7 mmol) were reacted with tetrabutylammonium fluoride (1 equiv.) in tetrahydrofurane (2.5 mL).", [["diethyl [(4-(2,3,5tri-O-benzoyl-b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)(aryl or alkylamino)(phenyl)methyl]phosphonates 4a-jH", "CHEMICAL", 42, 168], ["trimethylsilyl ethynyl phenyl a-aminophosphonates", "CHEMICAL", 180, 229], ["tetrabutylammonium fluoride", "CHEMICAL", 261, 288], ["tetrahydrofurane", "CHEMICAL", 303, 319], ["diethyl [(4-(2,3,5tri-O-benzoyl-b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)(aryl or alkylamino)(phenyl)methyl]phosphonates", "CHEMICAL", 42, 162], ["jH", "CHEMICAL", 166, 168], ["trimethylsilyl ethynyl phenyl a-aminophosphonates", "CHEMICAL", 180, 229], ["tetrabutylammonium fluoride", "CHEMICAL", 261, 288], ["tetrahydrofurane", "CHEMICAL", 303, 319], ["diethyl [(4-(2,3,5tri-O-benzoyl-b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)(aryl or alkylamino)(phenyl)methyl]phosphonates 4a-jH", "SIMPLE_CHEMICAL", 42, 168], ["trimethylsilyl ethynyl phenyl a-aminophosphonates 2", "SIMPLE_CHEMICAL", 180, 231], ["tetrabutylammonium fluoride", "SIMPLE_CHEMICAL", 261, 288], ["1 equiv.", "SIMPLE_CHEMICAL", 290, 298], ["tetrahydrofurane", "SIMPLE_CHEMICAL", 303, 319], ["General procedure", "TREATMENT", 3, 20], ["the synthesis of diethyl", "TREATMENT", 25, 49], ["benzoyl-b-D-ribofuranos-1-yl)", "TREATMENT", 66, 95], ["aryl or alkylamino)(phenyl)methyl]phosphonates", "TREATMENT", 116, 162], ["jH NMR", "TREATMENT", 166, 172], ["The trimethylsilyl ethynyl phenyl a-aminophosphonates", "TREATMENT", 176, 229], ["tetrabutylammonium fluoride", "TREATMENT", 261, 288]]], ["After 30 min of stirring at room temperature, the reaction mixture was purified by silica gel column chromatography to get ethynyl phenyl aaminophosphonates (3a-j).H NMR andThe terminal alkyne 3 (0.5 mmol) and b-azido-ribose (2.5 equiv.) and triethyl amine (1.1 equiv.) were mixed with CuI (0.1 equiv.).", [["silica gel", "CHEMICAL", 83, 93], ["ethynyl phenyl aaminophosphonates", "CHEMICAL", 123, 156], ["H", "CHEMICAL", 164, 165], ["alkyne", "CHEMICAL", 186, 192], ["b-azido-ribose", "CHEMICAL", 210, 224], ["triethyl amine", "CHEMICAL", 242, 256], ["CuI", "CHEMICAL", 286, 289], ["silica gel", "CHEMICAL", 83, 93], ["ethynyl phenyl aaminophosphonates", "CHEMICAL", 123, 156], ["H", "CHEMICAL", 164, 165], ["alkyne", "CHEMICAL", 186, 192], ["b-azido-ribose", "CHEMICAL", 210, 224], ["triethyl amine", "CHEMICAL", 242, 256], ["CuI", "CHEMICAL", 286, 289], ["silica", "SIMPLE_CHEMICAL", 83, 89], ["ethynyl phenyl aaminophosphonates", "SIMPLE_CHEMICAL", 123, 156], ["b-azido-ribose", "SIMPLE_CHEMICAL", 210, 224], ["2.5 equiv.", "SIMPLE_CHEMICAL", 226, 236], ["triethyl amine", "SIMPLE_CHEMICAL", 242, 256], ["CuI", "SIMPLE_CHEMICAL", 286, 289], ["the reaction mixture", "TREATMENT", 46, 66], ["silica gel column chromatography", "TREATMENT", 83, 115], ["ethynyl phenyl aaminophosphonates", "TREATMENT", 123, 156], ["H NMR", "TEST", 164, 169], ["The terminal alkyne", "TREATMENT", 173, 192], ["b-azido-ribose", "TREATMENT", 210, 224], ["triethyl amine", "TREATMENT", 242, 256], ["CuI", "TREATMENT", 286, 289]]], ["The reaction mixture was homogenized in dry acetonitrile (1 mL) and stirred for 5 min.", [["dry acetonitrile", "CHEMICAL", 40, 56], ["acetonitrile", "CHEMICAL", 44, 56], ["The reaction mixture", "PROBLEM", 0, 20], ["dry acetonitrile", "TREATMENT", 40, 56]]], ["The solvent was evaporated under vacuum.", [["The solvent", "TREATMENT", 0, 11], ["vacuum", "OBSERVATION", 33, 39]]], ["The reaction mixture was then irradiated at the power level 400 W for 2-5 min.", [["The reaction mixture", "PROBLEM", 0, 20]]], ["The residue was purified on silica gel using ethyl acetate/hexane as eluent.", [["silica gel", "CHEMICAL", 28, 38], ["ethyl acetate/hexane", "CHEMICAL", 45, 65], ["silica gel", "CHEMICAL", 28, 38], ["ethyl acetate", "CHEMICAL", 45, 58], ["hexane", "CHEMICAL", 59, 65], ["silica", "SIMPLE_CHEMICAL", 28, 34], ["ethyl acetate", "SIMPLE_CHEMICAL", 45, 58], ["hexane", "SIMPLE_CHEMICAL", 59, 65], ["The residue", "PROBLEM", 0, 11], ["silica gel", "TREATMENT", 28, 38], ["ethyl acetate/hexane", "TREATMENT", 45, 65]]]], "b4da4ff0d2d40c002ea40eb0e610f4949ffaa28a": [["Children with severe acute kidney injury (AKI)Children with AKI need supportive therapy to optimize their general recovery, and recovery of their kidney function.", [["kidney", "ANATOMY", 27, 33], ["kidney", "ANATOMY", 146, 152], ["acute kidney injury", "DISEASE", 21, 40], ["AKI", "DISEASE", 42, 45], ["AKI", "DISEASE", 60, 63], ["Children", "ORGANISM", 0, 8], ["kidney", "ORGAN", 27, 33], ["kidney", "ORGAN", 146, 152], ["Children", "SPECIES", 0, 8], ["Children", "SPECIES", 46, 54], ["severe acute kidney injury", "PROBLEM", 14, 40], ["AKI", "PROBLEM", 60, 63], ["supportive therapy", "TREATMENT", 69, 87], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["kidney", "ANATOMY", 27, 33], ["injury", "OBSERVATION", 34, 40], ["kidney", "ANATOMY", 146, 152]]], ["In some severe cases, KRT is also required.", [["some severe cases", "PROBLEM", 3, 20], ["KRT", "TREATMENT", 22, 25], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20]]], ["Patients with very little or no urine output are most at risk of complications such as lifethreatening hyperkalaemia or fluid overload; where it is available, early initiation of KRT should be considered for these patients.Children with severe acute kidney injury (AKI)Healthy kidneys maintain the balance of children's fluid status and blood pressure, electrolytes, acid-base balance.", [["urine", "ANATOMY", 32, 37], ["fluid", "ANATOMY", 120, 125], ["kidney", "ANATOMY", 250, 256], ["kidneys", "ANATOMY", 277, 284], ["fluid", "ANATOMY", 320, 325], ["blood", "ANATOMY", 337, 342], ["hyperkalaemia", "DISEASE", 103, 116], ["fluid overload", "DISEASE", 120, 134], ["acute kidney injury", "DISEASE", 244, 263], ["AKI", "DISEASE", 265, 268], ["Patients", "ORGANISM", 0, 8], ["urine", "ORGANISM_SUBSTANCE", 32, 37], ["fluid", "ORGANISM_SUBSTANCE", 120, 125], ["KRT", "SIMPLE_CHEMICAL", 179, 182], ["patients", "ORGANISM", 214, 222], ["Children", "ORGANISM", 223, 231], ["kidney", "ORGAN", 250, 256], ["kidneys", "ORGAN", 277, 284], ["children", "ORGANISM", 309, 317], ["fluid", "ORGANISM_SUBSTANCE", 320, 325], ["blood", "ORGANISM_SUBSTANCE", 337, 342], ["electrolytes", "SIMPLE_CHEMICAL", 353, 365], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 214, 222], ["Children", "SPECIES", 223, 231], ["children", "SPECIES", 309, 317], ["urine output", "PROBLEM", 32, 44], ["complications", "PROBLEM", 65, 78], ["lifethreatening hyperkalaemia", "PROBLEM", 87, 116], ["fluid overload", "PROBLEM", 120, 134], ["KRT", "TREATMENT", 179, 182], ["severe acute kidney injury", "PROBLEM", 237, 263], ["fluid status", "TEST", 320, 332], ["blood pressure", "TEST", 337, 351], ["electrolytes", "TEST", 353, 365], ["acid-base balance", "TEST", 367, 384], ["complications", "OBSERVATION", 65, 78], ["hyperkalaemia", "OBSERVATION", 103, 116], ["fluid overload", "OBSERVATION", 120, 134], ["severe", "OBSERVATION_MODIFIER", 237, 243], ["acute", "OBSERVATION_MODIFIER", 244, 249], ["kidney", "ANATOMY", 250, 256], ["injury", "OBSERVATION", 257, 263], ["AKI", "OBSERVATION", 265, 268], ["kidneys", "ANATOMY", 277, 284]]], ["Absolute indications for kidney replacement therapy include hyperkalaemia, intravascular volume overload/systemic hypertension, metabolic acidosis and severe symptomatic uraemia which do not improve with medical management.", [["kidney", "ANATOMY", 25, 31], ["intravascular", "ANATOMY", 75, 88], ["hyperkalaemia", "DISEASE", 60, 73], ["intravascular volume overload", "DISEASE", 75, 104], ["hypertension", "DISEASE", 114, 126], ["metabolic acidosis", "DISEASE", 128, 146], ["uraemia", "DISEASE", 170, 177], ["kidney", "ORGAN", 25, 31], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["Absolute indications", "TREATMENT", 0, 20], ["kidney replacement therapy", "TREATMENT", 25, 51], ["hyperkalaemia", "PROBLEM", 60, 73], ["intravascular volume overload", "PROBLEM", 75, 104], ["systemic hypertension", "PROBLEM", 105, 126], ["metabolic acidosis", "PROBLEM", 128, 146], ["severe symptomatic uraemia", "PROBLEM", 151, 177], ["medical management", "TREATMENT", 204, 222], ["kidney", "ANATOMY", 25, 31], ["replacement", "OBSERVATION", 32, 43], ["hyperkalaemia", "OBSERVATION", 60, 73], ["intravascular volume overload", "OBSERVATION", 75, 104], ["systemic", "OBSERVATION_MODIFIER", 105, 113], ["hypertension", "OBSERVATION", 114, 126], ["metabolic acidosis", "OBSERVATION", 128, 146], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["symptomatic", "OBSERVATION_MODIFIER", 158, 169], ["uraemia", "OBSERVATION", 170, 177]]], ["This is most likely to be the case for a child passing little or no urine (see Box 1) .Infants with severe symptomatic hyperammonaemiaChildren with metabolic disorders such urea cycle defects can present with life threatening encephalopathy secondary to hyperammonaemia.", [["urine", "ANATOMY", 68, 73], ["hyperammonaemiaChildren", "DISEASE", 119, 142], ["metabolic disorders", "DISEASE", 148, 167], ["urea", "CHEMICAL", 173, 177], ["encephalopathy", "DISEASE", 226, 240], ["hyperammonaemia", "DISEASE", 254, 269], ["urea", "CHEMICAL", 173, 177], ["urine", "ORGANISM_SUBSTANCE", 68, 73], ["Infants", "SPECIES", 87, 94], ["severe symptomatic hyperammonaemiaChildren", "PROBLEM", 100, 142], ["metabolic disorders", "PROBLEM", 148, 167], ["such urea cycle defects", "PROBLEM", 168, 191], ["life threatening encephalopathy", "PROBLEM", 209, 240], ["hyperammonaemia", "PROBLEM", 254, 269], ["most likely", "UNCERTAINTY", 8, 19], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["symptomatic", "OBSERVATION_MODIFIER", 107, 118], ["hyperammonaemiaChildren", "OBSERVATION", 119, 142], ["metabolic disorders", "OBSERVATION", 148, 167], ["hyperammonaemia", "OBSERVATION", 254, 269]]], ["Recent international guidelines recommend kidney replacement therapy in the most severely affected patients.", [["kidney", "ANATOMY", 42, 48], ["kidney", "ORGAN", 42, 48], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Recent international guidelines", "TREATMENT", 0, 31], ["kidney replacement therapy", "TREATMENT", 42, 68], ["kidney", "ANATOMY", 42, 48], ["replacement", "OBSERVATION", 49, 60]]], ["Hyperammonaemia and certain toxins can also be managed with high clearance dialysis to ameliorate initial toxicity before maintenance therapies are established.Infants with severe symptomatic hyperammonaemiaWhen should acute kidney replacement therapy be started?Infants with severe symptomatic hyperammonaemiaAside from the immediate life-threatening consequences of metabolic disturbance (e.g. hyperkalaemia resulting in cardiac arrhythmia and non-resolving acidosis), there are other considerations when deciding if a child should receive acute KRT.Infants with severe symptomatic hyperammonaemiaIn adult patients requiring intensive care, early proactive initiation of KRT is associated with lower patient mortality and better recovery of kidney function.", [["kidney", "ANATOMY", 225, 231], ["cardiac", "ANATOMY", 423, 430], ["kidney", "ANATOMY", 743, 749], ["Hyperammonaemia", "DISEASE", 0, 15], ["toxicity", "DISEASE", 106, 114], ["hyperammonaemiaWhen", "DISEASE", 192, 211], ["hyperammonaemiaAside", "DISEASE", 295, 315], ["metabolic disturbance", "DISEASE", 368, 389], ["hyperkalaemia", "DISEASE", 396, 409], ["cardiac arrhythmia", "DISEASE", 423, 441], ["acidosis", "DISEASE", 460, 468], ["Infants", "ORGANISM", 160, 167], ["kidney", "ORGAN", 225, 231], ["Infants", "ORGANISM", 263, 270], ["cardiac", "ORGAN", 423, 430], ["patients", "ORGANISM", 608, 616], ["patient", "ORGANISM", 702, 709], ["kidney", "ORGAN", 743, 749], ["Infants", "SPECIES", 160, 167], ["Infants", "SPECIES", 263, 270], ["Infants", "SPECIES", 552, 559], ["patients", "SPECIES", 608, 616], ["patient", "SPECIES", 702, 709], ["Hyperammonaemia", "PROBLEM", 0, 15], ["certain toxins", "PROBLEM", 20, 34], ["high clearance dialysis", "TREATMENT", 60, 83], ["initial toxicity", "PROBLEM", 98, 114], ["maintenance therapies", "TREATMENT", 122, 143], ["severe symptomatic hyperammonaemiaWhen", "PROBLEM", 173, 211], ["acute kidney replacement therapy", "TREATMENT", 219, 251], ["severe symptomatic hyperammonaemiaAside", "PROBLEM", 276, 315], ["metabolic disturbance", "PROBLEM", 368, 389], ["hyperkalaemia", "PROBLEM", 396, 409], ["cardiac arrhythmia", "PROBLEM", 423, 441], ["non-resolving acidosis", "PROBLEM", 446, 468], ["acute KRT", "TREATMENT", 542, 551], ["severe symptomatic hyperammonaemiaIn adult", "PROBLEM", 565, 607], ["intensive care", "TREATMENT", 627, 641], ["KRT", "TREATMENT", 673, 676], ["lower patient mortality", "PROBLEM", 696, 719], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["symptomatic", "OBSERVATION_MODIFIER", 180, 191], ["kidney", "ANATOMY", 225, 231], ["replacement", "OBSERVATION", 232, 243], ["severe", "OBSERVATION_MODIFIER", 276, 282], ["symptomatic", "OBSERVATION_MODIFIER", 283, 294], ["hyperammonaemiaAside", "OBSERVATION", 295, 315], ["metabolic disturbance", "OBSERVATION", 368, 389], ["cardiac", "ANATOMY", 423, 430], ["arrhythmia", "OBSERVATION", 431, 441], ["acidosis", "OBSERVATION", 460, 468], ["severe", "OBSERVATION_MODIFIER", 565, 571], ["symptomatic", "OBSERVATION_MODIFIER", 572, 583], ["kidney", "ANATOMY", 743, 749]]], ["Evidence is also emerging to support proactive kidney replacement therapy in children with severe AKI, in particular those with significant fluid overload.", [["kidney", "ANATOMY", 47, 53], ["fluid", "ANATOMY", 140, 145], ["AKI", "DISEASE", 98, 101], ["fluid overload", "DISEASE", 140, 154], ["kidney", "ORGAN", 47, 53], ["children", "ORGANISM", 77, 85], ["fluid", "ORGANISM_SUBSTANCE", 140, 145], ["children", "SPECIES", 77, 85], ["support proactive kidney replacement therapy", "TREATMENT", 29, 73], ["severe AKI", "PROBLEM", 91, 101], ["significant fluid overload", "PROBLEM", 128, 154], ["kidney", "ANATOMY", 47, 53], ["replacement", "OBSERVATION", 54, 65], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["AKI", "OBSERVATION", 98, 101], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["fluid overload", "OBSERVATION", 140, 154]]], ["Retrospective studies support early initiation of kidney replacement therapy to aid recovery of both the child, and their kidney function.", [["kidney", "ANATOMY", 50, 56], ["kidney", "ANATOMY", 122, 128], ["kidney", "ORGAN", 50, 56], ["child", "ORGANISM", 105, 110], ["kidney", "ORGAN", 122, 128], ["child", "SPECIES", 105, 110], ["Retrospective studies", "TEST", 0, 21], ["kidney replacement therapy", "TREATMENT", 50, 76], ["kidney", "ANATOMY", 50, 56], ["replacement", "OBSERVATION", 57, 68], ["kidney", "ANATOMY", 122, 128]]], ["Any child for whom kidney replacement therapy may be required warrants early discussion with a paediatric nephrology team.Infants with severe symptomatic hyperammonaemiaWhich modalities of kidney replacement therapy are used to manage AKI?Infants with severe symptomatic hyperammonaemiaContinuous kidney replacement therapy for AKI Continuous kidney replacement therapy is generally used in paediatric intensive care (see Box 3 for another example).", [["kidney", "ANATOMY", 19, 25], ["kidney", "ANATOMY", 189, 195], ["kidney", "ANATOMY", 297, 303], ["kidney", "ANATOMY", 343, 349], ["AKI", "DISEASE", 235, 238], ["AKI", "DISEASE", 328, 331], ["kidney", "ORGAN", 19, 25], ["Infants", "ORGANISM", 122, 129], ["kidney", "ORGAN", 189, 195], ["Infants", "ORGANISM", 239, 246], ["kidney", "ORGAN", 297, 303], ["kidney", "ORGAN", 343, 349], ["Infants", "SPECIES", 122, 129], ["Infants", "SPECIES", 239, 246], ["whom kidney replacement therapy", "TREATMENT", 14, 45], ["severe symptomatic hyperammonaemiaWhich", "PROBLEM", 135, 174], ["kidney replacement therapy", "TREATMENT", 189, 215], ["AKI", "PROBLEM", 235, 238], ["severe symptomatic hyperammonaemiaContinuous kidney replacement therapy", "TREATMENT", 252, 323], ["AKI", "PROBLEM", 328, 331], ["Continuous kidney replacement therapy", "TREATMENT", 332, 369], ["kidney", "ANATOMY", 19, 25], ["replacement", "OBSERVATION", 26, 37], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["symptomatic", "OBSERVATION_MODIFIER", 142, 153], ["hyperammonaemiaWhich", "OBSERVATION", 154, 174], ["kidney", "ANATOMY", 189, 195], ["replacement therapy", "OBSERVATION", 196, 215], ["severe", "OBSERVATION_MODIFIER", 252, 258], ["symptomatic", "OBSERVATION_MODIFIER", 259, 270], ["hyperammonaemiaContinuous", "OBSERVATION", 271, 296], ["kidney", "ANATOMY", 297, 303], ["replacement therapy", "OBSERVATION", 304, 323], ["kidney", "ANATOMY", 343, 349], ["replacement", "OBSERVATION", 350, 361]]], ["Because treatment runs continuously, it mimics continuous kidney function and is therefore more physiological than intermittent dialysis.", [["kidney", "ANATOMY", 58, 64], ["kidney", "ORGAN", 58, 64], ["intermittent dialysis", "TREATMENT", 115, 136], ["kidney", "ANATOMY", 58, 64]]], ["Various continuous kidney replacement modalities are used; the most common in UK PICUs is continuous veno-venous haemofiltration (CVVH).", [["kidney", "ANATOMY", 19, 25], ["kidney", "ORGAN", 19, 25], ["Various continuous kidney replacement modalities", "TREATMENT", 0, 48], ["continuous veno-venous haemofiltration", "TREATMENT", 90, 128], ["CVVH", "TREATMENT", 130, 134], ["kidney", "ANATOMY", 19, 25], ["replacement", "OBSERVATION", 26, 37], ["veno-venous haemofiltration", "OBSERVATION", 101, 128]]], ["Figure 1 shows a typical continuous kidney replacement therapy machine.Infants with severe symptomatic hyperammonaemiaCVVH uses convection to clear solutes such as urea from the circulation.", [["kidney", "ANATOMY", 36, 42], ["hyperammonaemiaCVVH", "DISEASE", 103, 122], ["urea", "CHEMICAL", 164, 168], ["urea", "CHEMICAL", 164, 168], ["kidney", "ORGAN", 36, 42], ["Infants", "ORGANISM", 71, 78], ["urea", "SIMPLE_CHEMICAL", 164, 168], ["Infants", "SPECIES", 71, 78], ["a typical continuous kidney replacement therapy machine", "TREATMENT", 15, 70], ["severe symptomatic hyperammonaemiaCVVH", "PROBLEM", 84, 122], ["kidney", "ANATOMY", 36, 42], ["replacement", "OBSERVATION", 43, 54], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["symptomatic", "OBSERVATION_MODIFIER", 91, 102], ["hyperammonaemiaCVVH", "OBSERVATION", 103, 122], ["circulation", "ANATOMY", 178, 189]]], ["Aqueous fluid with low molecular weight solutes is filtered from plasma through the dialyser membrane, with larger molecular weight molecules such as albumin retained in the circuit.", [["Aqueous fluid", "ANATOMY", 0, 13], ["plasma", "ANATOMY", 65, 71], ["dialyser membrane", "ANATOMY", 84, 101], ["Aqueous fluid", "ORGANISM_SUBSTANCE", 0, 13], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["dialyser membrane", "CELLULAR_COMPONENT", 84, 101], ["albumin", "GENE_OR_GENE_PRODUCT", 150, 157], ["albumin", "PROTEIN", 150, 157], ["Aqueous fluid", "TEST", 0, 13], ["low molecular weight solutes", "PROBLEM", 19, 47], ["plasma through the dialyser membrane", "TREATMENT", 65, 101], ["larger molecular weight molecules", "PROBLEM", 108, 141], ["albumin", "TEST", 150, 157], ["fluid", "OBSERVATION", 8, 13], ["low molecular", "OBSERVATION_MODIFIER", 19, 32], ["dialyser membrane", "OBSERVATION", 84, 101], ["larger", "OBSERVATION_MODIFIER", 108, 114], ["weight molecules", "OBSERVATION", 125, 141], ["circuit", "ANATOMY_MODIFIER", 174, 181]]], ["Filtered fluid is discarded and substituted with crystalloid replacement fluid.", [["Filtered fluid", "TREATMENT", 0, 14], ["crystalloid replacement fluid", "TREATMENT", 49, 78], ["fluid", "OBSERVATION", 9, 14], ["replacement fluid", "OBSERVATION", 61, 78]]], ["The composition of replacement fluid can be tailored according to the patient's electrolyte levels.", [["fluid", "ORGANISM_SUBSTANCE", 31, 36], ["patient", "ORGANISM", 70, 77], ["electrolyte", "SIMPLE_CHEMICAL", 80, 91], ["patient", "SPECIES", 70, 77], ["replacement fluid", "TREATMENT", 19, 36], ["the patient's electrolyte levels", "TEST", 66, 98], ["replacement fluid", "OBSERVATION", 19, 36]]], ["The rate of replacement fluid is adjusted to achieve a desired net fluid balance for the patient.", [["fluid", "ORGANISM_SUBSTANCE", 24, 29], ["fluid", "ORGANISM_SUBSTANCE", 67, 72], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["The rate of replacement fluid", "TREATMENT", 0, 29]]], ["To remove fluid from the patient, the rate of replacement is lower than the filtration rate.Infants with severe symptomatic hyperammonaemiaIf high solute clearance rates are needed, for example to establish rapid control of severe hyperammonaemia, diffusive clearance can be used together with convective clearance.", [["fluid", "ANATOMY", 10, 15], ["hyperammonaemia", "DISEASE", 231, 246], ["fluid", "ORGANISM_SUBSTANCE", 10, 15], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["Infants", "SPECIES", 92, 99], ["fluid", "TREATMENT", 10, 15], ["the rate of replacement", "TREATMENT", 34, 57], ["the filtration rate", "TEST", 72, 91], ["severe symptomatic hyperammonaemiaIf high solute clearance rates", "PROBLEM", 105, 169], ["severe hyperammonaemia", "PROBLEM", 224, 246], ["diffusive clearance", "TREATMENT", 248, 267], ["convective clearance", "TREATMENT", 294, 314], ["fluid", "OBSERVATION", 10, 15], ["replacement", "OBSERVATION", 46, 57], ["lower", "OBSERVATION_MODIFIER", 61, 66], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["symptomatic", "OBSERVATION_MODIFIER", 112, 123], ["severe", "OBSERVATION_MODIFIER", 224, 230], ["hyperammonaemia", "OBSERVATION", 231, 246]]], ["The combination of diffusive clearance (dialysis) and convective clearance (filtration) is known as continuous veno-venohaemodiafiltration (CVVHDF).", [["diffusive clearance (dialysis", "TREATMENT", 19, 48], ["convective clearance (filtration", "TREATMENT", 54, 86], ["continuous veno-venohaemodiafiltration (CVVHDF", "TREATMENT", 100, 146], ["diffusive", "OBSERVATION_MODIFIER", 19, 28], ["clearance", "OBSERVATION_MODIFIER", 29, 38]]], ["Vascular access is needed with a large (typically minimum 10 Fr) central venous catheter to allow sufficient blood flow through the circuit and dialyser (typically 100e500 mL/minute).Infants with severe symptomatic hyperammonaemiaExtracorporeal circuits are anticoagulated to reduce clotting, particularly in the filter membrane.", [["Vascular", "ANATOMY", 0, 8], ["venous", "ANATOMY", 73, 79], ["blood", "ANATOMY", 109, 114], ["filter membrane", "ANATOMY", 313, 328], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["venous", "MULTI-TISSUE_STRUCTURE", 73, 79], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["membrane", "CELLULAR_COMPONENT", 320, 328], ["Infants", "SPECIES", 183, 190], ["a large (typically minimum 10 Fr) central venous catheter", "TREATMENT", 31, 88], ["the circuit", "TREATMENT", 128, 139], ["dialyser", "TREATMENT", 144, 152], ["severe symptomatic hyperammonaemiaExtracorporeal circuits", "TREATMENT", 196, 253], ["clotting", "PROBLEM", 283, 291], ["the filter membrane", "TREATMENT", 309, 328], ["large", "OBSERVATION_MODIFIER", 33, 38], ["central", "ANATOMY_MODIFIER", 65, 72], ["venous", "ANATOMY", 73, 79], ["catheter", "OBSERVATION", 80, 88], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["symptomatic", "OBSERVATION_MODIFIER", 203, 214], ["hyperammonaemiaExtracorporeal circuits", "OBSERVATION", 215, 253], ["clotting", "OBSERVATION", 283, 291], ["filter membrane", "OBSERVATION", 313, 328]]], ["Heparin can be used, although the patient will receive some heparin and therefore a degree of systemic anticoagulation.", [["Heparin", "CHEMICAL", 0, 7], ["heparin", "CHEMICAL", 60, 67], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["patient", "ORGANISM", 34, 41], ["heparin", "SIMPLE_CHEMICAL", 60, 67], ["patient", "SPECIES", 34, 41], ["Heparin", "TREATMENT", 0, 7], ["some heparin", "TREATMENT", 55, 67], ["systemic anticoagulation", "TREATMENT", 94, 118], ["systemic", "OBSERVATION_MODIFIER", 94, 102], ["anticoagulation", "OBSERVATION", 103, 118]]], ["Citrate is an alternative which allows anticoagulation of the extracorporeal circuit, but not the patient.", [["extracorporeal", "ANATOMY", 62, 76], ["Citrate", "CHEMICAL", 0, 7], ["Citrate", "CHEMICAL", 0, 7], ["Citrate", "SIMPLE_CHEMICAL", 0, 7], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["Citrate", "TREATMENT", 0, 7], ["an alternative", "TREATMENT", 11, 25], ["anticoagulation of the extracorporeal circuit", "TREATMENT", 39, 84], ["extracorporeal circuit", "OBSERVATION", 62, 84]]], ["Citrate works by complexing with calcium and thereby inactivating the clotting cascade in the extracorporeal circuit.", [["extracorporeal", "ANATOMY", 94, 108], ["Citrate", "CHEMICAL", 0, 7], ["calcium", "CHEMICAL", 33, 40], ["Citrate", "CHEMICAL", 0, 7], ["calcium", "CHEMICAL", 33, 40], ["Citrate", "SIMPLE_CHEMICAL", 0, 7], ["calcium", "SIMPLE_CHEMICAL", 33, 40], ["Citrate", "TREATMENT", 0, 7], ["calcium", "TREATMENT", 33, 40], ["the clotting cascade", "TREATMENT", 66, 86], ["the extracorporeal circuit", "TREATMENT", 90, 116], ["clotting cascade", "OBSERVATION", 70, 86], ["extracorporeal circuit", "OBSERVATION", 94, 116]]], ["During treatment, exogenous calcium is then infused back into blood as it re-enters the patient, thereby restoring functional coagulation in the patient.", [["blood", "ANATOMY", 62, 67], ["calcium", "CHEMICAL", 28, 35], ["calcium", "CHEMICAL", 28, 35], ["calcium", "SIMPLE_CHEMICAL", 28, 35], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 145, 152], ["treatment", "TREATMENT", 7, 16], ["exogenous calcium", "TREATMENT", 18, 35], ["functional coagulation", "OBSERVATION", 115, 137]]], ["The balance of citrate levels in the extracorporeal circuit, and calcium infusion to the patient must be carefully managed to avoid complications such as symptomatic hypocalcaemia and citrate toxicity, although these are rare in children with normal liver function.Continuous kidney replacement therapy in neonatesFor infants and neonates, extracorporeal therapies carry additional risks because the extracorporeal circuit volume represents a greater proportion of the small child's circulating blood volume than for larger children.", [["extracorporeal", "ANATOMY", 37, 51], ["liver", "ANATOMY", 250, 255], ["kidney", "ANATOMY", 276, 282], ["extracorporeal", "ANATOMY", 400, 414], ["blood", "ANATOMY", 495, 500], ["citrate", "CHEMICAL", 15, 22], ["calcium", "CHEMICAL", 65, 72], ["hypocalcaemia", "DISEASE", 166, 179], ["citrate", "CHEMICAL", 184, 191], ["toxicity", "DISEASE", 192, 200], ["citrate", "CHEMICAL", 15, 22], ["calcium", "CHEMICAL", 65, 72], ["citrate", "CHEMICAL", 184, 191], ["citrate", "SIMPLE_CHEMICAL", 15, 22], ["calcium", "SIMPLE_CHEMICAL", 65, 72], ["patient", "ORGANISM", 89, 96], ["citrate", "SIMPLE_CHEMICAL", 184, 191], ["children", "ORGANISM", 229, 237], ["liver", "ORGAN", 250, 255], ["kidney", "ORGAN", 276, 282], ["infants", "ORGANISM", 318, 325], ["extracorporeal circuit", "MULTI-TISSUE_STRUCTURE", 400, 422], ["blood", "ORGANISM_SUBSTANCE", 495, 500], ["children", "ORGANISM", 524, 532], ["patient", "SPECIES", 89, 96], ["children", "SPECIES", 229, 237], ["infants", "SPECIES", 318, 325], ["children", "SPECIES", 524, 532], ["citrate levels", "TREATMENT", 15, 29], ["the extracorporeal circuit", "TREATMENT", 33, 59], ["calcium infusion", "TREATMENT", 65, 81], ["complications", "PROBLEM", 132, 145], ["symptomatic hypocalcaemia", "PROBLEM", 154, 179], ["citrate toxicity", "PROBLEM", 184, 200], ["Continuous kidney replacement therapy", "TREATMENT", 265, 302], ["extracorporeal therapies", "TREATMENT", 340, 364], ["the extracorporeal circuit volume", "TREATMENT", 396, 429], ["extracorporeal circuit", "ANATOMY", 37, 59], ["symptomatic", "OBSERVATION_MODIFIER", 154, 165], ["hypocalcaemia", "OBSERVATION", 166, 179], ["liver", "ANATOMY", 250, 255], ["kidney", "ANATOMY", 276, 282], ["replacement", "OBSERVATION", 283, 294], ["extracorporeal circuit", "OBSERVATION", 400, 422], ["greater", "OBSERVATION_MODIFIER", 443, 450], ["small", "OBSERVATION_MODIFIER", 469, 474]]], ["Traditionally, peritoneal dialysis was the only option for babies weighing less than approximately 2.5 kg, however in recent years two novel systems have been developed for infants and are currently undergoing evaluation in clinical trials.", [["peritoneal", "ANATOMY", 15, 25], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 15, 25], ["babies", "ORGANISM", 59, 65], ["infants", "ORGANISM", 173, 180], ["infants", "SPECIES", 173, 180], ["peritoneal dialysis", "TREATMENT", 15, 34], ["evaluation", "TEST", 210, 220], ["peritoneal", "ANATOMY", 15, 25], ["dialysis", "OBSERVATION", 26, 34]]], ["The Newcastle Infant Dialysis and Ultrafiltration System (NIDUS) uses a simple but novel system to achieve clearance and fluid removal.", [["fluid", "ANATOMY", 121, 126], ["The Newcastle Infant Dialysis", "TREATMENT", 0, 29], ["Ultrafiltration System", "TREATMENT", 34, 56], ["a simple but novel system", "TREATMENT", 70, 95], ["fluid removal", "TREATMENT", 121, 134]]], ["It uses a similar principle as an exchange blood transfusion: an aliquot of blood is removed from the patient, dialysed, and then returned to the patient.", [["blood", "ANATOMY", 43, 48], ["blood", "ANATOMY", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["patient", "ORGANISM", 102, 109], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 102, 109], ["patient", "SPECIES", 146, 153], ["an exchange blood transfusion", "TREATMENT", 31, 60], ["an aliquot of blood", "TREATMENT", 62, 81]]], ["Because the NIDUSKRT in acute kidney injuryA 4 year old girl presents to the emergency department with a 2 day history of bloody diarrhoea and worsening lethargy following a school trip to a petting farm.", [["kidney", "ANATOMY", 30, 36], ["acute kidney injuryA", "DISEASE", 24, 44], ["diarrhoea", "DISEASE", 129, 138], ["lethargy", "DISEASE", 153, 161], ["kidney", "ORGAN", 30, 36], ["NIDUSKRT", "DNA", 12, 20], ["girl", "SPECIES", 56, 60], ["acute kidney injuryA", "PROBLEM", 24, 44], ["bloody diarrhoea", "PROBLEM", 122, 138], ["worsening lethargy", "PROBLEM", 143, 161], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["kidney", "ANATOMY", 30, 36], ["worsening", "OBSERVATION_MODIFIER", 143, 152], ["lethargy", "OBSERVATION", 153, 161]]], ["She is pale and lethargic, but warm peripherally and well perfused with systolic blood pressure 118 mmHg measured manually.", [["blood", "ANATOMY", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["lethargic", "PROBLEM", 16, 25], ["systolic blood pressure", "TEST", 72, 95], ["pale", "OBSERVATION", 7, 11], ["lethargic", "OBSERVATION", 16, 25], ["warm", "OBSERVATION", 31, 35], ["perfused", "OBSERVATION", 58, 66]]], ["Initial blood results show Hb 46 g/L, platelets 14, WBC 21, Na 134 mmol/L, K 7.3 mmol/L, urea 46 mmol/L, bicarbonate 12 mmol/L, creatinine 456 mmol/L. She is unable to pass urine for urinalysis.", [["blood", "ANATOMY", 8, 13], ["platelets", "ANATOMY", 38, 47], ["urine", "ANATOMY", 173, 178], ["Na", "CHEMICAL", 60, 62], ["urea", "CHEMICAL", 89, 93], ["bicarbonate", "CHEMICAL", 105, 116], ["creatinine", "CHEMICAL", 128, 138], ["Na", "CHEMICAL", 60, 62], ["urea", "CHEMICAL", 89, 93], ["bicarbonate", "CHEMICAL", 105, 116], ["creatinine", "CHEMICAL", 128, 138], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["Hb", "GENE_OR_GENE_PRODUCT", 27, 29], ["platelets", "CELL", 38, 47], ["urea", "SIMPLE_CHEMICAL", 89, 93], ["bicarbonate", "SIMPLE_CHEMICAL", 105, 116], ["creatinine", "SIMPLE_CHEMICAL", 128, 138], ["urine", "ORGANISM_SUBSTANCE", 173, 178], ["Hb", "PROTEIN", 27, 29], ["platelets", "CELL_TYPE", 38, 47], ["Hb", "TEST", 27, 29], ["platelets", "TEST", 38, 47], ["WBC", "TEST", 52, 55], ["Na", "TEST", 60, 62], ["mmol", "TEST", 67, 71], ["L", "TEST", 72, 73], ["K", "TEST", 75, 76], ["mmol", "TEST", 81, 85], ["L", "TEST", 86, 87], ["urea", "TEST", 89, 93], ["mmol", "TEST", 97, 101], ["bicarbonate", "TEST", 105, 116], ["creatinine", "TEST", 128, 138], ["urinalysis", "TEST", 183, 193]]], ["You suspect Shiga toxin associated haemolytic Uraemic Syndrome.", [["Shiga toxin", "CHEMICAL", 12, 23], ["haemolytic Uraemic Syndrome", "DISEASE", 35, 62], ["Shiga toxin", "GENE_OR_GENE_PRODUCT", 12, 23], ["Shiga toxin", "PROTEIN", 12, 23], ["Shiga toxin", "PROBLEM", 12, 23], ["haemolytic Uraemic Syndrome", "PROBLEM", 35, 62], ["Shiga", "OBSERVATION_MODIFIER", 12, 17], ["toxin associated", "OBSERVATION_MODIFIER", 18, 34], ["haemolytic", "OBSERVATION_MODIFIER", 35, 45], ["Uraemic Syndrome", "OBSERVATION", 46, 62]]], ["After medical management of hyperkalaemia with calcium gluconate, sodium bicarbonate, intravenous fluid bolus and furosemide, she does not pass urine over the subsequent 4 hours.", [["intravenous", "ANATOMY", 86, 97], ["urine", "ANATOMY", 144, 149], ["hyperkalaemia", "DISEASE", 28, 41], ["calcium gluconate", "CHEMICAL", 47, 64], ["sodium bicarbonate", "CHEMICAL", 66, 84], ["furosemide", "CHEMICAL", 114, 124], ["calcium gluconate", "CHEMICAL", 47, 64], ["sodium bicarbonate", "CHEMICAL", 66, 84], ["furosemide", "CHEMICAL", 114, 124], ["calcium gluconate", "SIMPLE_CHEMICAL", 47, 64], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 66, 84], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 86, 97], ["fluid", "ORGANISM_SUBSTANCE", 98, 103], ["furosemide", "SIMPLE_CHEMICAL", 114, 124], ["urine", "ORGANISM_SUBSTANCE", 144, 149], ["medical management", "TREATMENT", 6, 24], ["hyperkalaemia", "PROBLEM", 28, 41], ["calcium gluconate", "TREATMENT", 47, 64], ["sodium bicarbonate", "TREATMENT", 66, 84], ["intravenous fluid bolus", "TREATMENT", 86, 109], ["furosemide", "TREATMENT", 114, 124], ["hyperkalaemia", "OBSERVATION", 28, 41]]], ["Her bladder appears empty on ultrasound.", [["bladder", "ANATOMY", 4, 11], ["bladder", "ORGAN", 4, 11], ["ultrasound", "TEST", 29, 39], ["bladder", "ANATOMY", 4, 11], ["empty", "OBSERVATION", 20, 25]]], ["After discussion with the tertiary paediatric nephrology unit, she is transferred for kidney replacement therapy.", [["kidney", "ANATOMY", 86, 92], ["kidney", "ORGAN", 86, 92], ["kidney replacement therapy", "TREATMENT", 86, 112], ["kidney", "ANATOMY", 86, 92], ["replacement", "OBSERVATION", 93, 104]]], ["A peritoneal dialysis catheter is placed on the emergency theatre list, and acute peritoneal dialysis commenced that night.", [["peritoneal", "ANATOMY", 2, 12], ["peritoneal", "ANATOMY", 82, 92], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 2, 12], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 82, 92], ["A peritoneal dialysis catheter", "TREATMENT", 0, 30], ["acute peritoneal dialysis", "TREATMENT", 76, 101], ["peritoneal", "ANATOMY", 2, 12], ["dialysis catheter", "OBSERVATION", 13, 30], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["peritoneal", "ANATOMY", 82, 92], ["dialysis", "OBSERVATION", 93, 101]]], ["Within 4 hours, her plasma potassium concentration has reduced to 4.3 mmol/L with urea 37 mmol/L. She receives peritoneal dialysis for 5 days until her urine output returns and kidney function recovers.Box 1 KRT in hyperammonaemiaA 5-day-old boy with a history of worsening irritability and vomiting presented with cyanosis, gasping and no spontaneous movement.", [["plasma", "ANATOMY", 20, 26], ["peritoneal", "ANATOMY", 111, 121], ["urine", "ANATOMY", 152, 157], ["kidney", "ANATOMY", 177, 183], ["potassium", "CHEMICAL", 27, 36], ["urea", "CHEMICAL", 82, 86], ["irritability", "DISEASE", 274, 286], ["vomiting", "DISEASE", 291, 299], ["cyanosis", "DISEASE", 315, 323], ["potassium", "CHEMICAL", 27, 36], ["urea", "CHEMICAL", 82, 86], ["plasma", "ORGANISM_SUBSTANCE", 20, 26], ["potassium", "SIMPLE_CHEMICAL", 27, 36], ["urea", "SIMPLE_CHEMICAL", 82, 86], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 111, 121], ["urine", "ORGANISM_SUBSTANCE", 152, 157], ["kidney", "ORGAN", 177, 183], ["Box 1 KRT", "GENE_OR_GENE_PRODUCT", 202, 211], ["boy", "ORGANISM", 242, 245], ["Box 1 KRT", "DNA", 202, 211], ["boy", "SPECIES", 242, 245], ["her plasma potassium concentration", "TEST", 16, 50], ["urea", "TEST", 82, 86], ["peritoneal dialysis", "TREATMENT", 111, 130], ["her urine output", "TEST", 148, 164], ["kidney function", "TEST", 177, 192], ["worsening irritability", "PROBLEM", 264, 286], ["vomiting", "PROBLEM", 291, 299], ["cyanosis", "PROBLEM", 315, 323], ["gasping", "PROBLEM", 325, 332], ["spontaneous movement", "PROBLEM", 340, 360], ["peritoneal", "ANATOMY", 111, 121], ["dialysis", "OBSERVATION", 122, 130], ["kidney", "ANATOMY", 177, 183], ["worsening", "OBSERVATION_MODIFIER", 264, 273], ["irritability", "OBSERVATION", 274, 286], ["cyanosis", "OBSERVATION", 315, 323], ["no", "UNCERTAINTY", 337, 339], ["spontaneous movement", "OBSERVATION", 340, 360]]], ["He was haemodynamically unstable.", [["haemodynamically unstable", "PROBLEM", 7, 32], ["haemodynamically", "OBSERVATION_MODIFIER", 7, 23], ["unstable", "OBSERVATION", 24, 32]]], ["Initial investigations showed plasma ammonia concentration 857 mmol/L, and a urea cycle disorder was suspected.", [["plasma", "ANATOMY", 30, 36], ["ammonia", "CHEMICAL", 37, 44], ["urea", "CHEMICAL", 77, 81], ["ammonia", "CHEMICAL", 37, 44], ["urea", "CHEMICAL", 77, 81], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["ammonia", "SIMPLE_CHEMICAL", 37, 44], ["urea", "SIMPLE_CHEMICAL", 77, 81], ["Initial investigations", "TEST", 0, 22], ["plasma ammonia concentration", "TEST", 30, 58], ["a urea cycle disorder", "PROBLEM", 75, 96]]], ["He was ventilated.", [["He", "ORGANISM", 0, 2], ["ventilated", "TREATMENT", 7, 17], ["ventilated", "OBSERVATION", 7, 17]]], ["Because of his haemodynamic instability and very high ammonia level causing encephalopathy, a double lumen central venous catheter was inserted and continuous kidney replacement therapy (CVVHDF) was started.", [["lumen", "ANATOMY", 101, 106], ["venous", "ANATOMY", 115, 121], ["kidney", "ANATOMY", 159, 165], ["ammonia", "CHEMICAL", 54, 61], ["encephalopathy", "DISEASE", 76, 90], ["ammonia", "CHEMICAL", 54, 61], ["ammonia", "SIMPLE_CHEMICAL", 54, 61], ["venous", "MULTI-TISSUE_STRUCTURE", 115, 121], ["kidney", "ORGAN", 159, 165], ["his haemodynamic instability", "PROBLEM", 11, 39], ["very high ammonia level", "PROBLEM", 44, 67], ["encephalopathy", "PROBLEM", 76, 90], ["a double lumen central venous catheter", "TREATMENT", 92, 130], ["continuous kidney replacement therapy", "TREATMENT", 148, 185], ["CVVHDF", "TREATMENT", 187, 193], ["haemodynamic instability", "OBSERVATION", 15, 39], ["very", "OBSERVATION_MODIFIER", 44, 48], ["high ammonia", "OBSERVATION", 49, 61], ["encephalopathy", "OBSERVATION", 76, 90], ["lumen", "ANATOMY_MODIFIER", 101, 106], ["central", "ANATOMY_MODIFIER", 107, 114], ["venous", "ANATOMY", 115, 121], ["catheter", "OBSERVATION", 122, 130], ["kidney", "ANATOMY", 159, 165], ["replacement", "OBSERVATION", 166, 177]]], ["After one hour of CVVHDF he began moving spontaneously.", [["CVVHDF", "TREATMENT", 18, 24]]], ["After 2 hours, plasma ammonia concentration had decreased to 342 mmol/L. A diagnosis of OTC deficiency was subsequently made, and he went on to receive a successful liver transplant.", [["plasma", "ANATOMY", 15, 21], ["liver", "ANATOMY", 165, 170], ["ammonia", "CHEMICAL", 22, 29], ["OTC deficiency", "DISEASE", 88, 102], ["ammonia", "CHEMICAL", 22, 29], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["ammonia", "SIMPLE_CHEMICAL", 22, 29], ["OTC", "CANCER", 88, 91], ["liver", "ORGAN", 165, 170], ["plasma ammonia concentration", "TEST", 15, 43], ["OTC deficiency", "PROBLEM", 88, 102], ["a successful liver transplant", "TREATMENT", 152, 181], ["OTC deficiency", "OBSERVATION", 88, 102], ["liver", "ANATOMY", 165, 170], ["transplant", "OBSERVATION", 171, 181]]], ["Possible indications for KRT in treatment of hyperammonaemia 1 : C Rapidly deteriorating neurological status, coma, or cerebral oedema C Persistently high blood ammonia levels >400 mmol/L (681 mg/dL) refractory to non-kidney replacement therapy (NKRT) medical measures C Rapid rise in ammonia levels >300 mmol/L (511 mg/dL) within a few hours that cannot be controlled via NKRT medical measures Box 2Short-term CVVH as a bridge to recovery in PIMS-TSA 6 year old boy presents to the emergency department with fever, sore throat, lethargy, erythematous rash, cracked lips, neck pain and diarrhoea.", [["neurological", "ANATOMY", 89, 101], ["cerebral", "ANATOMY", 119, 127], ["blood", "ANATOMY", 155, 160], ["non-kidney", "ANATOMY", 214, 224], ["lips", "ANATOMY", 566, 570], ["neck", "ANATOMY", 572, 576], ["KRT", "CHEMICAL", 25, 28], ["hyperammonaemia", "DISEASE", 45, 60], ["coma", "DISEASE", 110, 114], ["cerebral oedema", "DISEASE", 119, 134], ["ammonia", "CHEMICAL", 161, 168], ["ammonia", "CHEMICAL", 285, 292], ["fever", "DISEASE", 509, 514], ["sore throat", "DISEASE", 516, 527], ["lethargy", "DISEASE", 529, 537], ["rash", "DISEASE", 552, 556], ["cracked lips", "DISEASE", 558, 570], ["neck pain", "DISEASE", 572, 581], ["diarrhoea", "DISEASE", 586, 595], ["ammonia", "CHEMICAL", 161, 168], ["ammonia", "CHEMICAL", 285, 292], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["ammonia", "SIMPLE_CHEMICAL", 161, 168], ["ammonia", "SIMPLE_CHEMICAL", 285, 292], ["boy", "ORGANISM", 463, 466], ["lips", "ORGANISM_SUBDIVISION", 566, 570], ["neck", "ORGANISM_SUBDIVISION", 572, 576], ["boy", "SPECIES", 463, 466], ["KRT", "TREATMENT", 25, 28], ["hyperammonaemia", "PROBLEM", 45, 60], ["Rapidly deteriorating neurological status", "PROBLEM", 67, 108], ["coma", "PROBLEM", 110, 114], ["cerebral oedema", "PROBLEM", 119, 134], ["Persistently high blood ammonia levels", "PROBLEM", 137, 175], ["non-kidney replacement therapy", "TREATMENT", 214, 244], ["medical measures", "TREATMENT", 252, 268], ["Rapid rise", "PROBLEM", 271, 281], ["ammonia levels", "TEST", 285, 299], ["CVVH", "TREATMENT", 411, 415], ["fever", "PROBLEM", 509, 514], ["sore throat", "PROBLEM", 516, 527], ["lethargy", "PROBLEM", 529, 537], ["erythematous rash", "PROBLEM", 539, 556], ["cracked lips", "PROBLEM", 558, 570], ["neck pain", "PROBLEM", 572, 581], ["diarrhoea", "PROBLEM", 586, 595], ["hyperammonaemia", "OBSERVATION", 45, 60], ["cerebral", "ANATOMY", 119, 127], ["oedema", "OBSERVATION", 128, 134], ["fever", "OBSERVATION", 509, 514], ["sore throat", "ANATOMY", 516, 527], ["erythematous", "OBSERVATION_MODIFIER", 539, 551], ["rash", "OBSERVATION", 552, 556], ["lips", "ANATOMY", 566, 570], ["neck", "ANATOMY", 572, 576], ["pain", "OBSERVATION", 577, 581], ["diarrhoea", "OBSERVATION", 586, 595]]], ["He has not passed urine for 24 hours.", [["urine", "ANATOMY", 18, 23], ["He", "ORGANISM", 0, 2], ["urine", "ORGANISM_SUBSTANCE", 18, 23]]], ["He is breathing in air but hypotensive and shocked with systolic blood pressure 68 mmHg.", [["blood", "ANATOMY", 65, 70], ["hypotensive", "DISEASE", 27, 38], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["hypotensive", "PROBLEM", 27, 38], ["systolic blood pressure", "TEST", 56, 79], ["breathing", "OBSERVATION", 6, 15], ["air", "OBSERVATION", 19, 22], ["hypotensive", "OBSERVATION", 27, 38]]], ["On examination, he has an erythematous rash, bleeding cracked lips, conjunctival injection, and lymphadenopathy.", [["erythematous", "ANATOMY", 26, 38], ["lips", "ANATOMY", 62, 66], ["conjunctival", "ANATOMY", 68, 80], ["rash", "DISEASE", 39, 43], ["bleeding", "DISEASE", 45, 53], ["lymphadenopathy", "DISEASE", 96, 111], ["lips", "ORGANISM_SUBDIVISION", 62, 66], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 68, 80], ["examination", "TEST", 3, 14], ["an erythematous rash", "PROBLEM", 23, 43], ["bleeding cracked lips", "PROBLEM", 45, 66], ["conjunctival injection", "PROBLEM", 68, 90], ["lymphadenopathy", "PROBLEM", 96, 111], ["erythematous", "OBSERVATION_MODIFIER", 26, 38], ["rash", "OBSERVATION", 39, 43], ["bleeding", "OBSERVATION", 45, 53], ["lips", "ANATOMY", 62, 66], ["conjunctival", "ANATOMY", 68, 80], ["lymphadenopathy", "OBSERVATION", 96, 111]]], ["Investigations show pH 7.28, 22.5 HCO3, Lactate 2.2, WBC 18.2, Hb 94, plt 36, Troponin 109, Ferritin: 6698, potassium 7.4 mmol/L, urea: 42.9 mmol/L, creatinine 321 mmol/l.", [["Lactate", "CHEMICAL", 40, 47], ["potassium", "CHEMICAL", 108, 117], ["urea", "CHEMICAL", 130, 134], ["creatinine", "CHEMICAL", 149, 159], ["HCO3", "CHEMICAL", 34, 38], ["Lactate", "CHEMICAL", 40, 47], ["potassium", "CHEMICAL", 108, 117], ["urea", "CHEMICAL", 130, 134], ["creatinine", "CHEMICAL", 149, 159], ["Lactate", "SIMPLE_CHEMICAL", 40, 47], ["Troponin 109", "GENE_OR_GENE_PRODUCT", 78, 90], ["Ferritin", "GENE_OR_GENE_PRODUCT", 92, 100], ["potassium", "SIMPLE_CHEMICAL", 108, 117], ["urea", "SIMPLE_CHEMICAL", 130, 134], ["creatinine", "SIMPLE_CHEMICAL", 149, 159], ["Investigations", "TEST", 0, 14], ["pH", "TEST", 20, 22], ["HCO3", "TEST", 34, 38], ["Lactate", "TEST", 40, 47], ["WBC", "TEST", 53, 56], ["Hb", "TEST", 63, 65], ["plt", "TEST", 70, 73], ["Troponin", "TEST", 78, 86], ["Ferritin", "TEST", 92, 100], ["potassium", "TEST", 108, 117], ["mmol", "TEST", 122, 126], ["urea", "TEST", 130, 134], ["mmol", "TEST", 141, 145], ["creatinine", "TEST", 149, 159]]], ["Chest X-ray shows bilateral infiltrates.", [["Chest X-ray", "TEST", 0, 11], ["bilateral infiltrates", "PROBLEM", 18, 39], ["bilateral", "ANATOMY_MODIFIER", 18, 27], ["infiltrates", "OBSERVATION", 28, 39]]], ["Following fluid resuscitation with 40 ml/kg isotonic fluid, blood pressure and perfusion improve however he passes no urine.", [["fluid", "ANATOMY", 10, 15], ["blood", "ANATOMY", 60, 65], ["urine", "ANATOMY", 118, 123], ["fluid", "ORGANISM_SUBSTANCE", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["urine", "ORGANISM_SUBSTANCE", 118, 123], ["fluid resuscitation", "TREATMENT", 10, 29], ["isotonic fluid", "TREATMENT", 44, 58], ["blood pressure", "TEST", 60, 74]]], ["Plasma potassium concentration remains elevated at 7.2 mmol/L. After discussion with the paediatric intensive care and paediatric nephrology units, he is transferred for kidney replacement therapy.", [["kidney", "ANATOMY", 170, 176], ["potassium", "CHEMICAL", 7, 16], ["potassium", "CHEMICAL", 7, 16], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["potassium", "SIMPLE_CHEMICAL", 7, 16], ["kidney", "ORGAN", 170, 176], ["Plasma potassium concentration", "TEST", 0, 30], ["elevated", "PROBLEM", 39, 47], ["kidney replacement therapy", "TREATMENT", 170, 196], ["kidney", "ANATOMY", 170, 176], ["replacement", "OBSERVATION", 177, 188]]], ["Following transfer to PICU, a temporary central venous catheter (Vascath) is inserted under anaesthetic, and continus venovenohaemofiltraton started.", [["venous", "ANATOMY", 48, 54], ["venovenohaemofiltraton", "CHEMICAL", 118, 140], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 48, 63], ["venovenohaemofiltraton", "SIMPLE_CHEMICAL", 118, 140], ["a temporary central venous catheter (Vascath)", "TREATMENT", 28, 73], ["anaesthetic", "TREATMENT", 92, 103], ["continus venovenohaemofiltraton", "TREATMENT", 109, 140], ["central", "ANATOMY_MODIFIER", 40, 47], ["venous", "ANATOMY", 48, 54], ["catheter", "OBSERVATION", 55, 63]]], ["After 24 hours, plasma electrolyte and acid-base status normalized.", [["plasma", "ANATOMY", 16, 22], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["electrolyte", "SIMPLE_CHEMICAL", 23, 34], ["acid", "SIMPLE_CHEMICAL", 39, 43], ["plasma electrolyte", "TEST", 16, 34], ["acid-base status", "TEST", 39, 55], ["base", "ANATOMY_MODIFIER", 44, 48]]], ["After 48 hours of supportive care, he begins to pass urine and CVVH is discontinued.", [["urine", "ANATOMY", 53, 58], ["urine", "ORGANISM_SUBSTANCE", 53, 58], ["supportive care", "TREATMENT", 18, 33], ["CVVH", "TREATMENT", 63, 67]]], ["Nasopharyngeal aspirate for respiratory viral pCR is positive for Covid-19.", [["Nasopharyngeal aspirate", "ANATOMY", 0, 23], ["respiratory", "ANATOMY", 28, 39], ["respiratory viral pCR", "DISEASE", 28, 49], ["Nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 23], ["Nasopharyngeal aspirate", "TEST", 0, 23], ["respiratory viral pCR", "TEST", 28, 49], ["Covid", "TEST", 66, 71], ["aspirate", "OBSERVATION", 15, 23]]], ["A diagnosis of Paediatric Inflammatory Multisystem Syndrome Temporally related to SARS-CoV-2 infection (PIMS-TS) is made.Box 3SYMPOSIUM: NEPHROLOGY PAEDIATRICS AND CHILD HEALTH xxx:xxx does not use a continuous circuit, vascular access requirements are less stringent than other therapies, and infants as small as 800 g bodyweight can be dialysed via a 22 gauge cannula.", [["vascular", "ANATOMY", 220, 228], ["Inflammatory Multisystem Syndrome", "DISEASE", 26, 59], ["SARS-CoV-2 infection", "DISEASE", 82, 102], ["vascular", "MULTI-TISSUE_STRUCTURE", 220, 228], ["infants", "ORGANISM", 294, 301], ["infants", "SPECIES", 294, 301], ["SARS-CoV-2", "SPECIES", 82, 92], ["Paediatric Inflammatory Multisystem Syndrome", "PROBLEM", 15, 59], ["SARS", "PROBLEM", 82, 86], ["CoV-2 infection", "PROBLEM", 87, 102], ["a continuous circuit", "TREATMENT", 198, 218], ["vascular access requirements", "TREATMENT", 220, 248], ["other therapies", "TREATMENT", 273, 288], ["a 22 gauge cannula", "TREATMENT", 351, 369], ["Paediatric", "OBSERVATION_MODIFIER", 15, 25], ["Inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["Multisystem Syndrome", "OBSERVATION", 39, 59], ["infection", "OBSERVATION", 93, 102], ["vascular", "ANATOMY", 220, 228]]], ["2 The CARdiorenal PEDIatric EMergency (CARPEDIEM) machine has also been developed to allow continuous kidney replacement therapy in infants.", [["kidney", "ANATOMY", 102, 108], ["kidney", "ORGAN", 102, 108], ["infants", "ORGANISM", 132, 139], ["infants", "SPECIES", 132, 139], ["continuous kidney replacement therapy", "TREATMENT", 91, 128], ["CARdiorenal", "ANATOMY", 6, 17], ["kidney", "ANATOMY", 102, 108], ["replacement", "OBSERVATION", 109, 120]]], ["This is a continuous circuit therapy that requires double lumen vascular access which has been used to dialyse small infants with success.", [["lumen vascular", "ANATOMY", 58, 72], ["vascular", "MULTI-TISSUE_STRUCTURE", 64, 72], ["infants", "ORGANISM", 117, 124], ["infants", "SPECIES", 117, 124], ["a continuous circuit therapy", "TREATMENT", 8, 36], ["double lumen vascular access", "TREATMENT", 51, 79], ["lumen", "ANATOMY_MODIFIER", 58, 63], ["vascular", "ANATOMY", 64, 72]]], ["3 Intermittent kidney replacement therapy for AKI Whilst continuous kidney replacement therapy allows superior physiological control of fluid and solute removal, it is generally only used in intensive care.", [["kidney", "ANATOMY", 15, 21], ["kidney", "ANATOMY", 68, 74], ["AKI", "DISEASE", 46, 49], ["kidney", "ORGAN", 15, 21], ["kidney", "ORGAN", 68, 74], ["fluid", "ORGANISM_SUBSTANCE", 136, 141], ["solute", "SIMPLE_CHEMICAL", 146, 152], ["Intermittent kidney replacement therapy", "TREATMENT", 2, 41], ["AKI", "PROBLEM", 46, 49], ["continuous kidney replacement therapy", "TREATMENT", 57, 94], ["fluid and solute removal", "TREATMENT", 136, 160], ["kidney", "ANATOMY", 15, 21], ["replacement", "OBSERVATION", 22, 33], ["AKI", "OBSERVATION", 46, 49], ["kidney", "ANATOMY", 68, 74], ["replacement", "OBSERVATION", 75, 86], ["fluid", "OBSERVATION", 136, 141]]], ["Some children with AKI require kidney replacement for several days or weeks before sufficient recovery of their kidney function allows kidney support to be discontinued.", [["kidney", "ANATOMY", 31, 37], ["kidney", "ANATOMY", 112, 118], ["kidney", "ANATOMY", 135, 141], ["AKI", "DISEASE", 19, 22], ["children", "ORGANISM", 5, 13], ["kidney", "ORGAN", 31, 37], ["kidney", "ORGAN", 112, 118], ["kidney", "ORGAN", 135, 141], ["children", "SPECIES", 5, 13], ["AKI", "PROBLEM", 19, 22], ["kidney replacement", "TREATMENT", 31, 49], ["kidney support", "TREATMENT", 135, 149], ["AKI", "OBSERVATION", 19, 22], ["kidney", "ANATOMY", 31, 37], ["replacement", "OBSERVATION", 38, 49], ["kidney", "ANATOMY", 112, 118], ["kidney", "ANATOMY", 135, 141]]], ["For children not requiring respiratory or circulatory support on PICU, intermittent dialysis on a paediatric nephrology ward is used.", [["respiratory", "ANATOMY", 27, 38], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["circulatory support", "TREATMENT", 42, 61], ["intermittent dialysis", "TREATMENT", 71, 92]]], ["Options include both acute peritoneal dialysis and haemodialysis; choice of modality depends on the needs of the individual child and paediatric nephrology unit practices.Children with end-stage kidney disease (ESKD)Most children with ESKD receive KRT.", [["peritoneal", "ANATOMY", 27, 37], ["kidney", "ANATOMY", 195, 201], ["end-stage kidney disease", "DISEASE", 185, 209], ["ESKD", "DISEASE", 211, 215], ["ESKD", "DISEASE", 235, 239], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 27, 37], ["Children", "ORGANISM", 171, 179], ["kidney", "ORGAN", 195, 201], ["children", "ORGANISM", 221, 229], ["Children", "SPECIES", 171, 179], ["children", "SPECIES", 221, 229], ["both acute peritoneal dialysis", "TREATMENT", 16, 46], ["haemodialysis", "TREATMENT", 51, 64], ["end-stage kidney disease", "PROBLEM", 185, 209], ["ESKD", "PROBLEM", 235, 239], ["KRT", "TREATMENT", 248, 251], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["peritoneal", "ANATOMY", 27, 37], ["dialysis", "OBSERVATION", 38, 46], ["-stage", "OBSERVATION_MODIFIER", 188, 194], ["kidney", "ANATOMY", 195, 201], ["disease", "OBSERVATION", 202, 209]]], ["The choice of KRT modality depends on factors such as size of the child, timing of the child's presentation to nephrology services, family factors that influence suitability for home dialysis therapies, medical comorbidities which may preclude certain modalities for individual patients, and practice patterns of the treating paediatric nephrology unit.", [["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["KRT modality", "TREATMENT", 14, 26], ["home dialysis therapies", "TREATMENT", 178, 201], ["medical comorbidities", "PROBLEM", 203, 224]]], ["For example, haemodialysis is technically challenging in small infants because the volume of blood circulating in the extracorporeal dialysis circuit represents a relatively large proportion of the child's total blood volume.", [["blood", "ANATOMY", 93, 98], ["extracorporeal", "ANATOMY", 118, 132], ["blood", "ANATOMY", 212, 217], ["infants", "ORGANISM", 63, 70], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["blood", "ORGANISM_SUBSTANCE", 212, 217], ["infants", "SPECIES", 63, 70], ["haemodialysis", "TREATMENT", 13, 26], ["the extracorporeal dialysis circuit", "TREATMENT", 114, 149], ["haemodialysis", "OBSERVATION", 13, 26], ["small", "OBSERVATION_MODIFIER", 57, 62], ["extracorporeal", "OBSERVATION_MODIFIER", 118, 132], ["dialysis circuit", "OBSERVATION", 133, 149], ["relatively", "OBSERVATION_MODIFIER", 163, 173], ["large", "OBSERVATION_MODIFIER", 174, 179], ["proportion", "OBSERVATION_MODIFIER", 180, 190]]], ["Peritoneal dialysis is generally preferred in infants but may not be feasible for those who have had previous abdominal surgery with a stoma.", [["Peritoneal", "ANATOMY", 0, 10], ["abdominal", "ANATOMY", 110, 119], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 0, 10], ["infants", "ORGANISM", 46, 53], ["abdominal", "ORGANISM_SUBDIVISION", 110, 119], ["infants", "SPECIES", 46, 53], ["Peritoneal dialysis", "TREATMENT", 0, 19], ["previous abdominal surgery", "TREATMENT", 101, 127], ["a stoma", "TREATMENT", 133, 140], ["dialysis", "OBSERVATION", 11, 19], ["abdominal", "ANATOMY", 110, 119], ["surgery", "OBSERVATION", 120, 127], ["stoma", "OBSERVATION", 135, 140]]], ["Pre-emptive transplantation is preferred for children with ESKD; this may not be feasible for children who present at a late stage as workup for kidney transplantation typically takes several months.Children with end-stage kidney disease (ESKD)For children with ESKD, dialysis is generally used as a bridge to kidney transplantation.", [["kidney", "ANATOMY", 145, 151], ["kidney", "ANATOMY", 223, 229], ["kidney", "ANATOMY", 310, 316], ["ESKD", "DISEASE", 59, 63], ["end-stage kidney disease", "DISEASE", 213, 237], ["ESKD", "DISEASE", 239, 243], ["ESKD", "DISEASE", 262, 266], ["children", "ORGANISM", 45, 53], ["children", "ORGANISM", 94, 102], ["kidney", "ORGAN", 145, 151], ["Children", "ORGANISM", 199, 207], ["kidney", "ORGAN", 223, 229], ["children", "ORGANISM", 248, 256], ["kidney", "ORGAN", 310, 316], ["children", "SPECIES", 45, 53], ["children", "SPECIES", 94, 102], ["Children", "SPECIES", 199, 207], ["children", "SPECIES", 248, 256], ["Pre-emptive transplantation", "TREATMENT", 0, 27], ["workup", "TEST", 134, 140], ["kidney transplantation", "TREATMENT", 145, 167], ["end-stage kidney disease", "PROBLEM", 213, 237], ["ESKD", "PROBLEM", 262, 266], ["dialysis", "TREATMENT", 268, 276], ["a bridge to kidney transplantation", "TREATMENT", 298, 332], ["kidney", "ANATOMY", 145, 151], ["transplantation", "OBSERVATION", 152, 167], ["-stage", "OBSERVATION_MODIFIER", 216, 222], ["kidney", "ANATOMY", 223, 229], ["disease", "OBSERVATION", 230, 237], ["kidney", "ANATOMY", 310, 316], ["transplantation", "OBSERVATION", 317, 332]]], ["Home therapies (peritoneal dialysis or home haemodialysis) are usually preferable however the family situation may not be suitable to safely undertake dialysis at home.", [["peritoneal", "ANATOMY", 16, 26], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 16, 26], ["Home therapies", "TREATMENT", 0, 14], ["peritoneal dialysis", "TREATMENT", 16, 35], ["home haemodialysis", "TREATMENT", 39, 57], ["dialysis", "TREATMENT", 151, 159], ["peritoneal", "ANATOMY", 16, 26]]], ["Decisions about KRT are made in partnership with the family with support of a kidney multi-professional team including specialist nurses, family support workers, dieticians, social workers, psychologists, play therapists and doctors.Children with end-stage kidney disease (ESKD)For some children with extensive co-morbidites, the burdens of KRT may be considered greater than its benefits for the individual child.", [["kidney", "ANATOMY", 78, 84], ["kidney", "ANATOMY", 257, 263], ["end-stage kidney disease", "DISEASE", 247, 271], ["ESKD", "DISEASE", 273, 277], ["KRT", "CANCER", 16, 19], ["kidney", "ORGAN", 78, 84], ["Children", "ORGANISM", 233, 241], ["kidney", "ORGAN", 257, 263], ["children", "ORGANISM", 287, 295], ["Children", "SPECIES", 233, 241], ["children", "SPECIES", 287, 295], ["KRT", "TREATMENT", 16, 19], ["end-stage kidney disease", "PROBLEM", 247, 271], ["extensive co-morbidites", "PROBLEM", 301, 324], ["KRT", "TREATMENT", 341, 344], ["kidney", "ANATOMY", 78, 84], ["-stage", "OBSERVATION_MODIFIER", 250, 256], ["kidney", "ANATOMY", 257, 263], ["disease", "OBSERVATION", 264, 271]]], ["In such situations, the child's family may opt for a conservative pathway with a focus on symptom control.Pre-emptive kidney transplantFirst-choice kidney replacement therapy for children with ESKD is a pre-emptive kidney transplant, i.e. transplant before dialysis is required.", [["kidney", "ANATOMY", 118, 124], ["kidney", "ANATOMY", 148, 154], ["kidney", "ANATOMY", 215, 221], ["ESKD", "DISEASE", 193, 197], ["child", "ORGANISM", 24, 29], ["kidney", "ORGAN", 118, 124], ["kidney", "ORGAN", 148, 154], ["children", "ORGANISM", 179, 187], ["kidney", "ORGAN", 215, 221], ["children", "SPECIES", 179, 187], ["a conservative pathway", "TREATMENT", 51, 73], ["symptom control", "TREATMENT", 90, 105], ["Pre-emptive kidney transplant", "TREATMENT", 106, 135], ["First-choice kidney replacement therapy", "TREATMENT", 135, 174], ["ESKD", "TREATMENT", 193, 197], ["a pre-emptive kidney transplant", "TREATMENT", 201, 232], ["transplant", "TREATMENT", 239, 249], ["dialysis", "TREATMENT", 257, 265], ["kidney", "ANATOMY", 118, 124], ["transplant", "OBSERVATION", 125, 135], ["kidney", "ANATOMY", 148, 154], ["replacement", "OBSERVATION", 155, 166], ["kidney", "ANATOMY", 215, 221], ["transplant", "OBSERVATION", 222, 232]]], ["A living related donor transplant is preferable to deceased donor transplant and has favourable transplant longevity.", [["A living related donor transplant", "TREATMENT", 0, 33], ["donor transplant", "TREATMENT", 60, 76], ["transplant", "OBSERVATION", 23, 33], ["transplant", "OBSERVATION", 66, 76], ["favourable", "OBSERVATION_MODIFIER", 85, 95], ["transplant longevity", "OBSERVATION", 96, 116]]], ["For many children with ESKD, pre-emptive living donor transplant is achieved, however it is not always feasible for various reasons including size of the child, availability of a suitable living donor and timing of presentation with ESKD.Pre-emptive kidney transplantChildren must be at least 10 kg bodyweight for kidney transplantation.", [["kidney", "ANATOMY", 250, 256], ["kidney", "ANATOMY", 314, 320], ["ESKD", "DISEASE", 23, 27], ["ESKD", "DISEASE", 233, 237], ["children", "ORGANISM", 9, 17], ["kidney", "ORGAN", 250, 256], ["Children", "ORGANISM", 267, 275], ["kidney", "ORGAN", 314, 320], ["children", "SPECIES", 9, 17], ["Children", "SPECIES", 267, 275], ["ESKD", "PROBLEM", 23, 27], ["pre-emptive living donor transplant", "TREATMENT", 29, 64], ["a suitable living donor", "TREATMENT", 177, 200], ["ESKD", "PROBLEM", 233, 237], ["Pre-emptive kidney transplant", "TREATMENT", 238, 267], ["kidney transplantation", "TREATMENT", 314, 336], ["kidney", "ANATOMY", 250, 256], ["transplant", "OBSERVATION", 257, 267], ["kidney", "ANATOMY", 314, 320], ["transplantation", "OBSERVATION", 321, 336]]], ["Extensive preparation for both the recipient and donor is essential.", [["Extensive preparation", "TREATMENT", 0, 21]]], ["Donor and recipient blood group and HLA tissue typing bloods are used to assess compatibly.", [["blood", "ANATOMY", 20, 25], ["tissue", "ANATOMY", 40, 46], ["bloods", "ANATOMY", 54, 60], ["Donor", "CELL", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["HLA tissue", "TISSUE", 36, 46], ["bloods", "ORGANISM_SUBSTANCE", 54, 60], ["Donor", "TREATMENT", 0, 5], ["recipient blood group", "TEST", 10, 31], ["HLA tissue typing bloods", "TEST", 36, 60]]], ["Vascular imaging is performed to ensure patency of vessels for the transplant operation (iliac vessels or aorta/inferior vena cava in small children).", [["Vascular", "ANATOMY", 0, 8], ["vessels", "ANATOMY", 51, 58], ["iliac vessels", "ANATOMY", 89, 102], ["aorta", "ANATOMY", 106, 111], ["inferior vena cava", "ANATOMY", 112, 130], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vessels", "MULTI-TISSUE_STRUCTURE", 51, 58], ["iliac vessels", "MULTI-TISSUE_STRUCTURE", 89, 102], ["aorta", "MULTI-TISSUE_STRUCTURE", 106, 111], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 112, 130], ["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148], ["Vascular imaging", "TEST", 0, 16], ["the transplant operation", "TREATMENT", 63, 87], ["aorta/inferior vena cava", "TREATMENT", 106, 130], ["patency", "OBSERVATION", 40, 47], ["vessels", "ANATOMY", 51, 58], ["transplant", "OBSERVATION", 67, 77], ["iliac vessels", "ANATOMY", 89, 102], ["aorta", "ANATOMY", 106, 111], ["inferior vena cava", "ANATOMY", 112, 130], ["small", "OBSERVATION_MODIFIER", 134, 139]]], ["A recent echocardiogram is needed to ensure that the child's heart will support the fluid loading required at the time of transplant operation.", [["heart", "ANATOMY", 61, 66], ["fluid", "ANATOMY", 84, 89], ["child", "ORGANISM", 53, 58], ["heart", "ORGAN", 61, 66], ["fluid", "ORGANISM_SUBSTANCE", 84, 89], ["A recent echocardiogram", "TEST", 0, 23], ["the fluid loading", "TREATMENT", 80, 97], ["transplant operation", "TREATMENT", 122, 142], ["heart", "ANATOMY", 61, 66], ["fluid loading", "OBSERVATION", 84, 97]]], ["Additional vaccinations are needed prior to receiving transplant immunosuppressive medications.", [["Additional vaccinations", "TREATMENT", 0, 23], ["transplant immunosuppressive medications", "TREATMENT", 54, 94]]], ["Bladder function must be assessed to ensure that urinary drainage from the transplant can be established.", [["Bladder", "ANATOMY", 0, 7], ["urinary", "ANATOMY", 49, 56], ["Bladder", "ORGAN", 0, 7], ["urinary", "ORGANISM_SUBDIVISION", 49, 56], ["urinary drainage", "TREATMENT", 49, 65], ["the transplant", "TREATMENT", 71, 85], ["urinary", "ANATOMY", 49, 56], ["drainage", "OBSERVATION", 57, 65]]], ["A detailed psychosocial assessment with play therapy preparation for the child is needed so that they are fully prepared for the operation and post-transplant care.", [["child", "ORGANISM", 73, 78], ["A detailed psychosocial assessment", "TEST", 0, 34], ["therapy preparation", "TREATMENT", 45, 64], ["the operation", "TREATMENT", 125, 138], ["post-transplant care", "TREATMENT", 143, 163]]], ["This preparation takes several months, and is vital to ensure the safety and optimisation of the transplant for the child.Pre-emptive kidney transplantWhen successfully transplanted, children's appetite, growth, energy levels and overall wellbeing improve.", [["kidney", "ANATOMY", 134, 140], ["child", "ORGANISM", 116, 121], ["kidney", "ORGAN", 134, 140], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191], ["the transplant", "TREATMENT", 93, 107], ["Pre-emptive kidney transplant", "TREATMENT", 122, 151], ["energy levels", "TEST", 212, 225], ["transplant", "OBSERVATION", 97, 107], ["kidney", "ANATOMY", 134, 140], ["transplant", "OBSERVATION", 141, 151]]], ["The duration for which a kidney transplant provides sufficient function varies.", [["kidney", "ANATOMY", 25, 31], ["kidney", "ORGAN", 25, 31], ["a kidney transplant", "TREATMENT", 23, 42], ["kidney", "ANATOMY", 25, 31], ["transplant", "OBSERVATION", 32, 42]]], ["The most significant factor influencing this is concordance with immunosuppressive medication.", [["immunosuppressive medication", "TREATMENT", 65, 93], ["most significant", "OBSERVATION_MODIFIER", 4, 20]]], ["Transplants typically last somewhere in the region of 15 years, although this varies considerably according to quality of the donor organ, concordance with immunosuppressive medication, native kidney disease, bladder drainage and other factors.", [["organ", "ANATOMY", 132, 137], ["kidney", "ANATOMY", 193, 199], ["bladder", "ANATOMY", 209, 216], ["kidney disease", "DISEASE", 193, 207], ["organ", "ORGAN", 132, 137], ["kidney", "ORGAN", 193, 199], ["bladder", "ORGAN", 209, 216], ["Transplants", "TREATMENT", 0, 11], ["immunosuppressive medication", "TREATMENT", 156, 184], ["native kidney disease", "PROBLEM", 186, 207], ["bladder drainage", "TREATMENT", 209, 225], ["other factors", "PROBLEM", 230, 243], ["kidney", "ANATOMY", 193, 199], ["disease", "OBSERVATION", 200, 207], ["bladder", "ANATOMY", 209, 216], ["drainage", "OBSERVATION", 217, 225]]], ["See Box 4.Peritoneal dialysis (PD)In PD, the peritoneal membrane is utilized to exchange solutes and water.", [["Peritoneal", "ANATOMY", 10, 20], ["peritoneal membrane", "ANATOMY", 45, 64], ["PD", "DISEASE", 37, 39], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 10, 20], ["peritoneal membrane", "MULTI-TISSUE_STRUCTURE", 45, 64], ["water", "SIMPLE_CHEMICAL", 101, 106], ["Box 4", "DNA", 4, 9], ["Peritoneal dialysis (PD)", "TREATMENT", 10, 34], ["PD", "TREATMENT", 37, 39], ["the peritoneal membrane", "TREATMENT", 41, 64], ["dialysis", "OBSERVATION", 21, 29], ["peritoneal membrane", "ANATOMY", 45, 64]]], ["Solutes such as urea, phosphate, potassium and sodium diffuse out of peritoneal capillaries into dialysate solution which is instilled into the abdomen via a peritoneal dialysis catheter.", [["peritoneal capillaries", "ANATOMY", 69, 91], ["abdomen", "ANATOMY", 144, 151], ["peritoneal", "ANATOMY", 158, 168], ["urea", "CHEMICAL", 16, 20], ["phosphate", "CHEMICAL", 22, 31], ["potassium", "CHEMICAL", 33, 42], ["sodium", "CHEMICAL", 47, 53], ["urea", "CHEMICAL", 16, 20], ["phosphate", "CHEMICAL", 22, 31], ["potassium", "CHEMICAL", 33, 42], ["sodium", "CHEMICAL", 47, 53], ["urea", "SIMPLE_CHEMICAL", 16, 20], ["phosphate", "SIMPLE_CHEMICAL", 22, 31], ["potassium", "SIMPLE_CHEMICAL", 33, 42], ["sodium", "SIMPLE_CHEMICAL", 47, 53], ["peritoneal capillaries", "MULTI-TISSUE_STRUCTURE", 69, 91], ["abdomen", "ORGAN", 144, 151], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 158, 168], ["urea, phosphate, potassium", "TEST", 16, 42], ["sodium diffuse out of peritoneal capillaries", "PROBLEM", 47, 91], ["dialysate solution", "TREATMENT", 97, 115], ["a peritoneal dialysis catheter", "TREATMENT", 156, 186], ["diffuse", "OBSERVATION_MODIFIER", 54, 61], ["peritoneal capillaries", "ANATOMY", 69, 91], ["abdomen", "ANATOMY", 144, 151], ["peritoneal", "ANATOMY", 158, 168], ["dialysis catheter", "OBSERVATION", 169, 186]]], ["Excess intravascular fluid is drawn from peritoneal capillaries by the osmotic load of the dialysate fluid.", [["intravascular fluid", "ANATOMY", 7, 26], ["peritoneal capillaries", "ANATOMY", 41, 63], ["dialysate fluid", "ANATOMY", 91, 106], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 7, 20], ["fluid", "ORGANISM_SUBSTANCE", 21, 26], ["peritoneal capillaries", "MULTI-TISSUE_STRUCTURE", 41, 63], ["dialysate fluid", "ORGANISM_SUBSTANCE", 91, 106], ["Excess intravascular fluid", "PROBLEM", 0, 26], ["peritoneal capillaries", "TEST", 41, 63], ["the dialysate fluid", "TREATMENT", 87, 106], ["intravascular fluid", "OBSERVATION", 7, 26], ["peritoneal", "ANATOMY", 41, 51], ["capillaries", "ANATOMY_MODIFIER", 52, 63], ["dialysate fluid", "OBSERVATION", 91, 106]]], ["Spent dialysate fluid is then drained to an effluent bag.Peritoneal dialysis (PD)PD access comprises an intra-abdominal catheter.", [["Peritoneal", "ANATOMY", 57, 67], ["intra-abdominal", "ANATOMY", 104, 119], ["dialysate", "ORGANISM_SUBSTANCE", 6, 15], ["fluid", "ORGANISM_SUBSTANCE", 16, 21], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 57, 67], ["Spent dialysate fluid", "TREATMENT", 0, 21], ["an effluent bag", "TREATMENT", 41, 56], ["Peritoneal dialysis (PD)PD access", "TREATMENT", 57, 90], ["an intra-abdominal catheter", "TREATMENT", 101, 128], ["fluid", "OBSERVATION", 16, 21], ["effluent bag", "OBSERVATION", 44, 56], ["dialysis", "OBSERVATION", 68, 76], ["intra-abdominal", "ANATOMY", 104, 119], ["catheter", "OBSERVATION", 120, 128]]], ["During surgical catheter placement, the catheter is tunnelled through the abdominal wall; two cuffs minimise infection risk.", [["catheter", "ANATOMY", 16, 24], ["abdominal wall", "ANATOMY", 74, 88], ["infection", "DISEASE", 109, 118], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 74, 88], ["surgical catheter placement", "TREATMENT", 7, 34], ["the catheter", "TREATMENT", 36, 48], ["two cuffs minimise infection risk", "PROBLEM", 90, 123], ["catheter placement", "OBSERVATION", 16, 34], ["catheter", "OBSERVATION", 40, 48], ["tunnelled", "OBSERVATION", 52, 61], ["abdominal wall", "ANATOMY", 74, 88], ["two", "OBSERVATION_MODIFIER", 90, 93], ["cuffs", "OBSERVATION_MODIFIER", 94, 99], ["minimise", "OBSERVATION_MODIFIER", 100, 108], ["infection", "OBSERVATION", 109, 118]]], ["The tip of the catheter is usually coiled in the pelvis.", [["pelvis", "ANATOMY", 49, 55], ["pelvis", "ORGAN", 49, 55], ["the catheter", "TREATMENT", 11, 23], ["tip", "OBSERVATION_MODIFIER", 4, 7], ["catheter", "OBSERVATION", 15, 23], ["usually", "OBSERVATION_MODIFIER", 27, 34], ["coiled", "OBSERVATION", 35, 41], ["pelvis", "ANATOMY", 49, 55]]], ["Constipation can affect catheter position and function.Peritoneal dialysis (PD)For most children on PD, automated peritoneal dialysis (APD) is performed overnight during sleep.", [["catheter", "ANATOMY", 24, 32], ["Peritoneal", "ANATOMY", 55, 65], ["peritoneal", "ANATOMY", 114, 124], ["Constipation", "DISEASE", 0, 12], ["PD", "DISEASE", 100, 102], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 55, 65], ["children", "ORGANISM", 88, 96], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 114, 124], ["children", "SPECIES", 88, 96], ["Constipation", "PROBLEM", 0, 12], ["Peritoneal dialysis (PD)", "TREATMENT", 55, 79], ["PD", "TREATMENT", 100, 102], ["automated peritoneal dialysis", "TREATMENT", 104, 133], ["catheter", "OBSERVATION", 24, 32], ["dialysis", "OBSERVATION", 66, 74], ["peritoneal", "ANATOMY", 114, 124], ["dialysis", "OBSERVATION", 125, 133]]], ["An APD machine cycles heated dialysate fluid from sterile bags into the patient's abdomen, leaves it to dwell within the abdomen for a specified time, then drains spent fluid to an effluent bag.", [["abdomen", "ANATOMY", 82, 89], ["abdomen", "ANATOMY", 121, 128], ["patient", "ORGANISM", 72, 79], ["abdomen", "ORGANISM_SUBDIVISION", 82, 89], ["abdomen", "ORGAN", 121, 128], ["patient", "SPECIES", 72, 79], ["An APD machine cycles heated dialysate fluid", "TREATMENT", 0, 44], ["sterile bags", "TREATMENT", 50, 62], ["an effluent bag", "TREATMENT", 178, 193], ["abdomen", "ANATOMY", 82, 89], ["abdomen", "ANATOMY", 121, 128], ["drains", "OBSERVATION", 156, 162], ["effluent bag", "OBSERVATION", 181, 193]]], ["This automated cycle is repeated approximately 6e12 times, depending on the dialysis prescription.Life after kidney transplantationA 5 year old boy has been under the care of the paediatric nephrology team since birth following antenatal detection of dysplastic kidneys.", [["kidney", "ANATOMY", 109, 115], ["dysplastic kidneys", "ANATOMY", 251, 269], ["kidney", "ORGAN", 109, 115], ["boy", "ORGANISM", 144, 147], ["kidneys", "ORGAN", 262, 269], ["boy", "SPECIES", 144, 147], ["the dialysis prescription", "TREATMENT", 72, 97], ["dysplastic kidneys", "PROBLEM", 251, 269], ["kidney", "ANATOMY", 109, 115], ["dysplastic", "OBSERVATION", 251, 261], ["kidneys", "ANATOMY", 262, 269]]], ["For the first 5 years of life he had advanced chronic kidney disease with polyuria.", [["kidney", "ANATOMY", 54, 60], ["chronic kidney disease", "DISEASE", 46, 68], ["polyuria", "DISEASE", 74, 82], ["kidney", "ORGAN", 54, 60], ["advanced chronic kidney disease", "PROBLEM", 37, 68], ["polyuria", "PROBLEM", 74, 82], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["kidney", "ANATOMY", 54, 60], ["disease", "OBSERVATION", 61, 68], ["polyuria", "OBSERVATION", 74, 82]]], ["With regular input from paediatric renal dieticians, specialist nurses and a paediatric nephrologist he grew along the ninth centile and maintained acceptable blood count (on darbepoietin and iron supplements), bone chemistry (on vitamin D and phosphate binders) and acid-base status (on sodium bicarbonate supplementation).", [["renal", "ANATOMY", 35, 40], ["blood", "ANATOMY", 159, 164], ["bone", "ANATOMY", 211, 215], ["darbepoietin", "CHEMICAL", 175, 187], ["iron", "CHEMICAL", 192, 196], ["vitamin D", "CHEMICAL", 230, 239], ["phosphate", "CHEMICAL", 244, 253], ["sodium bicarbonate", "CHEMICAL", 288, 306], ["darbepoietin", "CHEMICAL", 175, 187], ["iron", "CHEMICAL", 192, 196], ["vitamin D", "CHEMICAL", 230, 239], ["phosphate", "CHEMICAL", 244, 253], ["sodium bicarbonate", "CHEMICAL", 288, 306], ["renal", "ORGAN", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["darbepoietin", "SIMPLE_CHEMICAL", 175, 187], ["iron", "SIMPLE_CHEMICAL", 192, 196], ["bone", "TISSUE", 211, 215], ["vitamin D", "SIMPLE_CHEMICAL", 230, 239], ["phosphate binders", "SIMPLE_CHEMICAL", 244, 261], ["sodium", "SIMPLE_CHEMICAL", 288, 294], ["bicarbonate", "SIMPLE_CHEMICAL", 295, 306], ["blood count", "TEST", 159, 170], ["darbepoietin", "TREATMENT", 175, 187], ["iron supplements", "TREATMENT", 192, 208], ["bone chemistry", "TEST", 211, 225], ["vitamin D and phosphate binders", "TREATMENT", 230, 261], ["acid-base status", "TEST", 267, 283], ["sodium bicarbonate supplementation", "TREATMENT", 288, 322], ["renal", "ANATOMY", 35, 40], ["base", "ANATOMY_MODIFIER", 272, 276]]], ["When he reached 3 years of age, his father underwent living kidney donor workup in preparation for transplant when required.", [["kidney", "ANATOMY", 60, 66], ["kidney", "ORGAN", 60, 66], ["living kidney donor workup", "TEST", 53, 79], ["transplant", "TREATMENT", 99, 109], ["kidney", "ANATOMY", 60, 66]]], ["At 5 years of age, the child began to experience worsening symptoms of reduced appetite and vomiting and high blood pressure.", [["blood", "ANATOMY", 110, 115], ["vomiting", "DISEASE", 92, 100], ["child", "ORGANISM", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["child", "SPECIES", 23, 28], ["worsening symptoms", "PROBLEM", 49, 67], ["reduced appetite", "PROBLEM", 71, 87], ["vomiting", "PROBLEM", 92, 100], ["high blood pressure", "PROBLEM", 105, 124]]], ["A decision was taken to proceed with preemptive living related donor transplant.", [["preemptive living related donor transplant", "TREATMENT", 37, 79], ["transplant", "OBSERVATION", 69, 79]]], ["Three months following transplant he had normal kidney function, blood count and blood pressure taking regular immunosuppressive medication.", [["kidney", "ANATOMY", 48, 54], ["blood", "ANATOMY", 65, 70], ["blood", "ANATOMY", 81, 86], ["kidney", "ORGAN", 48, 54], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["transplant", "TREATMENT", 23, 33], ["blood count", "TEST", 65, 76], ["blood pressure", "TEST", 81, 95], ["regular immunosuppressive medication", "TREATMENT", 103, 139], ["kidney", "ANATOMY", 48, 54]]], ["His energy levels had markedly improved, as had his appetite and growth.", [["His energy levels", "TEST", 0, 17], ["markedly", "OBSERVATION_MODIFIER", 22, 30], ["improved", "OBSERVATION_MODIFIER", 31, 39]]], ["Later that year, he won a silver medal for swimming at the annual national transplant games.", [["silver medal", "CHEMICAL", 26, 38], ["silver", "CHEMICAL", 26, 32]]], ["Continuous ambulatory peritoneal dialysis (CAPD) can be used as an alternative but is generally preferred for adults.", [["peritoneal", "ANATOMY", 22, 32], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 22, 32], ["Continuous ambulatory peritoneal dialysis (CAPD)", "TREATMENT", 0, 48], ["peritoneal", "ANATOMY", 22, 32]]], ["CAPD involves the patient or parents undertaking manual exchanges of dialysate fluid several times in a 24-hour period without the need for a machine.Life after kidney transplantationPeritoneal dialysis is a home therapy which can be successfully undertaken even in very small and young babies (See Box 5).", [["kidney", "ANATOMY", 161, 167], ["Peritoneal", "ANATOMY", 183, 193], ["patient", "ORGANISM", 18, 25], ["kidney", "ORGAN", 161, 167], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 183, 193], ["patient", "SPECIES", 18, 25], ["CAPD", "TREATMENT", 0, 4], ["manual exchanges of dialysate fluid", "TREATMENT", 49, 84], ["a machine", "TREATMENT", 140, 149], ["kidney transplantation", "TREATMENT", 161, 183], ["Peritoneal dialysis", "TREATMENT", 183, 202], ["a home therapy", "TREATMENT", 206, 220], ["kidney", "ANATOMY", 161, 167], ["transplantation", "OBSERVATION", 168, 183], ["dialysis", "OBSERVATION", 194, 202]]], ["Prior to embarking on peritoneal dialysis, specialist nurses usually undertake a home visit to ensure suitability of the child's home to accommodate dialysis fluid supplies and the machine.", [["peritoneal", "ANATOMY", 22, 32], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 22, 32], ["peritoneal dialysis", "TREATMENT", 22, 41], ["dialysis fluid supplies", "TREATMENT", 149, 172], ["the machine", "TREATMENT", 177, 188], ["peritoneal", "ANATOMY", 22, 32]]], ["Parents or carers are trained to undertake peritoneal dialysis for the child at home.Life after kidney transplantationPeritonitis is a common complication of peritoneal dialysis.", [["peritoneal", "ANATOMY", 43, 53], ["kidney", "ANATOMY", 96, 102], ["peritoneal", "ANATOMY", 158, 168], ["Peritonitis", "DISEASE", 118, 129], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["kidney", "ORGAN", 96, 102], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 158, 168], ["peritoneal dialysis", "TREATMENT", 43, 62], ["kidney transplantation", "TREATMENT", 96, 118], ["Peritonitis", "PROBLEM", 118, 129], ["a common complication", "PROBLEM", 133, 154], ["peritoneal dialysis", "TREATMENT", 158, 177], ["peritoneal", "ANATOMY", 43, 53], ["kidney", "ANATOMY", 96, 102], ["transplantation", "OBSERVATION", 103, 118], ["peritoneal", "ANATOMY", 158, 168], ["dialysis", "OBSERVATION", 169, 177]]], ["If a child experiences fever, vomiting, abdominal pain or cloudy peritoneal dialysis effluent fluid then urgent medical assessment is needed with advice from the paediatric nephrology team.", [["abdominal", "ANATOMY", 40, 49], ["peritoneal", "ANATOMY", 65, 75], ["fever", "DISEASE", 23, 28], ["vomiting", "DISEASE", 30, 38], ["abdominal pain", "DISEASE", 40, 54], ["abdominal", "ORGANISM_SUBDIVISION", 40, 49], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 65, 75], ["fever", "PROBLEM", 23, 28], ["vomiting", "PROBLEM", 30, 38], ["abdominal pain", "PROBLEM", 40, 54], ["cloudy peritoneal dialysis effluent fluid", "PROBLEM", 58, 99], ["urgent medical assessment", "TEST", 105, 130], ["abdominal", "ANATOMY", 40, 49], ["cloudy", "OBSERVATION_MODIFIER", 58, 64], ["peritoneal", "ANATOMY", 65, 75]]], ["A sample of peritoneal dialysis fluid should be sent urgently for microscopy, and treatment started with intraperitoneal antibiotics if microscopy is suggestive of infection.", [["sample", "ANATOMY", 2, 8], ["peritoneal", "ANATOMY", 12, 22], ["intraperitoneal", "ANATOMY", 105, 120], ["infection", "DISEASE", 164, 173], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 12, 22], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 120], ["peritoneal dialysis fluid", "TREATMENT", 12, 37], ["microscopy", "TEST", 66, 76], ["treatment", "TREATMENT", 82, 91], ["intraperitoneal antibiotics", "TREATMENT", 105, 132], ["microscopy", "TEST", 136, 146], ["infection", "PROBLEM", 164, 173], ["peritoneal", "ANATOMY", 12, 22], ["dialysis fluid", "OBSERVATION", 23, 37], ["suggestive of", "UNCERTAINTY", 150, 163], ["infection", "OBSERVATION", 164, 173]]], ["Intravenous antibiotics should be given if the child has signs of sepsis in discussion with the paediatric nephrology team.HaemodialysisHaemodialysis uses diffusion to clear solutes such as urea and potassium from the patient.", [["sepsis", "DISEASE", 66, 72], ["Haemodialysis", "DISEASE", 136, 149], ["urea", "CHEMICAL", 190, 194], ["potassium", "CHEMICAL", 199, 208], ["urea", "CHEMICAL", 190, 194], ["potassium", "CHEMICAL", 199, 208], ["child", "ORGANISM", 47, 52], ["urea", "SIMPLE_CHEMICAL", 190, 194], ["potassium", "SIMPLE_CHEMICAL", 199, 208], ["patient", "ORGANISM", 218, 225], ["patient", "SPECIES", 218, 225], ["Intravenous antibiotics", "TREATMENT", 0, 23], ["sepsis", "PROBLEM", 66, 72], ["HaemodialysisHaemodialysis", "TREATMENT", 123, 149], ["urea and potassium", "TEST", 190, 208], ["sepsis", "OBSERVATION", 66, 72]]], ["In addition, excess fluid is removed from the patient by ultrafiltration generated by a pressure difference across the dialysis membrane between the patient blood side (higher pressure) and the dialysate fluid side of the membrane.HaemodialysisA typical haemodialysis treatment regimen for children dialysed in a paediatric nephrology unit comprises three sessions per week, each session lasting between three and five hours.", [["membrane", "ANATOMY", 128, 136], ["blood", "ANATOMY", 157, 162], ["dialysate fluid", "ANATOMY", 194, 209], ["membrane", "ANATOMY", 222, 230], ["fluid", "ORGANISM_SUBSTANCE", 20, 25], ["patient", "ORGANISM", 46, 53], ["membrane", "CELLULAR_COMPONENT", 128, 136], ["patient", "ORGANISM", 149, 156], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["membrane", "CELLULAR_COMPONENT", 222, 230], ["children", "ORGANISM", 290, 298], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 149, 156], ["children", "SPECIES", 290, 298], ["excess fluid", "PROBLEM", 13, 25], ["ultrafiltration", "TREATMENT", 57, 72], ["a pressure difference", "PROBLEM", 86, 107], ["the dialysis membrane", "TREATMENT", 115, 136], ["the dialysate fluid", "TEST", 190, 209], ["Haemodialysis", "TREATMENT", 231, 244], ["A typical haemodialysis treatment regimen", "TREATMENT", 244, 285], ["excess", "OBSERVATION_MODIFIER", 13, 19], ["fluid", "OBSERVATION", 20, 25], ["dialysis membrane", "OBSERVATION", 119, 136], ["dialysate fluid", "OBSERVATION", 194, 209], ["membrane", "ANATOMY_MODIFIER", 222, 230]]], ["More frequent dialysis sessions are needed for infants because it is rarely possible to achieve adequate control of fluid status when receiving liquid feeds with three dialysis sessions per week.", [["fluid", "ANATOMY", 116, 121], ["infants", "ORGANISM", 47, 54], ["fluid", "ORGANISM_SUBSTANCE", 116, 121], ["infants", "SPECIES", 47, 54], ["frequent dialysis sessions", "TREATMENT", 5, 31], ["liquid feeds", "TREATMENT", 144, 156], ["three dialysis sessions", "TREATMENT", 162, 185], ["fluid", "OBSERVATION", 116, 121]]], ["This is because a limited volume of fluid can be safely removed from the child each session.HaemodialysisVascular access for haemodialysis must support high blood flows, typically up to 300 mL/minute.", [["fluid", "ANATOMY", 36, 41], ["blood", "ANATOMY", 157, 162], ["fluid", "ORGANISM_SUBSTANCE", 36, 41], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["a limited volume of fluid", "TREATMENT", 16, 41], ["HaemodialysisVascular access", "TREATMENT", 92, 120], ["haemodialysis", "TREATMENT", 125, 138], ["high blood flows", "PROBLEM", 152, 168], ["fluid", "OBSERVATION", 36, 41]]], ["Arteriovenous fistulae are the preferred form of access with lower rates of infection and malfunction than central venous dialysis catheters.", [["Arteriovenous fistulae", "ANATOMY", 0, 22], ["venous", "ANATOMY", 115, 121], ["Arteriovenous fistulae", "DISEASE", 0, 22], ["infection", "DISEASE", 76, 85], ["Arteriovenous fistulae", "PATHOLOGICAL_FORMATION", 0, 22], ["venous", "MULTI-TISSUE_STRUCTURE", 115, 121], ["Arteriovenous fistulae", "PROBLEM", 0, 22], ["infection", "PROBLEM", 76, 85], ["central venous dialysis catheters", "TREATMENT", 107, 140], ["fistulae", "OBSERVATION", 14, 22], ["infection", "OBSERVATION", 76, 85], ["central", "ANATOMY_MODIFIER", 107, 114], ["venous", "ANATOMY", 115, 121], ["dialysis catheters", "OBSERVATION", 122, 140]]], ["4 With support from specialist dialysis nurses and play therapists, many children can successfully needle their own arteriovenous fistulae.HaemodialysisAttending the paediatric nephrology unit three days per week impacts children's education, social interaction and quality of life.", [["arteriovenous fistulae", "ANATOMY", 116, 138], ["arteriovenous fistulae", "DISEASE", 116, 138], ["Haemodialysis", "DISEASE", 139, 152], ["children", "ORGANISM", 73, 81], ["arteriovenous fistulae", "PATHOLOGICAL_FORMATION", 116, 138], ["children", "ORGANISM", 221, 229], ["children", "SPECIES", 73, 81], ["children", "SPECIES", 221, 229], ["arteriovenous fistulae", "PROBLEM", 116, 138], ["arteriovenous", "ANATOMY", 116, 129], ["fistulae", "OBSERVATION", 130, 138]]], ["Teachers provide education during dialysis, and play therapists work with children to engage them in activities and games.", [["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["dialysis", "TREATMENT", 34, 42]]], ["Home dialysis therapies are preferred when feasible for the family (see Boxes 5 and 6).HaemodiafiltrationHaemodiafiltration uses both diffusion and convection to clear solutes from the patient.", [["patient", "ORGANISM", 185, 192], ["patient", "SPECIES", 185, 192], ["Home dialysis therapies", "TREATMENT", 0, 23], ["HaemodiafiltrationHaemodiafiltration", "TREATMENT", 87, 123]]], ["Convective clearance allows molecules with larger molecular weight known as \"middle molecules\" to be removed.", [["Convective clearance", "PROBLEM", 0, 20]]], ["Beta 2 microglobulin is an example of a middle molecule cleared by haemodiafiltration; by comparison urea is considered a small molecule and albumin a relatively large molecule.HaemodiafiltrationClinical trials comparing outcomes of adult patients treated with conventional haemodialysis to haemodiafiltration have shown variable results.", [["urea", "CHEMICAL", 101, 105], ["urea", "CHEMICAL", 101, 105], ["Beta 2 microglobulin", "GENE_OR_GENE_PRODUCT", 0, 20], ["urea", "SIMPLE_CHEMICAL", 101, 105], ["albumin", "GENE_OR_GENE_PRODUCT", 141, 148], ["patients", "ORGANISM", 239, 247], ["Beta 2 microglobulin", "PROTEIN", 0, 20], ["albumin", "PROTEIN", 141, 148], ["patients", "SPECIES", 239, 247], ["Beta 2 microglobulin", "TEST", 0, 20], ["a middle molecule", "PROBLEM", 38, 55], ["haemodiafiltration", "TREATMENT", 67, 85], ["comparison urea", "TEST", 90, 105], ["a small molecule and albumin a relatively large molecule", "PROBLEM", 120, 176], ["Haemodiafiltration", "TREATMENT", 177, 195], ["conventional haemodialysis", "TREATMENT", 261, 287], ["haemodiafiltration", "TREATMENT", 291, 309], ["middle", "ANATOMY_MODIFIER", 40, 46], ["haemodiafiltration", "OBSERVATION", 67, 85], ["small molecule", "OBSERVATION", 122, 136], ["relatively", "OBSERVATION_MODIFIER", 151, 161], ["large", "OBSERVATION_MODIFIER", 162, 167], ["molecule", "OBSERVATION", 168, 176]]], ["An international trial in children suggested a potential cardiovascuar benefit from haemodiafiltration over conventional haemodialysis treatment.", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34], ["haemodiafiltration", "TREATMENT", 84, 102], ["conventional haemodialysis treatment", "TREATMENT", 108, 144]]], ["5 Home haemodialysis Some families are capable of training to undertake haemodialysis for their child at home.", [["Home haemodialysis", "TREATMENT", 2, 20], ["haemodialysis", "TREATMENT", 72, 85]]], ["Parents are trained by specialist paediatric dialysis nurses to deliver dialysis care, with telephone support from a home haemodialysis team.HaemodiafiltrationVarious equipment set ups are available for home haemodialysis.", [["dialysis care", "TREATMENT", 72, 85], ["Haemodiafiltration", "TREATMENT", 141, 159], ["home haemodialysis", "TREATMENT", 203, 221]]], ["In children, the NxStage system is common comprizing a simplified dialysis machine and sterile bags of dialysate fluid delivered to the patient's home.", [["children", "ORGANISM", 3, 11], ["dialysate fluid", "ORGANISM_SUBSTANCE", 103, 118], ["patient", "ORGANISM", 136, 143], ["children", "SPECIES", 3, 11], ["patient", "SPECIES", 136, 143], ["a simplified dialysis machine", "TREATMENT", 53, 82], ["sterile bags of dialysate fluid", "TREATMENT", 87, 118]]], ["For adult patients, home adaptations for water purification with standard dialysis machines can be used.SummaryKidney replacement therapy can provide lifesaving support for children with severely impaired kidney function.", [["kidney", "ANATOMY", 205, 211], ["impaired kidney function", "DISEASE", 196, 220], ["patients", "ORGANISM", 10, 18], ["children", "ORGANISM", 173, 181], ["kidney", "ORGAN", 205, 211], ["patients", "SPECIES", 10, 18], ["children", "SPECIES", 173, 181], ["home adaptations", "TREATMENT", 20, 36], ["water purification", "TREATMENT", 41, 59], ["standard dialysis machines", "TREATMENT", 65, 91], ["SummaryKidney replacement therapy", "TREATMENT", 104, 137], ["lifesaving support", "TREATMENT", 150, 168], ["severely impaired kidney function", "PROBLEM", 187, 220], ["kidney", "ANATOMY", 205, 211]]], ["Children with anuric AKI can be supported until they recover sufficient kidney function; children with ESKD can be stabilized until they can receive a kidney transplant.", [["kidney", "ANATOMY", 72, 78], ["kidney", "ANATOMY", 151, 157], ["AKI", "DISEASE", 21, 24], ["ESKD", "DISEASE", 103, 107], ["Children", "ORGANISM", 0, 8], ["kidney", "ORGAN", 72, 78], ["children", "ORGANISM", 89, 97], ["kidney", "ORGAN", 151, 157], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 89, 97], ["anuric AKI", "PROBLEM", 14, 24], ["ESKD", "PROBLEM", 103, 107], ["a kidney transplant", "TREATMENT", 149, 168], ["AKI", "OBSERVATION", 21, 24], ["kidney", "ANATOMY", 151, 157], ["transplant", "OBSERVATION", 158, 168]]], ["Acute life threateningPD in a low-birthweight babyA boy is found to have bilateral hydronephrosis and small dysplastic kidneys on antenatal ultrasound.", [["kidneys", "ANATOMY", 119, 126], ["PD", "DISEASE", 22, 24], ["hydronephrosis", "DISEASE", 83, 97], ["boy", "ORGANISM", 52, 55], ["kidneys", "ORGAN", 119, 126], ["boy", "SPECIES", 52, 55], ["Acute life threateningPD", "PROBLEM", 0, 24], ["bilateral hydronephrosis", "PROBLEM", 73, 97], ["small dysplastic kidneys", "PROBLEM", 102, 126], ["antenatal ultrasound", "TEST", 130, 150], ["bilateral", "ANATOMY_MODIFIER", 73, 82], ["hydronephrosis", "OBSERVATION", 83, 97], ["small", "OBSERVATION_MODIFIER", 102, 107], ["dysplastic", "OBSERVATION", 108, 118], ["kidneys", "ANATOMY", 119, 126]]], ["He is born at 36 weeks gestation with birthweight 2.1 kg.", [["He", "ORGANISM", 0, 2], ["birthweight", "TEST", 38, 49]]], ["He passes very little urine and develops metabolic acidosis, electrolyte disturbance with hyperkalaemia (7.6 mmol/L) and progressive uraemia (26 mmol/L) by day 5.", [["urine", "ANATOMY", 22, 27], ["metabolic acidosis", "DISEASE", 41, 59], ["electrolyte disturbance", "DISEASE", 61, 84], ["hyperkalaemia", "DISEASE", 90, 103], ["uraemia", "DISEASE", 133, 140], ["urine", "ORGANISM_SUBSTANCE", 22, 27], ["very little urine", "PROBLEM", 10, 27], ["metabolic acidosis", "PROBLEM", 41, 59], ["electrolyte disturbance", "PROBLEM", 61, 84], ["hyperkalaemia", "PROBLEM", 90, 103], ["progressive uraemia", "PROBLEM", 121, 140], ["metabolic acidosis", "OBSERVATION", 41, 59], ["progressive", "OBSERVATION_MODIFIER", 121, 132], ["uraemia", "OBSERVATION", 133, 140]]], ["A peritoneal dialysis catheter is inserted, and dialysis commenced on day 5.", [["peritoneal", "ANATOMY", 2, 12], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 2, 12], ["A peritoneal dialysis catheter", "TREATMENT", 0, 30], ["dialysis", "TREATMENT", 48, 56], ["peritoneal", "ANATOMY", 2, 12], ["dialysis catheter", "OBSERVATION", 13, 30]]], ["Plasma potassium concentration improves to 4.3 mmol/L within 3 hours of commencing peritoneal dialysis.", [["peritoneal", "ANATOMY", 83, 93], ["potassium", "CHEMICAL", 7, 16], ["potassium", "CHEMICAL", 7, 16], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["potassium", "SIMPLE_CHEMICAL", 7, 16], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 83, 93], ["Plasma potassium concentration", "TEST", 0, 30], ["peritoneal dialysis", "TREATMENT", 83, 102], ["peritoneal", "ANATOMY", 83, 93], ["dialysis", "OBSERVATION", 94, 102]]], ["The peritoneal dialysis prescription is progressively optimized over the subsequent four weeks.", [["peritoneal", "ANATOMY", 4, 14], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 4, 14], ["The peritoneal dialysis prescription", "TREATMENT", 0, 36], ["peritoneal", "ANATOMY", 4, 14], ["dialysis", "OBSERVATION", 15, 23]]], ["With input from the paediatric renal dietician the nutritional prescription is optimized and he starts to gain nutritional weight.", [["renal", "ANATOMY", 31, 36], ["renal", "ORGAN", 31, 36], ["renal", "ANATOMY", 31, 36]]], ["Specialist peritoneal dialysis nurses train parents to undertake dialysis at home, and he is discharged home after 8 weeks.", [["peritoneal", "ANATOMY", 11, 21], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 11, 21], ["Specialist peritoneal dialysis nurses", "TREATMENT", 0, 37], ["dialysis", "TREATMENT", 65, 73], ["peritoneal", "ANATOMY", 11, 21]]], ["He is initially reviewed weekly in the infant dialysis clinic by a specialist dialysis nurse, dietician and paediatric nephrologist.Box 5Shifting between different dialysis modalities A 4-year-old boy receiving PD for ESKD secondary to kidney dysplasia experiences recurrent Pseudomonas peritonitis.", [["kidney dysplasia", "ANATOMY", 236, 252], ["PD", "DISEASE", 211, 213], ["ESKD", "DISEASE", 218, 222], ["kidney dysplasia", "DISEASE", 236, 252], ["Pseudomonas peritonitis", "DISEASE", 275, 298], ["boy", "ORGANISM", 197, 200], ["kidney", "ORGAN", 236, 242], ["boy", "SPECIES", 197, 200], ["different dialysis modalities", "TREATMENT", 154, 183], ["PD", "TREATMENT", 211, 213], ["ESKD", "PROBLEM", 218, 222], ["kidney dysplasia", "PROBLEM", 236, 252], ["recurrent Pseudomonas peritonitis", "PROBLEM", 265, 298], ["kidney", "ANATOMY", 236, 242], ["dysplasia", "OBSERVATION", 243, 252], ["Pseudomonas", "OBSERVATION_MODIFIER", 275, 286], ["peritonitis", "OBSERVATION", 287, 298]]], ["His PD catheter is removed, and a central venous catheter inserted to establish haemodialysis.", [["venous", "ANATOMY", 42, 48], ["PD", "DISEASE", 4, 6], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 42, 57], ["His PD catheter", "TREATMENT", 0, 15], ["a central venous catheter", "TREATMENT", 32, 57], ["haemodialysis", "TREATMENT", 80, 93], ["PD", "OBSERVATION_MODIFIER", 4, 6], ["catheter", "OBSERVATION", 7, 15], ["central", "ANATOMY_MODIFIER", 34, 41], ["venous", "ANATOMY", 42, 48], ["catheter", "OBSERVATION", 49, 57], ["haemodialysis", "OBSERVATION", 80, 93]]], ["His mother finds haemodialysis in the paediatric nephrology unit challenging, because this involves three four-hour sessions for three days every week, which take the entire day including travel.", [["haemodialysis", "TREATMENT", 17, 30], ["haemodialysis", "OBSERVATION", 17, 30]]], ["After discussion with the paediatric nephrologist and dialysis specialist nurses, the patient's mother is trained to undertake haemodialysis at home using a NxStage machine.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["haemodialysis", "TREATMENT", 127, 140], ["a NxStage machine", "TREATMENT", 155, 172]]], ["After 1 month of training, the boy is established on a home dialysis regimen of 5 sessions per week.", [["boy", "ORGANISM", 31, 34], ["training", "TREATMENT", 17, 25], ["a home dialysis regimen", "TREATMENT", 53, 76]]], ["This gives the family more time at home and allows relaxation of some dietary restrictions.Box 6SYMPOSIUM: NEPHROLOGY PAEDIATRICS AND CHILD HEALTH xxx:xxx hyperammonaemia can be rapidly controlled.", [["hyperammonaemia", "DISEASE", 155, 170], ["xxx hyperammonaemia", "PROBLEM", 151, 170], ["hyperammonaemia", "OBSERVATION", 155, 170]]], ["Kidney transplantation is the best long-term kidney replacement therapy to improve the symptoms, growth and wellbeing of children with ESKD.", [["Kidney", "ANATOMY", 0, 6], ["kidney", "ANATOMY", 45, 51], ["ESKD", "DISEASE", 135, 139], ["Kidney", "ORGAN", 0, 6], ["kidney", "ORGAN", 45, 51], ["children", "ORGANISM", 121, 129], ["children", "SPECIES", 121, 129], ["Kidney transplantation", "TREATMENT", 0, 22], ["long-term kidney replacement therapy", "TREATMENT", 35, 71], ["the symptoms", "PROBLEM", 83, 95], ["ESKD", "PROBLEM", 135, 139], ["transplantation", "OBSERVATION", 7, 22], ["long-term", "OBSERVATION_MODIFIER", 35, 44], ["kidney", "ANATOMY", 45, 51], ["replacement", "OBSERVATION", 52, 63]]], ["Early discussion with a paediatric nephrology team is advised for any child who may need kidney replacement therapy.Box 6Practice points C Kidney replacement therapy (KRT) is indicated in children whose renal function cannot adequately eliminate the byproducts of metabolism C Judicious early use of KRT may also improve the outcomes for individuals with AKI", [["kidney", "ANATOMY", 89, 95], ["renal", "ANATOMY", 203, 208], ["KRT", "CHEMICAL", 300, 303], ["AKI", "DISEASE", 355, 358], ["child", "ORGANISM", 70, 75], ["kidney", "ORGAN", 89, 95], ["children", "ORGANISM", 188, 196], ["renal", "ORGAN", 203, 208], ["KRT", "SIMPLE_CHEMICAL", 300, 303], ["children", "SPECIES", 188, 196], ["kidney replacement therapy", "TREATMENT", 89, 115], ["Box 6Practice", "TREATMENT", 116, 129], ["Kidney replacement therapy", "TREATMENT", 139, 165], ["KRT", "TREATMENT", 167, 170], ["KRT", "TREATMENT", 300, 303], ["AKI", "PROBLEM", 355, 358], ["kidney", "ANATOMY", 89, 95], ["replacement", "OBSERVATION", 96, 107], ["Kidney", "ANATOMY", 139, 145], ["replacement", "OBSERVATION", 146, 157], ["renal", "ANATOMY", 203, 208], ["AKI", "OBSERVATION", 355, 358]]]], "5b39506edca3994ab88bd9271e017841d3583eb6": [["Dear Editor:We are writing to provide an update to the article published in Brain, Behavior, and Immunity published on April 17, 2020 titled \"Meningoencephalitis without Respiratory Failure in a Young Female Patient with COVID-19 Infection in Downtown Los Angeles, Early April 2020\" by Duong et al. We were the consulting infectious disease team in this case.Updated Clinical CourseA 40-year-old woman with type 2 diabetes mellitus and obesity who presented with fever and syncope was admitted for encephalitis.", [["Meningoencephalitis", "DISEASE", 142, 161], ["Respiratory Failure", "DISEASE", 170, 189], ["Infection", "DISEASE", 230, 239], ["type 2 diabetes mellitus", "DISEASE", 407, 431], ["obesity", "DISEASE", 436, 443], ["fever", "DISEASE", 463, 468], ["syncope", "DISEASE", 473, 480], ["encephalitis", "DISEASE", 498, 510], ["woman", "ORGANISM", 396, 401], ["Patient", "SPECIES", 208, 215], ["woman", "SPECIES", 396, 401], ["Meningoencephalitis", "PROBLEM", 142, 161], ["Respiratory Failure", "PROBLEM", 170, 189], ["type 2 diabetes mellitus", "PROBLEM", 407, 431], ["obesity", "PROBLEM", 436, 443], ["fever", "PROBLEM", 463, 468], ["syncope", "PROBLEM", 473, 480], ["encephalitis", "PROBLEM", 498, 510], ["Brain", "ANATOMY", 76, 81], ["Meningoencephalitis", "OBSERVATION", 142, 161], ["Respiratory Failure", "OBSERVATION", 170, 189], ["mellitus", "OBSERVATION", 423, 431], ["obesity", "OBSERVATION", 436, 443], ["encephalitis", "OBSERVATION", 498, 510]]], ["Nasopharyngeal swab on admission was positive for SARS-CoV-2 and negative for influenza A and B viruses.", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["influenza A and B viruses", "DISEASE", 78, 103], ["Nasopharyngeal swab", "ORGANISM_SUBSTANCE", 0, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 50, 60], ["influenza A", "ORGANISM", 78, 89], ["B viruses", "ORGANISM", 94, 103], ["SARS-CoV", "SPECIES", 50, 58], ["influenza A", "SPECIES", 78, 89], ["Nasopharyngeal swab", "TEST", 0, 19], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["influenza", "PROBLEM", 78, 87]]], ["Cerebrospinal fluid (CSF) was negative for both bacterial culture and herpes simplex virus type 1 on polymerase chain reaction (PCR) assay.", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["herpes simplex", "DISEASE", 70, 84], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["CSF", "ORGANISM_SUBSTANCE", 21, 24], ["herpes simplex virus type 1", "ORGANISM", 70, 97], ["herpes simplex virus", "SPECIES", 70, 90], ["herpes simplex virus type 1", "SPECIES", 70, 97], ["Cerebrospinal fluid (CSF)", "TEST", 0, 25], ["both bacterial culture", "PROBLEM", 43, 65], ["herpes simplex virus type", "PROBLEM", 70, 95], ["polymerase chain reaction", "TEST", 101, 126], ["PCR", "TEST", 128, 131], ["fluid", "OBSERVATION", 14, 19]]], ["CSF was subsequently found to be positive for SARS-CoV-2 on reverse transcription polymerase chain reaction (Quest Diagnostics, San Juan Capistrano, CA).", [["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["CSF", "PROTEIN", 0, 3], ["SARS-CoV", "SPECIES", 46, 54], ["CSF", "TEST", 0, 3], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54]]], ["The patient was started on hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 27, 45], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["patient", "ORGANISM", 4, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["patient", "SPECIES", 4, 11], ["hydroxychloroquine", "TREATMENT", 27, 45]]], ["Her mental status gradually improved and returned to baseline without neurological deficits by hospital day 12.DiscussionThe majority COVID-19 patients present with respiratory symptoms and fever.", [["neurological", "ANATOMY", 70, 82], ["respiratory", "ANATOMY", 165, 176], ["neurological deficits", "DISEASE", 70, 91], ["respiratory symptoms", "DISEASE", 165, 185], ["fever", "DISEASE", 190, 195], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["neurological deficits", "PROBLEM", 70, 91], ["respiratory symptoms", "PROBLEM", 165, 185], ["fever", "PROBLEM", 190, 195], ["respiratory", "ANATOMY", 165, 176], ["fever", "OBSERVATION", 190, 195]]], ["Although rare, neurologic sequelae of COVID-19 have been reported, including syncope(1), Guillain-Barr\u00e9 syndrome(2), polyneuropathy(3), and stroke (4, 5) .", [["neurologic", "ANATOMY", 15, 25], ["syncope", "DISEASE", 77, 84], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 89, 112], ["polyneuropathy", "DISEASE", 117, 131], ["stroke", "DISEASE", 140, 146], ["COVID-19", "CHEMICAL", 38, 46], ["COVID", "TEST", 38, 43], ["syncope", "PROBLEM", 77, 84], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 89, 112], ["polyneuropathy", "PROBLEM", 117, 131], ["stroke", "PROBLEM", 140, 146], ["neurologic", "OBSERVATION_MODIFIER", 15, 25], ["sequelae", "OBSERVATION", 26, 34], ["Barr\u00e9 syndrome", "ANATOMY", 98, 112], ["polyneuropathy", "OBSERVATION", 117, 131], ["stroke", "OBSERVATION", 140, 146]]], ["We describe a case of SARS-CoV-2 infection that was entirely confined to the central nervous system, with no involvement of other organ systems.", [["central nervous system", "ANATOMY", 77, 99], ["organ", "ANATOMY", 130, 135], ["SARS-CoV-2 infection", "DISEASE", 22, 42], ["SARS-CoV-2", "ORGANISM", 22, 32], ["central nervous system", "ANATOMICAL_SYSTEM", 77, 99], ["organ", "ORGAN", 130, 135], ["SARS-CoV-2", "SPECIES", 22, 32], ["SARS", "PROBLEM", 22, 26], ["CoV-2 infection", "PROBLEM", 27, 42], ["involvement of other organ systems", "PROBLEM", 109, 143], ["infection", "OBSERVATION", 33, 42], ["central", "ANATOMY_MODIFIER", 77, 84], ["nervous system", "ANATOMY", 85, 99]]], ["Given the patient's clinical presentation and positive PCR testing for SARS-CoV-2 in the CSF, we propose that this case is most consistent with SARS-CoV-2 encephalitis.", [["SARS-CoV-2 encephalitis", "DISEASE", 144, 167], ["patient", "ORGANISM", 10, 17], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 71, 81], ["CSF", "GENE_OR_GENE_PRODUCT", 89, 92], ["SARS-CoV-2 encephalitis", "ORGANISM", 144, 167], ["patient", "SPECIES", 10, 17], ["SARS-CoV", "SPECIES", 71, 79], ["positive PCR testing", "TEST", 46, 66], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["SARS", "PROBLEM", 144, 148], ["CoV-2 encephalitis", "PROBLEM", 149, 167], ["CSF", "ANATOMY", 89, 92], ["most consistent with", "UNCERTAINTY", 123, 143], ["SARS", "OBSERVATION", 144, 148], ["encephalitis", "OBSERVATION", 155, 167]]], ["To our knowledge, this presentation of COVID-19 has not yet been reported and is important to consider as an atypical manifestation of the viral infection.", [["COVID-19", "CHEMICAL", 39, 47], ["viral infection", "DISEASE", 139, 154], ["COVID-19", "CELL", 39, 47], ["COVID-19", "DNA", 39, 47], ["COVID", "TEST", 39, 44], ["the viral infection", "PROBLEM", 135, 154], ["viral", "OBSERVATION_MODIFIER", 139, 144], ["infection", "OBSERVATION", 145, 154]]]], "ab4c508f4a6ff84276581ce0746b4a5768728d0f": [["BackgroundCanine parvovirus 2 (CPV-2), a member of the genus Protoparvovirus within the family Parvoviridae (the 2014 ICTV taxonomy, website: http://ictvonline.org/ virusTaxonomy.asp), is a small, highly contagious, nonenveloped icosahedral virus that causes acute gastroenteritis mainly in domestic dogs [1] [2] [3] [4] [5] .", [["gastroenteritis", "DISEASE", 265, 280], ["[1] [2] [3] [4]", "CHEMICAL", 305, 320], ["BackgroundCanine parvovirus 2", "ORGANISM", 0, 29], ["CPV-2", "ORGANISM", 31, 36], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 305, 324], ["BackgroundCanine parvovirus", "SPECIES", 0, 27], ["dogs", "SPECIES", 300, 304], ["BackgroundCanine parvovirus 2 (CPV-2", "SPECIES", 0, 36], ["BackgroundCanine parvovirus", "PROBLEM", 0, 27], ["a small, highly contagious, nonenveloped icosahedral virus", "PROBLEM", 188, 246], ["acute gastroenteritis", "PROBLEM", 259, 280], ["small", "OBSERVATION_MODIFIER", 190, 195], ["icosahedral virus", "OBSERVATION", 229, 246], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["gastroenteritis", "OBSERVATION", 265, 280]]], ["CPV infection is responsible for large numbers of animal deaths worldwide and one of the most dangerous infectious diseases in young puppies aged 2-6 months.", [["CPV infection", "DISEASE", 0, 13], ["deaths", "DISEASE", 57, 63], ["infectious diseases", "DISEASE", 104, 123], ["CPV", "ORGANISM", 0, 3], ["puppies", "ORGANISM_SUBDIVISION", 133, 140], ["CPV", "SPECIES", 0, 3], ["CPV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["responsible for", "UNCERTAINTY", 17, 32], ["large", "OBSERVATION_MODIFIER", 33, 38], ["numbers", "OBSERVATION_MODIFIER", 39, 46], ["dangerous", "OBSERVATION_MODIFIER", 94, 103], ["infectious", "OBSERVATION", 104, 114]]], ["The infected dogs develops acute gastroenteritis, which is characterized by vomiting, fever, diarrhoea (from mucoid to haemorrhagic), haemorrhagic enteritis, myocarditis and leucopoenia [6, 7] .BackgroundCPV contains a single-stranded DNA genome of approximately 5 kb, which encodes the capsid proteins 1, 2 and 3 (VP1, VP2 and VP3, respectively).", [["gastroenteritis", "DISEASE", 33, 48], ["vomiting", "DISEASE", 76, 84], ["fever", "DISEASE", 86, 91], ["diarrhoea", "DISEASE", 93, 102], ["haemorrhagic", "DISEASE", 119, 131], ["haemorrhagic enteritis", "DISEASE", 134, 156], ["myocarditis", "DISEASE", 158, 169], ["leucopoenia", "DISEASE", 174, 185], ["BackgroundCPV", "CHEMICAL", 194, 207], ["dogs", "ORGANISM", 13, 17], ["BackgroundCPV", "GENE_OR_GENE_PRODUCT", 194, 207], ["DNA", "CELLULAR_COMPONENT", 235, 238], ["capsid proteins 1", "GENE_OR_GENE_PRODUCT", 287, 304], ["2", "GENE_OR_GENE_PRODUCT", 306, 307], ["3", "GENE_OR_GENE_PRODUCT", 312, 313], ["VP1", "GENE_OR_GENE_PRODUCT", 315, 318], ["VP2", "GENE_OR_GENE_PRODUCT", 320, 323], ["VP3", "GENE_OR_GENE_PRODUCT", 328, 331], ["BackgroundCPV", "PROTEIN", 194, 207], ["single-stranded DNA genome", "DNA", 219, 245], ["capsid proteins 1, 2 and 3", "PROTEIN", 287, 313], ["VP1", "PROTEIN", 315, 318], ["VP2", "PROTEIN", 320, 323], ["VP3", "PROTEIN", 328, 331], ["dogs", "SPECIES", 13, 17], ["The infected dogs", "PROBLEM", 0, 17], ["acute gastroenteritis", "PROBLEM", 27, 48], ["vomiting", "PROBLEM", 76, 84], ["fever", "PROBLEM", 86, 91], ["diarrhoea", "PROBLEM", 93, 102], ["mucoid to haemorrhagic)", "PROBLEM", 109, 132], ["haemorrhagic enteritis", "PROBLEM", 134, 156], ["myocarditis", "PROBLEM", 158, 169], ["leucopoenia", "PROBLEM", 174, 185], ["the capsid proteins", "TEST", 283, 302], ["VP1", "TEST", 315, 318], ["VP2", "TEST", 320, 323], ["VP3", "TEST", 328, 331], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["dogs", "OBSERVATION", 13, 17], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["gastroenteritis", "OBSERVATION", 33, 48], ["vomiting", "OBSERVATION_MODIFIER", 76, 84], ["diarrhoea", "OBSERVATION", 93, 102], ["mucoid", "OBSERVATION_MODIFIER", 109, 115], ["haemorrhagic", "OBSERVATION_MODIFIER", 119, 131], ["haemorrhagic", "OBSERVATION_MODIFIER", 134, 146], ["enteritis", "OBSERVATION", 147, 156], ["myocarditis", "OBSERVATION", 158, 169]]], ["VP1 and VP2 are splice variants and mostly identical in sequence, exclusive of a 143-amino-acid (aa) N-terminal region unique to VP1, Whereas VP3 is derived from the cleavage of VP2 at the 5'-terminal region by host proteases [8] .", [["143-amino-acid", "CHEMICAL", 81, 95], ["amino-acid", "CHEMICAL", 85, 95], ["N", "CHEMICAL", 101, 102], ["VP1", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP2", "GENE_OR_GENE_PRODUCT", 8, 11], ["VP1", "GENE_OR_GENE_PRODUCT", 129, 132], ["VP3", "GENE_OR_GENE_PRODUCT", 142, 145], ["VP2", "GENE_OR_GENE_PRODUCT", 178, 181], ["VP1", "DNA", 0, 3], ["VP2", "DNA", 8, 11], ["143-amino-acid (aa) N-terminal region", "PROTEIN", 81, 118], ["VP1", "PROTEIN", 129, 132], ["VP3", "PROTEIN", 142, 145], ["VP2", "PROTEIN", 178, 181], ["5'-terminal region", "DNA", 189, 207], ["host proteases", "PROTEIN", 211, 225], ["VP1", "TEST", 0, 3], ["splice variants", "PROBLEM", 16, 31], ["amino-acid (aa) N-terminal region unique", "PROBLEM", 85, 125], ["VP1", "TEST", 129, 132], ["VP2", "TEST", 178, 181], ["VP2", "ANATOMY", 8, 11], ["splice variants", "OBSERVATION", 16, 31], ["terminal", "ANATOMY_MODIFIER", 103, 111], ["terminal", "ANATOMY_MODIFIER", 192, 200], ["region", "ANATOMY_MODIFIER", 201, 207], ["host proteases", "OBSERVATION", 211, 225]]], ["The full-length VP2 sequence (1755 bp) encodes the major capsid protein, which is 584 aa in length and plays an important role in determining viral host ranges, tissue tropisms, and genetic and antigenic properties [9, 10] .", [["tissue", "ANATOMY", 161, 167], ["VP2", "GENE_OR_GENE_PRODUCT", 16, 19], ["tissue", "TISSUE", 161, 167], ["full-length VP2 sequence", "DNA", 4, 28], ["major capsid protein", "PROTEIN", 51, 71], ["The full-length VP2 sequence", "TEST", 0, 28], ["bp", "TEST", 35, 37], ["tissue tropisms", "TEST", 161, 176]]], ["VP2 protein had been investigated as a candidate potential vaccine antigen due to its good immunogenicity [11] .", [["VP2", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP2 protein", "PROTEIN", 0, 11], ["VP2 protein", "TEST", 0, 11]]], ["CPV-2, first identified and described in 1978 in both the United States and Australia, is closely related to feline panleukopenia virus (FPV) [12] .", [["feline panleukopenia", "DISEASE", 109, 129], ["CPV-2", "ORGANISM", 0, 5], ["feline panleukopenia virus", "ORGANISM", 109, 135], ["feline panleukopenia virus", "SPECIES", 109, 135], ["CPV-2", "SPECIES", 0, 5], ["feline panleukopenia virus", "SPECIES", 109, 135], ["FPV", "SPECIES", 137, 140], ["CPV", "TEST", 0, 3], ["feline panleukopenia virus", "PROBLEM", 109, 135]]], ["A few years after its emergence, the original virus type CPV-2 was replaced worldwide by three new antigenic variants (i.e., CPV-2a, CPV-2b and CPV-2c) based on aa substitutions (CPV-2a: Val-555-Ile, Asp-305-Tyr, Ala-300-Gly, Ile-101-Thr and Met-87-Leu; CPV-2b: Ile-555-Val and Asp-426-Asn; CPV-2c: Asp-426-Glu) in the VP2 gene [12] [13] [14] [15] [16] [17] [18] .BackgroundIn China, CPV infections were first described in 1982 [9] .", [["Asp-426-Glu", "CHEMICAL", 299, 310], ["CPV infections", "DISEASE", 384, 398], ["Val", "CHEMICAL", 187, 190], ["Ile", "CHEMICAL", 195, 198], ["Asp", "CHEMICAL", 200, 203], ["Tyr", "CHEMICAL", 208, 211], ["Ala-300-Gly", "CHEMICAL", 213, 224], ["Ile", "CHEMICAL", 226, 229], ["Thr", "CHEMICAL", 234, 237], ["Met-87-Leu", "CHEMICAL", 242, 252], ["Ile-555-Val and Asp-426-Asn", "CHEMICAL", 262, 289], ["Asp-426-Glu", "CHEMICAL", 299, 310], ["CPV-2", "ORGANISM", 57, 62], ["CPV-2a", "ORGANISM", 125, 131], ["CPV-2b", "ORGANISM", 133, 139], ["CPV-2c", "ORGANISM", 144, 150], ["CPV-2a", "ORGANISM", 179, 185], ["Ala-300-Gly", "AMINO_ACID", 213, 224], ["Thr", "AMINO_ACID", 234, 237], ["Glu", "AMINO_ACID", 307, 310], ["13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 334, 362], ["CPV", "ORGANISM", 384, 387], ["CPV-2", "SPECIES", 57, 62], ["CPV-2a", "SPECIES", 125, 131], ["CPV", "SPECIES", 384, 387], ["the original virus type CPV", "TREATMENT", 33, 60], ["CPV", "TEST", 125, 128], ["CPV", "TEST", 133, 136], ["CPV", "TEST", 144, 147], ["aa substitutions", "TEST", 161, 177], ["CPV", "TEST", 179, 182], ["Val", "TEST", 187, 190], ["Asp", "TEST", 200, 203], ["Tyr", "TEST", 208, 211], ["Ala", "TEST", 213, 216], ["Ile", "TEST", 226, 229], ["Thr", "TEST", 234, 237], ["Met", "TEST", 242, 245], ["Leu", "TEST", 249, 252], ["CPV", "TEST", 254, 257], ["Ile", "TEST", 262, 265], ["Val", "TEST", 270, 273], ["Asp", "TEST", 278, 281], ["Asn", "TEST", 286, 289], ["CPV", "TEST", 291, 294], ["Asp", "TEST", 299, 302], ["Glu", "TEST", 307, 310], ["the VP2 gene", "TEST", 315, 327], ["CPV infections", "PROBLEM", 384, 398], ["infections", "OBSERVATION", 388, 398]]], ["A few years later, widespread outbreaks of canine haemorrhagic enteritis occurred throughout the country and CPV infection emerged as an important zoonosis of dogs because of the high morbidity and lethality associated with the virus [9] .", [["canine haemorrhagic enteritis", "DISEASE", 43, 72], ["CPV infection", "DISEASE", 109, 122], ["zoonosis", "DISEASE", 147, 155], ["canine", "ORGANISM", 43, 49], ["CPV", "ORGANISM", 109, 112], ["dogs", "ORGANISM", 159, 163], ["canine haemorrhagic enteritis", "SPECIES", 43, 72], ["dogs", "SPECIES", 159, 163], ["canine haemorrhagic enteritis", "SPECIES", 43, 72], ["CPV", "SPECIES", 109, 112], ["canine haemorrhagic enteritis", "PROBLEM", 43, 72], ["CPV infection", "PROBLEM", 109, 122], ["the high morbidity", "PROBLEM", 175, 193], ["lethality", "PROBLEM", 198, 207], ["the virus", "PROBLEM", 224, 233], ["few", "OBSERVATION_MODIFIER", 2, 5], ["widespread", "OBSERVATION_MODIFIER", 19, 29], ["outbreaks", "OBSERVATION_MODIFIER", 30, 39], ["canine", "OBSERVATION_MODIFIER", 43, 49], ["haemorrhagic", "OBSERVATION_MODIFIER", 50, 62], ["enteritis", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 113, 122]]], ["Recently, different CPV genotypes were observed in Heilongjiang, Jilin, Liaoning, Shandong, Hebei, Sichuan, Shenzhen, Gansu, Beijing, and Nanjing, as well as other areas in China [19] [20] [21] [22] .", [["CPV", "ORGANISM", 20, 23], ["CPV", "SPECIES", 20, 23], ["different CPV genotypes", "PROBLEM", 10, 33]]], ["However, no previous reports included information about the prevalent genotype of CPV in Henan province.BackgroundVaccination is considered the most effective method to control CPV infection.", [["BackgroundVaccination", "DISEASE", 104, 125], ["CPV infection", "DISEASE", 177, 190], ["CPV", "ORGANISM", 82, 85], ["CPV", "ORGANISM", 177, 180], ["CPV", "SPECIES", 82, 85], ["CPV", "SPECIES", 177, 180], ["BackgroundVaccination", "TREATMENT", 104, 125], ["CPV infection", "PROBLEM", 177, 190], ["infection", "OBSERVATION", 181, 190]]], ["However, antigenic differences may decrease the effectiveness of the vaccine based on the original antigenic type [23] .", [["antigenic differences", "PROBLEM", 9, 30], ["the vaccine", "TREATMENT", 65, 76]]], ["Therefore, it is important to elucidate the epidemiology and molecular characterization of CPV strains currently circulating in Henan province.", [["CPV", "ORGANISM", 91, 94], ["CPV", "SPECIES", 91, 94], ["CPV strains", "PROBLEM", 91, 102]]], ["Hence, in this study, we investigated the epidemiology of CPV infection among domestic dogs in Henan province and the molecular characterization of CPV by polymerase chain reaction (PCR) followed by direct sequencing of isolates collected from 2009 to 2014.", [["CPV infection", "DISEASE", 58, 71], ["CPV", "ORGANISM", 58, 61], ["dogs", "ORGANISM", 87, 91], ["CPV", "ORGANISM", 148, 151], ["dogs", "SPECIES", 87, 91], ["CPV", "SPECIES", 58, 61], ["CPV", "SPECIES", 148, 151], ["this study", "TEST", 10, 20], ["CPV infection", "PROBLEM", 58, 71], ["polymerase chain reaction", "PROBLEM", 155, 180], ["PCR", "TEST", 182, 185], ["direct sequencing of isolates", "TEST", 199, 228], ["infection", "OBSERVATION", 62, 71]]], ["The findings of this study constructed a basis for the further understanding of the evolution of CPV, will help to improve measures to prevent and control the spread of CPV and to developt effective vaccines against CPV infection.Ethics statementAll animal procedures carried out in this study were approved by the Animal Care and Use Committee of Henan University of Science and Technology.", [["CPV", "DISEASE", 169, 172], ["CPV infection", "DISEASE", 216, 229], ["CPV", "ORGANISM", 97, 100], ["CPV", "ORGANISM", 169, 172], ["CPV", "ORGANISM", 216, 219], ["CPV", "SPECIES", 97, 100], ["CPV", "SPECIES", 169, 172], ["CPV", "SPECIES", 216, 219], ["this study", "TEST", 16, 26], ["CPV", "PROBLEM", 97, 100], ["CPV", "PROBLEM", 169, 172], ["effective vaccines", "TREATMENT", 189, 207], ["CPV infection", "PROBLEM", 216, 229], ["All animal procedures", "TEST", 246, 267], ["this study", "TEST", 283, 293], ["infection", "OBSERVATION", 220, 229]]], ["Permission to collect samples was acquired from the owner of each animal.", [["samples", "ANATOMY", 22, 29]]], ["Samples were collected by a single skilled veterinarian.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["No specific permissions were required for collection of field samples because they were collected from public or non-protected areas.Samples collectionNineteen thousand nine hundred seven dogs from pet hospitals in the cities of Luoyang, Anyang, Jiaozuo, Sanmenxia, Xinxiang, and Zhengzhou in Henan province from March 2009 to December 2014 were investigated.", [["Samples", "ANATOMY", 133, 140], ["dogs", "ORGANISM", 188, 192], ["dogs", "SPECIES", 188, 192], ["collection of field samples", "TEST", 42, 69], ["Samples collection", "TEST", 133, 151], ["Jiaozuo", "TREATMENT", 246, 253], ["Sanmenxia", "TREATMENT", 255, 264], ["Xinxiang", "TREATMENT", 266, 274], ["Zhengzhou", "TREATMENT", 280, 289]]], ["Among the 19,907 dogs, infections of dogs with active vomiting, fever, diarrhoea and haemorrhagic enteritis were detected using a CPV colloidal gold test strip (Bionote, Inc., Hwaseong, Gyeonggi Province, south Korea), according to the manufacturer's protocol.", [["infections", "DISEASE", 23, 33], ["active vomiting", "DISEASE", 47, 62], ["fever", "DISEASE", 64, 69], ["diarrhoea", "DISEASE", 71, 80], ["haemorrhagic enteritis", "DISEASE", 85, 107], ["dogs", "ORGANISM", 17, 21], ["dogs", "ORGANISM", 37, 41], ["dogs", "SPECIES", 17, 21], ["dogs", "SPECIES", 37, 41], ["CPV", "SPECIES", 130, 133], ["infections of dogs", "PROBLEM", 23, 41], ["active vomiting", "PROBLEM", 47, 62], ["fever", "PROBLEM", 64, 69], ["diarrhoea", "PROBLEM", 71, 80], ["haemorrhagic enteritis", "PROBLEM", 85, 107], ["a CPV colloidal gold test strip", "TEST", 128, 159], ["the manufacturer's protocol", "TREATMENT", 232, 259], ["active", "OBSERVATION_MODIFIER", 47, 53], ["haemorrhagic", "OBSERVATION_MODIFIER", 85, 97], ["enteritis", "OBSERVATION", 98, 107]]], ["Suspected CPV-positive dogs were confirmed by positive results of the CPV colloidal gold test strip.", [["CPV", "ORGANISM", 10, 13], ["dogs", "ORGANISM", 23, 27], ["CPV", "ORGANISM", 70, 73], ["dogs", "SPECIES", 23, 27], ["CPV", "SPECIES", 10, 13], ["CPV", "SPECIES", 70, 73], ["CPV", "PROBLEM", 10, 13], ["positive dogs", "PROBLEM", 14, 27], ["the CPV colloidal gold test strip", "TEST", 66, 99], ["positive dogs", "OBSERVATION", 14, 27]]], ["Then, faecal samples from suspected CPV-positive dogs were transferred to our laboratory for detection of canine distemper virus (CDV) and canine coronavirus (CCoV) using a CDV or CCoV colloidal gold test strip (Bionote, Inc.), respectively, and for detection of coccidium, ancylostome, roundworm, tapeworm, babesiosis and nematode by microscopy [24] according to the characteristic of these parasites.", [["faecal samples", "ANATOMY", 6, 20], ["ancylostome", "ANATOMY", 274, 285], ["canine distemper virus", "DISEASE", 106, 128], ["coccidium", "CHEMICAL", 263, 272], ["tapeworm", "DISEASE", 298, 306], ["babesiosis", "DISEASE", 308, 318], ["faecal samples", "ORGANISM_SUBSTANCE", 6, 20], ["CPV", "ORGANISM", 36, 39], ["dogs", "ORGANISM", 49, 53], ["canine distemper virus", "ORGANISM", 106, 128], ["CDV", "ORGANISM", 130, 133], ["canine coronavirus", "ORGANISM", 139, 157], ["CCoV", "CANCER", 159, 163], ["CDV", "ORGANISM", 173, 176], ["coccidium", "GENE_OR_GENE_PRODUCT", 263, 272], ["ancylostome", "GENE_OR_GENE_PRODUCT", 274, 285], ["dogs", "SPECIES", 49, 53], ["canine distemper virus", "SPECIES", 106, 128], ["canine coronavirus", "SPECIES", 139, 157], ["CPV", "SPECIES", 36, 39], ["canine distemper virus", "SPECIES", 106, 128], ["CDV", "SPECIES", 130, 133], ["canine coronavirus", "SPECIES", 139, 157], ["CCoV", "SPECIES", 159, 163], ["CDV", "SPECIES", 173, 176], ["CCoV", "SPECIES", 180, 184], ["faecal samples", "TEST", 6, 20], ["CPV", "TEST", 36, 39], ["canine distemper virus", "PROBLEM", 106, 128], ["a CDV", "TREATMENT", 171, 176], ["CCoV colloidal gold test strip", "TEST", 180, 210], ["coccidium", "PROBLEM", 263, 272], ["tapeworm", "PROBLEM", 298, 306], ["babesiosis", "PROBLEM", 308, 318], ["parasites", "OBSERVATION", 392, 401]]], ["Additionally, the supernatant of faecal samples emulsified in 0.1 M phosphatebuffered saline (pH 7.2) and centrifuged (10,000 g for 10 min at 4-8\u00b0C) [8] was collected for detection of the partial VP2 gene and complete VP2 gene by PCR.Detection of CPV genomeViral DNA was prepared by boiling the supernatant for 10 min and chilling immediately on ice as previously described [25] .", [["supernatant", "ANATOMY", 18, 29], ["faecal samples", "ANATOMY", 33, 47], ["supernatant", "ANATOMY", 295, 306], ["faecal samples", "ORGANISM_SUBSTANCE", 33, 47], ["saline", "SIMPLE_CHEMICAL", 86, 92], ["VP2", "GENE_OR_GENE_PRODUCT", 196, 199], ["VP2", "GENE_OR_GENE_PRODUCT", 218, 221], ["CPV", "ORGANISM", 247, 250], ["DNA", "CELLULAR_COMPONENT", 263, 266], ["VP2 gene", "DNA", 196, 204], ["VP2 gene", "DNA", 218, 226], ["CPV genomeViral DNA", "DNA", 247, 266], ["CPV", "SPECIES", 247, 250], ["faecal samples", "TEST", 33, 47], ["0.1 M phosphatebuffered saline", "TREATMENT", 62, 92], ["pH", "TEST", 94, 96], ["the partial VP2 gene", "PROBLEM", 184, 204], ["PCR", "TEST", 230, 233], ["CPV genomeViral DNA", "PROBLEM", 247, 266]]], ["Specific primers ( Table 1) for detection of the CPV genome were designed using Primer Premier 5.0 software (Premier Biosoft International, Palto Alto, CA, 85 USA) based on the conserved sequence of a previously published CPV genome sequence (GenBank accession no.: NC001539.1).", [["CPV", "ORGANISM", 49, 52], ["CPV genome", "DNA", 49, 59], ["CPV genome sequence", "DNA", 222, 241], ["CPV", "SPECIES", 49, 52], ["CPV", "SPECIES", 222, 225], ["the CPV genome", "PROBLEM", 45, 59]]], ["The PCR reaction volume was 25 \u03bcl, which included 12.5 \u03bcl of PCR Master Mix (Sangon Biotech Company, Shanghai, China), 1 \u03bcl of each primer, 1 \u03bcl of supernatant, and 9.5 \u03bcl of ultrapure water.", [["supernatant", "ANATOMY", 148, 159], ["The PCR reaction volume", "TEST", 0, 23], ["supernatant", "TREATMENT", 148, 159], ["ultrapure water", "TREATMENT", 175, 190]]], ["The PCR reaction included an initial denaturation step at 95\u00b0C for 10 min followed by 30 cycles of 98\u00b0C for 30 s, 55\u00b0C for 30 s, and 72\u00b0C for 40 s, and 72\u00b0C for 10 min.", [["The PCR reaction", "TEST", 0, 16], ["an initial denaturation step", "PROBLEM", 26, 54], ["initial", "OBSERVATION_MODIFIER", 29, 36], ["denaturation", "OBSERVATION", 37, 49]]], ["A commercial vaccine was used as a positive control and sterile water was used as a negative control.", [["A commercial vaccine", "TREATMENT", 0, 20], ["a positive control", "TREATMENT", 33, 51], ["sterile water", "TREATMENT", 56, 69]]], ["The PCR-positive products were sent to Sangon Biotech Company for bidirectional single pass sequence analysis.", [["The PCR", "TEST", 0, 7], ["bidirectional single pass sequence analysis", "TEST", 66, 109]]], ["Then, all PCR-positive sequences were aligned and three phylogenetic trees based on partial VP2 sequences were constructed by the Clustal W method using the MegAlign program (DNASTAR, Inc., Madison, WI, USA) [20] .Detection of the complete VP2 geneViral DNA from diverse branches was prepared as described in this study.", [["VP2", "GENE_OR_GENE_PRODUCT", 240, 243], ["DNA", "CELLULAR_COMPONENT", 254, 257], ["PCR-positive sequences", "DNA", 10, 32], ["VP2 sequences", "DNA", 92, 105], ["VP2 geneViral DNA", "DNA", 240, 257], ["all PCR", "TEST", 6, 13], ["partial VP2 sequences", "TEST", 84, 105], ["the Clustal W method", "TREATMENT", 126, 146], ["the MegAlign program", "TREATMENT", 153, 173], ["the complete VP2 geneViral DNA", "PROBLEM", 227, 257], ["this study", "TEST", 309, 319], ["VP2 geneViral DNA", "OBSERVATION", 240, 257], ["diverse", "OBSERVATION_MODIFIER", 263, 270], ["branches", "OBSERVATION_MODIFIER", 271, 279]]], ["The primers ( Table 1) for detection of the complete VP2 gene were designed using Primer Premier 5.0 software based on the consensus sequence of previously published CPV genomes (GenBank accession no.: JQ268284.1).", [["VP2", "GENE_OR_GENE_PRODUCT", 53, 56], ["CPV", "ORGANISM", 166, 169], ["VP2 gene", "DNA", 53, 61], ["consensus sequence", "DNA", 123, 141], ["CPV genomes", "DNA", 166, 177], ["CPV", "SPECIES", 166, 169], ["the complete VP2 gene", "PROBLEM", 40, 61]]], ["The PCR reaction volume was 25 \u03bcl, which included 12.5 \u03bcl of PCR Master Mix (Sangon Biotech Company), 1 \u03bcl of each primer, 1 \u03bcl of supernatant, and 9.5 \u03bcl of ultrapure water.", [["supernatant", "ANATOMY", 131, 142], ["The PCR reaction volume", "TEST", 0, 23], ["ultrapure water", "TREATMENT", 158, 173]]], ["The PCR reaction included an initial denaturation step at 95\u00b0C for 10 min followed by 30 cycles of 98\u00b0C for 30 s, 48\u00b0C for 50 s, and 72\u00b0C for 120 s, and a final extension of 72\u00b0C for 10 min.", [["The PCR reaction", "TEST", 0, 16], ["an initial denaturation step", "PROBLEM", 26, 54], ["initial", "OBSERVATION_MODIFIER", 29, 36], ["denaturation", "OBSERVATION", 37, 49]]], ["Sterile water was used as a negative control.", [["Sterile water", "TREATMENT", 0, 13], ["a negative control", "TREATMENT", 26, 44]]], ["The PCR positive products were sent to Sangon Biotech Company for bidirectional single pass sequence analysis.", [["The PCR", "TEST", 0, 7], ["bidirectional single pass sequence analysis", "TEST", 66, 109]]], ["The specificity of the sequences was then compared with those in the GenBank database using BLAST algorithm.Sequence and phylogenetic analysesThe complete VP2 nucleotide sequences and aa sequences of our samples were aligned with reference CPV sequences from different animals and areas using MegAlign sequence alignment software (DNASTAR 6.0) [26] .", [["samples", "ANATOMY", 204, 211], ["VP2", "GENE_OR_GENE_PRODUCT", 155, 158], ["samples", "CANCER", 204, 211], ["VP2 nucleotide sequences", "DNA", 155, 179], ["CPV sequences", "DNA", 240, 253], ["CPV", "SPECIES", 240, 243], ["BLAST algorithm", "TEST", 92, 107], ["Sequence", "TEST", 108, 116], ["phylogenetic analyses", "TEST", 121, 142], ["The complete VP2 nucleotide sequences", "TEST", 142, 179], ["aa sequences", "TEST", 184, 196], ["our samples", "TEST", 200, 211], ["reference CPV sequences", "TEST", 230, 253], ["MegAlign sequence alignment software", "TEST", 293, 329], ["DNASTAR", "TEST", 331, 338]]], ["The phylogenetic analyses based on complete VP2 nucleotide sequences from the CPV isolates in this study and 25 reference CPV strains were conducted by the neighbour-joining method and a Kimura 2-parameter model using Molecular Evolutionary Genetics Analysis (MEGA 5.0) software [27] .", [["nucleotide", "CHEMICAL", 48, 58], ["VP2", "GENE_OR_GENE_PRODUCT", 44, 47], ["CPV", "ORGANISM", 78, 81], ["CPV", "ORGANISM", 122, 125], ["VP2 nucleotide sequences", "DNA", 44, 68], ["CPV", "SPECIES", 78, 81], ["CPV", "SPECIES", 122, 125], ["The phylogenetic analyses", "TEST", 0, 25], ["complete VP2 nucleotide sequences", "TEST", 35, 68], ["the CPV isolates", "TEST", 74, 90], ["this study", "TEST", 94, 104], ["CPV strains", "TEST", 122, 133]]], ["The confidence level of branching in the phylogenetic tree was evaluated by the bootstrap test based on 1000 resamplings.", [["the bootstrap test", "TEST", 76, 94], ["branching", "OBSERVATION_MODIFIER", 24, 33], ["phylogenetic tree", "OBSERVATION", 41, 58]]], ["A bootstrap value of \u2265 70 % was considered significant for phylogenetic groupings [20] .", [["A bootstrap value", "TEST", 0, 17]]], ["To determine the genotype of the CPV isolates in this study, the complete VP2 aa sequences were aligned with reference CPV sequences (NCBI GenBank accession no.: M38245.1, M24003.1, M74849.1, KT156832.1, KT156834.1 and KT156833.1) using the DNAMAN software package (Lynnon Biosoft, San Ramon, CA, USA) [18] .", [["CPV", "ORGANISM", 33, 36], ["VP2", "ORGANISM", 74, 77], ["VP2 aa sequences", "DNA", 74, 90], ["reference CPV sequences", "DNA", 109, 132], ["CPV", "SPECIES", 33, 36], ["CPV", "SPECIES", 119, 122], ["NCBI GenBank accession no.: M38245.1", "SPECIES", 134, 170], ["this study", "TEST", 49, 59], ["the complete VP2 aa sequences", "TEST", 61, 90], ["reference CPV sequences", "TEST", 109, 132], ["KT156832.1", "TEST", 192, 202], ["KT", "TEST", 219, 221]]], ["The complete VP2 DNA sequences were also submitted to the GenBank database for assignment of accession numbers.Questionnaire surveyA questionnaire survey was created to further elucidate the epidemiology of CPV infection among domestic dogs between 2009 and 2014, as previously described with some modifications [28] .", [["CPV infection", "DISEASE", 207, 220], ["VP2", "GENE_OR_GENE_PRODUCT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["CPV", "ORGANISM", 207, 210], ["dogs", "ORGANISM", 236, 240], ["VP2 DNA sequences", "DNA", 13, 30], ["dogs", "SPECIES", 236, 240], ["CPV", "SPECIES", 207, 210], ["The complete VP2 DNA sequences", "TEST", 0, 30], ["Questionnaire surveyA questionnaire survey", "TEST", 111, 153], ["CPV infection", "PROBLEM", 207, 220], ["CPV", "OBSERVATION_MODIFIER", 207, 210], ["infection", "OBSERVATION", 211, 220]]], ["The questionnaire inquired about the followed topics: 'CPV-positive' (yes/no), 'year' (2009-2014), 'month' (spring, 3-5, summer, 6-8, autumn, 9-11, winter, 12-2), 'age' (1, 2, 3, 4, 5, 6, 6-9, 9-12, 12-36, >36 months), 'sex' (male or female), 'purebred' (yes/no), 'vaccination' (unvaccinated, intermittent vaccination: inoculation as part of an unofficial immune program, complete vaccination: inoculation as part of an official immune program), 'co-infection' (pathogen).Statistical analysisStatistical analysis to assess significant differences of morbidity was performed using SPSS version 17.0 software.", [["infection", "DISEASE", 450, 459], ["CPV", "ORGANISM", 55, 58], ["inoculation", "PROBLEM", 319, 330], ["an unofficial immune program", "TREATMENT", 342, 370], ["inoculation", "PROBLEM", 394, 405], ["an official immune program", "TREATMENT", 417, 443], ["'co-infection'", "PROBLEM", 446, 460], ["Statistical analysisStatistical analysis", "TEST", 472, 512], ["significant differences of morbidity", "PROBLEM", 523, 559], ["SPSS version", "TEST", 580, 592], ["infection", "OBSERVATION", 450, 459]]], ["A p-value <0.05 was considered statistically significant.Morbidity of CPV infection in dogs from Henan provinceOne thousand one hundred seventy eight CPV-positive cases were identified by the CPV colloidal gold test strip.", [["CPV infection", "DISEASE", 70, 83], ["CPV", "ORGANISM", 70, 73], ["dogs", "ORGANISM", 87, 91], ["CPV", "ORGANISM", 150, 153], ["dogs", "SPECIES", 87, 91], ["CPV", "SPECIES", 70, 73], ["CPV", "SPECIES", 150, 153], ["CPV", "SPECIES", 192, 195], ["A p-value", "TEST", 0, 9], ["Morbidity of CPV infection in dogs", "PROBLEM", 57, 91], ["the CPV colloidal gold test strip", "TEST", 188, 221], ["CPV", "OBSERVATION_MODIFIER", 70, 73], ["infection", "OBSERVATION", 74, 83]]], ["PCR analysis confirmed that 1169 (99.24 %) of these cases were CPV-positive.", [["CPV", "ORGANISM", 63, 66], ["CPV", "SPECIES", 63, 66], ["PCR analysis", "TEST", 0, 12], ["these cases", "TEST", 46, 57], ["CPV", "TEST", 63, 66], ["positive", "OBSERVATION", 67, 75]]], ["Of the 1169 partial VP2 sequences, 33 were submitted to the NCBI Genbank database under the accession numbers KF772192-KF772224.", [["KF772192-KF772224", "CHEMICAL", 110, 127], ["1169 partial VP2 sequences", "DNA", 7, 33], ["partial VP2 sequences", "TEST", 12, 33]]], ["The morbidity of CPV infection between 2009 and 2014 was 5.87 % (1169/19907).", [["CPV infection", "DISEASE", 17, 30], ["CPV", "ORGANISM", 17, 20], ["CPV", "SPECIES", 17, 20], ["CPV infection", "PROBLEM", 17, 30], ["morbidity", "OBSERVATION_MODIFIER", 4, 13], ["CPV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30]]], ["The annual morbidity rate ranged from 4.16 to 8.06 % with the highest morbidity recorded in 2009 and the lowest in 2012 (Fig. 1 ), but morbidity was not significant (P > 0.05) between March 2009 and December 2014.", [["The annual morbidity rate", "TEST", 0, 25], ["morbidity", "PROBLEM", 135, 144]]], ["In addition, we observed a significant influence of age on morbidity (P < 0.05, Fig. 2 ).", [["morbidity", "TEST", 59, 68], ["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["Morbidity was relatively high among puppies during the first 4 month of life with the highest rate occurring in the third month.", [["Morbidity", "PROBLEM", 0, 9], ["high", "OBSERVATION_MODIFIER", 25, 29]]], ["Afterward, the morbidity rate gradually decreased.", [["the morbidity rate", "TEST", 11, 29], ["gradually", "OBSERVATION_MODIFIER", 30, 39], ["decreased", "OBSERVATION_MODIFIER", 40, 49]]], ["Seasonal morbidity ranged from 4.89 to 7.32 % with the highest during the Spring (Fig. 3) .", [["Seasonal morbidity", "TEST", 0, 18]]], ["However, as a whole, differences in morbidity according to Fig. 1Genotyping of CPVComparisons of the aa sequences among the seven isolates and the six reference strains revealed that Glu426, which is unique to strain CPV 2c, was not observed in any strain in this study.", [["Glu426", "CHEMICAL", 183, 189], ["Glu426", "GENE_OR_GENE_PRODUCT", 183, 189], ["CPV 2c", "ORGANISM", 217, 223], ["Glu426", "PROTEIN", 183, 189], ["CPV", "SPECIES", 217, 220], ["the aa sequences", "TEST", 97, 113], ["the six reference strains", "TEST", 143, 168], ["this study", "TEST", 259, 269]]], ["Mutations at aa 426 (N-426-D) and aa 297 (S-297-A) were found in one isolate (GenBank accession no.: KJ438800), which was typed as a new CPV-2b variant.", [["CPV-2b", "GENE_OR_GENE_PRODUCT", 137, 143], ["CPV-2b variant", "PROTEIN", 137, 151], ["GenBank accession no.: KJ438800", "SPECIES", 78, 109], ["Mutations", "TEST", 0, 9], ["aa", "TEST", 34, 36], ["a new CPV-2b variant", "PROBLEM", 131, 151], ["2b variant", "OBSERVATION", 141, 151]]], ["The other isolates were typed as new CPV-2a variants due to the aa substitutions of N426 and A297 ( were CPV-positive by PCR assay, suggesting a good correlation between the antigen-detection test and molecular methods, with only nine samples being recognized as false positives.", [["CPV-2a", "ORGANISM", 37, 43], ["A297", "GENE_OR_GENE_PRODUCT", 93, 97], ["CPV-2a", "SPECIES", 37, 43], ["CPV", "SPECIES", 105, 108], ["new CPV", "TEST", 33, 40], ["the aa substitutions", "TEST", 60, 80], ["CPV", "TEST", 105, 108], ["PCR assay", "TEST", 121, 130], ["the antigen", "TEST", 170, 181], ["detection test", "TEST", 182, 196], ["molecular methods", "TEST", 201, 218], ["false positives", "PROBLEM", 263, 278]]], ["In this study, the morbidity of CPV infection was 5.87 % (1169/19907), which was lower than in recent reports from China [20, 29] .", [["CPV infection", "DISEASE", 32, 45], ["CPV", "ORGANISM", 32, 35], ["CPV", "SPECIES", 32, 35], ["this study", "TEST", 3, 13], ["CPV infection", "PROBLEM", 32, 45], ["morbidity", "OBSERVATION_MODIFIER", 19, 28], ["CPV", "OBSERVATION_MODIFIER", 32, 35], ["infection", "OBSERVATION", 36, 45], ["lower", "OBSERVATION_MODIFIER", 81, 86]]], ["The sample size in this study was much larger than samples size described previously, thus these results should represent a more accurate estimate of morbidity of CPV infection.", [["sample", "ANATOMY", 4, 10], ["samples", "ANATOMY", 51, 58], ["CPV infection", "DISEASE", 163, 176], ["samples", "CANCER", 51, 58], ["CPV", "ORGANISM", 163, 166], ["CPV", "SPECIES", 163, 166], ["The sample size", "TEST", 0, 15], ["this study", "TEST", 19, 29], ["CPV infection", "PROBLEM", 163, 176], ["sample", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["larger", "OBSERVATION_MODIFIER", 39, 45], ["size", "OBSERVATION_MODIFIER", 59, 63], ["CPV", "OBSERVATION_MODIFIER", 163, 166], ["infection", "OBSERVATION", 167, 176]]], ["Additionally, the \u03c7 2 test results showed that the morbidity of CPV infection fluctuated only slightly (P > 0.05) within the 6-years period of this study (2009) (2010) (2011) (2012) (2013) (2014) .Genotyping of CPVThe results of this study showed that morbidity in the spring (months 3-5) and autumn (months 9-11) were relatively higher than observed during the other seasons, but the morbidity in Heilongjiang province differed from that reported for other provinces [29] , suggesting variations in morbidity according to the season in different regions of China.", [["CPV infection", "DISEASE", 64, 77], ["CPV", "ORGANISM", 64, 67], ["CPV", "SPECIES", 64, 67], ["the \u03c7 2 test results", "TEST", 14, 34], ["the morbidity of CPV infection", "PROBLEM", 47, 77], ["this study", "TEST", 143, 153], ["this study", "TEST", 229, 239], ["morbidity", "PROBLEM", 252, 261], ["variations in morbidity", "PROBLEM", 486, 509], ["morbidity", "OBSERVATION_MODIFIER", 51, 60], ["CPV", "OBSERVATION_MODIFIER", 64, 67], ["infection", "OBSERVATION", 68, 77], ["slightly", "OBSERVATION_MODIFIER", 94, 102], ["morbidity", "OBSERVATION", 252, 261], ["higher", "OBSERVATION_MODIFIER", 330, 336]]], ["In addition, our work demonstrated a clear association of CPV infection with dog age (p < 0.05), which in accordance with the results reported by Geng et al. [29] and Cavalli et al. [30] .", [["CPV infection", "DISEASE", 58, 71], ["CPV", "ORGANISM", 58, 61], ["dog", "ORGANISM", 77, 80], ["CPV", "SPECIES", 58, 61], ["CPV infection", "PROBLEM", 58, 71], ["CPV", "OBSERVATION_MODIFIER", 58, 61], ["infection", "OBSERVATION", 62, 71]]], ["Although the causes of this tendency have not yet been fully elucidated, we hypothesise that the low morbidity in dogs aged < 30 days most likely resulted from acquired maternal antibody, while the high morbidity in dogs aged 30-120 days most likely resulted from decreasing maternal antibody concentrations and stress due to weaning, and the low morbidity in dogs aged >120 days was most likely attributable to the development of adaptive immune responses [31, 32] .", [["dogs", "ORGANISM", 114, 118], ["dogs", "ORGANISM", 216, 220], ["dogs", "ORGANISM", 360, 364], ["dogs", "SPECIES", 114, 118], ["dogs", "SPECIES", 216, 220], ["dogs", "SPECIES", 360, 364], ["this tendency", "PROBLEM", 23, 36], ["the low morbidity", "PROBLEM", 93, 110], ["acquired maternal antibody", "PROBLEM", 160, 186], ["decreasing maternal antibody concentrations", "PROBLEM", 264, 307], ["stress", "PROBLEM", 312, 318], ["the low morbidity", "PROBLEM", 339, 356], ["low", "OBSERVATION_MODIFIER", 97, 100], ["decreasing", "OBSERVATION_MODIFIER", 264, 274], ["antibody concentrations", "OBSERVATION", 284, 307]]], ["The finding of more male dogs in this study was consistent with those in other parts of the world, suggesting that there also is a preference of male over female dogs in Henan province [28] .", [["dogs", "ORGANISM", 25, 29], ["dogs", "ORGANISM", 162, 166], ["dogs", "SPECIES", 25, 29], ["dogs", "SPECIES", 162, 166], ["this study", "TEST", 33, 43]]], ["Besides, to the best of our knowledge, this study is the first to report that morbidity (5.88 %) in domestic male dogs was similar to that (5.86 %) in domestic female dogs.", [["dogs", "ORGANISM", 114, 118], ["dogs", "ORGANISM", 167, 171], ["dogs", "SPECIES", 114, 118], ["dogs", "SPECIES", 167, 171], ["this study", "TEST", 39, 49], ["morbidity", "TEST", 78, 87]]], ["CPV infection occurs in both unvaccinated and vaccinated dogs, in accordance with the finding of recent reports in China [29, 33] .", [["CPV infection", "DISEASE", 0, 13], ["CPV", "ORGANISM", 0, 3], ["dogs", "ORGANISM", 57, 61], ["dogs", "SPECIES", 57, 61], ["CPV", "SPECIES", 0, 3], ["CPV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["In this study, the CPVpositive rate was highest among unvaccinated dogs, followed by intermittently vaccinated dogs and completely vaccinated dogs, suggesting that vaccines used in Henan province may play an important role in prevention and control CPV infection.", [["CPV infection", "DISEASE", 249, 262], ["dogs", "ORGANISM", 67, 71], ["dogs", "ORGANISM", 111, 115], ["dogs", "ORGANISM", 142, 146], ["CPV", "ORGANISM", 249, 252], ["dogs", "SPECIES", 67, 71], ["dogs", "SPECIES", 111, 115], ["dogs", "SPECIES", 142, 146], ["CPV", "SPECIES", 249, 252], ["this study", "TEST", 3, 13], ["the CPVpositive rate", "TEST", 15, 35], ["intermittently vaccinated dogs", "TREATMENT", 85, 115], ["completely vaccinated dogs", "PROBLEM", 120, 146], ["vaccines", "TREATMENT", 164, 172], ["CPV infection", "PROBLEM", 249, 262], ["infection", "OBSERVATION", 253, 262]]], ["Our work also indicated that the CPV-positive rate was higher among purebred dogs as compared to mutts.", [["CPV", "ORGANISM", 33, 36], ["dogs", "ORGANISM", 77, 81], ["dogs", "SPECIES", 77, 81], ["CPV", "SPECIES", 33, 36], ["the CPV", "TEST", 29, 36], ["positive rate", "PROBLEM", 37, 50], ["purebred dogs", "PROBLEM", 68, 81]]], ["This result suggested that mutts may have greater resistance to CPV, which should be investigated in future studies.Genotyping of CPVIn this study, CPV infection was identified alongside other pathogens in 230 (19.67 %) of 1169 CPV-positive samples.", [["samples", "ANATOMY", 241, 248], ["CPV infection", "DISEASE", 148, 161], ["CPV", "ORGANISM", 64, 67], ["CPV", "ORGANISM", 148, 151], ["CPV", "ORGANISM", 228, 231], ["CPV", "SPECIES", 64, 67], ["CPV", "SPECIES", 148, 151], ["CPV", "SPECIES", 228, 231], ["greater resistance to CPV", "PROBLEM", 42, 67], ["future studies", "TEST", 101, 115], ["this study", "TEST", 136, 146], ["CPV infection", "PROBLEM", 148, 161], ["other pathogens", "TEST", 187, 202], ["CPV", "TEST", 228, 231], ["greater", "OBSERVATION_MODIFIER", 42, 49], ["resistance", "OBSERVATION", 50, 60], ["infection", "OBSERVATION", 152, 161]]], ["The pathogens that accompanied CPV were coccidium, CDV, CCoV, hookworm, roundworm, tapeworm and Babesia spp., suggesting that these pathogens should be considered in vaccination programs to controlGenotyping of CPVThis studyGenotyping of CPVIdentical amino acids are represented by -CPV outbreaks [34] .", [["hookworm, roundworm, tapeworm and Babesia spp.", "DISEASE", 62, 108], ["amino acids", "CHEMICAL", 251, 262], ["amino acids", "CHEMICAL", 251, 262], ["CPV", "ORGANISM", 31, 34], ["CDV", "ORGANISM", 51, 54], ["CCoV", "GENE_OR_GENE_PRODUCT", 56, 60], ["hookworm", "ORGANISM", 62, 70], ["Babesia spp.", "ORGANISM", 96, 108], ["CPVIdentical", "SIMPLE_CHEMICAL", 238, 250], ["amino acids", "AMINO_ACID", 251, 262], ["Babesia spp.", "SPECIES", 96, 108], ["CPV", "SPECIES", 31, 34], ["CDV", "SPECIES", 51, 54], ["CCoV", "SPECIES", 56, 60], ["Babesia spp.", "SPECIES", 96, 108], ["The pathogens", "PROBLEM", 0, 13], ["CPV", "PROBLEM", 31, 34], ["CDV", "PROBLEM", 51, 54], ["tapeworm", "TREATMENT", 83, 91], ["Babesia spp.", "PROBLEM", 96, 108], ["these pathogens", "PROBLEM", 126, 141], ["vaccination programs", "TREATMENT", 166, 186], ["CPVThis study", "TEST", 211, 224], ["CPVIdentical amino acids", "TREATMENT", 238, 262]]], ["The co-infection of CPV with CDV or CCoV in this study was in agreement with previous study in China [29] and other countries [30, 35, 36] .", [["CPV", "ORGANISM", 20, 23], ["CDV", "ORGANISM", 29, 32], ["CPV", "SPECIES", 20, 23], ["CDV", "SPECIES", 29, 32], ["CCoV", "SPECIES", 36, 40], ["The co-infection of CPV", "PROBLEM", 0, 23], ["CDV", "PROBLEM", 29, 32], ["this study", "TEST", 44, 54], ["previous study", "TEST", 77, 91], ["co-infection", "OBSERVATION", 4, 16]]], ["Additionally, studies in China [37] and France [38] suggested that dogs harbouring roundworm or trichomonads were especially susceptible to CPV infection.", [["roundworm", "ANATOMY", 83, 92], ["trichomonads", "ANATOMY", 96, 108], ["CPV infection", "DISEASE", 140, 153], ["dogs", "ORGANISM", 67, 71], ["CPV", "ORGANISM", 140, 143], ["dogs", "SPECIES", 67, 71], ["CPV", "SPECIES", 140, 143], ["dogs harbouring roundworm", "PROBLEM", 67, 92], ["trichomonads", "PROBLEM", 96, 108], ["CPV infection", "PROBLEM", 140, 153], ["infection", "OBSERVATION", 144, 153]]], ["Also, this study is the first to report the co-infection of CPV with coccidium, hookworm, tapeworm or Babesia spp., and co-infection of two pathogens with CPV was also found in one sample.", [["coccidium", "CHEMICAL", 69, 78], ["hookworm, tapeworm", "DISEASE", 80, 98], ["Babesia spp.", "DISEASE", 102, 114], ["CPV", "ORGANISM", 60, 63], ["coccidium", "GENE_OR_GENE_PRODUCT", 69, 78], ["hookworm", "ORGANISM", 80, 88], ["Babesia spp.", "ORGANISM", 102, 114], ["CPV", "ORGANISM", 155, 158], ["Babesia spp.", "SPECIES", 102, 114], ["CPV", "SPECIES", 60, 63], ["Babesia spp.", "SPECIES", 102, 114], ["CPV", "SPECIES", 155, 158], ["this study", "TEST", 6, 16], ["CPV", "PROBLEM", 60, 63], ["coccidium", "TREATMENT", 69, 78], ["hookworm", "PROBLEM", 80, 88], ["tapeworm", "PROBLEM", 90, 98], ["Babesia spp.", "PROBLEM", 102, 114], ["co-infection of two pathogens", "PROBLEM", 120, 149], ["CPV", "PROBLEM", 155, 158], ["co-infection", "OBSERVATION", 44, 56]]], ["Point mutations in the VP2 protein have been associated with the CPV types because the fragment encodes for at least one informative aa (residue 426) of the VP2 protein, which in used to differentiate CPV2a (Asn), CPV2b (Asp) and CPV2c (Glu) [9] .", [["Asn", "CHEMICAL", 208, 211], ["Asp", "CHEMICAL", 221, 224], ["Glu", "CHEMICAL", 237, 240], ["VP2", "GENE_OR_GENE_PRODUCT", 23, 26], ["VP2", "GENE_OR_GENE_PRODUCT", 157, 160], ["CPV2a", "GENE_OR_GENE_PRODUCT", 201, 206], ["Asn", "GENE_OR_GENE_PRODUCT", 208, 211], ["CPV2b (Asp)", "GENE_OR_GENE_PRODUCT", 214, 225], ["CPV2c (Glu)", "GENE_OR_GENE_PRODUCT", 230, 241], ["VP2 protein", "PROTEIN", 23, 34], ["VP2 protein", "PROTEIN", 157, 168], ["CPV2a", "PROTEIN", 201, 206], ["CPV2b", "PROTEIN", 214, 219], ["CPV", "SPECIES", 65, 68], ["Point mutations in the VP2 protein", "PROBLEM", 0, 34], ["the CPV types", "PROBLEM", 61, 74], ["the fragment encodes", "PROBLEM", 83, 103], ["the VP2 protein", "TEST", 153, 168], ["CPV2b", "TEST", 214, 219], ["Asp", "TEST", 221, 224], ["CPV2c (Glu)", "TEST", 230, 241]]], ["The Ser297Ala mutation was used as a marker of the new CPV-2a/2b variant [29] .", [["Ser297Ala", "GENE_OR_GENE_PRODUCT", 4, 13], ["Ser297Ala", "PROTEIN", 4, 13], ["the new CPV", "TEST", 47, 58]]], ["CPV-2c was first identified in Jilin province, and subsequently identified in Shandong province, Heilongjiang province and Beijing [19, 29, 33] .", [["CPV-2c", "GENE_OR_GENE_PRODUCT", 0, 6], ["CPV-2c", "SPECIES", 0, 6]]], ["CPV-2c was not detected in this study, while the new CPV-2a variant is more prevalent than new CPV-2b variant in Henan province.", [["CPV-2c", "GENE_OR_GENE_PRODUCT", 0, 6], ["CPV-2a", "ORGANISM", 53, 59], ["CPV-2b", "ORGANISM", 95, 101], ["CPV", "SPECIES", 0, 3], ["CPV-2a", "SPECIES", 53, 59], ["CPV-2b", "SPECIES", 95, 101], ["CPV", "TEST", 0, 3], ["this study", "TEST", 27, 37], ["2b variant", "OBSERVATION", 99, 109]]], ["In this study, the prevalence of new CPV-2a and new CPV-2b is in agreement with most of the reports in other provinces of China [6, 8, 9, 20, 29, 33, 39, 40] and other countries [26, [41] [42] [43] [44] [45] .", [["CPV-2a", "ORGANISM", 37, 43], ["CPV-2b", "ORGANISM", 52, 58], ["[41] [42] [43] [44", "SIMPLE_CHEMICAL", 183, 201], ["CPV-2a", "SPECIES", 37, 43], ["CPV-2b", "SPECIES", 52, 58], ["this study", "TEST", 3, 13], ["other countries", "TEST", 162, 177], ["new", "OBSERVATION_MODIFIER", 33, 36], ["CPV", "OBSERVATION", 37, 40]]], ["The presence of the new CPV-2a and CPV-2b variants in this study suggests that CPV-2 strains circulating in Henan province also exhibit genetic variations.Genotyping of CPVVP2 encodes a viral capsid protein that is the major structural protein of CPV-2 and is involved in the host immune response.", [["CPV-2a", "ORGANISM", 24, 30], ["CPV-2b", "ORGANISM", 35, 41], ["CPV-2 strains", "ORGANISM", 79, 92], ["CPVVP2", "GENE_OR_GENE_PRODUCT", 169, 175], ["CPV-2", "GENE_OR_GENE_PRODUCT", 247, 252], ["CPV-2a and CPV-2b variants", "DNA", 24, 50], ["CPVVP2", "DNA", 169, 175], ["viral capsid protein", "PROTEIN", 186, 206], ["major structural protein", "PROTEIN", 219, 243], ["CPV-2a", "SPECIES", 24, 30], ["CPV-2b", "SPECIES", 35, 41], ["CPV-2", "SPECIES", 79, 84], ["CPV-2", "SPECIES", 247, 252], ["the new CPV", "TEST", 16, 27], ["CPV-2b variants", "PROBLEM", 35, 50], ["this study", "TEST", 54, 64], ["CPV", "PROBLEM", 79, 82], ["genetic variations", "PROBLEM", 136, 154], ["a viral capsid protein", "PROBLEM", 184, 206], ["new", "OBSERVATION_MODIFIER", 20, 23], ["CPV", "OBSERVATION", 24, 27], ["2b variants", "OBSERVATION", 39, 50], ["genetic variations", "OBSERVATION", 136, 154], ["viral capsid protein", "OBSERVATION", 186, 206]]], ["Therefore, a small number of mutations may result in increased pathogenicity [26] .", [["a small number of mutations", "PROBLEM", 11, 38], ["increased pathogenicity", "PROBLEM", 53, 76], ["small", "OBSERVATION_MODIFIER", 13, 18], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["pathogenicity", "OBSERVATION", 63, 76]]], ["In this study, the aa sequences from the seven VP2 gene products revealed little variability at residues 322, 334 and 348, which was basically consistent with reference CPV sequences.", [["VP2", "GENE_OR_GENE_PRODUCT", 47, 50], ["VP2 gene products", "PROTEIN", 47, 64], ["CPV sequences", "DNA", 169, 182], ["CPV", "SPECIES", 169, 172], ["this study", "TEST", 3, 13], ["the aa sequences", "TEST", 15, 31], ["little variability at residues", "PROBLEM", 74, 104], ["reference CPV sequences", "TEST", 159, 182], ["little", "OBSERVATION_MODIFIER", 74, 80], ["variability", "OBSERVATION_MODIFIER", 81, 92], ["consistent with", "UNCERTAINTY", 143, 158]]], ["The aa sequences from seven VP2 gene products revealed great variability at residues 267, 324, 341 and 440.", [["VP2", "GENE_OR_GENE_PRODUCT", 28, 31], ["VP2 gene products", "PROTEIN", 28, 45], ["The aa sequences", "TEST", 0, 16], ["great variability at residues", "PROBLEM", 55, 84], ["great variability", "OBSERVATION", 55, 72]]], ["Residue 267, located between loops 1 and 2 of the VP2 protein, is the main component of the antigen.", [["Residue 267", "AMINO_ACID", 0, 11], ["VP2", "GENE_OR_GENE_PRODUCT", 50, 53], ["VP2 protein", "PROTEIN", 50, 61], ["Residue", "TEST", 0, 7], ["the VP2 protein", "TEST", 46, 61], ["loops", "ANATOMY_MODIFIER", 29, 34], ["VP2 protein", "ANATOMY", 50, 61], ["main", "OBSERVATION_MODIFIER", 70, 74], ["component", "OBSERVATION_MODIFIER", 75, 84]]], ["However, a mutation to residue 267 may not influence the antigenicity of CPV because it is not exposed on the capsid surface, as was reported for strain CPV-2a from China and Thailand and strain CPV-2b from Vietnam [45] .", [["surface", "ANATOMY", 117, 124], ["CPV", "ORGANISM", 73, 76], ["CPV-2a", "ORGANISM", 153, 159], ["CPV-2b", "ORGANISM", 195, 201], ["CPV", "SPECIES", 73, 76], ["CPV-2a", "SPECIES", 153, 159], ["CPV-2b", "SPECIES", 195, 201], ["a mutation to residue", "PROBLEM", 9, 30], ["CPV", "PROBLEM", 73, 76], ["strain CPV", "PROBLEM", 146, 156]]], ["Residue 324 is subject to positive selection and may influence the aa sequences at residue 323, which is known to be involved in host range via binding with the canine transferrin receptor.", [["residue 323", "AMINO_ACID", 83, 94], ["canine", "ORGANISM", 161, 167], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 168, 188], ["canine transferrin receptor", "PROTEIN", 161, 188], ["canine", "SPECIES", 161, 167], ["positive selection", "TREATMENT", 26, 44], ["the aa sequences at residue", "TEST", 63, 90], ["the canine transferrin receptor", "TREATMENT", 157, 188]]], ["A mutation at residue 323 may influence interactions between residues in neighbouring loops of either the same VP2 molecule or the threefold-related VP2, thereby greatly decreasing replication in canine cells [26] .", [["cells", "ANATOMY", 203, 208], ["residue 323", "AMINO_ACID", 14, 25], ["VP2 molecule", "GENE_OR_GENE_PRODUCT", 111, 123], ["VP2", "GENE_OR_GENE_PRODUCT", 149, 152], ["canine cells", "CELL", 196, 208], ["VP2 molecule", "PROTEIN", 111, 123], ["VP2", "PROTEIN", 149, 152], ["canine cells", "CELL_TYPE", 196, 208], ["canine", "SPECIES", 196, 202], ["A mutation at residue", "PROBLEM", 0, 21], ["VP2", "PROBLEM", 149, 152], ["decreasing", "OBSERVATION_MODIFIER", 170, 180], ["replication", "OBSERVATION_MODIFIER", 181, 192]]], ["The Y-324-I mutation in CPV-2a strains has been reported in China [8, 20, 39] and other countries [43, 45] .", [["Y-324-I", "CHEMICAL", 4, 11], ["Y-324-I", "GENE_OR_GENE_PRODUCT", 4, 11], ["CPV-2a", "ORGANISM", 24, 30], ["Y-324-I mutation", "DNA", 4, 20], ["CPV-2a", "SPECIES", 24, 30], ["The Y", "TEST", 0, 5], ["CPV", "TEST", 24, 27]]], ["Interestingly, variations of residue 440 (within the GH loop) occurred.", [["residue 440", "AMINO_ACID", 29, 40], ["GH loop", "PROTEIN", 53, 60]]], ["Reportedly, the high substitution rate in this region is associated with the evolution of antigenic variants in circulating parvovirus types [46] , such as strains CPV-2a and CPV-2b from other provinces in China [9, 29] .", [["parvovirus", "ORGANISM", 124, 134], ["CPV-2a", "ORGANISM", 164, 170], ["CPV-2b", "ORGANISM", 175, 181], ["CPV-2a", "SPECIES", 164, 170], ["CPV-2b", "SPECIES", 175, 181], ["the high substitution rate", "PROBLEM", 12, 38], ["antigenic variants", "PROBLEM", 90, 108], ["circulating parvovirus types", "PROBLEM", 112, 140], ["strains CPV", "TEST", 156, 167], ["CPV", "TEST", 175, 178], ["high substitution", "OBSERVATION", 16, 33], ["antigenic variants", "OBSERVATION", 90, 108]]], ["However, the significance of a mutation at residue 341 is unclear and warrants further investigations.Genotyping of CPVPrevious reports suggested that the new CPV-2a variant was the most prevalent in China, followed by CPV-2b and CPV-2c, in accordance with the results of the present study.", [["residue 341", "AMINO_ACID", 43, 54], ["CPV-2a", "ORGANISM", 159, 165], ["CPV-2b", "ORGANISM", 219, 225], ["CPV-2c", "ORGANISM", 230, 236], ["CPV-2a variant", "DNA", 159, 173], ["CPV-2a", "SPECIES", 159, 165], ["CPV-2b", "SPECIES", 219, 225], ["CPV-2c", "SPECIES", 230, 236], ["a mutation at residue", "PROBLEM", 29, 50], ["further investigations", "TEST", 79, 101], ["CPV", "TEST", 219, 222], ["the present study", "TEST", 272, 289]]], ["However, it is necessary to collect more samples form Henan province for further genotyping to improve our understanding of the evolution of CPV in China.ConclusionsOur results disclosed novel epidemiological information of CPV infection in Henan province.", [["CPV infection", "DISEASE", 224, 237], ["CPV", "ORGANISM", 141, 144], ["CPV", "ORGANISM", 224, 227], ["CPV", "SPECIES", 141, 144], ["CPV", "SPECIES", 224, 227], ["further genotyping", "TREATMENT", 73, 91], ["CPV", "PROBLEM", 141, 144], ["CPV infection", "PROBLEM", 224, 237], ["CPV infection", "OBSERVATION", 224, 237]]], ["VP2 sequences data revealed that the new CPV-2a variant is more prevalent than the new CPV-2b variant in Henan province.", [["VP2", "GENE_OR_GENE_PRODUCT", 0, 3], ["CPV-2a", "ORGANISM", 41, 47], ["CPV-2b", "ORGANISM", 87, 93], ["VP2 sequences", "DNA", 0, 13], ["CPV-2a", "SPECIES", 41, 47], ["CPV-2b", "SPECIES", 87, 93], ["VP2 sequences data", "TEST", 0, 18], ["the new CPV", "TEST", 33, 44], ["2a variant", "OBSERVATION", 45, 55], ["more prevalent", "OBSERVATION_MODIFIER", 59, 73], ["2b variant", "OBSERVATION", 91, 101]]], ["CPV-2c was not observed in this study.", [["CPV-2c", "GENE_OR_GENE_PRODUCT", 0, 6], ["CPV", "SPECIES", 0, 3], ["CPV", "TEST", 0, 3], ["this study", "TEST", 27, 37], ["not observed", "UNCERTAINTY", 11, 23]]], ["The findings of this study are expected to facilitate a better understanding of the current status of CPV-2 infection among dogs in China.AbbreviationsCCoV, canine coronavirus; CDV, canine distemper virus; CPV, canine parvovirus; FPV, feline panleukopenia virus; PCR, polymerase chain reaction", [["CPV-2 infection", "DISEASE", 102, 117], ["canine distemper", "DISEASE", 182, 198], ["canine parvovirus", "DISEASE", 211, 228], ["feline panleukopenia", "DISEASE", 235, 255], ["CPV-2", "ORGANISM", 102, 107], ["dogs", "ORGANISM", 124, 128], ["canine coronavirus", "ORGANISM", 157, 175], ["CDV", "ORGANISM", 177, 180], ["canine distemper virus", "ORGANISM", 182, 204], ["CPV", "ORGANISM", 206, 209], ["canine parvovirus", "ORGANISM", 211, 228], ["FPV", "ORGANISM", 230, 233], ["feline panleukopenia virus", "ORGANISM", 235, 261], ["dogs", "SPECIES", 124, 128], ["canine coronavirus", "SPECIES", 157, 175], ["canine distemper virus", "SPECIES", 182, 204], ["canine parvovirus", "SPECIES", 211, 228], ["feline panleukopenia virus", "SPECIES", 235, 261], ["CPV-2", "SPECIES", 102, 107], ["canine coronavirus", "SPECIES", 157, 175], ["CDV", "SPECIES", 177, 180], ["canine distemper virus", "SPECIES", 182, 204], ["CPV", "SPECIES", 206, 209], ["canine parvovirus", "SPECIES", 211, 228], ["FPV", "SPECIES", 230, 233], ["feline panleukopenia virus", "SPECIES", 235, 261], ["this study", "TEST", 16, 26], ["CPV", "PROBLEM", 102, 105], ["2 infection", "PROBLEM", 106, 117], ["AbbreviationsCCoV", "TEST", 138, 155], ["canine coronavirus", "PROBLEM", 157, 175], ["CDV", "PROBLEM", 177, 180], ["canine distemper virus", "PROBLEM", 182, 204], ["CPV", "PROBLEM", 206, 209], ["canine parvovirus", "PROBLEM", 211, 228], ["FPV", "PROBLEM", 230, 233], ["feline panleukopenia virus", "PROBLEM", 235, 261], ["PCR", "TEST", 263, 266], ["polymerase chain reaction", "PROBLEM", 268, 293], ["infection", "OBSERVATION", 108, 117]]]], "PMC7161789": [["IntroductionAvian infectious bronchitis (AIB) is an acute respiratory disease mainly found in young chickens in commercial poultry farms, causing significant economic losses.", [["respiratory", "ANATOMY", 58, 69], ["infectious bronchitis", "DISEASE", 18, 39], ["AIB", "CHEMICAL", 41, 44], ["respiratory disease", "DISEASE", 58, 77], ["chickens", "ORGANISM", 100, 108], ["chickens", "SPECIES", 100, 108], ["chickens", "SPECIES", 100, 108], ["IntroductionAvian infectious bronchitis (AIB)", "PROBLEM", 0, 45], ["an acute respiratory disease", "PROBLEM", 49, 77], ["significant economic losses", "PROBLEM", 146, 173], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["bronchitis", "OBSERVATION", 29, 39], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory disease", "OBSERVATION", 58, 77], ["young", "OBSERVATION_MODIFIER", 94, 99], ["chickens", "OBSERVATION", 100, 108], ["significant", "OBSERVATION_MODIFIER", 146, 157], ["economic losses", "OBSERVATION", 158, 173]]], ["The prevalence of infectious bronchitis virus (IBV) is pandemic in a number of countries including India and assumes a variety of clinical forms, ranging from a respiratory disease to infection of the oviduct leading to permanent damage to immature birds and in hens, leading to reduced egg production and a nephropathogenic form of IBV causing acute nephritis, urolithiasis, and mortality 1.", [["respiratory", "ANATOMY", 161, 172], ["oviduct", "ANATOMY", 201, 208], ["egg", "ANATOMY", 287, 290], ["infectious bronchitis virus", "DISEASE", 18, 45], ["respiratory disease", "DISEASE", 161, 180], ["infection of the oviduct", "DISEASE", 184, 208], ["IBV", "DISEASE", 333, 336], ["acute nephritis", "DISEASE", 345, 360], ["urolithiasis", "DISEASE", 362, 374], ["infectious bronchitis virus", "ORGANISM", 18, 45], ["oviduct", "ORGAN", 201, 208], ["birds", "ORGANISM", 249, 254], ["egg", "ORGANISM_SUBSTANCE", 287, 290], ["IBV", "ORGANISM", 333, 336], ["infectious bronchitis virus", "SPECIES", 18, 45], ["infectious bronchitis virus", "SPECIES", 18, 45], ["IBV", "SPECIES", 47, 50], ["IBV", "SPECIES", 333, 336], ["infectious bronchitis virus", "PROBLEM", 18, 45], ["pandemic", "PROBLEM", 55, 63], ["a respiratory disease", "PROBLEM", 159, 180], ["infection of the oviduct", "PROBLEM", 184, 208], ["permanent damage to immature birds", "PROBLEM", 220, 254], ["reduced egg production", "PROBLEM", 279, 301], ["IBV", "PROBLEM", 333, 336], ["acute nephritis", "PROBLEM", 345, 360], ["urolithiasis", "PROBLEM", 362, 374], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["bronchitis virus", "OBSERVATION", 29, 45], ["respiratory disease", "OBSERVATION", 161, 180], ["infection", "OBSERVATION", 184, 193], ["oviduct", "ANATOMY", 201, 208], ["permanent", "OBSERVATION_MODIFIER", 220, 229], ["damage", "OBSERVATION", 230, 236], ["immature birds", "OBSERVATION", 240, 254], ["reduced egg production", "OBSERVATION", 279, 301], ["IBV", "OBSERVATION", 333, 336], ["acute", "OBSERVATION_MODIFIER", 345, 350], ["nephritis", "OBSERVATION", 351, 360], ["urolithiasis", "OBSERVATION", 362, 374]]], ["IBV, a causative agent of AIB disease, belongs to the genus Gammacoronavirus, subfamily Coronavirinae, family Coronaviridae, and order Nidovirales (International Committee on Taxonomy of Viruses (ICTV) 2011).", [["AIB", "CHEMICAL", 26, 29], ["IBV", "ORGANISM", 0, 3], ["AIB", "SIMPLE_CHEMICAL", 26, 29], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 60, 76], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3], ["AIB disease", "PROBLEM", 26, 37]]], ["The genome of IBV is a positive\u2010sense single\u2010stranded RNA of about 27.6 kb with the following genomic organization: 5\u2032\u2010Pol\u2010S\u20103a\u20103b\u2010E\u2010M\u20105a\u20105b\u2010N\u2010untranslated region\u20103\u2032 2.IntroductionAll coronaviruses maintain a set of essential genes, including those that encode the polymerase (Pol), spike (S), small membrane (E), membrane (M), and nucleocapsid (N) proteins 3.", [["membrane", "ANATOMY", 300, 308], ["membrane", "ANATOMY", 314, 322], ["IBV", "ORGANISM", 14, 17], ["coronaviruses", "ORGANISM", 184, 197], ["Pol", "GENE_OR_GENE_PRODUCT", 277, 280], ["spike (S)", "GENE_OR_GENE_PRODUCT", 283, 292], ["small membrane (E)", "GENE_OR_GENE_PRODUCT", 294, 312], ["membrane", "CELLULAR_COMPONENT", 314, 322], ["nucleocapsid (N) proteins 3", "GENE_OR_GENE_PRODUCT", 332, 359], ["positive\u2010sense single\u2010stranded RNA", "RNA", 23, 57], ["Pol\u2010S", "DNA", 119, 124], ["3a\u20103b", "DNA", 125, 130], ["E", "DNA", 131, 132], ["M\u20105a\u20105b", "DNA", 133, 140], ["N\u2010untranslated region", "DNA", 141, 162], ["essential genes", "DNA", 216, 231], ["polymerase", "PROTEIN", 265, 275], ["Pol", "PROTEIN", 277, 280], ["spike (S)", "PROTEIN", 283, 292], ["small membrane (E), membrane (M)", "PROTEIN", 294, 326], ["nucleocapsid (N) proteins 3", "PROTEIN", 332, 359], ["IBV", "SPECIES", 14, 17], ["Pol\u2010S", "TEST", 119, 124], ["E", "TEST", 131, 132], ["the polymerase", "TEST", 261, 275], ["small membrane (E), membrane (M), and nucleocapsid (N) proteins 3", "PROBLEM", 294, 359], ["small membrane", "ANATOMY", 294, 308]]], ["The spike gene is translated as a precursor spike So, which is posttranslationally cleaved by host serine protease into S1 and S2 at cleavage sequence motif 4.", [["serine", "CHEMICAL", 99, 105], ["S1", "GENE_OR_GENE_PRODUCT", 120, 122], ["S2", "GENE_OR_GENE_PRODUCT", 127, 129], ["spike gene", "DNA", 4, 14], ["host serine protease", "PROTEIN", 94, 114], ["S1", "PROTEIN", 120, 122], ["S2", "PROTEIN", 127, 129], ["cleavage sequence motif 4", "PROTEIN", 133, 158], ["a precursor spike", "PROBLEM", 32, 49]]], ["The S1 protein is the primary cause of antigenic variations in IBV and contains the serotype\u2010specific neutralization epitopes, whereas the envelope and membrane proteins are conserved.", [["membrane", "ANATOMY", 152, 160], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["IBV", "ORGANISM", 63, 66], ["membrane", "CELLULAR_COMPONENT", 152, 160], ["S1 protein", "PROTEIN", 4, 14], ["serotype\u2010specific neutralization epitopes", "PROTEIN", 84, 125], ["envelope and membrane proteins", "PROTEIN", 139, 169], ["IBV", "SPECIES", 63, 66], ["antigenic variations in IBV", "PROBLEM", 39, 66], ["the serotype\u2010specific neutralization epitopes", "PROBLEM", 80, 125], ["the envelope and membrane proteins", "PROBLEM", 135, 169], ["S1", "ANATOMY", 4, 6], ["protein", "OBSERVATION", 7, 14], ["antigenic variations", "OBSERVATION", 39, 59], ["IBV", "OBSERVATION", 63, 66], ["serotype\u2010specific", "OBSERVATION_MODIFIER", 84, 101], ["neutralization epitopes", "OBSERVATION", 102, 125], ["membrane proteins", "OBSERVATION", 152, 169]]], ["Antigenic variation among IBV strains is common 1, 5, 6, 7, 8; the major prevalent form of IBV in the Indian subcontinent is respiratory and nephropathogenic forms 9.IntroductionThe IBV classification of different serotypes is based largely on virus\u2010neutralization tests, a gold standard test for serodiagnosis of infectious bronchitis in infected birds.", [["respiratory", "ANATOMY", 125, 136], ["infectious bronchitis", "DISEASE", 314, 335], ["IBV strains", "ORGANISM", 26, 37], ["IBV", "ORGANISM", 91, 94], ["birds", "ORGANISM", 348, 353], ["IBV", "SPECIES", 26, 29], ["IBV", "SPECIES", 91, 94], ["IBV", "SPECIES", 182, 185], ["Antigenic variation", "PROBLEM", 0, 19], ["IBV strains", "PROBLEM", 26, 37], ["IBV", "PROBLEM", 91, 94], ["respiratory and nephropathogenic forms", "PROBLEM", 125, 163], ["The IBV classification", "TREATMENT", 178, 200], ["different serotypes", "PROBLEM", 204, 223], ["virus\u2010neutralization tests", "TEST", 244, 270], ["a gold standard test", "TEST", 272, 292], ["infectious bronchitis", "PROBLEM", 314, 335], ["IBV strains", "OBSERVATION", 26, 37], ["IBV", "OBSERVATION", 91, 94], ["respiratory", "ANATOMY", 125, 136], ["different", "OBSERVATION_MODIFIER", 204, 213], ["serotypes", "OBSERVATION", 214, 223], ["infectious", "OBSERVATION_MODIFIER", 314, 324], ["bronchitis", "OBSERVATION", 325, 335], ["infected birds", "OBSERVATION", 339, 353]]], ["Serotype determination is of trivial importance as different serotypes do not always cross protect.", [["Serotype determination", "TEST", 0, 22], ["trivial importance", "PROBLEM", 29, 47], ["different serotypes", "PROBLEM", 51, 70]]], ["Genotyping of IBV strains can also be done by genetic characterization of the spike glycoprotein gene by reverse transcription polymerase chain reaction (RT\u2010PCR), restriction fragment length polymorphism, and nucleotide sequencing, which for the most part correlates with the viral serotype 10, 11.", [["nucleotide", "CHEMICAL", 209, 219], ["nucleotide", "CHEMICAL", 209, 219], ["IBV", "ORGANISM", 14, 17], ["spike glycoprotein gene", "DNA", 78, 101], ["restriction fragment length polymorphism", "DNA", 163, 203], ["IBV", "SPECIES", 14, 17], ["IBV strains", "PROBLEM", 14, 25], ["the spike glycoprotein gene", "TREATMENT", 74, 101], ["reverse transcription polymerase chain reaction", "PROBLEM", 105, 152], ["RT\u2010PCR", "TEST", 154, 160], ["restriction fragment length polymorphism", "PROBLEM", 163, 203], ["nucleotide sequencing", "TEST", 209, 230], ["the viral serotype", "TEST", 272, 290], ["fragment", "OBSERVATION_MODIFIER", 175, 183], ["length", "OBSERVATION_MODIFIER", 184, 190]]], ["Nucleotide sequencing of the S1 gene is the foremost technique used for differentiation of IBV strains into various genotypes.", [["S1", "GENE_OR_GENE_PRODUCT", 29, 31], ["IBV", "ORGANISM", 91, 94], ["S1 gene", "DNA", 29, 36], ["IBV", "SPECIES", 91, 94], ["Nucleotide sequencing", "TEST", 0, 21], ["IBV strains into various genotypes", "PROBLEM", 91, 125]]], ["The emergence of antigenic variants is mostly attributed to variation in the spike gene by recombination 12, 13 and is investigated by nucleotide sequencing of the S1 portion of the S gene coding for the S1 subunit 14, 15, where most of the epitopes to which neutralizing antibodies bind are found 16.", [["nucleotide", "CHEMICAL", 135, 145], ["nucleotide", "CHEMICAL", 135, 145], ["spike gene", "DNA", 77, 87], ["recombination 12, 13", "DNA", 91, 111], ["S1 portion", "DNA", 164, 174], ["S gene", "DNA", 182, 188], ["S1 subunit 14, 15", "PROTEIN", 204, 221], ["epitopes", "PROTEIN", 241, 249], ["neutralizing antibodies", "PROTEIN", 259, 282], ["antigenic variants", "PROBLEM", 17, 35], ["nucleotide sequencing", "TEST", 135, 156], ["the S1 subunit", "TEST", 200, 214], ["the epitopes", "PROBLEM", 237, 249], ["neutralizing antibodies bind", "TEST", 259, 287], ["antigenic variants", "OBSERVATION", 17, 35]]], ["The impact of regular emergence of antigenic variants of the disease and subsequent vaccines used to control varies depending on different geographical locations.", [["the disease", "PROBLEM", 57, 68], ["subsequent vaccines", "TREATMENT", 73, 92], ["regular emergence", "OBSERVATION_MODIFIER", 14, 31], ["antigenic variants", "OBSERVATION", 35, 53], ["disease", "OBSERVATION", 61, 68]]], ["Genetic assessment of field isolates of viruses from outbreaks is essential for evaluation of vaccine efficiency on antigenic variants that arise.", [["Genetic assessment", "TEST", 0, 18], ["viruses", "PROBLEM", 40, 47], ["evaluation", "TEST", 80, 90], ["vaccine efficiency", "PROBLEM", 94, 112], ["antigenic variants", "PROBLEM", 116, 134], ["viruses", "OBSERVATION", 40, 47]]], ["A critical advantage of sequencing S1 is for comparison and analysis of sequences of unknown field isolates and variants with reference vaccine strains for establishing potential relatedness.", [["analysis of sequences", "TEST", 60, 81], ["reference vaccine strains", "TREATMENT", 126, 151]]], ["IBV vaccines currently used are either live attenuated or killed showing varying degrees of efficacy.", [["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["IBV vaccines", "TREATMENT", 0, 12]]], ["At present, many countries only permit live vaccines of the Massachusetts type, such as the H120 strain.", [["the H120 strain", "PROBLEM", 88, 103]]], ["In India, Verma, 17 for the first time reported the prevalence of IBV infections in chickens.", [["IBV infections", "DISEASE", 66, 80], ["IBV", "ORGANISM", 66, 69], ["chickens", "ORGANISM", 84, 92], ["chickens", "SPECIES", 84, 92], ["IBV", "SPECIES", 66, 69], ["chickens", "SPECIES", 84, 92], ["IBV infections in chickens", "PROBLEM", 66, 92], ["IBV", "OBSERVATION_MODIFIER", 66, 69], ["infections", "OBSERVATION", 70, 80]]], ["The emergence of a nephropathogenic IBV with a novel genotype in India has also been reported 9.", [["IBV", "ORGANISM", 36, 39], ["IBV", "SPECIES", 36, 39], ["a nephropathogenic IBV", "TREATMENT", 17, 39], ["IBV", "OBSERVATION", 36, 39]]], ["Recently, an outbreak of nephropathogenic AIB in broiler flocks was reported in the Chhattisgarh region of India 18.IntroductionIn this study, we amplified and sequenced the spike gene of the live infectious bronchitis attenuated vaccine virus, which is routinely used in India.", [["AIB", "CHEMICAL", 42, 45], ["infectious bronchitis", "DISEASE", 197, 218], ["AIB", "CHEMICAL", 42, 45], ["AIB", "SIMPLE_CHEMICAL", 42, 45], ["spike gene", "DNA", 174, 184], ["infectious bronchitis attenuated vaccine virus", "SPECIES", 197, 243], ["infectious bronchitis attenuated vaccine virus", "SPECIES", 197, 243], ["nephropathogenic AIB", "PROBLEM", 25, 45], ["broiler flocks", "TREATMENT", 49, 63], ["this study", "TEST", 131, 141], ["the live infectious bronchitis attenuated vaccine virus", "PROBLEM", 188, 243], ["outbreak", "OBSERVATION_MODIFIER", 13, 21], ["nephropathogenic AIB", "OBSERVATION", 25, 45], ["broiler flocks", "OBSERVATION", 49, 63]]], ["Bioinformatics was applied to evaluation of the spike gene for characterization and spike gene's relatedness with previously reported Indian IBV isolates.Virus ::: Materials and MethodsViral RNA was isolated from the AIB vaccine, living bp vet (Mass type strain; Ventri Biologicals, Pune, India).", [["AIB", "CHEMICAL", 217, 220], ["AIB", "CHEMICAL", 217, 220], ["IBV", "ORGANISM", 141, 144], ["Virus", "ORGANISM", 154, 159], ["AIB", "SIMPLE_CHEMICAL", 217, 220], ["spike gene", "DNA", 48, 58], ["spike gene", "DNA", 84, 94], ["MethodsViral RNA", "RNA", 178, 194], ["Indian IBV", "SPECIES", 134, 144], ["evaluation", "TEST", 30, 40], ["characterization", "TEST", 63, 79], ["spike gene's relatedness", "PROBLEM", 84, 108], ["Indian IBV isolates", "PROBLEM", 134, 153], ["MethodsViral RNA", "TREATMENT", 178, 194], ["the AIB vaccine", "TREATMENT", 213, 228], ["living bp vet (Mass type strain", "TREATMENT", 230, 261]]], ["A virus sample was obtained in a freeze\u2010dried form that was dissolved in 1 mL normal saline; 0.1 mL of the inoculum was inoculated in five 10\u2010day\u2010old specific pathogen free chicken eggs (Venky's Hatcheries, Pune, India), and the eggs were candled daily for 96 H. The allantoic fluid was collected and centrifuged at 1700 g for 10 Min at room temperature, and a supernatant was stored at \u201320\u00b0C until use.RNA isolation and RT\u2010PCR ::: Materials and MethodsTotal RNA from the infected allantoic fluid was extracted by a Trizol reagent (Sigma, St. Louis, MO, USA) as per the manufacturer's protocol.", [["sample", "ANATOMY", 8, 14], ["eggs", "ANATOMY", 181, 185], ["eggs", "ANATOMY", 229, 233], ["allantoic fluid", "ANATOMY", 267, 282], ["supernatant", "ANATOMY", 361, 372], ["allantoic fluid", "ANATOMY", 481, 496], ["chicken", "ORGANISM", 173, 180], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 181, 185], ["eggs", "ORGANISM", 229, 233], ["allantoic fluid", "ORGANISM_SUBSTANCE", 267, 282], ["allantoic fluid", "ORGANISM_SUBSTANCE", 481, 496], ["MethodsTotal RNA", "RNA", 446, 462], ["chicken", "SPECIES", 173, 180], ["chicken", "SPECIES", 173, 180], ["A virus sample", "TEST", 0, 14], ["normal saline", "TREATMENT", 78, 91], ["the inoculum", "TREATMENT", 103, 115], ["the eggs", "TREATMENT", 225, 233], ["The allantoic fluid", "TEST", 263, 282], ["RNA isolation", "TREATMENT", 403, 416], ["RT\u2010PCR", "TEST", 421, 427], ["Materials", "TREATMENT", 432, 441], ["MethodsTotal RNA", "TREATMENT", 446, 462], ["the infected allantoic fluid", "PROBLEM", 468, 496], ["a Trizol reagent", "TREATMENT", 514, 530], ["the manufacturer's protocol", "TREATMENT", 566, 593], ["virus", "OBSERVATION", 2, 7], ["MethodsTotal RNA", "OBSERVATION", 446, 462], ["infected", "OBSERVATION_MODIFIER", 472, 480], ["allantoic", "OBSERVATION_MODIFIER", 481, 490], ["fluid", "OBSERVATION", 491, 496]]], ["The extracted RNA was first reverse\u2010transcribed with gene\u2010specific primers and a thermoscript RT kit (Invitrogen, Carlsbad, CA, USA) to synthesize the first\u2010strand cDNA.", [["gene\u2010specific primers", "DNA", 53, 74], ["first\u2010strand cDNA", "DNA", 151, 168], ["The extracted RNA", "PROBLEM", 0, 17], ["gene\u2010specific primers", "TREATMENT", 53, 74], ["a thermoscript RT kit (Invitrogen", "TREATMENT", 79, 112]]], ["Synthesized cDNA was screened for the presence of IBV genome by a polymerase chain reaction (PCR) with a set of primers specific to the spike gene of IBV.", [["IBV", "ORGANISM", 50, 53], ["IBV", "ORGANISM", 150, 153], ["cDNA", "DNA", 12, 16], ["IBV genome", "DNA", 50, 60], ["spike gene", "DNA", 136, 146], ["IBV", "SPECIES", 50, 53], ["IBV", "SPECIES", 150, 153], ["Synthesized cDNA", "TREATMENT", 0, 16], ["IBV genome", "PROBLEM", 50, 60], ["a polymerase chain reaction", "PROBLEM", 64, 91], ["PCR", "TEST", 93, 96], ["a set of primers", "PROBLEM", 103, 119], ["IBV", "PROBLEM", 150, 153], ["IBV genome", "OBSERVATION", 50, 60]]], ["Primers were used to amplify the complete coding sequence (CDS) of the S gene including forward 5\u2032\u2010CCCGAATTCATGTTGGTAACACCTCTTTTACTAG\u20103 (EcoRI) (nucleotide position 20374\u201020398) and reverse primer 5\u2032\u2010GCGGAGCTCTTAAACAGACTTTTTAGGTC\u20103\u2032 (SacI) (nucleotide position 20843\u201323862), designed from Massachusetts M41 serotype (FJ904723).", [["nucleotide", "CHEMICAL", 145, 155], ["nucleotide", "CHEMICAL", 241, 251], ["EcoRI", "GENE_OR_GENE_PRODUCT", 137, 142], ["SacI", "GENE_OR_GENE_PRODUCT", 234, 238], ["coding sequence", "DNA", 42, 57], ["CDS", "DNA", 59, 62], ["S gene", "DNA", 71, 77], ["forward 5\u2032\u2010CCCGAATTCATGTTGGTAACACCTCTTTTACTAG\u20103", "DNA", 88, 135], ["EcoRI", "DNA", 137, 142], ["nucleotide position 20374\u201020398", "DNA", 145, 176], ["reverse primer 5", "DNA", 182, 198], ["SacI", "DNA", 234, 238], ["nucleotide position 20843\u201323862", "DNA", 241, 272], ["nucleotide position", "TEST", 145, 164], ["GCGGAGCTCTTAAACAGACTTTTTAGGTC", "TREATMENT", 200, 229]]], ["PCR amplification was carried out using Pfu DNA polymerase (Thermo Scientific, Waltham, MA, USA) with the following cycling conditions: 94\u00b0C for 5 Min followed by 30 cycles of 94\u00b0C for 1 Min, 60\u00b0C for 1 Min, 72\u00b0C for 1.5 Min, with a final extension of 72\u00b0C for 10 Min.", [["DNA", "CELLULAR_COMPONENT", 44, 47], ["Pfu DNA polymerase", "PROTEIN", 40, 58], ["PCR amplification", "TEST", 0, 17]]], ["The PCR\u2010amplified gene fragment was cloned with a cloning vector CloneJETTM (Thermo Scientific).", [["PCR\u2010amplified gene fragment", "DNA", 4, 31], ["cloning vector CloneJETTM", "DNA", 50, 75], ["The PCR\u2010amplified gene fragment", "PROBLEM", 0, 31], ["a cloning vector CloneJETTM", "TREATMENT", 48, 75], ["fragment", "OBSERVATION_MODIFIER", 23, 31]]], ["The size of amplicon was 3489 bp.", [["amplicon", "TEST", 12, 20], ["bp", "TEST", 30, 32], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["The PCR product was visualized by agar gel electrophoresis and confirmed by restriction enzyme digestion and sequencing.Sequence and phylogenetic analysis ::: Materials and MethodsSequences were analyzed using Chromas Lite 2.1.1.", [["The PCR product", "TEST", 0, 15], ["agar gel electrophoresis", "TEST", 34, 58], ["sequencing", "TEST", 109, 119], ["phylogenetic analysis", "TEST", 133, 154], ["MethodsSequences", "TEST", 173, 189], ["Chromas Lite", "TEST", 210, 222]]], ["The nucleotide sequence of the S gene of Indian IBV vaccine strain was assembled and aligned by clustalW 19 after Basic Local Alignment and Search Tool (BLAST) search with published IBV sequences deposited to the GenBank database.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["Indian IBV", "ORGANISM", 41, 51], ["IBV", "ORGANISM", 182, 185], ["S gene", "DNA", 31, 37], ["clustalW 19", "DNA", 96, 107], ["IBV sequences", "DNA", 182, 195], ["Indian IBV vaccine", "SPECIES", 41, 59], ["Indian IBV vaccine strain", "SPECIES", 41, 66], ["IBV", "SPECIES", 182, 185], ["The nucleotide sequence", "TEST", 0, 23], ["Indian IBV vaccine strain", "TREATMENT", 41, 66], ["published IBV sequences", "TREATMENT", 172, 195]]], ["Sequence identities by BLAST analysis were included in the alignment and phylogenetic tree construction.", [["Sequence identities", "TEST", 0, 19], ["BLAST analysis", "TEST", 23, 37]]], ["The multiple sequence alignments and phylogenetic tree construction with the neighbor joining method were performed using MEGA version 5 20.", [["The multiple sequence alignments", "TEST", 0, 32], ["MEGA version", "TEST", 122, 134]]], ["The bootstrap values were determined from 1,000 replicates of the original data.", [["The bootstrap values", "TEST", 0, 20], ["the original data", "TEST", 62, 79]]], ["Phylogenetic analysis of nucleic acid and deduced amino acid sequences was carried out with the neighbor joining method using the Jukes\u2013Cantor model and pairwise deletion.", [["nucleic acid", "CHEMICAL", 25, 37], ["amino acid", "CHEMICAL", 50, 60], ["amino acid", "CHEMICAL", 50, 60], ["nucleic acid", "SIMPLE_CHEMICAL", 25, 37], ["amino acid", "AMINO_ACID", 50, 60], ["Phylogenetic analysis", "TEST", 0, 21], ["nucleic acid", "TEST", 25, 37], ["deduced amino acid sequences", "TEST", 42, 70], ["the Jukes\u2013Cantor model", "TREATMENT", 126, 148], ["pairwise deletion", "PROBLEM", 153, 170], ["pairwise deletion", "OBSERVATION", 153, 170]]], ["The S gene sequences from the GenBank database, which were used for comparison or phylogenetic analysis in this study, are enlisted in Tables 1 and 2.Bioinformatics analysis ::: Materials and Methods", [["S gene sequences", "DNA", 4, 20], ["The S gene sequences", "TEST", 0, 20], ["the GenBank database", "TEST", 26, 46], ["phylogenetic analysis", "TEST", 82, 103], ["this study", "TEST", 107, 117], ["Bioinformatics analysis", "TEST", 150, 173], ["Methods", "TREATMENT", 192, 199]]]], "PMC7134322": [["By leveraging the power of Information and Communication Technologies (ICT) in public sectors or governments and making a city \u201csmart\u201d, e-governments and smart cities are emerging as a strategy to mitigate problems generated by the urban population growth and rapid urbanization, improve the efficiency of urban management and bring better life to residents.", [["rapid urbanization", "TREATMENT", 260, 278], ["urban management", "TREATMENT", 306, 322]]], ["However, as a giant system which involves various kinds of stakeholders, new technologies and complicated ICT subsystems, challenges such as complexity, interoperability and alignment between business goals and ICT implementations have been met [3, 4].", [["complicated ICT subsystems", "TREATMENT", 94, 120], ["ICT implementations", "TREATMENT", 211, 230]]], ["Especially, with the ever-expanding scale of cities, the continuous updating of ICT, and the higher expectations of people for a better life, how to make the advantages of ICT more effective and efficient becomes a problem.", [["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122], ["ICT", "TREATMENT", 172, 175]]], ["Enterprise Architecture (EA) has been adopted as an important tool to tackle such challenges [5] as they can help integrate ICT to achieve urban management, business operations and personal life goals.IntroductionAlthough some earlier studies on applying EA in public sectors, e-governments and smart cities have been performed, existing studies in this area are scattered and no strong research stream has been formulated [6].", [["EA", "CHEMICAL", 255, 257], ["urban management", "TREATMENT", 139, 155], ["business operations", "TREATMENT", 157, 176], ["some earlier studies", "TEST", 222, 242], ["existing studies", "TEST", 329, 345], ["strong research stream", "PROBLEM", 380, 402], ["scattered", "OBSERVATION_MODIFIER", 363, 372]]], ["As a result, general knowledge regarding EA in e-governments is difficult to be accumulated and be reused elsewhere.", [["EA", "CHEMICAL", 41, 43], ["EA in e-governments", "TREATMENT", 41, 60]]], ["To address this problem, we propose to characterize existing studies in this field by answering three important questions: why one research on applying EA in e-government or smart cities was required (motivation), what kind of outcome was contributed (contribution), and how the research was performed (method).", [["EA", "CHEMICAL", 152, 154], ["existing studies", "TEST", 52, 68], ["EA in e-government", "TREATMENT", 152, 170], ["smart cities", "TREATMENT", 174, 186]]], ["Starting on this characterization theme, we developed a framework and performed initial explorations by analyzing and grouping a set of studies in this area based on the framework.", [["initial explorations", "TEST", 80, 100], ["studies", "TEST", 136, 143]]], ["2, we introduce how we developed the thematic framework and selected scientific articles to perform the literature synthesis.", [["the literature synthesis", "TREATMENT", 100, 124]]], ["We then discuss the synthesis result and present some findings accordingly in Sect.", [["the synthesis result", "TEST", 16, 36]]], ["6, we talk about limitations of this study, point out some possible future research directions, and conclude this paper.MethodsWe aim to disclose fundamental knowledge about main research streams, critical issues, and possible future trends in the area of applying EA when developing ICT systems for public sectors, governments, and cities.", [["this study", "TEST", 32, 42]]], ["To address this, widely used three questions, namely Why, What, and How were employed in this study.", [["this study", "TEST", 89, 99]]], ["Because we have read these papers previously, we are familiar with the depth and breadth of the evidences in these studies.", [["these studies", "TEST", 109, 122]]], ["The three questions together with the enumerated answers constitute a framework for further literature synthesis.MethodsLater, we applied this framework to a larger set of studies and performed grouping and analysis.", [["further literature synthesis", "TREATMENT", 84, 112], ["MethodsLater", "TREATMENT", 113, 125], ["analysis", "TEST", 207, 215]]], ["Although our original interest domain is smart city, papers regarding applying EA in smart cities are rare.", [["EA", "CHEMICAL", 79, 81]]], ["Due to time and resources constraints, we put our focus on more recently published and highly qualified papers by restricting publication years and checking the relevance with this study.", [["this study", "TEST", 176, 186]]]], "e065050be0e1968316d85e3b4e24b023e236f7bb": [["IntroductionPrecision medicine has evolved in recent years allowing the incorporation of novel taxonomies and stratification of patients, and using standardized clinical endpoints, genetic and other biomarker information (1) .", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136]]], ["Its role in paediatric healthcare involves the selection of targeted diagnostic, therapeutic and prevention strategies matched to precise molecular, epidemiological and clinical profile of each patient; the management of respiratory syncytial virus (RSV) infection represents a good paradigm of precision medicine (2) .", [["respiratory syncytial virus (RSV) infection", "DISEASE", 221, 264], ["patient", "ORGANISM", 194, 201], ["respiratory syncytial virus", "ORGANISM", 221, 248], ["RSV", "ORGANISM", 250, 253], ["patient", "SPECIES", 194, 201], ["syncytial virus (RSV", "SPECIES", 233, 253], ["respiratory syncytial virus", "SPECIES", 221, 248], ["RSV", "SPECIES", 250, 253], ["prevention strategies", "TREATMENT", 97, 118], ["respiratory syncytial virus (RSV) infection", "PROBLEM", 221, 264], ["respiratory", "ANATOMY", 221, 232], ["syncytial virus", "OBSERVATION", 233, 248]]], ["RSV is a single-stranded RNA virus (Figs.", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["a single-stranded RNA virus", "PROBLEM", 7, 34], ["RNA virus", "OBSERVATION", 25, 34]]], ["1 and 2), which represents the most frequent viral cause of acute lower respiratory tract infection (ALRTI) in infants, with a worldwide distribution and seasonal occurrence (2) (3) (4) (5) .", [["lower respiratory tract", "ANATOMY", 66, 89], ["lower respiratory tract infection", "DISEASE", 66, 99], ["ALRTI", "DISEASE", 101, 106], ["lower", "ORGANISM_SUBDIVISION", 66, 71], ["respiratory tract", "ORGANISM_SUBDIVISION", 72, 89], ["infants", "ORGANISM", 111, 118], ["infants", "SPECIES", 111, 118], ["acute lower respiratory tract infection", "PROBLEM", 60, 99], ["most frequent", "OBSERVATION_MODIFIER", 31, 44], ["viral", "OBSERVATION", 45, 50], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["lower", "ANATOMY_MODIFIER", 66, 71], ["respiratory tract", "ANATOMY", 72, 89], ["infection", "OBSERVATION", 90, 99]]], ["It was first isolated in 1956 from nasal secretions of chimpanzees with rhinorrhea and coryza; the novel virus was initially named 'chimpanzee coryza agent' (ccA) (6, 7) .", [["nasal secretions", "ANATOMY", 35, 51], ["rhinorrhea", "DISEASE", 72, 82], ["nasal secretions", "ORGANISM_SUBSTANCE", 35, 51], ["chimpanzees", "ORGANISM", 55, 66], ["chimpanzee", "ORGANISM", 132, 142], ["chimpanzee coryza", "SPECIES", 132, 149], ["nasal secretions of chimpanzees", "PROBLEM", 35, 66], ["rhinorrhea", "PROBLEM", 72, 82], ["coryza", "PROBLEM", 87, 93], ["the novel virus", "PROBLEM", 95, 110], ["ccA", "ANATOMY", 158, 161]]], ["In the following year, when ccA was also isolated from children with ALRTI, it gained its final name due to the syncytia observed on electron microscopy; syncytia are formed by fusion of infected host cells with neighboring cells leading to the formation of multi-nucleate enlarged cells.", [["syncytia", "ANATOMY", 112, 120], ["syncytia", "ANATOMY", 154, 162], ["cells", "ANATOMY", 201, 206], ["cells", "ANATOMY", 224, 229], ["cells", "ANATOMY", 282, 287], ["ALRTI", "DISEASE", 69, 74], ["ccA", "GENE_OR_GENE_PRODUCT", 28, 31], ["children", "ORGANISM", 55, 63], ["syncytia", "CELL", 154, 162], ["host cells", "CELL", 196, 206], ["cells", "CELL", 224, 229], ["cells", "CELL", 282, 287], ["ccA", "PROTEIN", 28, 31], ["infected host cells", "CELL_TYPE", 187, 206], ["neighboring cells", "CELL_TYPE", 212, 229], ["multi-nucleate enlarged cells", "CELL_TYPE", 258, 287], ["children", "SPECIES", 55, 63], ["ALRTI", "TREATMENT", 69, 74], ["the syncytia", "PROBLEM", 108, 120], ["electron microscopy", "TEST", 133, 152], ["syncytia", "PROBLEM", 154, 162], ["infected host cells", "PROBLEM", 187, 206], ["neighboring cells", "PROBLEM", 212, 229], ["multi-nucleate enlarged cells", "PROBLEM", 258, 287], ["syncytia", "OBSERVATION", 112, 120], ["infected host cells", "OBSERVATION", 187, 206], ["neighboring cells", "OBSERVATION", 212, 229], ["multi-", "OBSERVATION_MODIFIER", 258, 264], ["nucleate", "OBSERVATION_MODIFIER", 264, 272], ["enlarged cells", "OBSERVATION", 273, 287]]], ["Although the formation of syncytia is the hallmark of the cytopathic effect of RSV that is associated with host cellular membrane merging, syncytia are not pathognomonic of RSV (8) .", [["syncytia", "ANATOMY", 26, 34], ["cellular membrane", "ANATOMY", 112, 129], ["syncytia", "ANATOMY", 139, 147], ["syncytia", "DISEASE", 26, 34], ["RSV", "DISEASE", 79, 82], ["syncytia", "CELL", 26, 34], ["RSV", "ORGANISM", 79, 82], ["cellular membrane", "CELLULAR_COMPONENT", 112, 129], ["syncytia", "CELLULAR_COMPONENT", 139, 147], ["RSV", "ORGANISM", 173, 176], ["RSV", "SPECIES", 79, 82], ["RSV", "SPECIES", 173, 176], ["syncytia", "PROBLEM", 26, 34], ["the cytopathic effect", "PROBLEM", 54, 75], ["RSV", "PROBLEM", 79, 82], ["host cellular membrane merging", "PROBLEM", 107, 137], ["syncytia", "PROBLEM", 139, 147], ["RSV", "PROBLEM", 173, 176], ["syncytia", "OBSERVATION", 26, 34], ["hallmark", "OBSERVATION_MODIFIER", 42, 50], ["cytopathic", "OBSERVATION_MODIFIER", 58, 68], ["RSV", "OBSERVATION", 79, 82], ["associated with", "UNCERTAINTY", 91, 106], ["host cellular membrane merging", "OBSERVATION", 107, 137]]], ["Syncytia are also observed in cell culture with several other viruses, such as parainfluenza, HSV-1, HIV and MeV.", [["cell culture", "ANATOMY", 30, 42], ["Syncytia", "DISEASE", 0, 8], ["parainfluenza, HSV-1, HIV and MeV.", "DISEASE", 79, 113], ["cell culture", "CELL", 30, 42], ["parainfluenza", "ORGANISM", 79, 92], ["HSV-1", "ORGANISM", 94, 99], ["HIV", "ORGANISM", 101, 104], ["MeV.", "ORGANISM", 109, 113], ["parainfluenza", "SPECIES", 79, 92], ["HSV-1", "SPECIES", 94, 99], ["HIV", "SPECIES", 101, 104], ["HSV-1", "SPECIES", 94, 99], ["HIV", "SPECIES", 101, 104], ["Syncytia", "PROBLEM", 0, 8], ["cell culture", "TEST", 30, 42], ["several other viruses", "PROBLEM", 48, 69], ["parainfluenza", "PROBLEM", 79, 92], ["HSV", "TEST", 94, 97], ["HIV", "PROBLEM", 101, 104], ["cell culture", "OBSERVATION", 30, 42], ["viruses", "OBSERVATION", 62, 69]]], ["Recently, the International committee on Taxonomy of Viruses (IcTV), which authorizes and organizes the classification and naming of viral species, grouped RSV under the genus Orthopneumovirus within the family Pneumoviridae (9, 10) .IntroductionBronchiolitis is the most common clinical manifestation of RSV infection in infants and although it is usually self-limiting, in infancy it accounts for a significant number of hospitalizations and paediatric intensive care unit (PIcU) admissions (3) . despite its association with relatively high morbidity and mortality in premature neonates and in certain paediatric populations with underlying conditions, such as immunodeficiency and congenital heart disease, RSV infection may also lead to hospitalization of previously healthy, full-term infants (11, 12) .", [["heart", "ANATOMY", 696, 701], ["Bronchiolitis", "DISEASE", 246, 259], ["RSV infection", "DISEASE", 305, 318], ["immunodeficiency", "DISEASE", 664, 680], ["congenital heart disease", "DISEASE", 685, 709], ["RSV infection", "DISEASE", 711, 724], ["RSV", "ORGANISM", 156, 159], ["RSV", "ORGANISM", 305, 308], ["infants", "ORGANISM", 322, 329], ["heart", "ORGAN", 696, 701], ["RSV", "ORGANISM", 711, 714], ["infants", "ORGANISM", 791, 798], ["infants", "SPECIES", 322, 329], ["infants", "SPECIES", 791, 798], ["RSV", "SPECIES", 156, 159], ["RSV", "SPECIES", 305, 308], ["RSV", "SPECIES", 711, 714], ["viral species", "PROBLEM", 133, 146], ["IntroductionBronchiolitis", "PROBLEM", 234, 259], ["RSV infection", "PROBLEM", 305, 318], ["relatively high morbidity", "PROBLEM", 528, 553], ["mortality in premature neonates", "PROBLEM", 558, 589], ["underlying conditions", "PROBLEM", 633, 654], ["immunodeficiency", "PROBLEM", 664, 680], ["congenital heart disease", "PROBLEM", 685, 709], ["RSV infection", "PROBLEM", 711, 724], ["Viruses", "OBSERVATION", 53, 60], ["viral species", "OBSERVATION", 133, 146], ["genus Orthopneumovirus", "OBSERVATION", 170, 192], ["Bronchiolitis", "OBSERVATION", 246, 259], ["most common", "OBSERVATION_MODIFIER", 267, 278], ["RSV", "OBSERVATION_MODIFIER", 305, 308], ["infection", "OBSERVATION", 309, 318], ["high", "OBSERVATION_MODIFIER", 539, 543], ["morbidity", "OBSERVATION", 544, 553], ["heart", "ANATOMY", 696, 701], ["disease", "OBSERVATION", 702, 709], ["RSV infection", "OBSERVATION", 711, 724]]], ["RSV-positive bronchiolitis is characterized by airway inflammation and oedema, mucus production and debris leading to airway obstruction and turbulent gas flow.", [["airway", "ANATOMY", 47, 53], ["mucus", "ANATOMY", 79, 84], ["airway", "ANATOMY", 118, 124], ["bronchiolitis", "DISEASE", 13, 26], ["airway inflammation", "DISEASE", 47, 66], ["oedema", "DISEASE", 71, 77], ["airway obstruction", "DISEASE", 118, 136], ["RSV", "ORGANISM", 0, 3], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["mucus", "ORGANISM_SUBSTANCE", 79, 84], ["airway", "MULTI-TISSUE_STRUCTURE", 118, 124], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["positive bronchiolitis", "PROBLEM", 4, 26], ["airway inflammation", "PROBLEM", 47, 66], ["oedema", "PROBLEM", 71, 77], ["mucus production", "PROBLEM", 79, 95], ["debris", "PROBLEM", 100, 106], ["airway obstruction", "PROBLEM", 118, 136], ["turbulent gas flow", "PROBLEM", 141, 159], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["bronchiolitis", "OBSERVATION", 13, 26], ["airway", "ANATOMY", 47, 53], ["inflammation", "OBSERVATION", 54, 66], ["oedema", "OBSERVATION", 71, 77], ["mucus production", "OBSERVATION", 79, 95], ["debris", "OBSERVATION", 100, 106], ["airway", "ANATOMY", 118, 124], ["obstruction", "OBSERVATION", 125, 136], ["turbulent", "OBSERVATION_MODIFIER", 141, 150], ["gas flow", "OBSERVATION", 151, 159]]], ["Even though various therapeutic interventions have been tried, such as bronchodilators, hypertonic saline and corticosteroids, supportive care remains the mainstay in most settings, with gentle suctioning of nasal secretions, prone position, fluid replacement and oxygen or respiratory support, as necessary.", [["nasal secretions", "ANATOMY", 208, 224], ["fluid", "ANATOMY", 242, 247], ["respiratory", "ANATOMY", 274, 285], ["oxygen", "CHEMICAL", 264, 270], ["oxygen", "CHEMICAL", 264, 270], ["hypertonic saline", "SIMPLE_CHEMICAL", 88, 105], ["oxygen", "SIMPLE_CHEMICAL", 264, 270], ["various therapeutic interventions", "TREATMENT", 12, 45], ["bronchodilators", "TREATMENT", 71, 86], ["hypertonic saline", "TREATMENT", 88, 105], ["corticosteroids", "TREATMENT", 110, 125], ["supportive care", "TREATMENT", 127, 142], ["gentle suctioning", "TREATMENT", 187, 204], ["nasal secretions", "PROBLEM", 208, 224], ["prone position", "TREATMENT", 226, 240], ["fluid replacement", "TREATMENT", 242, 259], ["oxygen", "TREATMENT", 264, 270], ["respiratory support", "TREATMENT", 274, 293], ["nasal", "ANATOMY", 208, 213], ["secretions", "OBSERVATION", 214, 224], ["fluid replacement", "OBSERVATION", 242, 259], ["respiratory support", "OBSERVATION", 274, 293]]], ["Several clinical trials on the management and prevention of RSV-positive bronchiolitis have been recently completed, are underway, or in development (3) . currently, there is rapid expansion of RSV vaccine candidate development and there is hope that one will become available in the near future.", [["bronchiolitis", "DISEASE", 73, 86], ["RSV", "ORGANISM", 60, 63], ["RSV", "ORGANISM", 194, 197], ["RSV", "SPECIES", 60, 63], ["RSV", "SPECIES", 194, 197], ["the management", "TREATMENT", 27, 41], ["RSV", "PROBLEM", 60, 63], ["positive bronchiolitis", "PROBLEM", 64, 86], ["RSV vaccine", "TREATMENT", 194, 205], ["RSV", "OBSERVATION", 60, 63], ["positive", "OBSERVATION_MODIFIER", 64, 72], ["bronchiolitis", "OBSERVATION", 73, 86], ["rapid", "OBSERVATION_MODIFIER", 175, 180], ["expansion", "OBSERVATION_MODIFIER", 181, 190], ["RSV vaccine", "OBSERVATION", 194, 205]]], ["Of course, the safety of vaccines proposed for primary immunization in an antigen na\u00efve child remains the top priority.IntroductionThis review article summarizes the key messages of the plenary lectures, oral presentations and posters of the '5th Workshop on Paediatric Virology' held in Sparta (Greece) on October 12th, 2019, which was focused on RSV (Table I)Epidemiology of RSV infectionUnderstanding the burden of RSV infections in real-time.", [["oral", "ANATOMY", 204, 208], ["RSV infection", "DISEASE", 377, 390], ["RSV infections", "DISEASE", 418, 432], ["oral", "ORGANISM_SUBDIVISION", 204, 208], ["RSV", "ORGANISM", 348, 351], ["RSV", "ORGANISM", 377, 380], ["RSV", "ORGANISM", 418, 421], ["RSV", "SPECIES", 348, 351], ["RSV", "SPECIES", 377, 380], ["RSV", "SPECIES", 418, 421], ["vaccines", "TREATMENT", 25, 33], ["primary immunization", "TREATMENT", 47, 67], ["RSV infection", "PROBLEM", 377, 390], ["RSV infections", "PROBLEM", 418, 432], ["RSV infection", "OBSERVATION", 377, 390], ["RSV", "OBSERVATION_MODIFIER", 418, 421], ["infections", "OBSERVATION", 422, 432]]], ["RSV poses significant disease burden in infants and children worldwide (13) , and the international paediatric community is only beginning to appreciate its global impact in both high and low resource settings (4, 14, 15) .", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 40, 47], ["children", "ORGANISM", 52, 60], ["infants", "SPECIES", 40, 47], ["children", "SPECIES", 52, 60], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["significant disease burden", "PROBLEM", 10, 36], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["disease", "OBSERVATION", 22, 29], ["high", "OBSERVATION_MODIFIER", 179, 183]]], ["The clinical presentation of an RSV infection depends on the patient's age and individual risk factors (16, 17) .", [["RSV infection", "DISEASE", 32, 45], ["RSV", "ORGANISM", 32, 35], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["RSV", "SPECIES", 32, 35], ["an RSV infection", "PROBLEM", 29, 45], ["individual risk factors", "PROBLEM", 79, 102], ["RSV", "OBSERVATION_MODIFIER", 32, 35], ["infection", "OBSERVATION", 36, 45]]], ["The concept of measuring individual-level differences in disease severity has drawn the attention of both public health stakeholders and regulatory agencies in recent years (18) (19) (20) .", [["measuring individual-level differences in disease severity", "PROBLEM", 15, 73], ["disease", "OBSERVATION", 57, 64]]], ["The impact of RSV infections of course should be differentiated from the disease caused by influenza and other viral respiratory infections (21, 22) .", [["respiratory", "ANATOMY", 117, 128], ["RSV infections", "DISEASE", 14, 28], ["influenza", "DISEASE", 91, 100], ["viral respiratory infections", "DISEASE", 111, 139], ["RSV", "ORGANISM", 14, 17], ["RSV", "SPECIES", 14, 17], ["RSV infections", "PROBLEM", 14, 28], ["the disease", "PROBLEM", 69, 80], ["influenza", "PROBLEM", 91, 100], ["other viral respiratory infections", "PROBLEM", 105, 139], ["RSV infections", "OBSERVATION", 14, 28], ["disease", "OBSERVATION", 73, 80], ["influenza", "OBSERVATION", 91, 100], ["viral", "OBSERVATION_MODIFIER", 111, 116], ["respiratory infections", "OBSERVATION", 117, 139]]], ["However, a recent extensive literature review and prospective cohort have shown that in infants and children this cannot be done based on clinical symptoms alone; distinguishing RSV from other viral respiratory infections requires laboratory confirmation (23, 24) .", [["respiratory", "ANATOMY", 199, 210], ["RSV", "DISEASE", 178, 181], ["respiratory infections", "DISEASE", 199, 221], ["infants", "ORGANISM", 88, 95], ["children", "ORGANISM", 100, 108], ["RSV", "ORGANISM", 178, 181], ["infants", "SPECIES", 88, 95], ["children", "SPECIES", 100, 108], ["RSV", "SPECIES", 178, 181], ["clinical symptoms", "PROBLEM", 138, 155], ["RSV", "PROBLEM", 178, 181], ["other viral respiratory infections", "PROBLEM", 187, 221], ["laboratory confirmation", "TEST", 231, 254], ["viral", "OBSERVATION_MODIFIER", 193, 198], ["respiratory", "ANATOMY", 199, 210], ["infections", "OBSERVATION", 211, 221]]], ["With RSV vaccines and antiviral agents in development, it will be important to: a) diagnose RSV infections in a timely manner; b) differentiate RSV from other forms of acute respiratory infections; and c) communicate the test results back to patients and parents/caregivers along with information on the individual disease risk and severity.Epidemiology of RSV infectionThe PEDSIDEA programme.", [["respiratory", "ANATOMY", 174, 185], ["infections", "DISEASE", 96, 106], ["RSV", "DISEASE", 144, 147], ["acute respiratory infections", "DISEASE", 168, 196], ["RSV infection", "DISEASE", 357, 370], ["RSV", "ORGANISM", 5, 8], ["RSV", "ORGANISM", 92, 95], ["RSV", "ORGANISM", 144, 147], ["patients", "ORGANISM", 242, 250], ["RSV", "ORGANISM", 357, 360], ["patients", "SPECIES", 242, 250], ["RSV", "SPECIES", 5, 8], ["RSV", "SPECIES", 92, 95], ["RSV", "SPECIES", 144, 147], ["RSV", "SPECIES", 357, 360], ["RSV vaccines", "TREATMENT", 5, 17], ["antiviral agents", "TREATMENT", 22, 38], ["RSV infections", "PROBLEM", 92, 106], ["RSV", "PROBLEM", 144, 147], ["acute respiratory infections", "PROBLEM", 168, 196], ["the test", "TEST", 217, 225], ["RSV infection", "PROBLEM", 357, 370], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["respiratory", "ANATOMY", 174, 185], ["infections", "OBSERVATION", 186, 196], ["RSV infection", "OBSERVATION", 357, 370]]], ["The Vienna Vaccine Safety Initiative (ViVI, https://www.vi-vi.org) is an international non-profit research organization which, in collaboration with academic institutions and public health agencies in Europe and the United States, has developed digital tools and programs to improve the quality of care for children and adults with ALRTI or influenza-like illnesses (ILI) (13, 25, 26) .", [["ALRTI", "DISEASE", 332, 337], ["influenza-like illnesses", "DISEASE", 341, 365], ["ILI", "DISEASE", 367, 370], ["children", "ORGANISM", 307, 315], ["children", "SPECIES", 307, 315], ["The Vienna Vaccine", "TREATMENT", 0, 18], ["ALRTI", "PROBLEM", 332, 337], ["influenza", "PROBLEM", 341, 350]]], ["Taking a person-centered approach, the ViVI disease Severity Score ('ViVI Score') is a mobile application enabling healthcare professionals to measure disease severity at the point of care within minutes.", [["person", "SPECIES", 9, 15], ["the ViVI disease Severity Score", "PROBLEM", 35, 66], ["'ViVI Score'", "TREATMENT", 68, 80], ["disease severity", "PROBLEM", 151, 167]]], ["It was designed to provide a uniform approach to define ad hoc severity at any given time point, based on extensive literature review as well as WHO criteria for uncomplicated and complicated ILI (27) .", [["ILI", "DISEASE", 192, 195], ["a uniform approach", "TREATMENT", 27, 45]]], ["In collaboration with the Robert Koch Institute, the ViVI Score was validated in a cohort of 6,000 children (age 0-18) in Berlin, Germany and subsequently used in a European pilot project entititled 'Partnering for Enhanced Digital Surveillance of Influenza-like disease and the Effectiveness of Antivirals and Vaccines' (PEdSIdEA) (27, 28) .", [["Influenza-like disease", "DISEASE", 248, 270], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["the ViVI Score", "TEST", 49, 63], ["Influenza", "PROBLEM", 248, 257], ["disease", "PROBLEM", 263, 270], ["Antivirals", "TREATMENT", 296, 306], ["Vaccines", "TREATMENT", 311, 319], ["Influenza", "OBSERVATION", 248, 257]]], ["Since then, the PEdSIdEA programme has been implemented in community clinic networks and adult intensive care units in the Unites States for the real-time digital surveillance of influenza and RSV disease incidence and severity at the point of care (29) .", [["influenza", "DISEASE", 179, 188], ["RSV disease", "DISEASE", 193, 204], ["RSV", "ORGANISM", 193, 196], ["RSV", "SPECIES", 193, 196], ["influenza", "PROBLEM", 179, 188], ["RSV disease incidence", "PROBLEM", 193, 214], ["severity", "PROBLEM", 219, 227]]], ["The programme is expected to continue monitoring, in great detail, the clinical outcomes of 'natural' RSV and other viral respiratory infections in children and adults, including patients at the extremes of age.", [["respiratory", "ANATOMY", 122, 133], ["RSV", "DISEASE", 102, 105], ["viral respiratory infections", "DISEASE", 116, 144], ["RSV", "ORGANISM", 102, 105], ["children", "ORGANISM", 148, 156], ["patients", "ORGANISM", 179, 187], ["children", "SPECIES", 148, 156], ["patients", "SPECIES", 179, 187], ["RSV", "SPECIES", 102, 105], ["monitoring", "TEST", 38, 48], ["'natural' RSV", "PROBLEM", 92, 105], ["other viral respiratory infections", "PROBLEM", 110, 144], ["viral", "OBSERVATION_MODIFIER", 116, 121], ["respiratory infections", "OBSERVATION", 122, 144]]], ["Understanding the real-world disease burden may help facilitate the study of the effectiveness of novel influenza and RSV antiviral agents and vaccines, once they become available (30) .Epidemiology of RSV infectionRSV infection: not for children only.", [["influenza", "DISEASE", 104, 113], ["RSV infectionRSV infection", "DISEASE", 202, 228], ["RSV", "ORGANISM", 118, 121], ["RSV", "ORGANISM", 202, 205], ["children", "ORGANISM", 238, 246], ["RSV", "SPECIES", 202, 205], ["children", "SPECIES", 238, 246], ["RSV", "SPECIES", 118, 121], ["RSV", "SPECIES", 202, 205], ["world disease burden", "PROBLEM", 23, 43], ["the study", "TEST", 64, 73], ["novel influenza", "TREATMENT", 98, 113], ["RSV antiviral agents", "TREATMENT", 118, 138], ["vaccines", "TREATMENT", 143, 151], ["RSV infectionRSV infection", "PROBLEM", 202, 228], ["RSV infectionRSV infection", "OBSERVATION", 202, 228]]], ["RSV was not recognized as a potentially serious problem in older adults until the 1970s, when outbreaks of the virus occurred in long-term care facilities for the elderly (31) (32) (33) .", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["the virus", "PROBLEM", 107, 116], ["virus", "OBSERVATION", 111, 116]]], ["Since then, additional studies in hospitalized adults have suggested that RSV may be an important cause of illness in adults.", [["RSV", "DISEASE", 74, 77], ["illness", "DISEASE", 107, 114], ["adults", "ORGANISM", 47, 53], ["RSV", "ORGANISM", 74, 77], ["RSV", "SPECIES", 74, 77], ["additional studies", "TEST", 12, 30], ["RSV", "PROBLEM", 74, 77], ["illness", "PROBLEM", 107, 114], ["RSV", "OBSERVATION", 74, 77]]], ["Molecular diagnostics suggest that RSV positive specimens are commonly identified in elderly and high-risk adults, in a frequency similar to that of seasonal influenza (31, 34) .", [["specimens", "ANATOMY", 48, 57], ["influenza", "DISEASE", 158, 167], ["RSV", "ORGANISM", 35, 38], ["adults", "ORGANISM", 107, 113], ["RSV", "SPECIES", 35, 38], ["Molecular diagnostics", "TEST", 0, 21], ["RSV positive specimens", "PROBLEM", 35, 57], ["seasonal influenza", "PROBLEM", 149, 167], ["seasonal", "OBSERVATION_MODIFIER", 149, 157], ["influenza", "OBSERVATION", 158, 167]]], ["Even though a positive RSV respiratory panel does not equate pathogenesis, it has been suggested that RSV may account for as much as 10,000 deaths annually in the United States among individuals above the age of 65 years (31) (32) (33) 35) .", [["deaths", "DISEASE", 140, 146], ["RSV", "ORGANISM", 23, 26], ["RSV", "ORGANISM", 102, 105], ["RSV", "SPECIES", 23, 26], ["RSV", "SPECIES", 102, 105], ["a positive RSV respiratory panel", "PROBLEM", 12, 44], ["RSV", "PROBLEM", 102, 105], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["RSV", "OBSERVATION", 23, 26], ["RSV", "OBSERVATION", 102, 105]]], ["This, in addition to the morbidity in infants, has stimulated interest in RSV vaccines and antiviral agents.", [["infants", "ORGANISM", 38, 45], ["RSV", "ORGANISM", 74, 77], ["infants", "SPECIES", 38, 45], ["RSV", "SPECIES", 74, 77], ["RSV vaccines", "TREATMENT", 74, 86], ["antiviral agents", "TREATMENT", 91, 107], ["morbidity", "OBSERVATION", 25, 34]]], ["Additional natural history studies are needed to better understand the actual burden of RSV infection among the elderly and high-risk adults.Pathogenesis, diagnosis and prognosis of RSV infectionThe immune response to RSV infection.", [["RSV infection", "DISEASE", 88, 101], ["RSV infection", "DISEASE", 182, 195], ["RSV infection", "DISEASE", 218, 231], ["RSV", "ORGANISM", 88, 91], ["RSV", "ORGANISM", 182, 185], ["RSV", "ORGANISM", 218, 221], ["RSV", "SPECIES", 88, 91], ["RSV", "SPECIES", 182, 185], ["RSV", "SPECIES", 218, 221], ["RSV infection", "PROBLEM", 88, 101], ["Pathogenesis", "PROBLEM", 141, 153], ["RSV infection", "PROBLEM", 182, 195], ["RSV infection", "PROBLEM", 218, 231], ["RSV", "OBSERVATION", 88, 91], ["RSV", "OBSERVATION_MODIFIER", 182, 185], ["infection", "OBSERVATION", 186, 195], ["RSV infection", "OBSERVATION", 218, 231]]], ["Maternal antibodies may be able to mitigate RSV disease severity in young infants (17, (36) (37) (38) .", [["RSV disease", "DISEASE", 44, 55], ["RSV", "ORGANISM", 44, 47], ["infants", "ORGANISM", 74, 81], ["Maternal antibodies", "PROTEIN", 0, 19], ["infants", "SPECIES", 74, 81], ["RSV", "SPECIES", 44, 47], ["Maternal antibodies", "PROBLEM", 0, 19], ["RSV disease severity", "PROBLEM", 44, 64]]], ["It is assumed that the transplacental passage of RSV-specific antibodies occurs predominately during the third trimester of pregnancy.", [["RSV", "ORGANISM", 49, 52], ["RSV-specific antibodies", "PROTEIN", 49, 72], ["RSV", "SPECIES", 49, 52], ["the transplacental passage of RSV-specific antibodies", "PROBLEM", 19, 72], ["RSV", "OBSERVATION", 49, 52]]], ["High titers can potentially protect term infants up to four months of age (38) .", [["infants", "ORGANISM", 41, 48], ["infants", "SPECIES", 41, 48], ["High titers", "PROBLEM", 0, 11]]], ["In premature infants, passive immunity may be 'compromised' (39) , but still has a role to play.", [["infants", "ORGANISM", 13, 20], ["infants", "SPECIES", 13, 20]]], ["The degree to which breast feeding may also contribute to passive immunity and to priming of immune system is currently under investigation (40) .", [["breast", "ANATOMY", 20, 26], ["immune system", "ANATOMY", 93, 106], ["breast", "ORGANISM_SUBDIVISION", 20, 26], ["breast", "ANATOMY", 20, 26]]], ["Once infection is established, the innate immune system plays a dual role in lowering the viral load and in mounting a secondary immune response.", [["infection", "DISEASE", 5, 14], ["infection", "PROBLEM", 5, 14], ["the viral load", "TEST", 86, 100], ["infection", "OBSERVATION", 5, 14], ["viral load", "OBSERVATION", 90, 100], ["secondary immune response", "OBSERVATION", 119, 144]]], ["Prematurity and other conditions that compromise the immune response may lead to reduced levels of antiviral cytokines, such as the interferons (41) .", [["Prematurity", "DISEASE", 0, 11], ["antiviral cytokines", "PROTEIN", 99, 118], ["interferons", "PROTEIN", 132, 143], ["Prematurity", "PROBLEM", 0, 11], ["other conditions", "PROBLEM", 16, 32], ["antiviral cytokines", "TREATMENT", 99, 118]]], ["In infants, reduced signaling by TLRs and altered antigen-presenting cell functions, including low interleukin (IL)-12 and enhanced IL-6 and IL-23 production, coupled with reduced activation of regulatory T cells, may result in an adaptive response that is skewed toward Th2 and Th17 and away from protective Th1 and cTL responses (42) .", [["cell", "ANATOMY", 69, 73], ["regulatory T cells", "ANATOMY", 194, 212], ["infants", "ORGANISM", 3, 10], ["TLRs", "GENE_OR_GENE_PRODUCT", 33, 37], ["cell", "CELL", 69, 73], ["interleukin (IL)-12", "GENE_OR_GENE_PRODUCT", 99, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 132, 136], ["IL-23", "GENE_OR_GENE_PRODUCT", 141, 146], ["T cells", "CELL", 205, 212], ["Th2", "CELL", 271, 274], ["Th17", "CELL", 279, 283], ["Th1", "GENE_OR_GENE_PRODUCT", 309, 312], ["cTL", "GENE_OR_GENE_PRODUCT", 317, 320], ["TLRs", "PROTEIN", 33, 37], ["interleukin (IL)-12", "PROTEIN", 99, 118], ["regulatory T cells", "CELL_TYPE", 194, 212], ["Th17", "CELL_TYPE", 279, 283], ["infants", "SPECIES", 3, 10], ["altered antigen", "PROBLEM", 42, 57], ["low interleukin (IL)", "PROBLEM", 95, 115], ["enhanced IL", "TEST", 123, 134], ["IL", "TEST", 141, 143], ["reduced activation of regulatory T cells", "PROBLEM", 172, 212], ["cell functions", "OBSERVATION", 69, 83], ["low interleukin", "OBSERVATION_MODIFIER", 95, 110]]], ["The potential specific role(s) of certain pattern recognition receptors in humans has/ve been suggested by the fact that certain TLR missense mutations are associated to a phenotype with propensity to wheezing (43) .", [["wheezing", "DISEASE", 201, 209], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 42, 71], ["humans", "ORGANISM", 75, 81], ["TLR", "GENE_OR_GENE_PRODUCT", 129, 132], ["pattern recognition receptors", "PROTEIN", 42, 71], ["TLR", "PROTEIN", 129, 132], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["certain TLR missense mutations", "PROBLEM", 121, 151], ["a phenotype", "PROBLEM", 170, 181], ["wheezing", "PROBLEM", 201, 209]]], ["Apart from the individual genetics (44), the stage of lung maturation among term and premature infants also impacts on the Th1 to Th2 switch.", [["lung", "ANATOMY", 54, 58], ["lung", "ORGAN", 54, 58], ["infants", "ORGANISM", 95, 102], ["Th1", "GENE_OR_GENE_PRODUCT", 123, 126], ["Th2", "GENE_OR_GENE_PRODUCT", 130, 133], ["infants", "SPECIES", 95, 102], ["lung maturation", "PROBLEM", 54, 69], ["premature infants", "PROBLEM", 85, 102], ["the Th1 to Th2 switch", "TREATMENT", 119, 140], ["lung", "ANATOMY", 54, 58], ["maturation", "OBSERVATION", 59, 69]]], ["In the case of prematurity, the mucosa prior to alveolarization is being deluged with Th2 inflammatory responses, even in the earlier stages of bronchopulmonary dysplasia (45) .", [["mucosa", "ANATOMY", 32, 38], ["bronchopulmonary dysplasia", "ANATOMY", 144, 170], ["prematurity", "DISEASE", 15, 26], ["alveolarization", "DISEASE", 48, 63], ["bronchopulmonary dysplasia", "DISEASE", 144, 170], ["mucosa", "MULTI-TISSUE_STRUCTURE", 32, 38], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 144, 170], ["prematurity", "PROBLEM", 15, 26], ["the mucosa", "PROBLEM", 28, 38], ["alveolarization", "PROBLEM", 48, 63], ["Th2 inflammatory responses", "PROBLEM", 86, 112], ["bronchopulmonary dysplasia", "PROBLEM", 144, 170], ["prematurity", "OBSERVATION", 15, 26], ["mucosa", "ANATOMY", 32, 38], ["alveolarization", "OBSERVATION", 48, 63], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["bronchopulmonary", "ANATOMY", 144, 160], ["dysplasia", "OBSERVATION", 161, 170]]], ["Impaired Th1 activation, coupled with little or no B cell memory, and inhibition of antibody production by IFN\u03b3, produces low-titer, low-affinity antibody (46) .", [["B cell", "ANATOMY", 51, 57], ["IFN\u03b3", "CHEMICAL", 107, 111], ["Th1", "GENE_OR_GENE_PRODUCT", 9, 12], ["B cell", "CELL", 51, 57], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 107, 111], ["IFN\u03b3", "PROTEIN", 107, 111], ["low-affinity antibody", "PROTEIN", 133, 154], ["Impaired Th1 activation", "PROBLEM", 0, 23], ["B cell memory", "PROBLEM", 51, 64], ["antibody production", "PROBLEM", 84, 103], ["low-titer", "PROBLEM", 122, 131], ["low-affinity antibody", "PROBLEM", 133, 154], ["Th1 activation", "OBSERVATION", 9, 23]]], ["The result may be a poorly protective and dysregulated defense mechanism that leads to bronchiolitis in susceptible infants (43) .", [["bronchiolitis", "DISEASE", 87, 100], ["infants", "ORGANISM", 116, 123], ["infants", "SPECIES", 116, 123], ["a poorly protective and dysregulated defense mechanism", "PROBLEM", 18, 72], ["bronchiolitis in susceptible infants", "PROBLEM", 87, 123], ["may be", "UNCERTAINTY", 11, 17], ["poorly protective", "OBSERVATION_MODIFIER", 20, 37], ["bronchiolitis", "OBSERVATION", 87, 100]]], ["Later, the host immune response is permanently oriented to the direction of wheezing exacerbations, specifically triggered by RSV (47) .MicroRNAs as potential bio-markers in RSV infection.MicroRNAs (miRNAs) are involved in post-transcriptional gene regulation and play significant roles in the maintenance of the airway epithelial barrier of the respiratory tract (48) (49) (50) (51) (52) (53) (54) (55) (56) . miRNAs have been implicated in the modulation of antiviral defense mounted by host innate and adaptive immunity, involving not only immune effector and inflammatory cells, but also parenchymal cells (50) .", [["airway epithelial", "ANATOMY", 313, 330], ["respiratory tract", "ANATOMY", 346, 363], ["immune effector", "ANATOMY", 543, 558], ["inflammatory cells", "ANATOMY", 563, 581], ["parenchymal cells", "ANATOMY", 592, 609], ["wheezing", "DISEASE", 76, 84], ["RSV infection", "DISEASE", 174, 187], ["RSV", "ORGANISM", 126, 129], ["RSV", "ORGANISM", 174, 177], ["airway epithelial barrier", "TISSUE", 313, 338], ["immune effector", "CELL", 543, 558], ["inflammatory cells", "CELL", 563, 581], ["parenchymal cells", "CELL", 592, 609], ["miRNAs", "DNA", 199, 205], ["inflammatory cells", "CELL_TYPE", 563, 581], ["parenchymal cells", "CELL_TYPE", 592, 609], ["RSV", "SPECIES", 126, 129], ["RSV", "SPECIES", 174, 177], ["wheezing exacerbations", "PROBLEM", 76, 98], ["MicroRNAs", "TEST", 136, 145], ["potential bio-markers", "PROBLEM", 149, 170], ["RSV infection", "PROBLEM", 174, 187], ["MicroRNAs (miRNAs)", "TEST", 188, 206], ["the respiratory tract", "TEST", 342, 363], ["inflammatory cells", "PROBLEM", 563, 581], ["parenchymal cells", "PROBLEM", 592, 609], ["RSV infection", "OBSERVATION", 174, 187], ["airway", "ANATOMY", 313, 319], ["epithelial", "ANATOMY_MODIFIER", 320, 330], ["respiratory tract", "ANATOMY", 346, 363], ["antiviral defense", "OBSERVATION", 460, 477], ["inflammatory cells", "OBSERVATION", 563, 581], ["parenchymal", "ANATOMY_MODIFIER", 592, 603]]], ["Respiratory viruses, including RSV, attack, as a primary target, the epithelial cells of the respiratory tract causing an altered expression of distinct miRNAs in the airway cells.", [["epithelial cells", "ANATOMY", 69, 85], ["respiratory tract", "ANATOMY", 93, 110], ["airway cells", "ANATOMY", 167, 179], ["Respiratory viruses", "DISEASE", 0, 19], ["RSV", "ORGANISM", 31, 34], ["epithelial cells", "CELL", 69, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 93, 110], ["airway cells", "CELL", 167, 179], ["epithelial cells", "CELL_TYPE", 69, 85], ["airway cells", "CELL_TYPE", 167, 179], ["RSV", "SPECIES", 31, 34], ["Respiratory viruses", "PROBLEM", 0, 19], ["RSV", "PROBLEM", 31, 34], ["attack", "PROBLEM", 36, 42], ["the respiratory tract", "PROBLEM", 89, 110], ["distinct miRNAs in the airway cells", "PROBLEM", 144, 179], ["viruses", "OBSERVATION", 12, 19], ["RSV", "OBSERVATION", 31, 34], ["epithelial cells", "OBSERVATION", 69, 85], ["respiratory tract", "ANATOMY", 93, 110], ["altered", "OBSERVATION_MODIFIER", 122, 129], ["expression", "OBSERVATION_MODIFIER", 130, 140], ["distinct miRNAs", "OBSERVATION", 144, 159], ["airway cells", "OBSERVATION", 167, 179]]], ["The human innate immune response inhibits RSV replication early after inoculation, mainly through the action of interferons (53) .", [["human", "ORGANISM", 4, 9], ["RSV", "ORGANISM", 42, 45], ["interferons", "GENE_OR_GENE_PRODUCT", 112, 123], ["interferons", "PROTEIN", 112, 123], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["RSV", "SPECIES", 42, 45], ["The human innate immune response", "TREATMENT", 0, 32], ["RSV replication", "TREATMENT", 42, 57], ["inoculation", "PROBLEM", 70, 81]]], ["Multiple miRNAs are induced by infection in a cell-type-specific fashion (51) .", [["cell", "ANATOMY", 46, 50], ["infection", "DISEASE", 31, 40], ["cell", "CELL", 46, 50], ["Multiple miRNAs", "PROBLEM", 0, 15], ["infection", "PROBLEM", 31, 40], ["miRNAs", "OBSERVATION", 9, 15], ["infection", "OBSERVATION", 31, 40]]], ["RSV appears to alter host cell gene expression also through regulation of expression of miRNAs related to the interferon response (50, 53) .", [["cell", "ANATOMY", 26, 30], ["RSV", "ORGANISM", 0, 3], ["host cell", "CELL", 21, 30], ["interferon", "GENE_OR_GENE_PRODUCT", 110, 120], ["interferon", "PROTEIN", 110, 120], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["expression of miRNAs", "PROBLEM", 74, 94], ["host cell", "OBSERVATION", 21, 30], ["gene expression", "OBSERVATION", 31, 46], ["miRNAs", "ANATOMY", 88, 94]]], ["Abnormal expression of miRNAs has been detected in both peripheral blood cells and airway epithelial cells in RSV-infected infants (54) .", [["peripheral blood cells", "ANATOMY", 56, 78], ["airway epithelial cells", "ANATOMY", 83, 106], ["RSV-infected", "DISEASE", 110, 122], ["peripheral blood cells", "CELL", 56, 78], ["airway epithelial cells", "CELL", 83, 106], ["RSV", "ORGANISM", 110, 113], ["infants", "ORGANISM", 123, 130], ["peripheral blood cells", "CELL_TYPE", 56, 78], ["airway epithelial cells", "CELL_TYPE", 83, 106], ["infants", "SPECIES", 123, 130], ["RSV", "SPECIES", 110, 113], ["Abnormal expression of miRNAs", "PROBLEM", 0, 29], ["miRNAs", "OBSERVATION", 23, 29], ["both", "ANATOMY_MODIFIER", 51, 55], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["blood cells", "ANATOMY", 67, 78], ["airway", "ANATOMY", 83, 89], ["epithelial cells", "OBSERVATION", 90, 106], ["infected", "OBSERVATION_MODIFIER", 114, 122]]], ["Understanding alterations in miRNA expression profiles and identifying miRNA target genes in relation to the pathogenesis of RSV may help clarify the mechanisms of virus-host interactions, and immune dysfunction leading to airway hyper-reactivity and chronic respiratory diseases, such as asthma (49,50,53,54).", [["airway", "ANATOMY", 223, 229], ["respiratory", "ANATOMY", 259, 270], ["RSV", "DISEASE", 125, 128], ["immune dysfunction", "DISEASE", 193, 211], ["airway hyper-reactivity", "DISEASE", 223, 246], ["chronic respiratory diseases", "DISEASE", 251, 279], ["asthma", "DISEASE", 289, 295], ["RSV", "ORGANISM", 125, 128], ["airway", "MULTI-TISSUE_STRUCTURE", 223, 229], ["miRNA target genes", "DNA", 71, 89], ["RSV", "SPECIES", 125, 128], ["Understanding alterations in miRNA expression profiles", "PROBLEM", 0, 54], ["miRNA target genes", "PROBLEM", 71, 89], ["RSV", "PROBLEM", 125, 128], ["virus", "PROBLEM", 164, 169], ["immune dysfunction", "PROBLEM", 193, 211], ["airway hyper-reactivity", "PROBLEM", 223, 246], ["chronic respiratory diseases", "PROBLEM", 251, 279], ["asthma", "PROBLEM", 289, 295], ["airway", "ANATOMY", 223, 229], ["hyper", "OBSERVATION", 230, 235], ["chronic", "OBSERVATION_MODIFIER", 251, 258], ["respiratory diseases", "OBSERVATION", 259, 279], ["asthma", "OBSERVATION", 289, 295]]], ["There are several methods for the purification, quantification andEpidemiology of RSV infectionBeing able to compare severity over time and/or across cohorts is useful in hospital-based QI programmes but also in multi-centre networks, such as PEdSIdEA Understanding the real-world disease burden caused by RSV will facilitate the study of the effectiveness of antivirals and vaccines, once they become available Recent epidemiological data indicate that RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of non-pandemic influenza RSV and immune response Maternal RSV-specific antibodies transmitted transplacentally during the third trimester of pregnancy are related to RSV disease severity in young infants RSV and miRNAs A greater understanding of miRNAs may enable them to be used as biomarkers of severe RSV infection and as novel targets for treatment or prophylaxis of RSV infection RSV and thrombocytosis Thrombocytosis in RSV-positive bronchiolitis does not require routine prophylactic anti-platelet treatment or further investigations RSV and asthma There is compelling evidence that severe respiratory infection induced by RSV is associated with subsequent development of asthma later in childhood Further understanding of the role of RSV in asthma pathogenesis will enable our understanding of the impact of future vaccines against RSV in asthma prevention RSV as a cause of PIBO There are only few reports in the literature of children with PIBO secondary to RSV as a single infection Further research is required in order to investigate the potential impact of RSV co-infection in the severity and worse outcome in children with PIBO Imaging of RSV infection Although imaging cannot diagnose RSV infection, it is important to identify the possible pattern of viral disease, in order to avoid unnecessary administration of antibiotic therapy and predict possible late effects Standard radiological techniques, including cT, are unable to distinguish between acute bronchiolitis caused by RSV versus that caused by other respiratory viruses HRcT of the lungs may be required to assess possible bronchial thickening and remodeling, the development of bronchiectasis and air-trapping Antivirals against RSV Ribavirin is currently the only licensed antiviral medication used to treat RSV infection; it has very limited efficacy and multiple toxicities, which means its use is usually reserved for severely immunocompromised children due to ethical and technical constraints human challenge models are only undertaken in adults, but if a product is shown to be efficacious in this setting it allows a faster move to trials in children than traditional trials which often take much longer to do A greater understanding of individual data in newly developed pharmaceutical agents against RSV will potentially lead to future personalized treatment regimens RSV and PIcU HFNc might have a role as a rescue therapy for children with RSV-positive bronchiolitis admitted to PIcU to reduce their requirement for high-cost intensive care Heliox could be useful in addition to standard medical care in the management of children with RSV-positive bronchiolitis admitted to PIcU characterization of miRNA expression profiles in biofluids, whole blood samples and tissue samples obtained in in vivo studies (55) .", [["respiratory", "ANATOMY", 1161, 1172], ["lungs", "ANATOMY", 2125, 2130], ["bronchial", "ANATOMY", 2166, 2175], ["biofluids", "ANATOMY", 3285, 3294], ["whole blood samples", "ANATOMY", 3296, 3315], ["tissue samples", "ANATOMY", 3320, 3334], ["RSV", "DISEASE", 306, 309], ["RSV infection", "DISEASE", 454, 467], ["influenza", "DISEASE", 579, 588], ["RSV disease", "DISEASE", 730, 741], ["RSV infection", "DISEASE", 868, 881], ["RSV infection", "DISEASE", 935, 948], ["RSV", "DISEASE", 949, 952], ["thrombocytosis", "DISEASE", 957, 971], ["Thrombocytosis", "DISEASE", 972, 986], ["bronchiolitis", "DISEASE", 1003, 1016], ["RSV", "DISEASE", 1105, 1108], ["asthma", "DISEASE", 1113, 1119], ["respiratory infection", "DISEASE", 1161, 1182], ["RSV", "DISEASE", 1194, 1197], ["asthma", "DISEASE", 1243, 1249], ["asthma", "DISEASE", 1313, 1319], ["RSV", "DISEASE", 1404, 1407], ["asthma", "DISEASE", 1411, 1417], ["RSV", "DISEASE", 1429, 1432], ["PIBO", "DISEASE", 1514, 1518], ["RSV", "DISEASE", 1532, 1535], ["infection", "DISEASE", 1548, 1557], ["RSV co-infection", "DISEASE", 1635, 1651], ["RSV infection", "DISEASE", 1719, 1732], ["RSV infection", "DISEASE", 1766, 1779], ["viral disease", "DISEASE", 1833, 1846], ["bronchiolitis", "DISEASE", 2037, 2050], ["RSV", "DISEASE", 2061, 2064], ["bronchiectasis", "DISEASE", 2222, 2236], ["Ribavirin", "CHEMICAL", 2277, 2286], ["RSV infection", "DISEASE", 2353, 2366], ["toxicities", "DISEASE", 2410, 2420], ["RSV", "DISEASE", 2854, 2857], ["HFNc", "CHEMICAL", 2935, 2939], ["bronchiolitis", "DISEASE", 3009, 3022], ["bronchiolitis", "DISEASE", 3205, 3218], ["Ribavirin", "CHEMICAL", 2277, 2286], ["RSV", "ORGANISM", 82, 85], ["RSV", "ORGANISM", 306, 309], ["RSV", "ORGANISM", 454, 457], ["adults", "ORGANISM", 517, 523], ["non-pandemic influenza RSV", "ORGANISM", 566, 592], ["Maternal RSV", "ORGANISM", 613, 625], ["RSV", "ORGANISM", 730, 733], ["infants", "ORGANISM", 760, 767], ["RSV", "ORGANISM", 768, 771], ["RSV", "ORGANISM", 868, 871], ["RSV", "ORGANISM", 935, 938], ["RSV", "ORGANISM", 949, 952], ["RSV", "ORGANISM", 990, 993], ["RSV", "ORGANISM", 1105, 1108], ["RSV", "ORGANISM", 1194, 1197], ["RSV", "ORGANISM", 1306, 1309], ["RSV", "ORGANISM", 1404, 1407], ["RSV", "ORGANISM", 1429, 1432], ["children", "ORGANISM", 1500, 1508], ["PIBO", "CANCER", 1514, 1518], ["RSV", "ORGANISM", 1532, 1535], ["RSV", "ORGANISM", 1635, 1638], ["children", "ORGANISM", 1689, 1697], ["RSV", "ORGANISM", 1719, 1722], ["RSV", "ORGANISM", 1766, 1769], ["RSV", "ORGANISM", 2061, 2064], ["lungs", "ORGAN", 2125, 2130], ["bronchial", "MULTI-TISSUE_STRUCTURE", 2166, 2175], ["RSV", "ORGANISM", 2273, 2276], ["Ribavirin", "SIMPLE_CHEMICAL", 2277, 2286], ["RSV", "ORGANISM", 2353, 2356], ["children", "ORGANISM", 2493, 2501], ["human", "ORGANISM", 2543, 2548], ["children", "ORGANISM", 2694, 2702], ["RSV", "ORGANISM", 2854, 2857], ["RSV", "ORGANISM", 2922, 2925], ["PIcU HFNc", "ORGANISM", 2930, 2939], ["children", "ORGANISM", 2982, 2990], ["RSV", "ORGANISM", 2996, 2999], ["Heliox", "SIMPLE_CHEMICAL", 3097, 3103], ["children", "ORGANISM", 3178, 3186], ["RSV", "ORGANISM", 3192, 3195], ["blood samples", "ORGANISM_SUBSTANCE", 3302, 3315], ["tissue samples", "TISSUE", 3320, 3334], ["Maternal RSV-specific antibodies", "PROTEIN", 613, 645], ["RSV", "SPECIES", 589, 592], ["infants", "SPECIES", 760, 767], ["RSV", "SPECIES", 949, 952], ["children", "SPECIES", 1500, 1508], ["children", "SPECIES", 1689, 1697], ["children", "SPECIES", 2493, 2501], ["human", "SPECIES", 2543, 2548], ["children", "SPECIES", 2694, 2702], ["children", "SPECIES", 2982, 2990], ["children", "SPECIES", 3178, 3186], ["RSV", "SPECIES", 82, 85], ["RSV", "SPECIES", 306, 309], ["RSV", "SPECIES", 454, 457], ["RSV", "SPECIES", 589, 592], ["RSV", "SPECIES", 622, 625], ["RSV", "SPECIES", 730, 733], ["RSV", "SPECIES", 768, 771], ["RSV", "SPECIES", 868, 871], ["RSV", "SPECIES", 935, 938], ["RSV", "SPECIES", 949, 952], ["RSV", "SPECIES", 990, 993], ["RSV", "SPECIES", 1105, 1108], ["RSV", "SPECIES", 1194, 1197], ["RSV", "SPECIES", 1306, 1309], ["RSV", "SPECIES", 1404, 1407], ["RSV", "SPECIES", 1429, 1432], ["PIBO", "SPECIES", 1447, 1451], ["RSV", "SPECIES", 1532, 1535], ["RSV", "SPECIES", 1635, 1638], ["RSV", "SPECIES", 1719, 1722], ["RSV", "SPECIES", 1766, 1769], ["RSV", "SPECIES", 2061, 2064], ["RSV", "SPECIES", 2273, 2276], ["RSV", "SPECIES", 2353, 2356], ["human", "SPECIES", 2543, 2548], ["RSV", "SPECIES", 2854, 2857], ["RSV", "SPECIES", 2922, 2925], ["PIcU", "SPECIES", 2930, 2934], ["RSV", "SPECIES", 2996, 2999], ["RSV", "SPECIES", 3192, 3195], ["the purification", "TEST", 30, 46], ["RSV infectionBeing", "PROBLEM", 82, 100], ["world disease burden", "PROBLEM", 275, 295], ["RSV", "PROBLEM", 306, 309], ["the study", "TEST", 326, 335], ["antivirals", "TREATMENT", 360, 370], ["vaccines", "TREATMENT", 375, 383], ["Recent epidemiological data", "TEST", 412, 439], ["RSV infection", "PROBLEM", 454, 467], ["a disease burden", "PROBLEM", 530, 546], ["non-pandemic influenza RSV", "PROBLEM", 566, 592], ["immune response", "PROBLEM", 597, 612], ["Maternal RSV", "PROBLEM", 613, 625], ["specific antibodies", "PROBLEM", 626, 645], ["RSV disease severity", "PROBLEM", 730, 750], ["severe RSV infection", "PROBLEM", 861, 881], ["treatment", "TREATMENT", 907, 916], ["prophylaxis", "TREATMENT", 920, 931], ["RSV infection", "PROBLEM", 935, 948], ["RSV", "PROBLEM", 949, 952], ["thrombocytosis Thrombocytosis", "PROBLEM", 957, 986], ["RSV", "PROBLEM", 990, 993], ["positive bronchiolitis", "PROBLEM", 994, 1016], ["routine prophylactic anti-platelet treatment", "TREATMENT", 1034, 1078], ["further investigations", "TEST", 1082, 1104], ["RSV", "PROBLEM", 1105, 1108], ["asthma", "PROBLEM", 1113, 1119], ["severe respiratory infection", "PROBLEM", 1154, 1182], ["RSV", "PROBLEM", 1194, 1197], ["asthma", "PROBLEM", 1243, 1249], ["RSV", "PROBLEM", 1306, 1309], ["asthma pathogenesis", "PROBLEM", 1313, 1332], ["future vaccines", "TREATMENT", 1380, 1395], ["RSV", "PROBLEM", 1404, 1407], ["RSV", "PROBLEM", 1429, 1432], ["PIBO", "PROBLEM", 1447, 1451], ["PIBO", "TREATMENT", 1514, 1518], ["RSV", "PROBLEM", 1532, 1535], ["a single infection", "PROBLEM", 1539, 1557], ["RSV co-infection", "PROBLEM", 1635, 1651], ["PIBO Imaging", "TEST", 1703, 1715], ["RSV infection", "PROBLEM", 1719, 1732], ["imaging", "TEST", 1742, 1749], ["RSV infection", "PROBLEM", 1766, 1779], ["viral disease", "PROBLEM", 1833, 1846], ["antibiotic therapy", "TREATMENT", 1896, 1914], ["late effects", "PROBLEM", 1936, 1948], ["cT", "TEST", 1993, 1995], ["acute bronchiolitis", "PROBLEM", 2031, 2050], ["RSV", "PROBLEM", 2061, 2064], ["other respiratory viruses HRcT of the lungs", "PROBLEM", 2087, 2130], ["bronchial thickening", "PROBLEM", 2166, 2186], ["bronchiectasis", "PROBLEM", 2222, 2236], ["air-trapping Antivirals", "TREATMENT", 2241, 2264], ["RSV Ribavirin", "TREATMENT", 2273, 2286], ["licensed antiviral medication", "TREATMENT", 2309, 2338], ["RSV infection", "PROBLEM", 2353, 2366], ["multiple toxicities", "PROBLEM", 2401, 2420], ["severely immunocompromised children", "PROBLEM", 2466, 2501], ["traditional trials", "TREATMENT", 2708, 2726], ["pharmaceutical agents", "TREATMENT", 2824, 2845], ["RSV", "PROBLEM", 2854, 2857], ["personalized treatment regimens", "TREATMENT", 2890, 2921], ["RSV", "TREATMENT", 2922, 2925], ["PIcU HFNc", "TREATMENT", 2930, 2939], ["a rescue therapy", "TREATMENT", 2961, 2977], ["RSV", "PROBLEM", 2996, 2999], ["positive bronchiolitis", "PROBLEM", 3000, 3022], ["high-cost intensive care Heliox", "TREATMENT", 3072, 3103], ["standard medical care", "TREATMENT", 3135, 3156], ["RSV", "PROBLEM", 3192, 3195], ["positive bronchiolitis", "PROBLEM", 3196, 3218], ["miRNA expression profiles in biofluids", "PROBLEM", 3256, 3294], ["whole blood samples", "TEST", 3296, 3315], ["tissue samples", "TEST", 3320, 3334], ["vivo studies", "TEST", 3350, 3362], ["infection", "OBSERVATION", 458, 467], ["RSV disease", "OBSERVATION", 730, 741], ["miRNAs", "ANATOMY", 776, 782], ["severe", "OBSERVATION_MODIFIER", 861, 867], ["RSV", "OBSERVATION", 868, 871], ["bronchiolitis", "OBSERVATION", 1003, 1016], ["asthma", "OBSERVATION", 1113, 1119], ["compelling evidence that", "UNCERTAINTY", 1129, 1153], ["severe", "OBSERVATION_MODIFIER", 1154, 1160], ["respiratory", "OBSERVATION_MODIFIER", 1161, 1172], ["infection", "OBSERVATION", 1173, 1182], ["RSV", "OBSERVATION", 1194, 1197], ["asthma", "OBSERVATION", 1243, 1249], ["RSV", "OBSERVATION", 1306, 1309], ["few", "OBSERVATION_MODIFIER", 1467, 1470], ["RSV", "OBSERVATION", 1532, 1535], ["infection", "OBSERVATION", 1548, 1557], ["RSV co-infection", "OBSERVATION", 1635, 1651], ["RSV infection", "OBSERVATION", 1719, 1732], ["infection", "OBSERVATION", 1770, 1779], ["viral disease", "OBSERVATION", 1833, 1846], ["acute", "OBSERVATION_MODIFIER", 2031, 2036], ["bronchiolitis", "OBSERVATION", 2037, 2050], ["RSV", "OBSERVATION", 2061, 2064], ["respiratory viruses", "OBSERVATION", 2093, 2112], ["lungs", "ANATOMY", 2125, 2130], ["bronchial", "ANATOMY", 2166, 2175], ["thickening", "OBSERVATION", 2176, 2186], ["bronchiectasis", "OBSERVATION", 2222, 2236], ["infection", "OBSERVATION", 2357, 2366], ["multiple", "OBSERVATION_MODIFIER", 2401, 2409], ["toxicities", "OBSERVATION", 2410, 2420], ["bronchiolitis", "OBSERVATION", 3009, 3022], ["bronchiolitis", "OBSERVATION", 3205, 3218], ["miRNA expression", "OBSERVATION", 3256, 3272]]], ["Further research on miRNAs is expected to clarify their value as biomarkers of RSV infections and their sequelae (i.e., recurrent wheezing and asthma).Epidemiology of RSV infectionThrombocytosis and RSV infection.", [["RSV infections", "DISEASE", 79, 93], ["wheezing", "DISEASE", 130, 138], ["asthma", "DISEASE", 143, 149], ["RSV infection", "DISEASE", 167, 180], ["Thrombocytosis", "DISEASE", 180, 194], ["RSV infection", "DISEASE", 199, 212], ["RSV", "ORGANISM", 79, 82], ["RSV", "ORGANISM", 167, 170], ["RSV", "ORGANISM", 199, 202], ["RSV", "SPECIES", 167, 170], ["RSV", "SPECIES", 199, 202], ["RSV", "SPECIES", 79, 82], ["RSV", "SPECIES", 167, 170], ["RSV", "SPECIES", 199, 202], ["RSV infections", "PROBLEM", 79, 93], ["their sequelae", "PROBLEM", 98, 112], ["recurrent wheezing", "PROBLEM", 120, 138], ["asthma", "PROBLEM", 143, 149], ["RSV infection", "PROBLEM", 167, 180], ["Thrombocytosis", "PROBLEM", 180, 194], ["RSV infection", "PROBLEM", 199, 212], ["RSV", "ANATOMY", 79, 82], ["infections", "OBSERVATION", 83, 93], ["asthma", "OBSERVATION", 143, 149], ["RSV", "ANATOMY", 167, 170], ["infection", "OBSERVATION", 171, 180], ["RSV", "OBSERVATION_MODIFIER", 199, 202], ["infection", "OBSERVATION", 203, 212]]], ["The most frequent causes of secondary thrombocytosis in childhood are acute respiratory tract infections (57) (58) (59) (60) (61) .", [["respiratory", "ANATOMY", 76, 87], ["thrombocytosis", "DISEASE", 38, 52], ["acute respiratory tract infections", "DISEASE", 70, 104], ["secondary thrombocytosis", "PROBLEM", 28, 52], ["acute respiratory tract infections", "PROBLEM", 70, 104], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["secondary", "OBSERVATION_MODIFIER", 28, 37], ["thrombocytosis", "OBSERVATION", 38, 52], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93]]], ["To date, several authors have reported significantly higher mean platelet counts in patients with RSV than in patients with other acute respiratory tract infections (61) (62) (63) (64) .", [["platelet", "ANATOMY", 65, 73], ["RSV", "DISEASE", 98, 101], ["acute respiratory tract infections", "DISEASE", 130, 164], ["platelet", "CELL", 65, 73], ["patients", "ORGANISM", 84, 92], ["RSV", "ORGANISM", 98, 101], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 110, 118], ["RSV", "SPECIES", 98, 101], ["significantly higher mean platelet counts", "PROBLEM", 39, 80], ["RSV", "PROBLEM", 98, 101], ["other acute respiratory tract infections", "PROBLEM", 124, 164], ["platelet counts", "OBSERVATION", 65, 80], ["RSV", "OBSERVATION", 98, 101], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["respiratory tract", "ANATOMY", 136, 153]]], ["Thrombocytosis is more likely to occur in younger patients, who have clinical manifestations of wheezing and dyspnoea (62, 64) .", [["Thrombocytosis", "DISEASE", 0, 14], ["wheezing", "DISEASE", 96, 104], ["dyspnoea", "DISEASE", 109, 117], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["Thrombocytosis", "PROBLEM", 0, 14], ["wheezing", "PROBLEM", 96, 104], ["dyspnoea", "PROBLEM", 109, 117], ["more likely", "UNCERTAINTY", 18, 29], ["wheezing", "OBSERVATION", 96, 104]]], ["Moreover, thrombocytosis has been suggested as an early marker of RSV infection (62) .", [["thrombocytosis", "DISEASE", 10, 24], ["RSV infection", "DISEASE", 66, 79], ["RSV", "ORGANISM", 66, 69], ["RSV", "SPECIES", 66, 69], ["thrombocytosis", "PROBLEM", 10, 24], ["RSV infection", "PROBLEM", 66, 79], ["thrombocytosis", "OBSERVATION", 10, 24], ["early", "OBSERVATION_MODIFIER", 50, 55], ["RSV", "OBSERVATION_MODIFIER", 66, 69], ["infection", "OBSERVATION", 70, 79]]], ["Excessive thrombocytosis has also been detected at an early stage in cases of RSV-positive bronchiolitis (65) .", [["thrombocytosis", "DISEASE", 10, 24], ["bronchiolitis", "DISEASE", 91, 104], ["RSV", "ORGANISM", 78, 81], ["RSV", "SPECIES", 78, 81], ["Excessive thrombocytosis", "PROBLEM", 0, 24], ["RSV", "PROBLEM", 78, 81], ["positive bronchiolitis", "PROBLEM", 82, 104], ["thrombocytosis", "OBSERVATION", 10, 24], ["early stage", "OBSERVATION_MODIFIER", 54, 65], ["RSV", "OBSERVATION", 78, 81], ["positive", "OBSERVATION_MODIFIER", 82, 90], ["bronchiolitis", "OBSERVATION", 91, 104]]], ["It has been proposed that thrombocytotic patients have a more severe clinical course and longer duration of hospitalization and that the platelet count may be a useful clinical marker associated with ALRTI severity (61, 64, 66, 67) . conversely, other authors have found that platelet counts do not correlate with disease severity and clinical outcome (68, 69) .", [["platelet", "ANATOMY", 137, 145], ["platelet", "ANATOMY", 276, 284], ["patients", "ORGANISM", 41, 49], ["platelet", "CELL", 137, 145], ["platelet", "CELL", 276, 284], ["patients", "SPECIES", 41, 49], ["the platelet count", "TEST", 133, 151], ["ALRTI severity", "TEST", 200, 214], ["platelet counts", "TEST", 276, 291], ["disease severity", "PROBLEM", 314, 330], ["more severe", "OBSERVATION_MODIFIER", 57, 68]]], ["Routine prophylactic anti-platelet treatment or further investigations are not necessary in children with RSV-positive bronchiolitis and thrombocytosis (61, 68, 70) .RSV-positive bronchiolitis and asthma.There is compelling evidence that infants with severe RSV infection in the early months of life have a subsequent increased risk of developing recurrent wheezing and/or asthma, with a prevalence of up to 30% compared with non-RSV groups (71) (72) (73) (74) (75) .", [["bronchiolitis", "DISEASE", 119, 132], ["thrombocytosis", "DISEASE", 137, 151], ["bronchiolitis", "DISEASE", 179, 192], ["asthma", "DISEASE", 197, 203], ["RSV infection", "DISEASE", 258, 271], ["wheezing", "DISEASE", 357, 365], ["asthma", "DISEASE", 373, 379], ["children", "ORGANISM", 92, 100], ["RSV", "ORGANISM", 106, 109], ["RSV", "ORGANISM", 166, 169], ["infants", "ORGANISM", 238, 245], ["RSV", "ORGANISM", 258, 261], ["children", "SPECIES", 92, 100], ["infants", "SPECIES", 238, 245], ["RSV", "SPECIES", 106, 109], ["RSV", "SPECIES", 166, 169], ["RSV", "SPECIES", 258, 261], ["RSV", "SPECIES", 430, 433], ["Routine prophylactic anti-platelet treatment", "TREATMENT", 0, 44], ["further investigations", "TEST", 48, 70], ["RSV", "PROBLEM", 106, 109], ["positive bronchiolitis", "PROBLEM", 110, 132], ["thrombocytosis", "PROBLEM", 137, 151], ["RSV", "PROBLEM", 166, 169], ["bronchiolitis", "PROBLEM", 179, 192], ["asthma", "PROBLEM", 197, 203], ["severe RSV infection", "PROBLEM", 251, 271], ["recurrent wheezing", "PROBLEM", 347, 365], ["asthma", "PROBLEM", 373, 379], ["positive", "OBSERVATION_MODIFIER", 110, 118], ["bronchiolitis", "OBSERVATION", 119, 132], ["thrombocytosis", "OBSERVATION", 137, 151], ["positive", "OBSERVATION_MODIFIER", 170, 178], ["bronchiolitis", "OBSERVATION", 179, 192], ["asthma", "OBSERVATION", 197, 203], ["severe", "OBSERVATION_MODIFIER", 251, 257], ["RSV", "OBSERVATION_MODIFIER", 258, 261], ["infection", "OBSERVATION", 262, 271], ["increased", "OBSERVATION_MODIFIER", 318, 327], ["recurrent", "OBSERVATION_MODIFIER", 347, 356], ["wheezing", "OBSERVATION", 357, 365], ["asthma", "OBSERVATION", 373, 379]]], ["Whether this association is causal has been the subject of considerable debate on the potential role of RSV infection in the pathogenesis of asthma as well as the impact of asthma predisposition (genetic, environmental exposure, etc.) on the clinical course of RSV infection.", [["RSV infection", "DISEASE", 104, 117], ["asthma", "DISEASE", 141, 147], ["asthma predisposition", "DISEASE", 173, 194], ["RSV infection", "DISEASE", 261, 274], ["RSV", "ORGANISM", 104, 107], ["RSV", "ORGANISM", 261, 264], ["RSV", "SPECIES", 104, 107], ["RSV", "SPECIES", 261, 264], ["RSV infection", "PROBLEM", 104, 117], ["asthma", "PROBLEM", 141, 147], ["asthma predisposition", "PROBLEM", 173, 194], ["RSV infection", "PROBLEM", 261, 274], ["RSV", "OBSERVATION_MODIFIER", 104, 107], ["infection", "OBSERVATION", 108, 117], ["asthma", "OBSERVATION", 141, 147], ["asthma", "OBSERVATION", 173, 179], ["RSV", "ANATOMY", 261, 264], ["infection", "OBSERVATION", 265, 274]]], ["A recent large retrospective cohort analysis of Australian children born between 2000 and 2010 suggested that different subgroups of high risk children, who developed RSV disease within the first 2 years of life, continued to be at elevated risk of having a first asthma hospitalization beyond the age of 7 years (76).", [["RSV disease", "DISEASE", 167, 178], ["asthma", "DISEASE", 264, 270], ["children", "ORGANISM", 59, 67], ["children", "ORGANISM", 143, 151], ["RSV", "ORGANISM", 167, 170], ["children", "SPECIES", 59, 67], ["children", "SPECIES", 143, 151], ["RSV", "SPECIES", 167, 170], ["RSV disease", "PROBLEM", 167, 178], ["a first asthma hospitalization", "PROBLEM", 256, 286], ["large", "OBSERVATION_MODIFIER", 9, 14], ["RSV disease", "OBSERVATION", 167, 178]]], ["On the other hand, large epidemiological observational studies demonstrate that the vast majority of infants hospitalized for RSV bronchiolitis do not fit into an 'at-risk' group (atopy, family history, etc.), suggesting that viral or host factors not thought of as classical risk factors, may play a role in disease severity (74, 77) .", [["bronchiolitis", "DISEASE", 130, 143], ["infants", "ORGANISM", 101, 108], ["RSV", "ORGANISM", 126, 129], ["infants", "SPECIES", 101, 108], ["RSV", "SPECIES", 126, 129], ["large epidemiological observational studies", "TEST", 19, 62], ["RSV bronchiolitis", "PROBLEM", 126, 143], ["viral or host factors", "PROBLEM", 226, 247], ["a role in disease severity", "PROBLEM", 299, 325], ["large", "OBSERVATION_MODIFIER", 19, 24], ["bronchiolitis", "OBSERVATION", 130, 143]]], ["Prospective studies with RSV-immunoprophylaxis (e.g., palivizumab) suggest that long-term effects of RSV prophylaxis appear less efficacious in infants with a family history of atopy.", [["palivizumab", "CHEMICAL", 54, 65], ["atopy", "DISEASE", 177, 182], ["RSV", "ORGANISM", 25, 28], ["RSV", "ORGANISM", 101, 104], ["infants", "ORGANISM", 144, 151], ["infants", "SPECIES", 144, 151], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 101, 104], ["Prospective studies", "TEST", 0, 19], ["RSV", "PROBLEM", 25, 28], ["immunoprophylaxis", "TREATMENT", 29, 46], ["palivizumab", "TREATMENT", 54, 65], ["RSV prophylaxis", "TREATMENT", 101, 116], ["atopy", "PROBLEM", 177, 182], ["long-term", "OBSERVATION_MODIFIER", 80, 89]]], ["In addition, palivizumab decreases parent-reported recurrent wheeze, however the incidence of physician-diagnosed asthma is similar (78) .", [["palivizumab", "CHEMICAL", 13, 24], ["wheeze", "DISEASE", 61, 67], ["asthma", "DISEASE", 114, 120], ["palivizumab", "CHEMICAL", 13, 24], ["palivizumab", "SIMPLE_CHEMICAL", 13, 24], ["palivizumab", "TREATMENT", 13, 24], ["recurrent wheeze", "PROBLEM", 51, 67], ["asthma", "PROBLEM", 114, 120], ["recurrent", "OBSERVATION_MODIFIER", 51, 60], ["wheeze", "OBSERVATION", 61, 67], ["asthma", "OBSERVATION", 114, 120]]], ["A recent single-blind, randomized, placebo-controlled trial showed that RSV prevention in otherwise healthy preterm infants, did not have a major effect on asthma or lung function at the age of 6 years (79).", [["lung", "ANATOMY", 166, 170], ["asthma", "DISEASE", 156, 162], ["RSV", "ORGANISM", 72, 75], ["infants", "ORGANISM", 116, 123], ["lung", "ORGAN", 166, 170], ["infants", "SPECIES", 116, 123], ["RSV", "SPECIES", 72, 75], ["placebo", "TREATMENT", 35, 42], ["RSV prevention", "TREATMENT", 72, 86], ["asthma", "PROBLEM", 156, 162], ["lung function", "PROBLEM", 166, 179], ["RSV", "OBSERVATION", 72, 75], ["asthma", "OBSERVATION", 156, 162], ["lung", "ANATOMY", 166, 170]]], ["Considering the above findings, perhaps a more appropriate conclusion would be that RSV infection is important in the mechanism of wheezing development, at least in the first few years of life (80) .", [["RSV infection", "DISEASE", 84, 97], ["wheezing", "DISEASE", 131, 139], ["RSV", "ORGANISM", 84, 87], ["RSV", "SPECIES", 84, 87], ["RSV infection", "PROBLEM", 84, 97], ["wheezing", "PROBLEM", 131, 139], ["infection", "OBSERVATION", 88, 97], ["wheezing", "OBSERVATION", 131, 139]]], ["RSV possesses the ability to counteract host defense systems through complex mechanisms that facilitate viral replication.", [["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["host defense systems", "PROBLEM", 40, 60], ["viral replication", "TREATMENT", 104, 121], ["viral replication", "OBSERVATION", 104, 121]]], ["This significant increase in asthma frequency seems to be predominantly related to long-term changes in neuroimmune control of airway tone rather than to allergic sensitization.", [["airway", "ANATOMY", 127, 133], ["asthma", "DISEASE", 29, 35], ["allergic sensitization", "DISEASE", 154, 176], ["airway", "MULTI-TISSUE_STRUCTURE", 127, 133], ["asthma frequency", "PROBLEM", 29, 45], ["long-term changes", "PROBLEM", 83, 100], ["allergic sensitization", "PROBLEM", 154, 176], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["asthma", "OBSERVATION", 29, 35], ["long-term", "OBSERVATION_MODIFIER", 83, 92], ["airway", "ANATOMY", 127, 133]]], ["In contrast to RSV bronchiolitis, atopy has been clearly associated with childhood asthma development after RSV-induced early wheezing (81, 82) .", [["bronchiolitis", "DISEASE", 19, 32], ["atopy", "DISEASE", 34, 39], ["asthma", "DISEASE", 83, 89], ["wheezing", "DISEASE", 126, 134], ["RSV", "ORGANISM", 15, 18], ["RSV", "ORGANISM", 108, 111], ["RSV", "SPECIES", 15, 18], ["RSV", "SPECIES", 108, 111], ["RSV bronchiolitis", "PROBLEM", 15, 32], ["atopy", "PROBLEM", 34, 39], ["childhood asthma development", "PROBLEM", 73, 101], ["RSV", "PROBLEM", 108, 111], ["early wheezing", "PROBLEM", 120, 134], ["RSV bronchiolitis", "OBSERVATION", 15, 32], ["clearly associated with", "UNCERTAINTY", 49, 72], ["childhood", "OBSERVATION_MODIFIER", 73, 82], ["asthma", "OBSERVATION", 83, 89], ["RSV", "OBSERVATION", 108, 111], ["early", "OBSERVATION_MODIFIER", 120, 125], ["wheezing", "OBSERVATION", 126, 134]]], ["High-risk (parental atopy or asthma) birth cohort studies from Wisconsin, United States, and Australia have shown that young children suffering from RSV-induced wheezing episodes are at high risk of developing school-age asthma (81, 82) .", [["asthma", "DISEASE", 29, 35], ["RSV", "DISEASE", 149, 152], ["wheezing", "DISEASE", 161, 169], ["asthma", "DISEASE", 221, 227], ["children", "ORGANISM", 125, 133], ["RSV", "ORGANISM", 149, 152], ["children", "SPECIES", 125, 133], ["RSV", "SPECIES", 149, 152], ["asthma", "PROBLEM", 29, 35], ["RSV", "PROBLEM", 149, 152], ["wheezing episodes", "PROBLEM", 161, 178], ["asthma", "PROBLEM", 221, 227]]], ["Further prospective, follow-up studies are needed to clarify individual and environmental factors that promote more severe viral illnesses and long-term adverse respiratory outcome of children hospitalized for severe RSV infection. developing a greater understanding of the pathophysiological mechanisms through which RSV causes recurrent wheezing/asthma, will lead to an evidence-based prevention strategy and perhaps reduce the subsequent risk for asthma (71) .Predicting asthma following RSV-positive bronchiolitis.The biomarker ccL5 (previously known as RANTES, a \u03b2-chemoattractant for inflammatory cells including T-lymphocyte subsets), in the nasal epithelium during RSV bronchiolitis, is strongly predictive of physician-diagnosed asthma (83, 87) .", [["respiratory", "ANATOMY", 161, 172], ["inflammatory cells", "ANATOMY", 590, 608], ["T-lymphocyte", "ANATOMY", 619, 631], ["nasal epithelium", "ANATOMY", 649, 665], ["viral illnesses", "DISEASE", 123, 138], ["RSV infection", "DISEASE", 217, 230], ["RSV", "DISEASE", 318, 321], ["wheezing", "DISEASE", 339, 347], ["asthma", "DISEASE", 348, 354], ["asthma", "DISEASE", 450, 456], ["asthma", "DISEASE", 474, 480], ["bronchiolitis", "DISEASE", 504, 517], ["bronchiolitis", "DISEASE", 677, 690], ["asthma", "DISEASE", 738, 744], ["children", "ORGANISM", 184, 192], ["RSV", "ORGANISM", 217, 220], ["RSV", "ORGANISM", 318, 321], ["RSV", "ORGANISM", 491, 494], ["ccL5", "GENE_OR_GENE_PRODUCT", 532, 536], ["RANTES", "GENE_OR_GENE_PRODUCT", 558, 564], ["inflammatory cells", "CELL", 590, 608], ["T-lymphocyte", "CELL", 619, 631], ["nasal epithelium", "TISSUE", 649, 665], ["RSV", "ORGANISM", 673, 676], ["ccL5", "PROTEIN", 532, 536], ["RANTES", "PROTEIN", 558, 564], ["\u03b2-chemoattractant", "PROTEIN", 568, 585], ["inflammatory cells", "CELL_TYPE", 590, 608], ["T-lymphocyte subsets", "CELL_TYPE", 619, 639], ["children", "SPECIES", 184, 192], ["RSV", "SPECIES", 217, 220], ["RSV", "SPECIES", 318, 321], ["RSV", "SPECIES", 491, 494], ["RSV", "SPECIES", 673, 676], ["follow-up studies", "TEST", 21, 38], ["more severe viral illnesses", "PROBLEM", 111, 138], ["severe RSV infection", "PROBLEM", 210, 230], ["the pathophysiological mechanisms", "PROBLEM", 270, 303], ["recurrent wheezing", "PROBLEM", 329, 347], ["asthma", "PROBLEM", 348, 354], ["asthma", "PROBLEM", 450, 456], ["Predicting asthma", "PROBLEM", 463, 480], ["RSV", "PROBLEM", 491, 494], ["positive bronchiolitis", "PROBLEM", 495, 517], ["The biomarker ccL5", "TEST", 518, 536], ["RANTES", "TEST", 558, 564], ["inflammatory cells", "PROBLEM", 590, 608], ["T-lymphocyte subsets", "PROBLEM", 619, 639], ["the nasal epithelium", "PROBLEM", 645, 665], ["RSV bronchiolitis", "PROBLEM", 673, 690], ["asthma", "PROBLEM", 738, 744], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["RSV", "OBSERVATION", 217, 220], ["infection", "OBSERVATION", 221, 230], ["greater", "OBSERVATION_MODIFIER", 245, 252], ["recurrent", "OBSERVATION_MODIFIER", 329, 338], ["wheezing", "OBSERVATION", 339, 347], ["asthma", "OBSERVATION", 348, 354], ["asthma", "OBSERVATION", 474, 480], ["RSV", "OBSERVATION", 491, 494], ["positive", "OBSERVATION_MODIFIER", 495, 503], ["bronchiolitis", "OBSERVATION", 504, 517], ["ccL5", "OBSERVATION", 532, 536], ["inflammatory cells", "OBSERVATION", 590, 608], ["lymphocyte subsets", "OBSERVATION", 621, 639], ["nasal epithelium", "ANATOMY", 649, 665], ["RSV bronchiolitis", "OBSERVATION", 673, 690]]], ["Furthermore, it has been suggested that prematurely born infants have a predisposition to RSV infection-related respiratory morbidity, including subsequent respiratory dysfunction (44,85).", [["respiratory", "ANATOMY", 112, 123], ["respiratory", "ANATOMY", 156, 167], ["infection", "DISEASE", 94, 103], ["respiratory morbidity", "DISEASE", 112, 133], ["respiratory dysfunction", "DISEASE", 156, 179], ["infants", "ORGANISM", 57, 64], ["RSV", "ORGANISM", 90, 93], ["infants", "SPECIES", 57, 64], ["RSV", "SPECIES", 90, 93], ["RSV infection", "PROBLEM", 90, 103], ["respiratory morbidity", "PROBLEM", 112, 133], ["subsequent respiratory dysfunction", "PROBLEM", 145, 179], ["RSV infection", "OBSERVATION", 90, 103], ["respiratory morbidity", "OBSERVATION", 112, 133], ["respiratory dysfunction", "OBSERVATION", 156, 179]]], ["Single-nucleotide polymorphisms in genes coding for IL-8, IL-19, IL-20, IL-13, mannose-binding lectin, IFNG and RANTES, have been associated with wheezing following RSV LRTI in term-born infants (85) .", [["wheezing", "DISEASE", 146, 154], ["RSV LRTI", "DISEASE", 165, 173], ["mannose", "CHEMICAL", 79, 86], ["IL-8", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-19", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-20", "GENE_OR_GENE_PRODUCT", 65, 70], ["IL-13", "GENE_OR_GENE_PRODUCT", 72, 77], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 79, 101], ["IFNG", "GENE_OR_GENE_PRODUCT", 103, 107], ["RANTES", "GENE_OR_GENE_PRODUCT", 112, 118], ["RSV", "ORGANISM", 165, 168], ["infants", "ORGANISM", 187, 194], ["IL-13", "PROTEIN", 72, 77], ["mannose-binding lectin", "PROTEIN", 79, 101], ["IFNG", "PROTEIN", 103, 107], ["RANTES", "PROTEIN", 112, 118], ["infants", "SPECIES", 187, 194], ["RSV", "SPECIES", 165, 168], ["Single-nucleotide polymorphisms in genes", "TREATMENT", 0, 40], ["IL", "TEST", 52, 54], ["IL", "TEST", 58, 60], ["IL", "TEST", 65, 67], ["IL", "TEST", 72, 74], ["wheezing", "PROBLEM", 146, 154]]], ["The site of infection might be another important factor related to asthma risk, thus viral ALRTI in infancy indicates an increased risk of subsequent asthma, while gastrointestinal infections might be protective (86) .", [["gastrointestinal", "ANATOMY", 164, 180], ["infection", "DISEASE", 12, 21], ["asthma", "DISEASE", 67, 73], ["asthma", "DISEASE", 150, 156], ["gastrointestinal infections", "DISEASE", 164, 191], ["gastrointestinal", "ORGAN", 164, 180], ["infection", "PROBLEM", 12, 21], ["asthma risk", "PROBLEM", 67, 78], ["viral ALRTI in infancy", "PROBLEM", 85, 107], ["subsequent asthma", "PROBLEM", 139, 156], ["gastrointestinal infections", "PROBLEM", 164, 191], ["infection", "OBSERVATION", 12, 21], ["asthma", "OBSERVATION", 67, 73], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["asthma", "OBSERVATION", 150, 156]]], ["Asthma after severe RSV bronchiolitis is positively correlated with maternal asthma, exposure to high levels of dog allergen, aeroallergen sensitization and recurrent wheezing; day care attendance and white race have been associated with decreased asthma risk (87) .", [["Asthma", "DISEASE", 0, 6], ["bronchiolitis", "DISEASE", 24, 37], ["asthma", "DISEASE", 77, 83], ["aeroallergen sensitization", "DISEASE", 126, 152], ["wheezing", "DISEASE", 167, 175], ["asthma", "DISEASE", 248, 254], ["RSV", "ORGANISM", 20, 23], ["dog", "ORGANISM", 112, 115], ["dog", "SPECIES", 112, 115], ["RSV", "SPECIES", 20, 23], ["dog", "SPECIES", 112, 115], ["Asthma", "PROBLEM", 0, 6], ["severe RSV bronchiolitis", "PROBLEM", 13, 37], ["maternal asthma", "PROBLEM", 68, 83], ["dog allergen", "TREATMENT", 112, 124], ["aeroallergen sensitization", "PROBLEM", 126, 152], ["recurrent wheezing", "PROBLEM", 157, 175], ["decreased asthma risk", "PROBLEM", 238, 259], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["RSV bronchiolitis", "OBSERVATION", 20, 37], ["asthma", "OBSERVATION", 77, 83], ["recurrent", "OBSERVATION_MODIFIER", 157, 166], ["wheezing", "OBSERVATION", 167, 175], ["decreased", "OBSERVATION_MODIFIER", 238, 247], ["asthma", "OBSERVATION", 248, 254]]], ["Several host factors, including respiratory allergy and virus-induced interferon responses, viral virulence factors, individual risk factors (e.g., young age, especially the first 6 months of life, small lung size and genetics), and environmental exposures (e.g., exposure to tobacco smoke, airway microbiome) modify the risk of virus-induced wheezing and promote more severe wheezing illnesses and the risk for progression to asthma (86, 88) .", [["lung", "ANATOMY", 204, 208], ["airway", "ANATOMY", 291, 297], ["respiratory allergy", "DISEASE", 32, 51], ["wheezing", "DISEASE", 343, 351], ["wheezing illnesses", "DISEASE", 376, 394], ["asthma", "DISEASE", 427, 433], ["lung", "ORGAN", 204, 208], ["tobacco", "ORGANISM", 276, 283], ["airway microbiome", "MULTI-TISSUE_STRUCTURE", 291, 308], ["interferon", "PROTEIN", 70, 80], ["viral virulence factors", "PROTEIN", 92, 115], ["tobacco", "SPECIES", 276, 283], ["Several host factors", "PROBLEM", 0, 20], ["respiratory allergy", "PROBLEM", 32, 51], ["virus-induced interferon responses", "TREATMENT", 56, 90], ["viral virulence factors", "PROBLEM", 92, 115], ["small lung size", "PROBLEM", 198, 213], ["airway microbiome", "TREATMENT", 291, 308], ["virus", "PROBLEM", 329, 334], ["induced wheezing", "PROBLEM", 335, 351], ["severe wheezing illnesses", "PROBLEM", 369, 394], ["asthma", "PROBLEM", 427, 433], ["host factors", "OBSERVATION", 8, 20], ["respiratory", "ANATOMY", 32, 43], ["small", "OBSERVATION_MODIFIER", 198, 203], ["lung", "ANATOMY", 204, 208], ["size", "OBSERVATION_MODIFIER", 209, 213], ["virus", "OBSERVATION", 329, 334], ["severe", "OBSERVATION_MODIFIER", 369, 375], ["wheezing", "OBSERVATION", 376, 384], ["asthma", "OBSERVATION", 427, 433]]], ["The anti-RSV mAb palivizumab decreases the risk of severe RSV-induced illness and subsequent recurrent wheeze in prematurely born infants (89) .", [["palivizumab", "CHEMICAL", 17, 28], ["RSV-induced illness", "DISEASE", 58, 77], ["wheeze", "DISEASE", 103, 109], ["anti-RSV mAb", "GENE_OR_GENE_PRODUCT", 4, 16], ["RSV", "ORGANISM", 58, 61], ["infants", "ORGANISM", 130, 137], ["anti-RSV mAb", "PROTEIN", 4, 16], ["infants", "SPECIES", 130, 137], ["anti-RSV", "SPECIES", 4, 12], ["RSV", "SPECIES", 58, 61], ["The anti-RSV mAb palivizumab", "TREATMENT", 0, 28], ["severe RSV", "PROBLEM", 51, 61], ["induced illness", "PROBLEM", 62, 77], ["subsequent recurrent wheeze", "PROBLEM", 82, 109], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["RSV", "OBSERVATION", 58, 61], ["recurrent", "OBSERVATION_MODIFIER", 93, 102], ["wheeze", "OBSERVATION", 103, 109]]], ["Further understanding of the role of RSV in asthma pathogenesis may help develop vaccines against RSV as a way of asthma prevention.Post infectious bronchiolitis obliterans caused by RSV.Bronchiolitis obliterans (BO) is a chronic and irreversible lung disease leading to the obstruction and/or obliteration of the small airways (90) .", [["lung", "ANATOMY", 247, 251], ["small airways", "ANATOMY", 314, 327], ["asthma", "DISEASE", 44, 50], ["RSV", "DISEASE", 98, 101], ["asthma", "DISEASE", 114, 120], ["bronchiolitis obliterans", "DISEASE", 148, 172], ["RSV", "DISEASE", 183, 186], ["Bronchiolitis obliterans", "DISEASE", 187, 211], ["BO", "DISEASE", 213, 215], ["lung disease", "DISEASE", 247, 259], ["obstruction", "DISEASE", 275, 286], ["RSV", "ORGANISM", 37, 40], ["RSV", "ORGANISM", 98, 101], ["RSV", "ORGANISM", 183, 186], ["lung", "ORGAN", 247, 251], ["airways", "MULTI-TISSUE_STRUCTURE", 320, 327], ["RSV", "SPECIES", 37, 40], ["RSV", "SPECIES", 98, 101], ["RSV", "SPECIES", 183, 186], ["RSV", "PROBLEM", 37, 40], ["asthma pathogenesis", "PROBLEM", 44, 63], ["vaccines", "TREATMENT", 81, 89], ["RSV", "PROBLEM", 98, 101], ["asthma prevention", "TREATMENT", 114, 131], ["Post infectious bronchiolitis obliterans", "PROBLEM", 132, 172], ["RSV", "PROBLEM", 183, 186], ["Bronchiolitis obliterans (BO", "PROBLEM", 187, 215], ["a chronic and irreversible lung disease", "PROBLEM", 220, 259], ["the obstruction", "PROBLEM", 271, 286], ["obliteration of the small airways", "PROBLEM", 294, 327], ["RSV", "OBSERVATION", 37, 40], ["asthma", "OBSERVATION", 114, 120], ["infectious", "OBSERVATION_MODIFIER", 137, 147], ["bronchiolitis obliterans", "OBSERVATION", 148, 172], ["RSV", "OBSERVATION", 183, 186], ["obliterans", "OBSERVATION", 201, 211], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["irreversible", "OBSERVATION_MODIFIER", 234, 246], ["lung", "ANATOMY", 247, 251], ["disease", "OBSERVATION", 252, 259], ["obstruction", "OBSERVATION", 275, 286], ["obliteration", "OBSERVATION", 294, 306], ["small", "OBSERVATION_MODIFIER", 314, 319], ["airways", "ANATOMY", 320, 327]]], ["Most cases of BO in children are post infectious (PIBO) and are mainly associated with adenovirus infections, although other viruses may also be implicated, including measles, influenza, parainfluenza and RSV (91) (92) (93) .", [["BO", "DISEASE", 14, 16], ["PIBO", "DISEASE", 50, 54], ["adenovirus infections", "DISEASE", 87, 108], ["measles", "DISEASE", 167, 174], ["influenza", "DISEASE", 176, 185], ["parainfluenza", "DISEASE", 187, 200], ["BO", "CANCER", 14, 16], ["children", "ORGANISM", 20, 28], ["adenovirus", "ORGANISM", 87, 97], ["parainfluenza", "ORGANISM", 187, 200], ["RSV", "ORGANISM", 205, 208], ["children", "SPECIES", 20, 28], ["parainfluenza", "SPECIES", 187, 200], ["adenovirus", "SPECIES", 87, 97], ["RSV", "SPECIES", 205, 208], ["post infectious (PIBO)", "PROBLEM", 33, 55], ["adenovirus infections", "PROBLEM", 87, 108], ["other viruses", "PROBLEM", 119, 132], ["measles", "PROBLEM", 167, 174], ["influenza", "PROBLEM", 176, 185], ["parainfluenza", "PROBLEM", 187, 200], ["RSV", "TEST", 205, 208], ["infectious", "OBSERVATION", 38, 48], ["mainly associated with", "UNCERTAINTY", 64, 86], ["adenovirus", "OBSERVATION", 87, 97]]], ["An extensive search of the current literature in the context of the workshop demonstrated that RSV is detected in children with PIBO with an incidence ranging from 4.3 to 30% (94-103); however, there are only a few reports of children with PIBO secondary to RSV as a single infection.", [["RSV", "DISEASE", 95, 98], ["PIBO", "DISEASE", 128, 132], ["PIBO", "DISEASE", 240, 244], ["RSV", "DISEASE", 258, 261], ["infection", "DISEASE", 274, 283], ["RSV", "ORGANISM", 95, 98], ["children", "ORGANISM", 114, 122], ["PIBO", "CANCER", 128, 132], ["children", "ORGANISM", 226, 234], ["PIBO", "CANCER", 240, 244], ["RSV", "ORGANISM", 258, 261], ["children", "SPECIES", 114, 122], ["children", "SPECIES", 226, 234], ["RSV", "SPECIES", 95, 98], ["RSV", "SPECIES", 258, 261], ["RSV", "PROBLEM", 95, 98], ["PIBO", "TREATMENT", 128, 132], ["PIBO", "TREATMENT", 240, 244], ["RSV", "PROBLEM", 258, 261], ["a single infection", "PROBLEM", 265, 283], ["extensive", "OBSERVATION_MODIFIER", 3, 12], ["RSV", "OBSERVATION", 95, 98], ["RSV", "OBSERVATION", 258, 261], ["infection", "OBSERVATION", 274, 283]]], ["This creates skepticism about the aetiological role of RSV in PIBO.", [["RSV", "DISEASE", 55, 58], ["PIBO", "DISEASE", 62, 66], ["RSV", "ORGANISM", 55, 58], ["PIBO", "CANCER", 62, 66], ["RSV", "SPECIES", 55, 58], ["RSV in PIBO", "TREATMENT", 55, 66], ["skepticism", "OBSERVATION", 13, 23], ["RSV", "OBSERVATION", 55, 58]]], ["Further research is required to investigate the potential impact of RSV co-infection in the severity and outcome of children with PIBO.Imaging in children with RSV infectionChest radiography and RSV-positive bronchiolitis.", [["RSV co-infection", "DISEASE", 68, 84], ["PIBO", "DISEASE", 130, 134], ["RSV infection", "DISEASE", 160, 173], ["bronchiolitis", "DISEASE", 208, 221], ["RSV", "ORGANISM", 68, 71], ["children", "ORGANISM", 116, 124], ["children", "ORGANISM", 146, 154], ["RSV", "ORGANISM", 160, 163], ["RSV", "ORGANISM", 195, 198], ["children", "SPECIES", 116, 124], ["children", "SPECIES", 146, 154], ["RSV", "SPECIES", 68, 71], ["RSV", "SPECIES", 160, 163], ["RSV", "SPECIES", 195, 198], ["RSV co-infection", "PROBLEM", 68, 84], ["PIBO", "TREATMENT", 130, 134], ["Imaging", "TEST", 135, 142], ["RSV infection", "PROBLEM", 160, 173], ["Chest radiography", "TEST", 173, 190], ["RSV", "PROBLEM", 195, 198], ["positive bronchiolitis", "PROBLEM", 199, 221], ["RSV co-infection", "OBSERVATION", 68, 84], ["Chest", "ANATOMY", 173, 178], ["RSV", "ANATOMY", 195, 198], ["positive", "OBSERVATION_MODIFIER", 199, 207], ["bronchiolitis", "OBSERVATION", 208, 221]]], ["Although imaging cannot confirm the diagnosis of RSV infection, it is important to identify the possible pattern of viral disease, in order to avoid unnecessary administration of antibiotic therapy and to predict possible late effects (Figs.", [["RSV infection", "DISEASE", 49, 62], ["viral disease", "DISEASE", 116, 129], ["RSV", "ORGANISM", 49, 52], ["RSV", "SPECIES", 49, 52], ["imaging", "TEST", 9, 16], ["RSV infection", "PROBLEM", 49, 62], ["viral disease", "PROBLEM", 116, 129], ["antibiotic therapy", "TREATMENT", 179, 197], ["late effects (Figs", "PROBLEM", 222, 240], ["RSV", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62], ["viral disease", "OBSERVATION", 116, 129]]], ["The clinical syndrome of bronchiolitis is commonly diagnosed based on the patient's history and physical examination; chest radiography is not routinely recommended to reach the diagnosis due to recommended restriction of radiation exposure in the paediatric age group (104) (105) (106) . chest imaging, however, may be considered when a child with RSV infection and severe ALRTI is admitted to intensive care to better understand the extent of lung involvement and atelectasis, which is common in acute RSV infection (106).", [["lung", "ANATOMY", 445, 449], ["bronchiolitis", "DISEASE", 25, 38], ["RSV infection", "DISEASE", 349, 362], ["ALRTI", "DISEASE", 374, 379], ["atelectasis", "DISEASE", 466, 477], ["RSV infection", "DISEASE", 504, 517], ["patient", "ORGANISM", 74, 81], ["RSV", "ORGANISM", 349, 352], ["lung", "ORGAN", 445, 449], ["RSV", "ORGANISM", 504, 507], ["patient", "SPECIES", 74, 81], ["RSV", "SPECIES", 349, 352], ["RSV", "SPECIES", 504, 507], ["The clinical syndrome", "PROBLEM", 0, 21], ["bronchiolitis", "PROBLEM", 25, 38], ["physical examination", "TEST", 96, 116], ["chest radiography", "TEST", 118, 135], ["radiation exposure", "TREATMENT", 222, 240], ["chest imaging", "TEST", 289, 302], ["RSV infection", "PROBLEM", 349, 362], ["lung involvement", "PROBLEM", 445, 461], ["atelectasis", "PROBLEM", 466, 477], ["acute RSV infection", "PROBLEM", 498, 517], ["bronchiolitis", "OBSERVATION", 25, 38], ["chest", "ANATOMY", 118, 123], ["radiation exposure", "OBSERVATION", 222, 240], ["infection", "OBSERVATION", 353, 362], ["lung", "ANATOMY", 445, 449], ["involvement", "OBSERVATION", 450, 461], ["atelectasis", "OBSERVATION", 466, 477], ["common", "OBSERVATION_MODIFIER", 488, 494], ["acute", "OBSERVATION_MODIFIER", 498, 503], ["RSV", "OBSERVATION_MODIFIER", 504, 507], ["infection", "OBSERVATION", 508, 517]]], ["It is important to note that chest radiographs in children with RSV infection may be entirely normal or reveal non-specific findings, which are also encountered in other viral infections: most commonly, perihilar opacities and hyperinflation, atelectasis and rarely consolidation and bronchial cuffing or air-leak (107) .", [["chest", "ANATOMY", 29, 34], ["perihilar opacities", "ANATOMY", 203, 222], ["bronchial", "ANATOMY", 284, 293], ["RSV infection", "DISEASE", 64, 77], ["viral infections", "DISEASE", 170, 186], ["opacities", "DISEASE", 213, 222], ["hyperinflation", "DISEASE", 227, 241], ["atelectasis", "DISEASE", 243, 254], ["chest", "ORGANISM_SUBDIVISION", 29, 34], ["children", "ORGANISM", 50, 58], ["RSV", "ORGANISM", 64, 67], ["children", "SPECIES", 50, 58], ["RSV", "SPECIES", 64, 67], ["chest radiographs", "TEST", 29, 46], ["RSV infection", "PROBLEM", 64, 77], ["non-specific findings", "PROBLEM", 111, 132], ["other viral infections", "PROBLEM", 164, 186], ["perihilar opacities", "PROBLEM", 203, 222], ["hyperinflation", "PROBLEM", 227, 241], ["atelectasis", "PROBLEM", 243, 254], ["rarely consolidation", "PROBLEM", 259, 279], ["bronchial cuffing", "PROBLEM", 284, 301], ["air-leak", "PROBLEM", 305, 313], ["chest", "ANATOMY", 29, 34], ["non-specific", "OBSERVATION_MODIFIER", 111, 123], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["infections", "OBSERVATION", 176, 186], ["perihilar", "ANATOMY_MODIFIER", 203, 212], ["opacities", "OBSERVATION", 213, 222], ["hyperinflation", "OBSERVATION", 227, 241], ["atelectasis", "OBSERVATION", 243, 254], ["rarely", "OBSERVATION_MODIFIER", 259, 265], ["consolidation", "OBSERVATION", 266, 279], ["bronchial", "ANATOMY", 284, 293], ["cuffing", "OBSERVATION", 294, 301], ["air", "OBSERVATION_MODIFIER", 305, 308], ["leak", "OBSERVATION", 309, 313]]], ["Radiography is commonly obtained to rule out atelectasis and foreign body aspiration.", [["body", "ANATOMY", 69, 73], ["atelectasis", "DISEASE", 45, 56], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["Radiography", "TEST", 0, 11], ["atelectasis", "PROBLEM", 45, 56], ["foreign body aspiration", "PROBLEM", 61, 84], ["atelectasis", "OBSERVATION", 45, 56], ["foreign body", "OBSERVATION", 61, 73], ["aspiration", "OBSERVATION", 74, 84]]], ["Guidelines suggest performing a chest radiograph in the presence of significant respiratory distress or hospitalization (108) .", [["chest", "ANATOMY", 32, 37], ["respiratory", "ANATOMY", 80, 91], ["respiratory distress", "DISEASE", 80, 100], ["a chest radiograph", "TEST", 30, 48], ["significant respiratory distress", "PROBLEM", 68, 100], ["chest", "ANATOMY", 32, 37], ["significant", "OBSERVATION_MODIFIER", 68, 79], ["respiratory distress", "OBSERVATION", 80, 100]]], ["In newborns with RSV infection, the radiological pattern on chest radiography may be a predictor of clinical outcome (109) .", [["chest", "ANATOMY", 60, 65], ["RSV infection", "DISEASE", 17, 30], ["newborns", "ORGANISM", 3, 11], ["RSV", "ORGANISM", 17, 20], ["chest", "ORGAN", 60, 65], ["RSV", "SPECIES", 17, 20], ["RSV infection", "PROBLEM", 17, 30], ["chest radiography", "TEST", 60, 77], ["RSV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30], ["chest", "ANATOMY", 60, 65]]], ["However, it is highlighted that chest radiographs should not be routinely performed in children with bronchiolitis to avoid radiation exposure (106).", [["chest", "ANATOMY", 32, 37], ["bronchiolitis", "DISEASE", 101, 114], ["children", "ORGANISM", 87, 95], ["children", "SPECIES", 87, 95], ["chest radiographs", "TEST", 32, 49], ["bronchiolitis", "PROBLEM", 101, 114], ["radiation exposure", "PROBLEM", 124, 142], ["chest", "ANATOMY", 32, 37], ["bronchiolitis", "OBSERVATION", 101, 114]]], ["It is also important to emphasize that chest radiograph is not the right way to rule out bacterial infection (106); the correct diagnostic approach for bacterial or ventilator-associated pneumonia in children in the PIcU is to perform respiratory culture or Matrix-assisted laser desorption ionization time-of-flight (MALdI-TOF) mass spectrometry from sputum/aspirate or bronchoalveolar lavage (BAL) specimens.Imaging in children with RSV infectionChest CT and RSV-positive bronchiolitis.", [["chest", "ANATOMY", 39, 44], ["sputum", "ANATOMY", 352, 358], ["aspirate", "ANATOMY", 359, 367], ["bronchoalveolar lavage (BAL) specimens", "ANATOMY", 371, 409], ["bacterial infection", "DISEASE", 89, 108], ["pneumonia", "DISEASE", 187, 196], ["bronchiolitis", "DISEASE", 474, 487], ["chest", "ORGAN", 39, 44], ["children", "ORGANISM", 200, 208], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 371, 393], ["children", "ORGANISM", 421, 429], ["RSV", "ORGANISM", 435, 438], ["RSV", "ORGANISM", 461, 464], ["children", "SPECIES", 200, 208], ["children", "SPECIES", 421, 429], ["RSV", "SPECIES", 435, 438], ["RSV", "SPECIES", 461, 464], ["chest radiograph", "TEST", 39, 55], ["bacterial infection", "PROBLEM", 89, 108], ["bacterial or ventilator-associated pneumonia", "PROBLEM", 152, 196], ["respiratory culture", "TEST", 235, 254], ["Matrix-assisted laser desorption ionization", "TREATMENT", 258, 301], ["MALdI", "TEST", 318, 323], ["mass spectrometry", "PROBLEM", 329, 346], ["sputum/aspirate", "TEST", 352, 367], ["bronchoalveolar lavage (BAL) specimens", "TEST", 371, 409], ["Imaging", "TEST", 410, 417], ["RSV infectionChest CT", "TEST", 435, 456], ["RSV", "PROBLEM", 461, 464], ["positive bronchiolitis", "PROBLEM", 465, 487], ["chest", "ANATOMY", 39, 44], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["infection", "OBSERVATION", 99, 108], ["pneumonia", "OBSERVATION", 187, 196], ["bronchoalveolar lavage", "OBSERVATION", 371, 393], ["RSV", "ANATOMY", 461, 464], ["positive", "OBSERVATION_MODIFIER", 465, 473], ["bronchiolitis", "OBSERVATION", 474, 487]]], ["Several studies have revealed that standard radiological techniques, including computed tomography (cT), are frequently unable to distinguish between acute bronchiolitis changes caused by RSV vs. those caused by other respiratory viruses (104, 108) .", [["bronchiolitis", "DISEASE", 156, 169], ["RSV", "DISEASE", 188, 191], ["respiratory viruses", "DISEASE", 218, 237], ["RSV", "ORGANISM", 188, 191], ["RSV", "SPECIES", 188, 191], ["Several studies", "TEST", 0, 15], ["standard radiological techniques", "TEST", 35, 67], ["computed tomography (cT", "TEST", 79, 102], ["acute bronchiolitis changes", "PROBLEM", 150, 177], ["RSV", "PROBLEM", 188, 191], ["other respiratory viruses", "PROBLEM", 212, 237], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["bronchiolitis", "OBSERVATION", 156, 169], ["RSV", "OBSERVATION", 188, 191], ["respiratory viruses", "OBSERVATION", 218, 237]]], ["It is interesting that the radiographic findings, especially in high-resolution computed tomography (HRCT), reflect the histopathologic changes that RSV infection provokes: plugging or occlusion of the bronchiolar airway lumens by sloughed necrotic and irregular epithelium and exudate, combined with peri-bronchiolar infiltration and reaction with inflammatory cells and submucosal oedema.", [["bronchiolar airway lumens", "ANATOMY", 202, 227], ["necrotic", "ANATOMY", 240, 248], ["irregular epithelium", "ANATOMY", 253, 273], ["exudate", "ANATOMY", 278, 285], ["peri-bronchiolar", "ANATOMY", 301, 317], ["inflammatory cells", "ANATOMY", 349, 367], ["submucosal", "ANATOMY", 372, 382], ["RSV infection", "DISEASE", 149, 162], ["necrotic", "DISEASE", 240, 248], ["submucosal oedema", "DISEASE", 372, 389], ["RSV", "ORGANISM", 149, 152], ["bronchiolar airway lumens", "TISSUE", 202, 227], ["irregular epithelium", "TISSUE", 253, 273], ["exudate", "TISSUE", 278, 285], ["inflammatory cells", "CELL", 349, 367], ["submucosal oedema", "PATHOLOGICAL_FORMATION", 372, 389], ["inflammatory cells", "CELL_TYPE", 349, 367], ["RSV", "SPECIES", 149, 152], ["the radiographic findings", "TEST", 23, 48], ["HRCT", "TEST", 101, 105], ["the histopathologic changes", "PROBLEM", 116, 143], ["RSV infection", "PROBLEM", 149, 162], ["plugging", "PROBLEM", 173, 181], ["occlusion of the bronchiolar airway lumens", "PROBLEM", 185, 227], ["sloughed necrotic and irregular epithelium", "PROBLEM", 231, 273], ["exudate", "PROBLEM", 278, 285], ["peri-bronchiolar infiltration", "PROBLEM", 301, 330], ["reaction", "PROBLEM", 335, 343], ["inflammatory cells", "PROBLEM", 349, 367], ["submucosal oedema", "PROBLEM", 372, 389], ["RSV", "OBSERVATION_MODIFIER", 149, 152], ["infection", "OBSERVATION", 153, 162], ["plugging", "OBSERVATION", 173, 181], ["occlusion", "OBSERVATION", 185, 194], ["bronchiolar", "ANATOMY_MODIFIER", 202, 213], ["airway", "ANATOMY", 214, 220], ["lumens", "ANATOMY_MODIFIER", 221, 227], ["sloughed", "OBSERVATION_MODIFIER", 231, 239], ["necrotic", "OBSERVATION_MODIFIER", 240, 248], ["irregular", "OBSERVATION_MODIFIER", 253, 262], ["epithelium", "OBSERVATION_MODIFIER", 263, 273], ["exudate", "OBSERVATION_MODIFIER", 278, 285], ["peri-bronchiolar", "OBSERVATION_MODIFIER", 301, 317], ["infiltration", "OBSERVATION", 318, 330], ["inflammatory cells", "OBSERVATION", 349, 367], ["submucosal", "ANATOMY", 372, 382], ["oedema", "OBSERVATION", 383, 389]]], ["The infiltration is a combination of neutrophils entering the airway submucosa and epithelial cell debris in the airway lumens.", [["neutrophils", "ANATOMY", 37, 48], ["airway submucosa", "ANATOMY", 62, 78], ["epithelial cell debris", "ANATOMY", 83, 105], ["airway lumens", "ANATOMY", 113, 126], ["neutrophils", "CELL", 37, 48], ["airway submucosa", "TISSUE", 62, 78], ["epithelial cell debris", "TISSUE", 83, 105], ["airway lumens", "MULTI-TISSUE_STRUCTURE", 113, 126], ["neutrophils", "CELL_TYPE", 37, 48], ["The infiltration", "PROBLEM", 0, 16], ["neutrophils entering the airway submucosa", "PROBLEM", 37, 78], ["epithelial cell debris in the airway lumens", "PROBLEM", 83, 126], ["infiltration", "OBSERVATION", 4, 16], ["neutrophils", "OBSERVATION", 37, 48], ["airway submucosa", "ANATOMY", 62, 78], ["epithelial cell debris", "OBSERVATION", 83, 105], ["airway", "ANATOMY", 113, 119], ["lumens", "ANATOMY_MODIFIER", 120, 126]]], ["These cellular accumulations are likely to result in acute obstruction of the distal airways, an outcome much more likely to occur in the extremely narrow bronchioles of infants.", [["cellular", "ANATOMY", 6, 14], ["distal airways", "ANATOMY", 78, 92], ["bronchioles", "ANATOMY", 155, 166], ["obstruction of the distal airways", "DISEASE", 59, 92], ["cellular", "CELL", 6, 14], ["airways", "MULTI-TISSUE_STRUCTURE", 85, 92], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 155, 166], ["infants", "ORGANISM", 170, 177], ["infants", "SPECIES", 170, 177], ["These cellular accumulations", "PROBLEM", 0, 28], ["acute obstruction of the distal airways", "PROBLEM", 53, 92], ["cellular accumulations", "OBSERVATION", 6, 28], ["likely to result", "UNCERTAINTY", 33, 49], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["obstruction", "OBSERVATION", 59, 70], ["distal", "ANATOMY_MODIFIER", 78, 84], ["airways", "ANATOMY", 85, 92], ["extremely", "OBSERVATION_MODIFIER", 138, 147], ["narrow", "OBSERVATION_MODIFIER", 148, 154], ["bronchioles", "OBSERVATION", 155, 166]]], ["Because this is combined with the inherent loss of mechanical clearance of these small airways, it likely leads to increased spread of infection, augmented inflammation and clinical signs of wheezing/obstruction (110) .", [["airways", "ANATOMY", 87, 94], ["infection", "DISEASE", 135, 144], ["inflammation", "DISEASE", 156, 168], ["wheezing", "DISEASE", 191, 199], ["obstruction", "DISEASE", 200, 211], ["airways", "MULTI-TISSUE_STRUCTURE", 87, 94], ["the inherent loss of mechanical clearance of these small airways", "PROBLEM", 30, 94], ["infection", "PROBLEM", 135, 144], ["augmented inflammation", "PROBLEM", 146, 168], ["wheezing", "PROBLEM", 191, 199], ["obstruction", "PROBLEM", 200, 211], ["inherent", "OBSERVATION_MODIFIER", 34, 42], ["loss", "OBSERVATION_MODIFIER", 43, 47], ["mechanical clearance", "OBSERVATION", 51, 71], ["small", "OBSERVATION_MODIFIER", 81, 86], ["airways", "ANATOMY", 87, 94], ["likely leads to", "UNCERTAINTY", 99, 114], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["spread", "OBSERVATION_MODIFIER", 125, 131], ["infection", "OBSERVATION", 135, 144], ["inflammation", "OBSERVATION", 156, 168], ["wheezing", "OBSERVATION", 191, 199], ["obstruction", "OBSERVATION", 200, 211]]], ["Consistent with obstruction, the most common CT findings in RSV pneumonia include centrilobular nodules, ground-glass opacities, air-space consolidation, and peribronchial thickening (111) .", [["centrilobular nodules", "ANATOMY", 82, 103], ["air-space", "ANATOMY", 129, 138], ["peribronchial", "ANATOMY", 158, 171], ["obstruction", "DISEASE", 16, 27], ["pneumonia", "DISEASE", 64, 73], ["RSV", "ORGANISM", 60, 63], ["centrilobular nodules", "PATHOLOGICAL_FORMATION", 82, 103], ["RSV", "SPECIES", 60, 63], ["obstruction", "PROBLEM", 16, 27], ["RSV pneumonia", "PROBLEM", 60, 73], ["centrilobular nodules", "PROBLEM", 82, 103], ["ground-glass opacities", "PROBLEM", 105, 127], ["air-space consolidation", "PROBLEM", 129, 152], ["peribronchial thickening", "PROBLEM", 158, 182], ["obstruction", "OBSERVATION", 16, 27], ["RSV", "OBSERVATION_MODIFIER", 60, 63], ["pneumonia", "OBSERVATION", 64, 73], ["centrilobular", "OBSERVATION_MODIFIER", 82, 95], ["nodules", "OBSERVATION", 96, 103], ["ground", "OBSERVATION_MODIFIER", 105, 111], ["glass opacities", "OBSERVATION", 112, 127], ["air-space", "ANATOMY_MODIFIER", 129, 138], ["consolidation", "OBSERVATION", 139, 152], ["peribronchial", "ANATOMY_MODIFIER", 158, 171], ["thickening", "OBSERVATION", 172, 182]]], ["These findings have a bilateral, usually asymmetric, central and peripheral distribution.", [["a bilateral, usually asymmetric, central and peripheral distribution", "PROBLEM", 20, 88], ["bilateral", "ANATOMY_MODIFIER", 22, 31], ["usually", "OBSERVATION_MODIFIER", 33, 40], ["asymmetric", "OBSERVATION_MODIFIER", 41, 51], ["central", "ANATOMY_MODIFIER", 53, 60], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["distribution", "OBSERVATION_MODIFIER", 76, 88]]], ["Up to 40% of children with bronchiolitis will develop further wheezing episodes in the first five years of life.", [["bronchiolitis", "DISEASE", 27, 40], ["wheezing", "DISEASE", 62, 70], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["bronchiolitis", "PROBLEM", 27, 40], ["further wheezing episodes", "PROBLEM", 54, 79], ["bronchiolitis", "OBSERVATION", 27, 40]]], ["In very severe or atypical cases, HRCT of the lungs may be required to assess the extent of bronchial thickening and remodeling, the development of brochiectases and air-trapping (105) .CNS imaging and RSV infection.", [["lungs", "ANATOMY", 46, 51], ["bronchial", "ANATOMY", 92, 101], ["CNS", "ANATOMY", 186, 189], ["brochiectases", "DISEASE", 148, 161], ["air-trapping", "DISEASE", 166, 178], ["RSV infection", "DISEASE", 202, 215], ["lungs", "ORGAN", 46, 51], ["bronchial", "MULTI-TISSUE_STRUCTURE", 92, 101], ["CNS", "ANATOMICAL_SYSTEM", 186, 189], ["RSV", "ORGANISM", 202, 205], ["RSV", "SPECIES", 202, 205], ["very severe or atypical cases", "PROBLEM", 3, 32], ["HRCT of the lungs", "TEST", 34, 51], ["bronchial thickening", "PROBLEM", 92, 112], ["brochiectases", "PROBLEM", 148, 161], ["air-trapping", "PROBLEM", 166, 178], ["CNS imaging", "TEST", 186, 197], ["RSV infection", "PROBLEM", 202, 215], ["very", "OBSERVATION_MODIFIER", 3, 7], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["atypical", "OBSERVATION_MODIFIER", 18, 26], ["lungs", "ANATOMY", 46, 51], ["bronchial", "ANATOMY", 92, 101], ["thickening", "OBSERVATION", 102, 112], ["remodeling", "OBSERVATION_MODIFIER", 117, 127], ["brochiectases", "OBSERVATION", 148, 161], ["RSV", "ANATOMY", 202, 205], ["infection", "OBSERVATION", 206, 215]]], ["RSV infection is not alwaysrestricted to the airways. case reports have also described clinical pictures resembling viral encephalitis and/or encephalopathic syndromes with severe sequelae in isolated cases (112) .", [["airways", "ANATOMY", 45, 52], ["RSV infection", "DISEASE", 0, 13], ["viral encephalitis", "DISEASE", 116, 134], ["encephalopathic syndromes", "DISEASE", 142, 167], ["RSV", "ORGANISM", 0, 3], ["airways", "MULTI-TISSUE_STRUCTURE", 45, 52], ["RSV", "SPECIES", 0, 3], ["RSV infection", "PROBLEM", 0, 13], ["viral encephalitis", "PROBLEM", 116, 134], ["encephalopathic syndromes", "PROBLEM", 142, 167], ["severe sequelae in isolated cases", "PROBLEM", 173, 206], ["infection", "OBSERVATION", 4, 13], ["airways", "ANATOMY", 45, 52], ["viral encephalitis", "OBSERVATION", 116, 134], ["encephalopathic", "OBSERVATION_MODIFIER", 142, 157], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["sequelae", "OBSERVATION_MODIFIER", 180, 188]]], ["The mechanism of the spread of the RSV infection to the cNS compartment remains unclear (112) .", [["cNS compartment", "ANATOMY", 56, 71], ["RSV infection", "DISEASE", 35, 48], ["RSV", "ORGANISM", 35, 38], ["cNS compartment", "MULTI-TISSUE_STRUCTURE", 56, 71], ["RSV", "SPECIES", 35, 38], ["the RSV infection", "PROBLEM", 31, 48], ["spread", "OBSERVATION_MODIFIER", 21, 27], ["RSV", "OBSERVATION_MODIFIER", 35, 38], ["infection", "OBSERVATION", 39, 48], ["cNS", "ANATOMY", 56, 59], ["compartment", "ANATOMY_MODIFIER", 60, 71]]], ["Brain magnetic resonance imaging (MRI) in infants with cNS involvement has shown predominantly non-specific findings similar to those also encountered in other viral and/or limbic system encephalitides (113) .", [["cNS", "ANATOMY", 55, 58], ["limbic system encephalitides", "ANATOMY", 173, 201], ["viral and/or limbic system encephalitides", "DISEASE", 160, 201], ["infants", "ORGANISM", 42, 49], ["cNS", "CANCER", 55, 58], ["limbic system encephalitides", "CANCER", 173, 201], ["infants", "SPECIES", 42, 49], ["Brain magnetic resonance imaging", "TEST", 0, 32], ["MRI", "TEST", 34, 37], ["predominantly non-specific findings", "PROBLEM", 81, 116], ["predominantly", "OBSERVATION_MODIFIER", 81, 94], ["non-specific", "OBSERVATION_MODIFIER", 95, 107]]], ["In very rare instances, extra-pulmonary findings in RSV infection have also included acute necrotizing encephalopathy (ANE) and acute hepatic failure with encephalopathy (114) . clinicians should have a high suspicion of ANE in cases of children with a respiratory infection and acute neurological manifestations.Therapeutics of RSV infectionAntivirals against RSV.", [["hepatic", "ANATOMY", 134, 141], ["respiratory", "ANATOMY", 253, 264], ["neurological", "ANATOMY", 285, 297], ["RSV infection", "DISEASE", 52, 65], ["encephalopathy", "DISEASE", 103, 117], ["ANE", "DISEASE", 119, 122], ["acute hepatic failure", "DISEASE", 128, 149], ["encephalopathy", "DISEASE", 155, 169], ["ANE", "DISEASE", 221, 224], ["respiratory infection", "DISEASE", 253, 274], ["RSV infection", "DISEASE", 329, 342], ["RSV", "DISEASE", 361, 364], ["RSV", "ORGANISM", 52, 55], ["hepatic", "ORGAN", 134, 141], ["ANE", "CANCER", 221, 224], ["children", "ORGANISM", 237, 245], ["RSV", "ORGANISM", 329, 332], ["RSV", "ORGANISM", 361, 364], ["children", "SPECIES", 237, 245], ["RSV", "SPECIES", 52, 55], ["RSV", "SPECIES", 329, 332], ["RSV", "SPECIES", 361, 364], ["extra-pulmonary findings", "PROBLEM", 24, 48], ["RSV infection", "PROBLEM", 52, 65], ["acute necrotizing encephalopathy", "PROBLEM", 85, 117], ["acute hepatic failure", "PROBLEM", 128, 149], ["encephalopathy", "PROBLEM", 155, 169], ["a respiratory infection", "PROBLEM", 251, 274], ["acute neurological manifestations", "PROBLEM", 279, 312], ["RSV infection", "PROBLEM", 329, 342], ["Antivirals", "TREATMENT", 342, 352], ["RSV", "PROBLEM", 361, 364], ["very", "OBSERVATION_MODIFIER", 3, 7], ["rare", "OBSERVATION_MODIFIER", 8, 12], ["instances", "OBSERVATION", 13, 22], ["extra-pulmonary", "ANATOMY", 24, 39], ["RSV infection", "OBSERVATION", 52, 65], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["necrotizing", "OBSERVATION_MODIFIER", 91, 102], ["encephalopathy", "OBSERVATION", 103, 117], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["hepatic", "ANATOMY", 134, 141], ["failure", "OBSERVATION", 142, 149], ["encephalopathy", "OBSERVATION", 155, 169], ["respiratory", "ANATOMY", 253, 264], ["infection", "OBSERVATION", 265, 274], ["acute", "OBSERVATION_MODIFIER", 279, 284], ["RSV infection", "OBSERVATION", 329, 342]]], ["Thus far, ribavirin is the only antiviral agent that has ever been licensed for the treatment of RSV infection (115) .", [["ribavirin", "CHEMICAL", 10, 19], ["RSV infection", "DISEASE", 97, 110], ["ribavirin", "CHEMICAL", 10, 19], ["ribavirin", "SIMPLE_CHEMICAL", 10, 19], ["RSV", "ORGANISM", 97, 100], ["RSV", "SPECIES", 97, 100], ["ribavirin", "TREATMENT", 10, 19], ["antiviral agent", "TREATMENT", 32, 47], ["RSV infection", "PROBLEM", 97, 110], ["ribavirin", "OBSERVATION", 10, 19], ["RSV", "OBSERVATION_MODIFIER", 97, 100], ["infection", "OBSERVATION", 101, 110]]], ["However, its efficacy is not proven and due to significant toxicity its use has been primarily restricted to severe cases in immunocompromised patients with severe RSV-positive ALRTI (116) .", [["toxicity", "DISEASE", 59, 67], ["RSV-positive ALRTI", "DISEASE", 164, 182], ["patients", "ORGANISM", 143, 151], ["RSV", "ORGANISM", 164, 167], ["patients", "SPECIES", 143, 151], ["RSV", "SPECIES", 164, 167], ["significant toxicity", "PROBLEM", 47, 67], ["severe RSV", "PROBLEM", 157, 167], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["toxicity", "OBSERVATION", 59, 67], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["RSV", "OBSERVATION", 164, 167]]], ["Several other antiviral candidates have been developed since, but none have been licensed as yet.", [["Several other antiviral candidates", "TREATMENT", 0, 34], ["antiviral", "OBSERVATION", 14, 23]]], ["Types of molecules being tested include influenza antivirals, such as baloxavir, cc-42344, VIS410, immunoglobulin, hyperimmune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders, RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EdP-938, broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIdd-1931/EIdd-2801, as well as host directed strategies including nitazoxanide, eritoran, and diltiazem (117-119).", [["plasma", "ANATOMY", 127, 133], ["baloxavir", "CHEMICAL", 70, 79], ["cc-42344", "CHEMICAL", 81, 89], ["VIS410", "CHEMICAL", 91, 97], ["MHAA4549A", "CHEMICAL", 135, 144], ["pimodivir", "CHEMICAL", 146, 155], ["JNJ-63623872", "CHEMICAL", 157, 169], ["umifenovir", "CHEMICAL", 172, 182], ["HA minibinders", "CHEMICAL", 188, 202], ["presatovir", "CHEMICAL", 229, 239], ["GS-5806", "CHEMICAL", 241, 248], ["ziresovir", "CHEMICAL", 251, 260], ["AK0529", "CHEMICAL", 262, 268], ["lumicitabine", "CHEMICAL", 271, 283], ["ALS-008176", "CHEMICAL", 285, 295], ["JNJ-53718678", "CHEMICAL", 298, 310], ["JNJ-64417184", "CHEMICAL", 312, 324], ["EdP-938", "CHEMICAL", 330, 337], ["favipiravir", "CHEMICAL", 373, 384], ["VH244", "CHEMICAL", 386, 391], ["remdesivir", "CHEMICAL", 393, 403], ["EIdd-1931/EIdd-2801", "CHEMICAL", 409, 428], ["nitazoxanide", "CHEMICAL", 476, 488], ["eritoran", "CHEMICAL", 490, 498], ["diltiazem", "CHEMICAL", 504, 513], ["baloxavir", "CHEMICAL", 70, 79], ["cc-42344", "CHEMICAL", 81, 89], ["VIS410", "CHEMICAL", 91, 97], ["pimodivir", "CHEMICAL", 146, 155], ["JNJ-63623872", "CHEMICAL", 157, 169], ["umifenovir", "CHEMICAL", 172, 182], ["presatovir", "CHEMICAL", 229, 239], ["GS-5806", "CHEMICAL", 241, 248], ["ziresovir", "CHEMICAL", 251, 260], ["AK0529", "CHEMICAL", 262, 268], ["lumicitabine", "CHEMICAL", 271, 283], ["ALS-008176", "CHEMICAL", 285, 295], ["JNJ-53718678", "CHEMICAL", 298, 310], ["JNJ-64417184", "CHEMICAL", 312, 324], ["EdP-938", "CHEMICAL", 330, 337], ["favipiravir", "CHEMICAL", 373, 384], ["VH244", "CHEMICAL", 386, 391], ["remdesivir", "CHEMICAL", 393, 403], ["EIdd-1931", "CHEMICAL", 409, 418], ["EIdd-2801", "CHEMICAL", 419, 428], ["nitazoxanide", "CHEMICAL", 476, 488], ["eritoran", "CHEMICAL", 490, 498], ["diltiazem", "CHEMICAL", 504, 513], ["baloxavir", "SIMPLE_CHEMICAL", 70, 79], ["cc-42344", "SIMPLE_CHEMICAL", 81, 89], ["VIS410", "SIMPLE_CHEMICAL", 91, 97], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 99, 113], ["hyperimmune", "ORGANISM", 115, 126], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["MHAA4549A", "SIMPLE_CHEMICAL", 135, 144], ["pimodivir", "SIMPLE_CHEMICAL", 146, 155], ["JNJ-63623872", "SIMPLE_CHEMICAL", 157, 169], ["umifenovir", "SIMPLE_CHEMICAL", 172, 182], ["HA minibinders", "SIMPLE_CHEMICAL", 188, 202], ["RSV", "ORGANISM", 204, 207], ["presatovir", "SIMPLE_CHEMICAL", 229, 239], ["GS-5806", "SIMPLE_CHEMICAL", 241, 248], ["ziresovir", "SIMPLE_CHEMICAL", 251, 260], ["AK0529", "SIMPLE_CHEMICAL", 262, 268], ["lumicitabine", "SIMPLE_CHEMICAL", 271, 283], ["ALS-008176", "SIMPLE_CHEMICAL", 285, 295], ["JNJ-53718678", "SIMPLE_CHEMICAL", 298, 310], ["JNJ-64417184", "SIMPLE_CHEMICAL", 312, 324], ["EdP-938", "SIMPLE_CHEMICAL", 330, 337], ["favipiravir", "SIMPLE_CHEMICAL", 373, 384], ["VH244", "SIMPLE_CHEMICAL", 386, 391], ["remdesivir", "SIMPLE_CHEMICAL", 393, 403], ["EIdd-1931", "SIMPLE_CHEMICAL", 409, 418], ["EIdd-2801", "CELL", 419, 428], ["nitazoxanide", "SIMPLE_CHEMICAL", 476, 488], ["eritoran", "SIMPLE_CHEMICAL", 490, 498], ["diltiazem", "SIMPLE_CHEMICAL", 504, 513], ["immunoglobulin", "PROTEIN", 99, 113], ["hyperimmune", "SPECIES", 115, 126], ["RSV", "SPECIES", 204, 207], ["JNJ-53718678, JNJ-64417184", "SPECIES", 298, 324], ["EIdd-1931/EIdd-2801", "SPECIES", 409, 428], ["Types of molecules", "PROBLEM", 0, 18], ["influenza antivirals", "TREATMENT", 40, 60], ["baloxavir", "TEST", 70, 79], ["VIS410", "TREATMENT", 91, 97], ["immunoglobulin", "TREATMENT", 99, 113], ["hyperimmune plasma", "TREATMENT", 115, 133], ["MHAA4549A", "TREATMENT", 135, 144], ["pimodivir (JNJ", "TREATMENT", 146, 160], ["umifenovir", "TREATMENT", 172, 182], ["HA minibinders", "TREATMENT", 188, 202], ["RSV antivirals", "TREATMENT", 204, 218], ["presatovir", "TREATMENT", 229, 239], ["ziresovir", "TREATMENT", 251, 260], ["lumicitabine", "TREATMENT", 271, 283], ["EdP", "TEST", 330, 333], ["broad spectrum antivirals", "TREATMENT", 339, 364], ["favipiravir", "TREATMENT", 373, 384], ["VH244", "TREATMENT", 386, 391], ["remdesivir", "TREATMENT", 393, 403], ["nitazoxanide", "TREATMENT", 476, 488], ["eritoran", "TREATMENT", 490, 498], ["diltiazem", "TREATMENT", 504, 513]]], ["Novel molecules disrupt various stages of the virus life cycle, including cell entry, viral replication, and polymerization as well as after virus release through RSV neutralizing anti-or nanobodies (120) .Therapeutics of RSV infectionThe human challenge models.", [["cell", "ANATOMY", 74, 78], ["RSV infection", "DISEASE", 222, 235], ["cell", "CELL", 74, 78], ["RSV", "ORGANISM", 163, 166], ["RSV", "ORGANISM", 222, 225], ["human", "ORGANISM", 239, 244], ["human", "SPECIES", 239, 244], ["RSV", "SPECIES", 163, 166], ["RSV", "SPECIES", 222, 225], ["human", "SPECIES", 239, 244], ["Novel molecules", "PROBLEM", 0, 15], ["the virus life cycle", "TREATMENT", 42, 62], ["cell entry", "PROBLEM", 74, 84], ["viral replication", "TREATMENT", 86, 103], ["polymerization", "TREATMENT", 109, 123], ["RSV neutralizing anti-or nanobodies", "TREATMENT", 163, 198], ["RSV infection", "PROBLEM", 222, 235], ["viral replication", "OBSERVATION", 86, 103], ["RSV infection", "OBSERVATION", 222, 235]]], ["One method used occasionally in phase 2 clinical testing is human challenge models (115) .", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["clinical testing", "TEST", 40, 56]]], ["This method was used in Phase 2a clinical testing of the non-fusion inhibitor EDP-938 (ClinicalTrials.gov Identifier: NcT03691623).", [["EDP-938", "CHEMICAL", 78, 85], ["EDP-938", "CHEMICAL", 78, 85], ["EDP-938", "SIMPLE_CHEMICAL", 78, 85]]], ["All participants were inoculated with a known strain of RSV and were then randomized to receive the medication or placebo.", [["participants", "ORGANISM", 4, 16], ["RSV", "ORGANISM", 56, 59], ["participants", "SPECIES", 4, 16], ["RSV", "SPECIES", 56, 59], ["a known strain of RSV", "PROBLEM", 38, 59], ["the medication", "TREATMENT", 96, 110], ["placebo", "TREATMENT", 114, 121]]], ["The advantage of this methodology is the removal of the variability in exposure with natural infection and the collection of samples at precise, known times after infection, which can aid with the understanding of the biological mechanisms of the infection and development of antiviral agents or vaccines (121, 122) . due to ethical and technical constraints, experimental studies are only undertaken in adults, but if a product is shown to be efficacious at this setting, a faster move to trials in paediatrics takes place than in traditional childhood trials.Therapeutics of RSV infectionRSV therapeutics and personalized medicine.", [["samples", "ANATOMY", 125, 132], ["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 163, 172], ["infection", "DISEASE", 247, 256], ["RSV", "ORGANISM", 577, 580], ["RSV", "SPECIES", 577, 580], ["this methodology", "TREATMENT", 17, 33], ["the removal", "TREATMENT", 37, 48], ["natural infection", "PROBLEM", 85, 102], ["infection", "PROBLEM", 163, 172], ["the infection", "PROBLEM", 243, 256], ["antiviral agents", "TREATMENT", 276, 292], ["vaccines", "TREATMENT", 296, 304], ["ethical and technical constraints", "PROBLEM", 325, 358], ["experimental studies", "TEST", 360, 380], ["RSV infectionRSV therapeutics", "TREATMENT", 577, 606], ["personalized medicine", "TREATMENT", 611, 632], ["infection", "OBSERVATION", 93, 102], ["infection", "OBSERVATION", 163, 172], ["infection", "OBSERVATION", 247, 256], ["RSV infectionRSV", "OBSERVATION", 577, 593]]], ["The current clinical data indicate that RSV disease dynamics may not be identical in all patients (2, 3, 115, 119) .", [["RSV disease", "DISEASE", 40, 51], ["RSV", "ORGANISM", 40, 43], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["RSV", "SPECIES", 40, 43], ["RSV disease dynamics", "PROBLEM", 40, 60], ["RSV disease", "OBSERVATION", 40, 51], ["may not be", "UNCERTAINTY", 61, 71]]], ["More research is needed to identify uniform clinical endpoints reflecting how patients function, thrive, and survive (US Food and drug Administration) and to understand inter-individual differences in disease presentation, with the goal of ultimately selecting the right treatment for the right patient.", [["patients", "ORGANISM", 78, 86], ["patient", "ORGANISM", 295, 302], ["patients", "SPECIES", 78, 86], ["patient", "SPECIES", 295, 302], ["drug Administration", "TREATMENT", 130, 149], ["the right treatment", "TREATMENT", 261, 280], ["right", "ANATOMY_MODIFIER", 265, 270], ["right", "ANATOMY_MODIFIER", 289, 294]]], ["A greater understanding of individual differences may ultimately lead to future personalized treatment strategies.", [["personalized treatment strategies", "TREATMENT", 80, 113], ["greater", "OBSERVATION_MODIFIER", 2, 9]]], ["Individualized approaches and a well-standardized methodology to assess disease severity at the time of enrolment, as well as during follow-up visits, will require integration of diagnostic, clinical and laboratory markers at the point of care (115) .", [["disease severity", "PROBLEM", 72, 88], ["laboratory markers", "TEST", 204, 222]]], ["Individualized targeted treatment will constitute an important step in improving outcomes in patients with RSV infection while minimizing toxicity.", [["RSV infection", "DISEASE", 107, 120], ["toxicity", "DISEASE", 138, 146], ["patients", "ORGANISM", 93, 101], ["RSV", "ORGANISM", 107, 110], ["patients", "SPECIES", 93, 101], ["RSV", "SPECIES", 107, 110], ["Individualized targeted treatment", "TREATMENT", 0, 33], ["RSV infection", "PROBLEM", 107, 120], ["minimizing toxicity", "PROBLEM", 127, 146], ["infection", "OBSERVATION", 111, 120]]], ["A greater understanding of individual data in newly developed pharmaceutical agents against RSV will potentially lead to future personalized treatment regimens.", [["RSV", "DISEASE", 92, 95], ["RSV", "ORGANISM", 92, 95], ["RSV", "SPECIES", 92, 95], ["pharmaceutical agents", "TREATMENT", 62, 83], ["RSV", "PROBLEM", 92, 95], ["personalized treatment regimens", "TREATMENT", 128, 159], ["greater", "OBSERVATION_MODIFIER", 2, 9]]], ["Applying such co-ordinated diagnostic, clinical and research efforts constitutes an important step in advancing paediatric care, improving outcomes and limiting global RSV morbidity and mortality.High-flow nasal cannula and RSV-positive bronchiolitis.Over the last decade, high-flow nasal cannula (HFNC) therapy has emerged as a new method to provide respiratory support in children with RSV-positive bronchiolitis (12, (123) (124) (125) (126) .", [["nasal", "ANATOMY", 206, 211], ["nasal", "ANATOMY", 283, 288], ["respiratory", "ANATOMY", 351, 362], ["bronchiolitis", "DISEASE", 237, 250], ["HFNC", "CHEMICAL", 298, 302], ["bronchiolitis", "DISEASE", 401, 414], ["RSV", "ORGANISM", 168, 171], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 206, 219], ["RSV", "ORGANISM", 224, 227], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 283, 296], ["children", "ORGANISM", 374, 382], ["RSV", "ORGANISM", 388, 391], ["children", "SPECIES", 374, 382], ["RSV", "SPECIES", 168, 171], ["RSV", "SPECIES", 224, 227], ["RSV", "SPECIES", 388, 391], ["advancing paediatric care", "TREATMENT", 102, 127], ["global RSV morbidity", "PROBLEM", 161, 181], ["High-flow nasal cannula", "TREATMENT", 196, 219], ["RSV", "PROBLEM", 224, 227], ["positive bronchiolitis", "PROBLEM", 228, 250], ["high-flow nasal cannula (HFNC", "TREATMENT", 273, 302], ["therapy", "TREATMENT", 304, 311], ["a new method", "TREATMENT", 327, 339], ["respiratory support", "TREATMENT", 351, 370], ["RSV", "PROBLEM", 388, 391], ["positive bronchiolitis", "PROBLEM", 392, 414], ["RSV morbidity", "OBSERVATION", 168, 181], ["flow nasal cannula", "OBSERVATION", 201, 219], ["RSV", "OBSERVATION", 224, 227], ["positive", "OBSERVATION_MODIFIER", 228, 236], ["bronchiolitis", "OBSERVATION", 237, 250], ["flow nasal cannula", "OBSERVATION", 278, 296], ["positive", "OBSERVATION_MODIFIER", 392, 400], ["bronchiolitis", "OBSERVATION", 401, 414]]], ["Its main advantages include its ease to set up and the fact that it is well tolerated, leading to better compliance, especially in comparison to other devices of non-invasive ventilation (125, 127) .", [["non-invasive ventilation", "TEST", 162, 186], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Initially, HFNc was trialed in infants with moderate to severe bronchiolitis admitted to PIcUs, but nowadays its application has expanded to paediatric wards, even to emergency departments, in order to avoid a PIcU admission (127, 128) .", [["bronchiolitis", "DISEASE", 63, 76], ["PIcU", "DISEASE", 210, 214], ["HFNc", "SIMPLE_CHEMICAL", 11, 15], ["infants", "ORGANISM", 31, 38], ["infants", "SPECIES", 31, 38], ["HFNc", "TREATMENT", 11, 15], ["moderate to severe bronchiolitis", "PROBLEM", 44, 76], ["moderate", "OBSERVATION_MODIFIER", 44, 52], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["bronchiolitis", "OBSERVATION", 63, 76]]], ["Recent data have shown that it does not significantly reduce time on oxygen compared with standard therapy, suggesting that early use of HFNc does not modify the underlying disease process (129) .", [["oxygen", "CHEMICAL", 69, 75], ["HFNc", "CHEMICAL", 137, 141], ["oxygen", "CHEMICAL", 69, 75], ["HFNc", "CHEMICAL", 137, 141], ["oxygen", "SIMPLE_CHEMICAL", 69, 75], ["HFNc", "SIMPLE_CHEMICAL", 137, 141], ["Recent data", "TEST", 0, 11], ["oxygen", "TREATMENT", 69, 75], ["standard therapy", "TREATMENT", 90, 106], ["HFNc", "TREATMENT", 137, 141], ["the underlying disease process", "PROBLEM", 158, 188], ["disease", "OBSERVATION", 173, 180]]], ["However, the proportion of children who experi-ence treatment failure is lower in HFNc and many of those who experience treatment failure on standard therapy can be rescued by HFNc.", [["children", "ORGANISM", 27, 35], ["HFNc", "CANCER", 82, 86], ["children", "SPECIES", 27, 35], ["treatment failure", "PROBLEM", 52, 69], ["treatment failure", "PROBLEM", 120, 137], ["standard therapy", "TREATMENT", 141, 157], ["HFNc", "TREATMENT", 176, 180], ["failure", "OBSERVATION", 62, 69], ["lower", "OBSERVATION_MODIFIER", 73, 78]]], ["Additional studies comparing HFNc with continuous positive airway pressure (cPAP) in the PIcU setting led to the same conclusion (130, 131) . consequently, HFNc may reduce the need for intubation and invasive respiratory support, thus potentially lowering costs and adverse effects of mechanical ventilation, such as ventilator-induced lung injury, infections and exposure to sedatives.", [["airway", "ANATOMY", 59, 65], ["respiratory", "ANATOMY", 209, 220], ["lung", "ANATOMY", 336, 340], ["HFNc", "CHEMICAL", 156, 160], ["ventilator-induced lung injury", "DISEASE", 317, 347], ["infections", "DISEASE", 349, 359], ["HFNc", "SIMPLE_CHEMICAL", 29, 33], ["airway", "MULTI-TISSUE_STRUCTURE", 59, 65], ["HFNc", "SIMPLE_CHEMICAL", 156, 160], ["lung", "ORGAN", 336, 340], ["Additional studies", "TEST", 0, 18], ["HFNc", "TREATMENT", 29, 33], ["continuous positive airway pressure", "TREATMENT", 39, 74], ["PAP", "TEST", 77, 80], ["HFNc", "TREATMENT", 156, 160], ["intubation", "TREATMENT", 185, 195], ["invasive respiratory support", "TREATMENT", 200, 228], ["mechanical ventilation", "TREATMENT", 285, 307], ["ventilator", "TREATMENT", 317, 327], ["lung injury", "PROBLEM", 336, 347], ["infections", "PROBLEM", 349, 359], ["sedatives", "TREATMENT", 376, 385], ["airway pressure", "OBSERVATION", 59, 74], ["mechanical ventilation", "OBSERVATION", 285, 307], ["lung", "ANATOMY", 336, 340], ["injury", "OBSERVATION", 341, 347], ["infections", "OBSERVATION", 349, 359]]], ["In addition to effectiveness, most studies have shown no adverse events with HFNc and have concluded that it is a relative safe method for use even in general wards or emergency departments (123) .", [["most studies", "TEST", 30, 42], ["adverse events", "PROBLEM", 57, 71], ["HFNc", "TREATMENT", 77, 81]]], ["Few cases of pneumothorax have been reported, abdominal distension has been less significant compared with CPAP, and the majority of infants have been able to be fed orally or by nasogastric tube (123, 127) .High-flow nasal cannula and RSV-positive bronchiolitis.Heliox and RSV-positive bronchiolitis.", [["abdominal", "ANATOMY", 46, 55], ["nasal", "ANATOMY", 218, 223], ["pneumothorax", "DISEASE", 13, 25], ["abdominal distension", "DISEASE", 46, 66], ["bronchiolitis", "DISEASE", 249, 262], ["Heliox", "CHEMICAL", 263, 269], ["bronchiolitis", "DISEASE", 287, 300], ["abdominal", "ORGANISM_SUBDIVISION", 46, 55], ["infants", "ORGANISM", 133, 140], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 179, 195], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 218, 231], ["RSV", "ORGANISM", 236, 239], ["Heliox", "SIMPLE_CHEMICAL", 263, 269], ["RSV", "ORGANISM", 274, 277], ["infants", "SPECIES", 133, 140], ["RSV", "SPECIES", 236, 239], ["RSV", "SPECIES", 274, 277], ["pneumothorax", "PROBLEM", 13, 25], ["abdominal distension", "PROBLEM", 46, 66], ["CPAP", "TREATMENT", 107, 111], ["High-flow nasal cannula", "TREATMENT", 208, 231], ["RSV", "PROBLEM", 236, 239], ["positive bronchiolitis", "PROBLEM", 240, 262], ["Heliox", "TREATMENT", 263, 269], ["RSV", "PROBLEM", 274, 277], ["positive bronchiolitis", "PROBLEM", 278, 300], ["pneumothorax", "OBSERVATION", 13, 25], ["abdominal", "ANATOMY", 46, 55], ["distension", "OBSERVATION", 56, 66], ["less", "OBSERVATION_MODIFIER", 76, 80], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["nasogastric tube", "OBSERVATION", 179, 195], ["flow nasal cannula", "OBSERVATION", 213, 231], ["RSV", "OBSERVATION", 236, 239], ["positive", "OBSERVATION_MODIFIER", 240, 248], ["bronchiolitis", "OBSERVATION", 249, 262], ["RSV", "OBSERVATION", 274, 277], ["positive", "OBSERVATION_MODIFIER", 278, 286], ["bronchiolitis", "OBSERVATION", 287, 300]]], ["Since RSV-positive bronchiolitis is associated with airway obstruction and turbulent gas flow, its clinical course can be improved by Heliox, which facilitates gas flow through high-resistance airways (132) (133) (134) (135) (136) (137) (138) .", [["airway", "ANATOMY", 52, 58], ["airways", "ANATOMY", 193, 200], ["bronchiolitis", "DISEASE", 19, 32], ["airway obstruction", "DISEASE", 52, 70], ["Heliox", "CHEMICAL", 134, 140], ["RSV", "ORGANISM", 6, 9], ["airway", "MULTI-TISSUE_STRUCTURE", 52, 58], ["Heliox", "SIMPLE_CHEMICAL", 134, 140], ["airways", "MULTI-TISSUE_STRUCTURE", 193, 200], ["RSV", "SPECIES", 6, 9], ["RSV", "PROBLEM", 6, 9], ["positive bronchiolitis", "PROBLEM", 10, 32], ["airway obstruction", "PROBLEM", 52, 70], ["turbulent gas flow", "PROBLEM", 75, 93], ["Heliox", "TREATMENT", 134, 140], ["gas flow", "TEST", 160, 168], ["high-resistance airways", "PROBLEM", 177, 200], ["positive", "OBSERVATION_MODIFIER", 10, 18], ["bronchiolitis", "OBSERVATION", 19, 32], ["associated with", "UNCERTAINTY", 36, 51], ["airway", "ANATOMY", 52, 58], ["obstruction", "OBSERVATION", 59, 70], ["turbulent", "OBSERVATION_MODIFIER", 75, 84], ["gas flow", "OBSERVATION", 85, 93], ["gas flow", "OBSERVATION", 160, 168], ["high", "OBSERVATION_MODIFIER", 177, 181], ["airways", "ANATOMY", 193, 200]]], ["Heliox is a mixture of helium-oxygen, which can be administered by all modes of ventilation in spontaneously breathing patients by face mask, HFNc or CPAP, and can be adjusted to specific ventilators in intubated children. current evidence suggests that the addition of Heliox may significantly reduce clinical scores evaluating respiratory distress and the respiratory rate, and may enhance cO 2 elimination in the first hour after starting treatment in infants with acute refractory RSV bronchiolitis (134, 139) .", [["respiratory", "ANATOMY", 329, 340], ["respiratory", "ANATOMY", 358, 369], ["Heliox", "CHEMICAL", 0, 6], ["helium-oxygen", "CHEMICAL", 23, 36], ["Heliox", "CHEMICAL", 270, 276], ["respiratory distress", "DISEASE", 329, 349], ["RSV bronchiolitis", "DISEASE", 485, 502], ["Heliox", "CHEMICAL", 0, 6], ["helium", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 30, 36], ["cO 2", "CHEMICAL", 392, 396], ["Heliox", "SIMPLE_CHEMICAL", 0, 6], ["helium-oxygen", "SIMPLE_CHEMICAL", 23, 36], ["patients", "ORGANISM", 119, 127], ["children", "ORGANISM", 213, 221], ["Heliox", "SIMPLE_CHEMICAL", 270, 276], ["cO 2", "GENE_OR_GENE_PRODUCT", 392, 396], ["infants", "ORGANISM", 455, 462], ["RSV", "ORGANISM", 485, 488], ["patients", "SPECIES", 119, 127], ["children", "SPECIES", 213, 221], ["infants", "SPECIES", 455, 462], ["RSV", "SPECIES", 485, 488], ["Heliox", "TREATMENT", 0, 6], ["helium-oxygen", "TREATMENT", 23, 36], ["ventilation", "TREATMENT", 80, 91], ["face mask", "TREATMENT", 131, 140], ["HFNc", "TREATMENT", 142, 146], ["CPAP", "TREATMENT", 150, 154], ["Heliox", "TREATMENT", 270, 276], ["clinical scores", "TEST", 302, 317], ["respiratory distress", "PROBLEM", 329, 349], ["the respiratory rate", "TEST", 354, 374], ["treatment", "TREATMENT", 442, 451], ["acute refractory RSV bronchiolitis", "PROBLEM", 468, 502], ["respiratory rate", "OBSERVATION", 358, 374], ["acute", "OBSERVATION_MODIFIER", 468, 473], ["refractory", "OBSERVATION_MODIFIER", 474, 484], ["RSV bronchiolitis", "OBSERVATION", 485, 502]]], ["Recently, Seliem and Sultan (140) reported that Heliox results in improvement of oxygenation when used with high flow nasal cannula in infants with acute RSV bronchiolitis, during the initial phase of therapy.", [["nasal", "ANATOMY", 118, 123], ["Heliox", "CHEMICAL", 48, 54], ["bronchiolitis", "DISEASE", 158, 171], ["Heliox", "SIMPLE_CHEMICAL", 48, 54], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 118, 131], ["RSV", "ORGANISM", 154, 157], ["infants", "SPECIES", 135, 142], ["RSV", "SPECIES", 154, 157], ["Heliox", "TREATMENT", 48, 54], ["high flow nasal cannula", "TREATMENT", 108, 131], ["acute RSV bronchiolitis", "PROBLEM", 148, 171], ["therapy", "TREATMENT", 201, 208], ["oxygenation", "OBSERVATION_MODIFIER", 81, 92], ["nasal cannula", "OBSERVATION", 118, 131], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["RSV bronchiolitis", "OBSERVATION", 154, 171]]], ["The combination of Heliox with CPAP also seems to be beneficial, as the application of CPAP may reduce the fiO 2 needed in these infants.", [["Heliox", "CHEMICAL", 19, 25], ["Heliox", "CHEMICAL", 19, 25], ["CPAP", "CHEMICAL", 31, 35], ["CPAP", "CHEMICAL", 87, 91], ["Heliox", "SIMPLE_CHEMICAL", 19, 25], ["CPAP", "SIMPLE_CHEMICAL", 31, 35], ["infants", "ORGANISM", 129, 136], ["infants", "SPECIES", 129, 136], ["Heliox", "TREATMENT", 19, 25], ["CPAP", "TREATMENT", 31, 35], ["CPAP", "TREATMENT", 87, 91], ["the fiO", "TREATMENT", 103, 110]]], ["However, no benefit has been observed in terms of need for intubation and mechanical ventilation, length of treatment or PIcU stay.", [["intubation", "TREATMENT", 59, 69], ["mechanical ventilation", "TREATMENT", 74, 96], ["treatment", "TREATMENT", 108, 117], ["no", "UNCERTAINTY", 9, 11]]], ["In addition, its application in the emergency department does not change the discharge rate (138, 139) .", [["the discharge rate", "TEST", 73, 91]]], ["More clinical trials are needed to define the population that may respond to Heliox and its place in the therapeutic regimens of RSV bronchiolitis.Prevention of RSV infectionPassive immunization and Palivizumab.", [["Heliox", "CHEMICAL", 77, 83], ["bronchiolitis", "DISEASE", 133, 146], ["RSV infectionPassive", "DISEASE", 161, 181], ["Palivizumab", "CHEMICAL", 199, 210], ["Heliox", "CHEMICAL", 77, 83], ["Palivizumab", "CHEMICAL", 199, 210], ["Heliox", "SIMPLE_CHEMICAL", 77, 83], ["RSV", "ORGANISM", 129, 132], ["RSV", "ORGANISM", 161, 164], ["Palivizumab", "SIMPLE_CHEMICAL", 199, 210], ["RSV", "SPECIES", 161, 164], ["RSV", "SPECIES", 129, 132], ["RSV", "SPECIES", 161, 164], ["Heliox", "TREATMENT", 77, 83], ["RSV bronchiolitis", "PROBLEM", 129, 146], ["RSV infectionPassive immunization", "TREATMENT", 161, 194], ["Palivizumab", "TREATMENT", 199, 210], ["RSV bronchiolitis", "OBSERVATION", 129, 146], ["RSV", "OBSERVATION", 161, 164]]], ["The prevention of RSV morbidity and mortality remains a global healthcare priority (115, 141) .", [["RSV", "DISEASE", 18, 21], ["RSV", "ORGANISM", 18, 21], ["RSV", "SPECIES", 18, 21], ["RSV morbidity", "PROBLEM", 18, 31], ["RSV morbidity", "OBSERVATION", 18, 31]]], ["According to the World Health Organization (WHO), the strategic focus for the prevention of RSV infection in children and adults includes the passive administration of immunoglobulins, as well as active immunization.", [["RSV infection", "DISEASE", 92, 105], ["RSV", "ORGANISM", 92, 95], ["children", "ORGANISM", 109, 117], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 168, 183], ["immunoglobulins", "PROTEIN", 168, 183], ["children", "SPECIES", 109, 117], ["RSV", "SPECIES", 92, 95], ["RSV infection", "PROBLEM", 92, 105], ["the passive administration of immunoglobulins", "TREATMENT", 138, 183], ["active immunization", "TREATMENT", 196, 215], ["RSV", "OBSERVATION_MODIFIER", 92, 95], ["infection", "OBSERVATION", 96, 105]]], ["Passive immunization is currently the only option available to infants less than 6 months of age, which can be achieved through administration of antibodies to the infant or through active immunization of the mother during pregnancy.", [["infants", "ORGANISM", 63, 70], ["infant", "ORGANISM", 164, 170], ["antibodies", "PROTEIN", 146, 156], ["infants", "SPECIES", 63, 70], ["infant", "SPECIES", 164, 170], ["Passive immunization", "TREATMENT", 0, 20], ["antibodies", "TREATMENT", 146, 156], ["active immunization", "TREATMENT", 182, 201]]], ["Passive immunity wanes fast over time, thus, active immunization is the preferred approach for infants above six months of age, as well as older children and adults, including the elderly (141).", [["infants", "ORGANISM", 95, 102], ["children", "ORGANISM", 145, 153], ["infants", "SPECIES", 95, 102], ["children", "SPECIES", 145, 153], ["active immunization", "TREATMENT", 45, 64]]], ["To date, there is only one product available for prevention of RSV infection, palivizumab, the monoclonal antibody (mAb) that has been shown to reduce hospital admission due to RSV infection in some high-risk infants by up to 80% (142) .", [["RSV infection", "DISEASE", 63, 76], ["palivizumab", "CHEMICAL", 78, 89], ["RSV infection", "DISEASE", 177, 190], ["RSV", "ORGANISM", 63, 66], ["palivizumab", "SIMPLE_CHEMICAL", 78, 89], ["RSV", "ORGANISM", 177, 180], ["infants", "ORGANISM", 209, 216], ["monoclonal antibody", "PROTEIN", 95, 114], ["mAb", "PROTEIN", 116, 119], ["infants", "SPECIES", 209, 216], ["RSV", "SPECIES", 63, 66], ["RSV", "SPECIES", 177, 180], ["RSV infection", "PROBLEM", 63, 76], ["palivizumab", "TREATMENT", 78, 89], ["the monoclonal antibody (mAb", "TREATMENT", 91, 119], ["RSV infection", "PROBLEM", 177, 190], ["RSV", "ANATOMY", 63, 66], ["infection", "OBSERVATION", 67, 76], ["RSV", "OBSERVATION_MODIFIER", 177, 180], ["infection", "OBSERVATION", 181, 190]]], ["It is expensive and, thus, reserved for high risk infants, mainly in high income countries.Prevention of RSV infectionActive immunization against RSV: looking back to the past.", [["RSV", "DISEASE", 146, 149], ["infants", "ORGANISM", 50, 57], ["RSV", "ORGANISM", 105, 108], ["RSV", "ORGANISM", 146, 149], ["infants", "SPECIES", 50, 57], ["RSV", "SPECIES", 105, 108], ["RSV", "SPECIES", 146, 149], ["high risk infants", "PROBLEM", 40, 57], ["RSV infectionActive immunization", "TREATMENT", 105, 137], ["RSV", "PROBLEM", 146, 149], ["RSV", "OBSERVATION", 105, 108]]], ["While antibodies are costly and transitory in their effect, active vaccination would represent the most cost-effective approach for the prevention of RSV infections and their transmission to high-risk individuals (115, 141) .", [["RSV infections", "DISEASE", 150, 164], ["RSV", "ORGANISM", 150, 153], ["antibodies", "PROTEIN", 6, 16], ["RSV", "SPECIES", 150, 153], ["active vaccination", "TREATMENT", 60, 78], ["RSV infections", "PROBLEM", 150, 164], ["RSV", "OBSERVATION", 150, 153]]], ["Up to date, several vaccine candidates are in development, but none have reached licensure yet (143, 144) .", [["several vaccine candidates", "TREATMENT", 12, 38]]], ["One of the main barriers for the development of RSV vaccines has been the fact that the majority of severe cases in infants occur within the first three months of life, i.e. at a time when active immunization is not really possible (145) .", [["RSV", "ORGANISM", 48, 51], ["infants", "ORGANISM", 116, 123], ["infants", "SPECIES", 116, 123], ["RSV", "SPECIES", 48, 51], ["RSV vaccines", "TREATMENT", 48, 60], ["severe cases in infants", "PROBLEM", 100, 123], ["active immunization", "TREATMENT", 189, 208], ["main", "OBSERVATION_MODIFIER", 11, 15], ["RSV", "OBSERVATION", 48, 51], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["cases", "OBSERVATION", 107, 112]]], ["Additional caution has been employed during vaccine design because of the failure of a historical vaccine [formalin inactivated RSV (FI-RSV)], which triggered a severe adverse effect, enhanced respiratory disease (ERd) (146) .", [["respiratory", "ANATOMY", 193, 204], ["formalin", "CHEMICAL", 107, 115], ["respiratory disease", "DISEASE", 193, 212], ["formalin", "CHEMICAL", 107, 115], ["RSV", "ORGANISM", 128, 131], ["FI-RSV", "ORGANISM", 133, 139], ["RSV", "SPECIES", 128, 131], ["RSV", "SPECIES", 136, 139], ["vaccine design", "TREATMENT", 44, 58], ["the failure", "PROBLEM", 70, 81], ["a historical vaccine", "TREATMENT", 85, 105], ["formalin inactivated RSV", "TREATMENT", 107, 131], ["a severe adverse effect", "PROBLEM", 159, 182], ["enhanced respiratory disease", "PROBLEM", 184, 212], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["adverse effect", "OBSERVATION", 168, 182], ["respiratory disease", "OBSERVATION", 193, 212]]], ["For more than 50 years live-attenuated vaccine approaches have been unsuccessful because of the difficulty in balancing immunogenicity and vaccine safety.", [["attenuated vaccine approaches", "TREATMENT", 28, 57], ["the difficulty in balancing immunogenicity", "PROBLEM", 92, 134], ["vaccine safety", "TREATMENT", 139, 153]]], ["It is worth noting that only live-attenuated vaccines have been tested for active infant immunization.Prevention of RSV infectionActive immunization against RSV: perspectives.", [["RSV", "DISEASE", 157, 160], ["RSV", "ORGANISM", 116, 119], ["RSV", "ORGANISM", 157, 160], ["RSV", "SPECIES", 116, 119], ["RSV", "SPECIES", 157, 160], ["live-attenuated vaccines", "TREATMENT", 29, 53], ["active infant immunization", "TREATMENT", 75, 101], ["RSV infectionActive immunization", "TREATMENT", 116, 148], ["RSV", "OBSERVATION", 116, 119]]], ["Recent breakthroughs in determining the structure and antigenic content of the RSV fusion (F) glycoprotein has enhanced interest in vaccine development research (115, 141, 147, 148) .", [["RSV", "ORGANISM", 79, 82], ["RSV fusion (F) glycoprotein", "PROTEIN", 79, 106], ["RSV", "SPECIES", 79, 82], ["Recent breakthroughs", "PROBLEM", 0, 20], ["the RSV fusion", "TREATMENT", 75, 89], ["breakthroughs", "OBSERVATION", 7, 20], ["antigenic content", "OBSERVATION", 54, 71], ["RSV fusion", "OBSERVATION", 79, 89]]], ["The general approaches to vaccine development include engineered viruses that use knowledge of RSV gene function, naturally attenuated chimeric virus combining genes from RSV-related viruses, viral vectors encoding RSV surface antigens, and nucleic acid vaccines using plasmid dNA or messenger RNA encoding RSV antigens (149, 150) .", [["surface", "ANATOMY", 219, 226], ["nucleic acid", "CHEMICAL", 241, 253], ["RSV", "ORGANISM", 95, 98], ["chimeric virus", "ORGANISM", 135, 149], ["RSV-related viruses", "ORGANISM", 171, 190], ["RSV surface antigens", "GENE_OR_GENE_PRODUCT", 215, 235], ["RSV", "ORGANISM", 307, 310], ["RSV surface antigens", "PROTEIN", 215, 235], ["plasmid dNA", "DNA", 269, 280], ["messenger RNA", "RNA", 284, 297], ["RSV antigens", "PROTEIN", 307, 319], ["RSV", "SPECIES", 95, 98], ["RSV", "SPECIES", 171, 174], ["RSV", "SPECIES", 215, 218], ["RSV", "SPECIES", 307, 310], ["vaccine development", "TREATMENT", 26, 45], ["engineered viruses", "PROBLEM", 54, 72], ["RSV gene function", "PROBLEM", 95, 112], ["naturally attenuated chimeric virus", "PROBLEM", 114, 149], ["RSV", "PROBLEM", 171, 174], ["related viruses", "PROBLEM", 175, 190], ["viral vectors", "TREATMENT", 192, 205], ["RSV surface antigens", "TREATMENT", 215, 235], ["nucleic acid vaccines", "TREATMENT", 241, 262], ["plasmid dNA", "TREATMENT", 269, 280], ["messenger RNA encoding RSV antigens", "PROBLEM", 284, 319]]], ["As of August 2019, 43 RSV vaccines were in development (151).", [["RSV", "ORGANISM", 22, 25], ["RSV", "SPECIES", 22, 25], ["RSV vaccines", "TREATMENT", 22, 34]]], ["Of these, 21 are in clinical trials in humans; 14 in Phase 1, five in Phase 2 and two (one just completed) in Phase 3.", [["humans", "ORGANISM", 39, 45], ["humans", "SPECIES", 39, 45], ["humans", "SPECIES", 39, 45]]], ["Twelve vaccines are in trials in children, four in pregnant women and 10 in older adults (some products are undergoing trials in more than one target population).", [["children", "ORGANISM", 33, 41], ["women", "ORGANISM", 60, 65], ["children", "SPECIES", 33, 41], ["women", "SPECIES", 60, 65], ["Twelve vaccines", "TREATMENT", 0, 15], ["trials", "TREATMENT", 119, 125]]], ["Vaccine types under investigation include live-attenuated/chimeric, particle-based, subunit and recombinant vector vaccines.", [["chimeric, particle-based, subunit", "PROTEIN", 58, 91], ["Vaccine", "TREATMENT", 0, 7], ["subunit and recombinant vector vaccines", "TREATMENT", 84, 123]]], ["This highlights the variety and breadth of immunization types and different populations that are being investigated to find an answer to the 60-year-old problem of producing a safe and effective RSV prophylactic agent.Prevention of RSV infectionThe ResVax.", [["RSV infection", "DISEASE", 232, 245], ["RSV", "ORGANISM", 195, 198], ["RSV", "ORGANISM", 232, 235], ["RSV", "SPECIES", 195, 198], ["RSV", "SPECIES", 232, 235], ["immunization types", "TREATMENT", 43, 61], ["effective RSV prophylactic agent", "TREATMENT", 185, 217], ["RSV infection", "PROBLEM", 232, 245], ["The ResVax", "TREATMENT", 245, 255], ["variety", "OBSERVATION_MODIFIER", 20, 27], ["breadth", "OBSERVATION_MODIFIER", 32, 39], ["RSV infection", "OBSERVATION", 232, 245]]], ["The most advanced candidate vaccine, ResVax, is an RSV fusion protein recombinant nanoparticle with aluminum phosphate as an adjuvant (115, 152, 153) .", [["ResVax", "CHEMICAL", 37, 43], ["aluminum phosphate", "CHEMICAL", 100, 118], ["aluminum phosphate", "CHEMICAL", 100, 118], ["ResVax", "SIMPLE_CHEMICAL", 37, 43], ["RSV", "ORGANISM", 51, 54], ["aluminum phosphate", "SIMPLE_CHEMICAL", 100, 118], ["RSV fusion protein", "PROTEIN", 51, 69], ["RSV", "SPECIES", 51, 54], ["The most advanced candidate vaccine", "TREATMENT", 0, 35], ["ResVax", "TREATMENT", 37, 43], ["an RSV fusion protein recombinant nanoparticle", "TREATMENT", 48, 94], ["aluminum phosphate", "TREATMENT", 100, 118], ["an adjuvant", "TREATMENT", 122, 133]]], ["The new approach to develop this vaccine is based on engineering small particles that carry altered RSV proteins.", [["RSV", "ORGANISM", 100, 103], ["RSV proteins", "PROTEIN", 100, 112], ["RSV", "SPECIES", 100, 103], ["this vaccine", "TREATMENT", 28, 40], ["engineering small particles", "TREATMENT", 53, 80], ["altered RSV proteins", "PROBLEM", 92, 112], ["new", "OBSERVATION_MODIFIER", 4, 7], ["RSV proteins", "OBSERVATION", 100, 112]]], ["The nanoparticles sensitize the immune system to the virus so that when a person comes in contact with it the immune system delivers a robust response.", [["person", "SPECIES", 74, 80], ["The nanoparticles", "TREATMENT", 0, 17]]], ["The Phase 3 clinical trial included more than 4,600 pregnant women examining the efficacy of prevention of RSV disease in infants through maternal immunization.", [["RSV disease", "DISEASE", 107, 118], ["women", "ORGANISM", 61, 66], ["RSV", "ORGANISM", 107, 110], ["infants", "ORGANISM", 122, 129], ["women", "SPECIES", 61, 66], ["infants", "SPECIES", 122, 129], ["RSV", "SPECIES", 107, 110], ["RSV disease", "PROBLEM", 107, 118], ["maternal immunization", "TREATMENT", 138, 159], ["RSV disease", "OBSERVATION", 107, 118]]], ["Although the trial narrowly missed its primary end point of a reduction in medically attended RSV-positive ALRTI, it showed a 44% vaccine efficacy against RSV hospitalization, 25% efficacy against all respiratory hospitalizations and 39% efficacy against all-cause severe hypoxaemia (152) .", [["respiratory", "ANATOMY", 201, 212], ["ALRTI", "DISEASE", 107, 112], ["RSV", "DISEASE", 155, 158], ["hypoxaemia", "DISEASE", 272, 282], ["RSV", "ORGANISM", 94, 97], ["RSV", "ORGANISM", 155, 158], ["RSV", "SPECIES", 94, 97], ["RSV", "SPECIES", 155, 158], ["a reduction", "TREATMENT", 60, 71], ["RSV", "TEST", 94, 97], ["RSV hospitalization", "TREATMENT", 155, 174], ["all respiratory hospitalizations", "PROBLEM", 197, 229], ["severe hypoxaemia", "PROBLEM", 265, 282], ["reduction", "OBSERVATION_MODIFIER", 62, 71], ["severe", "OBSERVATION_MODIFIER", 265, 271], ["hypoxaemia", "OBSERVATION", 272, 282]]], ["A possible route to licensure is currently being sought with the US Food and drug Administration (FdA) and European licensing agencies, bringing hope of a vaccine that could save the lives of countless young infants worldwide.AcknowledgementsWe would like to thank the participants of the '5th Workshop on Paediatric Virology' (Sparta, Greece, October 12th, 2019) for their comments, corrections and feedback.", [["infants", "ORGANISM", 208, 215], ["infants", "SPECIES", 208, 215], ["participants", "SPECIES", 269, 281], ["a vaccine", "TREATMENT", 153, 162]]], ["We would also like to thank the organizing committee the '24th World congress on Advances in Oncology' and the '24th International Symposium on Molecular Medicine' for the outstanding hosting of the workshop, as well as all members of the PVSG and the newly founded Institute of Paediatric Virology (IPV) based on the island of Euboea for their valuable contribution in the preparation of the manuscript.FundingNo funding was received.Availability of data and materialsNot applicable.Authors' contributionsAll authors (INM, SBd, BR, MT, GP, AP, EiK, cK, ElK, VA, PK, GPc and dAS) contributed to the conception and design of the study, wrote the original draft, edited and critically revised the manuscript, read and approved the final manuscript.Ethics approval and consent to participateNot applicable.Patient consent for publicationNot applicable.Competing interestsdAS is the Editor-in-chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article.", [["dAS", "PROTEIN", 575, 578], ["Patient", "SPECIES", 803, 810], ["Paediatric Virology (IPV)", "TREATMENT", 279, 304], ["SBd", "TEST", 524, 527], ["BR", "TEST", 529, 531], ["MT", "TEST", 533, 535], ["GP", "TEST", 537, 539], ["AP", "TEST", 541, 543], ["EiK", "TEST", 545, 548], ["cK", "TEST", 550, 552], ["PK", "TEST", 563, 565], ["GPc", "PROBLEM", 567, 570], ["the study", "TEST", 624, 633]]]], "b5479deab17e748b9eae412d4b18a8c71435e428": [["of these having observed cases of COVID-19 in their liver transplant recipients.", [["liver", "ANATOMY", 52, 57], ["COVID-19", "CHEMICAL", 34, 42], ["COVID-19", "CHEMICAL", 34, 42], ["liver", "ORGAN", 52, 57], ["COVID", "TEST", 34, 39], ["their liver transplant recipients", "TREATMENT", 46, 79], ["liver", "ANATOMY", 52, 57], ["transplant", "OBSERVATION", 58, 68]]], ["The cutoff for follow-up for this analysis was April 24, 2020.", [["this analysis", "TEST", 29, 42]]], ["Eight patients have been also included in the COVID-Hep registry but were not among the cases reported by Webb and colleagues.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["3 76 (74%) recipients were male and 27 (26%) were female.", [["recipients", "ORGANISM", 11, 21]]], ["Around half of patients had hypertension and two-fifths had diabetes (appendix).", [["hypertension", "DISEASE", 28, 40], ["diabetes", "DISEASE", 60, 68], ["patients", "ORGANISM", 15, 23], ["appendix", "ORGAN", 70, 78], ["patients", "SPECIES", 15, 23], ["hypertension", "PROBLEM", 28, 40], ["diabetes (appendix)", "PROBLEM", 60, 79], ["hypertension", "OBSERVATION", 28, 40], ["diabetes", "OBSERVATION", 60, 68], ["appendix", "ANATOMY", 70, 78]]], ["13 (13%) patients had a history of tobacco smoking.", [["smoking", "CHEMICAL", 43, 50], ["patients", "ORGANISM", 9, 17], ["tobacco", "ORGANISM", 35, 42], ["patients", "SPECIES", 9, 17], ["tobacco", "SPECIES", 35, 42]]], ["86 (85%) of 101 patients with available data were receiving tacrolimus as their primary immunosuppressant.", [["tacrolimus", "CHEMICAL", 60, 70], ["tacrolimus", "CHEMICAL", 60, 70], ["patients", "ORGANISM", 16, 24], ["tacrolimus", "SIMPLE_CHEMICAL", 60, 70], ["patients", "SPECIES", 16, 24], ["tacrolimus", "TREATMENT", 60, 70], ["their primary immunosuppressant", "TREATMENT", 74, 105]]], ["Severe acute respiratory syndrome coronavirus 2 infection was confirmed by RT-PCR of respiratory swabs in 100 (97%) of 103 cases.", [["respiratory swabs", "ANATOMY", 85, 102], ["acute respiratory syndrome coronavirus 2 infection", "DISEASE", 7, 57], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["Severe acute respiratory syndrome coronavirus 2 infection", "PROBLEM", 0, 57], ["RT-PCR", "TEST", 75, 81], ["respiratory swabs", "TEST", 85, 102], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["infection", "OBSERVATION", 48, 57], ["respiratory", "ANATOMY", 85, 96]]], ["The most common presenting symptoms were fever, cough, and shortness of breath (appendix).", [["fever", "DISEASE", 41, 46], ["cough", "DISEASE", 48, 53], ["shortness of breath", "DISEASE", 59, 78], ["appendix", "ORGAN", 80, 88], ["The most common presenting symptoms", "PROBLEM", 0, 35], ["fever", "PROBLEM", 41, 46], ["cough", "PROBLEM", 48, 53], ["shortness of breath", "PROBLEM", 59, 78], ["appendix", "ANATOMY", 80, 88]]], ["20 (19%) patients without clinically significant respiratory symptoms were monitored at home, 68 (66%) were admitted to a general ward, and 15 (15%) were admitted to intensive care units.", [["respiratory", "ANATOMY", 49, 60], ["respiratory symptoms", "DISEASE", 49, 69], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["clinically significant respiratory symptoms", "PROBLEM", 26, 69], ["without", "UNCERTAINTY", 18, 25]]], ["64 (62%) hospitalised patients had radiological findings that were consistent with viral pneumonia.", [["viral pneumonia", "DISEASE", 83, 98], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["radiological findings", "TEST", 35, 56], ["viral pneumonia", "PROBLEM", 83, 98], ["consistent with", "UNCERTAINTY", 67, 82], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["pneumonia", "OBSERVATION", 89, 98]]], ["68 (66%) patients required respir atory support, including oxygen supplementation (40 [59%] patients), non-invasive ventilation (15 [22%] patients), and mechanical ventilation (ten [15%] patients).", [["oxygen", "CHEMICAL", 59, 65], ["oxygen", "CHEMICAL", 59, 65], ["patients", "ORGANISM", 9, 17], ["oxygen", "SIMPLE_CHEMICAL", 59, 65], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 187, 195], ["respir atory support", "TREATMENT", 27, 47], ["oxygen supplementation", "TREATMENT", 59, 81], ["non-invasive ventilation", "TREATMENT", 103, 127], ["mechanical ventilation", "TREATMENT", 153, 175]]], ["The most frequent treatments for COVID-19 are reported in the appendix.", [["appendix", "ANATOMY", 62, 70], ["COVID-19", "CHEMICAL", 33, 41], ["COVID-19", "SIMPLE_CHEMICAL", 33, 41], ["appendix", "ORGAN", 62, 70], ["The most frequent treatments", "TREATMENT", 0, 28], ["COVID", "TEST", 33, 38], ["appendix", "ANATOMY", 62, 70]]]]}